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Abstract 
 
The investigation into the genome of the emerging pathogen reveals the genetic 
basis of the pathogen. In this study, Achromobacter xylosoxidans was used as an 
example for the genomic study of emerging pathogens. A. xylosoxidans is an 
emerging and opportunistic pathogen in patients with various underlying diseases, 
such as Cystic Fibrosis and cancers. 
 
In chapter 3, the objectives of the study were to compare and evaluate the 
approach for A. xylosoxidans identification. A wide range of methods, including 
phenotypic test, 16S rDNA gene sequencing, MALDI-TOF, RAPD and MLST, 
were utilised to demonstrate the species identification. MALDI-TOF was 
considered as the most appropriate method due to the least time consuming. The 
application of multiple approaches to identify A. xylosoxidans was suggested.  
 
In chapter 4, comprehensive genomic feature of A. xylosoxidans has not been 
elucidated. The objective of this study was to use comparative genomic tool to 
investigate genomic feature of A. xylosoxidans. The analysis revealed the opened 
pan-genome of the species. The core genome accounted for approximately 50% 
of the size of the genome. Furthermore, the analysis revealed recombination 
events in the core genome of the species. Interestingly, phylogenetic 
relationships demonstrated global distribution of the species without 
geographical structure. This study provided pan-genome structure of the species, 
allowing for studies of genetic exchange mechanism in the species. 
 
In chapter 5, the main objective of the chapter was to investigate the antibiotic 
resistance and genes associated with the resistance in the species. The whole 
genome sequence and bioinformatics were used to search for genes associated 
with antibiotic resistance phenotypes. Single-molecule real time (SMRT) 
sequencing was also used to investigate the integron. The analysis revealed 
conserved RND-type efflux transporters across the species. The complete 
genome sequence revealed class 1 integron carrying IMP-14 on the chromosome 
of multidrug resistant isolates. This study demonstrated the identification of 
antibiotic resistance genes using bioinformatics and SMRT sequencing. 
 
In chapter 6, the objective was to investigate the virulence of A. xylosoxidans in 
organism model. The great moth larva Galleria mellonella was used to test for 
the virulence of A. xylosoxidans. Bioinformatics analyses were conducted to 
predict genes associated with virulence determinants. The analysis resulted in 
hydrolase-containing protein and PscD type III secretion system predicted as 
virulence determinants based on G. mellonella infection model, paving the way 
for further studies. 
 
This study demonstrated the application of whole genome sequencing and 
bioinformatics to understand the biology of the emerging pathogen. The 
identification of the genome of the emerging pathogen is required for the 
facilitation of prevention and therapeutic in the future.  
Glossary 
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Glossary 
 
°C  Degree celcius 
DNA  Deoxyribonucleic acid 
FEV1  Forced expiratory volume in one second 
g  Gram 
h  Hour 
L  Litre 
MgCl2  Magnesium Chloride 
m  Metre 
μ  Micro 
mM  Millimolarity 
min  Minute 
M  Molarity 
mol  Mole 
n  Nano 
OD  Optical density 
pmole  Picomole 
RNA  Ribonucleic acid 
rDNA  Ribosomal DNA 
U.K.  United Kingdom 
U.S.  United States of America
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Chapter 1 
General Introduction 
 
Infectious diseases are still having a remarkable impact on the quality of life 
around the world. A recent survey by World Health Organization (WHO) shows 
that infectious diseases are in the top ten causes of death (Figure 1.1).  The 
largest causes of death are ischaemic cardiac diseases, stroke and chronic 
obstructive pulmonary disease (COPD). However, the 4
th
, 6
th
 and 7
th
 rank are 
infectious diseases: lower respiratory tract infection, Acquired Immune 
Deficiency Syndrome (AIDS) and diarrhoea, respectively. Focusing on countries 
grouped by national income, infectious diseases are in the three highest causes of 
death in low-income countries (Figure 1.2). 
 
Figure 1.1: The ten highest causes of death according to a world‟s 
population survey by WHO in 2012 
(http://www.who.int/mediacentre/factsheets/fs310/en/) 
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Figure 1.2: The ten highest causes of death in low-income countries 
according to a surveillance by WHO in 2012  
(http://www.who.int/mediacentre/factsheets/fs310/en/index1.html) 
 
Life-threatening infectious diseases such as poliomyelitis and small pox have 
been eliminated using vaccination. However, many of infectious diseases still 
remain with high virulence, such as Severe Acute Respiratory Syndrome (SARS) 
and Middle East Respiratory Syndrome (MERS). Bacterial infections still remain, 
and importantly, they are caused by antibiotic resistant pathogens. In addition, 
infections by emerging pathogens have become a troublesome factor for clinical 
medicine. 
 
The introductory part of this thesis will present the general situations of 
emerging infectious diseases and hospital-acquired infections. Furthermore, the 
impact of the diseases and prevention strategies will be addressed to state the 
importance of conducting the comprehensive research on emerging infectious 
diseases. 
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1.1. Emerging infectious diseases and hospital-acquired infections 
 
1.1.1. Emerging pathogens 
 
As infectious diseases remain one of the major causes of death in the global 
survey (Figure 1.1 and 1.2), emerging infectious diseases are becoming a 
challenge due to the lack of information about the pathogens, for example, the 
routes of transmission and the profile of drug resistance. Three possible 
mechanisms of how emerging infectious diseases occur have been proposed by 
Engering, Hogerwerf & Slingenbergh (2013): 
 
1. New hosts: The pathogen moves from one species to another species 
by accident. The driving factor of this event is usually a close contact 
between hosts such as human and animals. Common examples of the 
driving factors are the consumption of raw wild meat and the contact 
between human and domestic animals. The jump from one species to 
another species requires the adaptation of the pathogen in order to 
successfully survive in a new host. For example, the transmission of 
Streptococcus suis from pigs to human leads to serious infections, 
including, septicaemia and meningitis, in human (Wertheim et al., 
2009). This demonstrates a particular type of the transmission of 
pathogens from animals to humans, called „zoonosis‟. Another 
example of a bacterial zoonotic infection is cat scratch disease caused 
by Bartonella species (Chomel & Kasten, 2010).  
 
2. New phenotypes: This event happens when bacteria that have already 
existed in human. The external disturbances make bacteria adapt to 
survive in the body of the hosts, by expressing new phenotypes that 
enhance the viability under the changed environment. The common 
disturbances are the use of antibiotic and vaccination to eliminate the 
pathogens. Antibiotic resistance is, generally, expressed by emerging 
pathogens, as a new trait, to survive in the harsh environment of 
antibiotic use. The outbreak of drug resistance Acinetobacter 
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baumannii in nursing homes (Sengstock et al., 2010) and the outbreak 
of vaccine resistance Streptococcus pneumoniae in the US 
(Brueggemann et al., 2007) are the example of the expression of new 
trait of emerging pathogens. 
 
3. New geography: This mechanism is considered when the pathogens, 
which have already been endemic in a particular area, spread to 
different area on account of the change in physical factors such as 
temperature and land use. The spread of dengue haemorrhagic fever 
in Southeast Asian countries is one example 
(http://www.who.int/mediacentre/factsheets/fs117/en/). Climate 
change is usually a driving factor that triggers an outbreak of 
emerging pathogen. Global warming has a major effect on the 
emergence of diseases, particularly vector-borne diseases. For 
instance, the outbreak of dengue haemorrhagic fever in Europe was 
driven by climate change (Bouzid et al., 2014). In addition, the 
expansion of land use also contributes to the appearance of emerging 
infectious diseases. For instance, the extension of land use in th US 
between 1970s and 1980s accounted for the distribution of Lyme 
disease, which is caused by Borrelia burgdorferi, from northeastern 
area to the other area (Ciesielski et al., 1988). 
 
1.1.2. Hospital-acquired infection problem 
 
The emergence of rare pathogens and multidrug-resistant pathogens increasingly 
poses problems for clinical service in the hospital worldwide. Hospital-acquired 
infections, also known as „nosocomial infections‟, cause a major problem to 
healthcare providers. The term „hospital-acquired‟ infections usually refers to 
infections that develop, at least, 48 hours after hospital admission (Falcone et al., 
2011). Hospitals are places where emerging pathogens are often detected. For 
example, the emergence of Enterococcus faecium in the hospital is driven by the 
antibiotic resistance phenotype (Weber & Gold, 2003). Elizabethkingia 
meningoseptica has also been emerged as hospital-associated pathogen on 
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account of its antibiotic resistance and its adaptability to a new environment 
(Jean et al., 2014).  
 
According to a survey from Center for Disease Control and Prevention of the US, 
severe hospital-associated infections occur in 1 in every 25 hospitals 
(http://www.cdc.gov/HAI/surveillance/index.html). In European countries, the 
European Centre for Disease Prevention and Control survey reports that 
approximately 7% of the patients had hospital-associated infections and 35% of 
patients, who have hospital-acquired infections, are given at least one antibiotic. 
 
The most common types of nosocomial infections are the respiratory infection, 
surgical site infection, gastrointestinal tract infection, and urinary tract infection 
(Zarb et al., 2012). Medical devices can be the reservoirs for pathogens and help 
them spread to other patients. Considering the causes of infection, medical 
device-associated infection contributed approximately 25% of nosocomial 
infections in the US.  
 
1.1.2.1. Hospital-acquired respiratory infections 
 
Hospital-associated respiratory tract infections, in particular pneumonia, cause a 
number of problems to hospitalised patients. Most of the hospital-acquired 
pneumonia are associated with medical devices, especially in critical care unit. 
Endotracheal intubation is the most common cause of pneumonia in hospitals. 
The intubation provides the opportunity of lung infection via four possible routes 
(Kalanuria, Zai & Mirski, 2014): (1) micro-aspiration during the intubation, (2) 
biofilm formation of bacteria inside the tube during the intubation, (3) 
accumulation of secretion around the tube where bacteria can inhabit, and (4) 
minor trauma of muco-ciliary clearance system during the intubation. The three 
leading causes of hospital-acquired respiratory tract infections are Pseudomonas 
aeruginosa, Staphylococcus aureus, and Escherichia coli, and, importantly, most 
of them are antibiotic-resistance strains (Jones, 2010). Some emerging pathogens, 
such as A. xylosoxidans, are also causes of hospital-acquired infection, especially 
in Cystic Fibrosis infection (Kanellopoulou et al., 2004; Rønne Hansen et al., 
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2006; De Baets et al., 2007; Hansen et al., 2010; Lambiase et al., 2011; De Baets 
et al., 2013). Preventing the transmission of pathogens to patients is essential 
because most microbes that circulate in the hospital are antibiotic-resistance 
strains. Importantly, causing pathogens of hospital-acquired respiratory tract 
infections can be transmitted from person-to-person via air-borne route. The 
guideline from British Society for Antimicrobial and Chemotherapy recommends 
hand hygiene and the sterilisation of ventilators as a preventive guideline for 
hospital-acquired respiratory tract infections (Masterton et al., 2008). 
 
Figure 1.3: Important microorganisms in surgical site infection, reported by 
NHS hospital in the U.K. A graph is taken from „Surveillance of Surgical Site 
Infection in NHS Hospitals in England‟ (Public Health England, 2014). 
 
1.1.2.2. Hospital-acquired surgical site infections 
 
Infection near a surgical site is also concerning, because this type of infection 
accounts for approximately 15% of overall hospital-acquired infections 
(Watanabe et al., 2008). By definition, the surgical site infection is the infection 
that occurs near or at surgical incision region within 30 days after the operation. 
The incision of the skin allows bacteria to get into the body. In many cases, 
bacteria that colonise near the incision area serve as a cause of infections. For 
instance, S. aureus, in particular Methicillin-resistance strains, are commonly 
found at the surgical cut site (Manian et al., 2003). According to a report by 
2004/5 2013/142012/132011/122010/112009/102008/92007/82006/72005/6
0
50
45
40
35
30
25
20
15
10
5
%
 o
f 
in
p
a
ti
e
n
t 
s
u
rg
ic
a
l 
s
it
e
 i
n
fe
c
ti
o
n
 c
a
s
e
s
Enterobacteriaceae
S. aureus
MRSA
MSSA
CoNS
Enterococcus spp.
Chapter 1 
 7 
Public Health England, the prevalence of infections by Methicillin-resistance S. 
aureus gradually decreases from 40% to 16% of cases of surgical site infections, 
whereas the prevalence of infections caused by Enterobacteiaceae increases 
from 10% to 26% of cases of surgical site infections (Figure 1.3). Preventive 
strategies for surgical site infections include disinfecting skin‟s microbe before 
surgical operation and preventing staff-to-patient transmission during post-
operative period. However, certain underlying conditions, such as diabetes 
mellitus, obesity and smoking, increase the risk from being infected with those 
pathogens (Reichman & Greenberg, 2009). 
 
1.1.2.3. Hospital-acquired gastrointestinal tract infections 
 
Gastrointestinal infection during hospital admission is one of the most common 
hospital-acquired infections (http://www.cdc.gov/HAI/surveillance/index.html). 
Clostridium difficile is recognised as a key organism that contributes to a 
remarkable problem in health care system (Dubberke & Olsen, 2012). The 
infection is associated with the lack of gut commensals due to an overuse of 
antibiotic (Bignardi, 1998). C. difficile infection can be transmitted via air-borne 
route. Best et al. (2010) revealed the presence of C. difficile in aerosol around 
symptomatic C. difficile patients, allowing the airborne dissemination of the 
pathogen. Although nosocomial gastrointestinal infection is life threatening 
(Parashar et al., 2006; Marra et al., 2007), the infection and transmission of the 
pathogens is preventable. The principal practice is to decrease the risk of 
transmission from person to person. The prevention using non-medication 
procedures, including education, hygiene and isolation, reduces the incidence of 
hospital-associated C. difficile infection (You et al., 2014). Furthermore, 
decreasing the overuse of antibiotic in hospitalised patients can also reduce the 
number of C. difficile infection cases (Valiquette et al., 2007). Recently, the 
administration of the probiotics decreases the prevalence of C. difficile infection 
(McFarland, 2006). Faecal transplantation has also been proposed as an new 
treatment for C. difficile infection (Gens, Elshaboury & Holt, 2013). Nosocomial 
viral infections are more dominant than bacterial infections in children. Rotavirus 
and norovirus are considered as major aetiologic factors of nosocomial 
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gastrointestinal infection in children (Oh, Gaedicke & Schreier, 2003). These 
viruses can be transmitted from person to person via fecal-oral route. It was also 
reported that viral particles were found in stool samples of patients who had 
gastroenteritis symptoms (Brady et al., 1989). However, the infectivity of virus 
can be reduced by applying disinfectants on the surface whence the viruses are 
present (Sattar et al., 1983, 1994). 
 
1.1.2.4. Hospital-acquired urinary tract infections 
 
Urinary tract infection is a common problem in post-operation patients due to the 
retaining of urinary catheter. Urinary catheter is most frequently used medical 
device, accounted for 17% in Europe (Zarb et al., 2012) and 23% in the U.S. 
(Magill et al., 2014). Generally, bacteria colonise around the distal urethra area 
because the upward migration of the bacteria is prevented by the outward flow of 
urine. With the insertion of catheter, flow of urine through the urethra is 
restricted, allowing for the upward migration of the bacteria. The presence of 
bacteria in the urinary bladder can follow these three possible ways: (1) the tip of 
the catheter pushes bacteria from the distal urethra to the bladder, (2) the bacteria 
gradually migrate through the catheter surface into the bladder, and (3) the 
drainage bag is contaminated by the bacteria during preparing process (Barford 
& Coates, 2009). The most common cause of catheter-associated infection is E. 
coli (Wagenlehner, Weidner & Naber, 2005). Other species such as Enterococci 
spp., P. aeruginosa, and A. baumannii (Wagenlehner, Weidner & Naber, 2005; 
Djordjevic et al., 2013) are also considered as causes of catheter-associated 
infections. An ideal solution of this problem is to avoid using catheter or to 
decrease the duration of catheter intention (Hooton et al., 2010). Unfortunately, 
74% of hospitals in the U.S. have not monitored the duration of catheterisation 
(Saint et al., 2008). Alternative ways to reduce the infection are to use antibiotic-
coated catheter, to monitor the bladder using ultrasonography, and to prescribe 
prophylactic antibiotic after catheter removal (Hooton et al., 2010). 
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1.1.3. The burden of hospital-acquired infection and prevention strategies 
 
Hospital-acquired infections also cause a socio-economic burden. In the U.S., 
approximately two million patients suffer from hospital-acquired infections each 
year (Reed & Kemmerly, 2009). Hospital-acquired infections increase the length 
of hospital stay, leading to increase the probability of receiving pathogens 
circulating in the hospital. Nathwani et al. (2014) revealed that extra-period in 
the hospital increased the chance of infection from multidrug-resistance P. 
aeruginosa, compared to non-resistant strains. Considering economic burden, a 
meta-analysis conducted in the U.S. reports that hospital-acquired infections cost 
603 to 65,245 USD per case, and cost 8.3 – 11.5 billion USD per annum 
(Zimlichman et al., 2013). In the U.K., the infection costs approximately one 
billion GBP per annum (Plowman, 2000). Infection at surgical site contributes to 
the largest partition (33.7%), and catheter-associated infection contributes to the 
smallest partition (<1%). However, several studies showed that both cost and 
cases of hospital-acquired infection decreased after infection control and 
prevention have been launched (Reed & Kemmerly, 2009; Zimlichman et al., 
2013).  
 
As a result, some preventive strategies have been established. There are staffs 
responsible for infection control, have been set up in hospitals in many countries 
such as the U.K. (Plowman, 2000) and Japan (Morikane, 2012).  Briefly, the 
roles of infection control team are (1) to educate hospitals‟ staffs and public via 
campaigns such as hand cleaning, (2) to support hospital‟s staff in infection 
control‟s practice, and (3) to survey infection information in the hospital. To 
educate healthcare staff is the most important strategy. Danzman et al. (2013) 
reported that healthcare providers are important carriers of nosocomial pathogens. 
Direct contact by healthcare staffs allows for the transmission of the pathogens 
from health care providers to patients. Hand hygiene is, therefore, an appropriate 
and effective practice for health care workers. General cleaning of the surfaces, 
that are contacted by hospital‟s staffs and patients, in the hospital can also 
prevents the transmission of the pathogens (Dancer, 2014). Furthermore, 
guideline for each type of nosocomial infection such as Surgical Care 
Improvement Projects (SCIP) for surgical site infection (Bratzler & Hunt, 2006) 
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has been launched in order to reduce the prevalence of hospital-acquired 
infections. Apart from pathogen transmission, another problem troubling 
hospital-acquired infections is the resistance of pathogens to antimicrobial agents. 
 
1.2. Antibiotic resistance 
 
1.2.1. Antibiotic resistance: a multi-dimensional problem 
 
Antimicrobial resistance is a major problem worldwide 
(http://www.who.int/drugresistance/documents/surveillancereport/en/). Many 
common pathogens have become resistant to effective antibiotics, for example, 
carbapenem-resistant Klebsiella pneumoniae, fluoroquinolone resistant E. coli, 
3
rd
 generation cephalosporin resistant Neisseria gonorrhoeae, and methicillin 
resistant S. aureus. Innate resistance to antibiotic has been found in some 
pathogens, for example, A. xylosoxidans (Hu et al., 2015). In fact, this problem is, 
now, approaching the situation where only „last resort‟ drugs are available. 
 
1.2.1.1. Causes of antibiotic resistance 
 
Antibiotic resistance causes a huge problem to infections, especially hospital-
acquired infections. Antibiotics with better efficacy are needed for resistant 
bacteria treatment. Since the discovery of penicillin (Fleming, 1929), the 
researches for antibiotics have been on-going. The use of antibiotic to treat 
bacterial infection has been considered a major cause of drug resistance in 
bacteria. The first report of clinically important antibiotic resistance dated back 
to 1942 when penicillin-resistant S. aureus was described (Rammelkamp & 
Maxon, 1942). To develop to be antibiotic-resistant species, bacteria depict a 
natural selection theory that organisms with a positive selection under a 
particular environment can survive and reproduce. In other words, the bacteria 
that can maintain their fitness can survive. 
 
Chapter 1 
 11 
The emergence of antibiotic resistant strains follows natural selection driven by 
the use of antibiotic as an evolutionary pressure (Blázquez, Oliver & Gómez-
Gómez, 2002). The development of antibiotic resistance can be considered as an 
intrinsic development and an extrinsic development. For intrinsic process, the 
mutation of drug target-associated genes usually plays a role in this process. 
Kolar et al. (2001) revealed that cephalosporin-resistant bacteria increased as the 
use of cephalosporin increased, while resistant bacteria decreased when 
cephalosporin use is restricted. Likewise, a 13-year study in Taiwan showed the 
relationship between drug-resistance development and antibiotic use in the 
hospital (Hsueh, Chen & Luh, 2005). For extrinsic factor, the resistance can be 
transferred between the bacterial species. The observation of transferrable 
antibiotic resistance has been reported since 1959 (Ochiai et al., 1959) that 
horizontal gene transfer plays the role in the resistance of bacteria to the 
antibiotics (Maiden, 1998). The horizontal gene transfer, also known as lateral 
gene transfer, is a transmission of genes that send genetic element to other 
bacteria via the movement of mobile genetic elements (Frost et al., 2005). This 
type of the transfer of resistance gene has a huge impact on clinical microbiology 
because it demonstrates that resistance genes can be transferred not only to their 
offspring, but also to other bacteria. Taking all into consideration, the major 
cause of the distribution of antibiotic resistant pathogens is the inappropriate use 
of antibiotic. This also has a consequent impact on health financing. 
 
1.2.1.2. Economic burden of antibiotic resistance 
 
Antibiotic resistance does not only cause clinical burden, but it also causes the 
consequent economic burden.   In most cases, newer and more effective 
antibiotics are more expensive than first-line antibiotics. In pandemic area of 
drug resistant pathogens, doctors replace first-line antibiotics with higher potent 
antibiotics. For instance, in patients with otitis media (the inflammation of the 
middle ear), amoxicillin-clavulanic acid is prescribed instead of amoxicillin 
alone. This costs six times higher than the first-line antibiotic prescription. It also 
results in the establishment of the resistance to more potent antibiotics in 
community (Howard, 2004). Although there has been an investment in the 
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strategies to solve an antibiotic resistance problem, such as increasing research 
funding for new antibiotics discovery, the problem still remains because of the 
existing inappropriate use of the antibiotic. Preventive strategy can be an 
appropriate solution for this problem. The prevention for antibiotic resistance 
does not only reduce the severity of the problem, but also reduce the cost spent 
on newer antibiotics. The investment in the preventive strategies for antibiotic 
resistance is less than the investment in the prescription of higher antibiotics and 
new antibiotic research. For instance, using of gowns and gloves of healthcare 
providers reduced a number of vancomycin-resistant Enterococci, compared to 
using gloves alone (Puzniak et al., 2004). In addition to the cost of drug, 
infection from resistant microbes prolongs the length of hospital stay. Mauldin et 
al. (2010) addressed a significantly higher amount of additional hospitalisation 
cost spent on drug-resistant infection (29.3 %), compared to drug-susceptible 
infection. Taken together, it is important to note that antibiotic resistance 
problem affects the whole public health system, including biomedical research, 
healthcare service, and public health administration. 
 
1.2.2. Antibiotic resistance in hospital-acquired emerging infection 
 
Hospitals are important places where antibiotic resistant bacteria can be 
developed as a result of a high number of antibiotics used (Gold & Moellering, 
1996). Multidrug-resistant pathogens can circulate in hospital via hospital staffs 
and infected patients (Danzmann et al., 2013). This, consequently, leads to the 
spread of drug-resistant pathogens in the hospital, as exemplified by the local 
circulation of multidrug resistance P. aeruginosa, driven by hospital‟ staffs, in 
provincial hospital in Thailand (Kiddee et al., 2013). 
 
Clinically-naïve bacteria can often become human pathogens, often by 
expressing drug resistance, while they are circulating in the hospital. Some 
bacteria can transform from drug-susceptible strains to drug-resistance strains or 
some are accessing to the hospitals with intrinsic drug resistance. The emergence 
of methicillin-resistant S. aureus exemplifies the conversion into emerging 
pathogen by the expression of antibiotic resistance trait. Enterococci species 
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have adapted from commensals in human gut to be an emerging pathogen in 
nosocomial infection due to the intrinsic resistance to commonly used antibiotics 
(Morrison, Woodford & Cookson, 1997). Enterococci are recently resistant to 
linezolid, which is one of the top-line antibiotics (Auckland et al., 2002). 
Stenotrophomonas maltophila changes its susceptibility from non-resistance to 
resistance due to antibiotic pressure in the hospital (Looney, Narita & 
Mühlemann, 2009). Vartivarian et al. (1994) demonstrated that hospital isolates 
of S. maltophila became more resistant to major antibiotics, including 
fluoroquinolones, co-trimoxazole and cephalosporins over 11 years of the study, 
between 1981 and 1992. A. xylosoxidans have already been considered emerging 
pathogen due to the intrinsic resistance (Hu et al., 2015). Another example is that 
Elizabethkingia meningoseptica has become an emerging pathogen due to the 
multidrug resistance to bata-lactam antibiotics, particularly, carbapenems 
(González & Vila, 2012; Jean et al., 2014). Virulence of several emerging 
pathogens has not been elucidated. However, it is noteworthy that most of 
emerging hospital-acquired pathogens cause serious infections due to their drug-
resistance phenotypes. 
 
Multidrug resistance of the emerging opportunistic pathogens also exemplifies 
the problem of nosocomial infection. Patients, who have a high risk for infection, 
such as cancer, diabetes and immune-compromised condition, are prone to be 
infected by the microbes. An example of emerging nosocomial infection is Asaia 
lannensis infection in children with heart disease during hospitalisation 
(Juretschko, Beavers-May & Stovall, 2010). This species showed pan-antibiotic 
resistance to most antibiotics for Gram-negative bacteria such as beta-lactams 
and fluoroquinolones. Respiratory tract infection caused by A. xylosoxidans in 
epiglottic cancer also illustrates the role of emerging pathogens in opportunistic 
infection (Priyamvada, 2014). Resistance to antibiotic in some pathogens can be 
predicted because those resistance genes are carried as intrinsic genes. However, 
acquired resistance is an adaptation process driven by antibiotic use (Blázquez, 
Oliver & Gómez-Gómez, 2002). Therefore, the regulation and the use of 
antibiotic in certain region can indicate the prevalence of antibiotic resistant 
infection in the region. 
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1.3. Situation of antibiotic resistance in countries where are associated 
with this study: The U.K. and Thailand 
 
1.3.1. Antibiotic resistance problem in the U.K. 
 
The United Kingdom has faced serious antibiotic resistance problem since the 
existence of methicillin-resistant S. aureus (Barber, 1961). Major causes of 
antibiotic resistance problem in the U.K. are from both internal factor and 
external factor. For internal cause, improper prescription is a key that accelerates 
antibiotic resistance. Approximately 80-90 % of antibiotic prescriptions happen 
in primary and secondary health care unit (Shallcross & Davies, 2015). An 
observation between 1995 and 2011 reported that some antibiotics were 
prescribed in primary health care centres. For instance, 51% of patients with self-
limited cough and cold were prescribed antibiotics. Situation in secondary health 
care unit is worse than the one in primary units. The surveillance reported a 
significant increase in the use of broad-spectrum antibiotics, such as co-
amoxiclav and carbapenem (Hawker et al., 2014). To deal with the problems that 
need intensive follow-up, antimicrobial stewardship surveillance has commenced 
to improve the quality of prescription and to encourage reasonable prescription 
(Ashiru-Oredope & Hopkins, 2013). 
 
For external cause, antibiotic resistance in England is shown to be influenced by 
pathogens from the outside. Studies showed that antibiotic resistance of enteric 
fever in East London was associated with overseas travelling (Reddy et al., 2011; 
Dave et al., 2015). Studies also demonstrated that the majority of patients (92%) 
infected with antibiotic resistance Salmonella, had just been back from travelling 
abroad. The same study revealed that the antibiotic resistance of bacteria 
remained over seven years of the survey, between 2005 and 2012 (Dave et al., 
2015).  
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1.3.2. Antibiotic resistance problem in Thailand 
 
It has been acknowledged that antibiotic resistance affects public health in Asian 
countries (Kim et al., 2013; Chewapreecha et al., 2014). Thailand is one of the 
most famous destinations for travellers. Thailand has been reported as one of 
Asian countries that have confronted the antibiotic resisance challenge. A recent 
study in 2010 revealed that the resistance challenge in Thailand caused about 
39,000 deaths and costed up to 112 million pounds sterling (GBP) (exchange 
rate: 54 Thai baht per GBP) (Sumpradit et al., 2012). The access to antibiotic in 
Thailand has not been effectively controlled according to public health situation. 
For example, people in rural area prefer to purchase medicine from a chemist 
rather than to visit a medical doctor due to the imbalance of doctor-to-patient 
ratio and the inaccessibility of hospital visit. People can purchase antibiotic from 
the chemist with no need of medical prescription. This problem also happens in 
big cities, such as Bangkok. Several studies were shown that chemists distributed 
several antibiotics (Thamlikitkul, 1988; Apisarnthanarak et al., 2008). A study in 
Patumthani province suggested the positive correlation between the rise of 
antibiotic misuse and the resistance of antibiotic use (Apisarnthanarak & Mundy, 
2008). Inappropriate distribution of antibiotic through the chemist is considered 
as a major factor that triggers the antibiotic resistance (Apisarnthanarak et al., 
2008; Apisarnthanarak & Mundy, 2008). Furthermore, tertiary health care units 
and teaching hospitals experience antibiotic resistance‟s problems. Antibiotics 
are always given to patients who are hospitalised in order to prevent post-
operative infection (Apisarnthanarak et al., 2006). Surprisingly, the abuse of 
antibiotics is seen in the unit of internal medicine, which is specialised in the use 
of antibiotics (Kusuma Na Ayuthya et al., 2003; Apisarnthanarak et al., 2006). 
Although it has been recognised that the cause of antibiotic resistance is the 
overuse and inappropriate use of antibiotic, samples‟ collection and antibiogram 
cannot reveal the transmission of antibiotic resistance genes and the distribution 
of drug resistant pathogens. Whole genome sequencing is, therefore, an approach 
to reveal the genetic basis of resistance mechanisms and the molecular 
epidemiology of resistant pathogens. 
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1.4. Whole genome sequencing in clinical microbiology 
 
The study of epidemiology of infectious diseases historically depends on the 
number of symptomatic cases in particular location and time. This information 
has been used to build the inference to the transmission of pathogens. However, 
the classical data collection is not always enough for the investigation for the 
identity and the virulence of the pathogens. The application of whole genome 
sequencing on microbiological studies paves the way for the understanding of 
molecular epidemiology of pathogens, antibiotic resistance-associated genes, and 
virulence-associated genes (Grad & Lipsitch, 2014). 
1.4.1. Next-generation whole genome sequencing 
 
DNA sequencing is a groundbreaking invention of the 20
th
 century, allowing for 
biological studies in molecular level. The pioneering sequencing was invented by 
Sanger and his colleagues, using chain-terminating dideoxyribonucleotides 
(Sanger, Nicklen & Coulson, 1977). The current generation of DNA sequencers 
was introduced with an effort to improve the efficiency of DNA sequencing by 
reducing time and costs (Margulies et al., 2005). There are two next-generation 
sequencing platforms applied in this study: Illumina® platform and Pacific 
Biosciences® platform. 
 
Table 1.1: Next-generation sequencing platform used in this study (Loman et 
al., 2012; Radford et al., 2012) 
Sequencing 
technology 
Platform 
Run 
time 
Read 
length 
(bases) 
Gb 
per 
run 
Strength Weakness 
Sequencing 
by synthesis 
Illumina 
HiSeq 
11 days 2 × 100 600 
 High yield per 
run 
 Cost effective 
 Long run time 
 Short read 
lengths 
SMRT 
technology 
Pacific 
Bioscience
s RSII 
4 hours 10
3
-10
4
 
3 per 
day 
 Long read 
lengths 
 Short run time 
 High error rate 
 
 
Illumina‟s sequencing is performed by fragmenting genomic DNA and ligating 
the fragmented sequences with adapters (Figure 1.4) (Mardis, 2013). Following 
the preparation of the DNA library, the adapter-ligated DNAs are loaded into a 
flow cell to attache to pre-coated primers, which are complimentary to the 
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adapters, on the surface. This platform uses a unique process called „bridge 
amplification‟ (Figure 1.4). The free ends of the DNA fragment bend over to 
bind to a nearby complementary adapter, forming clusters of DNA on the slide. 
The sequencing process starts by the addition of fluorescently labelled dNTP. 
The addition‟s rate is one base at a time because of the presence of a blocking 
group at 3‟-OH preventing polymerisation reaction. The image sensor detects the 
wavelength and the intensity of fluorescent signals from the synthesised 
sequences, allowing for the generation of the nucleotide sequence. After the 
cleavage of fluorescent dye and deblocking 3‟-OH end, the synthesis of 
nucleotides can carry out. The reaction of nucleotide synthesis happens for up to 
300 bp before the synthesis of the second sequence commences. This process is 
called „sequencing by synthesis‟ (Mardis, 2013). Illumina sequencing has been 
claimed to be an accuracy and appropriate approach for high throughput; 
however, the sequencing has also been reported for the nucleotide substitution 
mistake over GC rich region (Dohm et al., 2008). 
 
 
 
Figure 1.4: DNA sequencing by Illumina® technology. During annealing, 
adapter-tagged single-stranded DNAs bind to a complementary primer (b). The 
replication then occurs (c-d). A free end of amplified sequences bind to 
complementary primer close to them during annealing (e), allowing for “cluster 
amplification” using bridge amplification (f-h).  
 
Single-molecule, real-time sequencing technology (SMRT) is on the basis of the 
undisturbed synthesis of single nucleotide sequence in each sequencing unit (Eid 
DNA template
Adapter Adapter
a) b) c) d)
e) f) g)
Cluster amplification
h)
Bridge amplification
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et al., 2009). The double-stranded DNA template of the sequencing is bound 
with adapters to achieve circularly hairpin formation. Then, the prepared DNA 
strands were trapped by the polymerases. Unlike Illumina‟s sequencing platform, 
polymerase enzymes are fixed on the bottom of the microcell, allowing only 
single DNA molecule to reach the DNA polymerase (Figure 1.5). The 
polymerisation is observed using „Zero-mode waveguide‟ (ZMW) (Levene et al., 
2003). Once fluororescent dye-tagged nucleotide reaches the bottom of the well, 
the fixed DNA polymerase cleaves the dye, as the base is incorporated. The 
instrument determines the added nucleotide by detecting the laser-stimulating 
emission from cleaved fluorescent dye. The SMRT technology can produce 
sequence reads up to 10,000 bp or longer (Roberts, Carneiro & Schatz, 2013). 
The SMRT approach is also able to resolve GC rich regions. Moreover, this 
technology allows for the complete assembly of microbial genome (Ribeiro et al., 
2012). Nevertheless, SMRT sequencing can produce a noticeable indel error due 
to the single-molecule sequencing (Laehnemann, Borkhardt & McHardy, 2015). 
The utilisation of hierarchical genome assembly process (HGAP) (Chin et al., 
2013) and reads from other platforms (hybrid assembly) pave the way to the 
error correction of SMRT approach (Laehnemann, Borkhardt & McHardy, 2015). 
 
Figure 1.5: DNA sequencing by SMRT sequencing. Double stranded DNA 
template is ligated to adapter to achieve hairpin structure. Then the template is 
captured by bottom-fixed DNA polymerase and sequenced. 
 
Double-stranded DNA Adapter ligation
Sequencing
SMRT cell
ZMW detection
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1.4.2. The application of whole genome sequencing in clinical 
microbiology 
 
Advances in molecular biology and DNA sequencing have been improving 
biological researches. One implementation of DNA sequencing is to reveal 
bacterial genomes. The beginning era of bacterial genome dated back to 1995 
when the first genome of Haemophilus influenzae Rd was successfully 
sequenced using the Sanger method (Fleischmann et al., 1995).  
 
Table 1.2: Examples of the application of whole genome sequencing 
approaches to bacterial infectious diseases. 
Application Study Organisms Reference 
Identification 
and 
epidemiology 
  
Outbreak in Germany Escherichia coli (Rasko et al., 2011) 
Identification and typing Achromobacter spp. 
(Spilker, Vandamme 
& LiPuma, 2012) 
Typing, diversity and 
epidemiological study 
Methicillin-resistant 
Staphylococcus aureus* 
(Enright et al., 2000; 
Harris et al., 2010, 
2013) 
Outbreak in Spain Legionella spp. 
(Sánchez-Busó et al., 
2014) 
Population structure Haemophilus parasuis (Howell et al., 2014) 
Outbreak in Denmark Salmonella spp. 
(Leekitcharoenphon 
et al., 2014) 
Outbreak in ICU in 
Germany 
Klebsiella pneumoniae* (Haller et al., 2015) 
Resistance 
gene 
identification 
   
Tetracycline resistance Bifidobacterium animalis 
(Gueimonde et al., 
2010) 
Rifampicin resistance 
Mycobacterium 
tuberculosis 
(Comas et al., 2012) 
Resistance integron 
Acinetobacter 
baumannii* 
(Zhu et al., 2014) 
Resistance prediction Escherichia coli (Tyson et al., 2015) 
Resistome identification Pseudomonas aeruginosa (Kos et al., 2015) 
Virulence gene 
identification 
  
Cobalamine biosynthesis 
and eut operon 
Morganella morganii* (Chen et al., 2012) 
Phosphilipase D family 
protein 
Klebsiella pneumoniae (Lery et al., 2014) 
Virulence prediction 
Methicillin-resistant 
Staphylococcus aureus 
(Laabei et al., 2014) 
A global transcriptional 
regulator of carbon 
catabolite repressor 
Enterococcus faecium 
(Somarajan et al., 
2014) 
Pathogenicity island 
prediction 
Helicobacter pylori (Ali et al., 2015) 
* hospital-acquired infections are included in the studies 
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The application of whole genome sequencing on microbiological studies has 
been continually reported as a routine use (Köser et al., 2012; Fricke & Rasko, 
2014), for example, diagnostic microbiology (Dunne, Westblade & Ford, 2012) 
and antibiotic resistance identification (Köser, Ellington & Peacock, 2014) 
(Table 1.2). This section aims to review the application of whole genome 
sequencing for microbiological studies, including, identification and gene 
profiling. 
 
In diagnostic microbiology, precise identification methods are important. 
However, growing bacteria from clinical sample is a bottleneck. Some bacteria 
need a long time to grow or are uncultivable. Moreover, conventional 
identification using biochemical reaction-based approach cannot clearly identify 
species that have similar phenotypes. To improve bacterial species identification, 
the sequencing of 16S rDNA gene has been used on the basis of the DNA 
sequence of 16S rDNA is conserved within species (Janda & Abbott, 2007). 
Together with the increasing size of DNA sequence database, molecular 
diagnosis using gene sequencing has become a powerful approach to identify 
bacterial species. In addition, DNA sequencing can be used to classify bacteria 
into strain level. Maiden et al. (1998) proposed multilocus sequence-based 
analysis to discriminate bacterial species in strain level. Multilocus gene analysis 
uses multiple housekeeping genes, which are usually conserved within a species, 
to group the isolates into „sequence types‟. Multiloci-based analyses are currently 
used in many bacterial analyses, for example, S. aureus (Enright et al., 2000; Feil 
et al., 2003) and Achromobacter spp. (Spilker, Vandamme & LiPuma, 2012). 
Furthermore, whole genome sequencing has become an obvious implementation 
to investigate the epidemiology of species, in particular during the outbreak. 
Epidemiology of the species can also be determined based on the phylogenetic 
relationship (Ypma, van Ballegooijen & Wallinga, 2013). For example, an 
outbreak of haemolytic uraemic syndrome-causing E. coli in Germany was 
determined using the whole genome sequencing and comparative genome 
analysis, revealing horizontal gene exchange as a driving factor of the outbreak 
(Rasko et al., 2011). Also, an outbreak of Klebsiella pneumoniae in neonatal 
intensive care unit was elucidated by the efficiency of whole genome sequencing 
(Haller et al., 2015).  
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The whole genome sequencing is also applied to detect genes associated with 
antibiotic resistance in bacteria. An observation by Gordon et al. (2014) 
demonstrated that genome inspection was able to determine a correlation 
between known resistance genes and less susceptible phenotypes with the 
sensitivity and the specificity of 97% and 95%, respectively. This provides 
genetic information of antibiotic resistance genes for drug of choice for empirical 
treatment. Previous studies have demonstrated the application of whole genome 
sequencing to identify antibiotic resistance genes, for instance, the identification 
of tetracycline-resistance genes in Bifidobacterium animalis (Gueimonde et al., 
2010).  Analyses using whole genome sequencing can address the dissemination 
of antibiotic resistance-associated moble genetic elements. This exemplifies by 
the identification of class 1 integron in A. baumannii using whole genome 
sequencing (Zhu et al., 2014). 
 
Apart from profiling antibiotic resistance genes, whole genome sequencing also 
has a potential to identify genetic determinants for the virulence of bacteria. For 
example, whole genome sequencing revealed genes encoding virulence-
associated factors such as type 3 secretion system components and fimbrial 
adhesion protein in a human opportunistic pathogen Morganella morganii (Chen 
et al., 2012). Also, whole genome sequencing, together with comparative 
genomic analysis, can predict virulence factors in pathogens, as exemplified by 
using a genome-wide association study for the prediction of virulence factors in 
MRSA (Laabei et al., 2014) 
 
1.4.3. The application of whole genome sequencing to emerging pathogens 
 
Emerging pathogenic bacteria often lack information important for clinical 
investigation. This information includes potential virulence factors and antibiotic 
resistance genes. The application of whole genome sequencing for species 
identification and gene identification can be used for the study of emerging 
pathogens 
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This transformative technology has been enhancing an ability to deal with public 
health‟s problem. The identification of Shiga toxin 2-carrying phage leading to 
the outbreak of E. coli in 2009 (Rasko et al., 2011) is an example of using whole 
genome sequencing to address the causing factor of the outbreak. In comparison 
with conventional microbiological study, whole genome sequencing does 
provide not only species identification but also genomic information of the 
pathogens. Researchers can retrieve a wealth of information, such as: species 
identity, virulence genes, antibiotic resistance genes, and genes associated with 
metabolic pathways, from the genome sequence. For example, a recent study 
addressed that the genome of Campylobacter ureolyticus, an emerging Gram-
negative pathogen that is found associated with Crohn‟s disease in children, were 
approximately 9-20% conserved between C. ureolyticus and other 
Campylobacter species (Bullman et al., 2013). Additionally, genomic analysis 
identified potential genes that are associated with the virulence of C. ureolyticus.  
Of 106 predicted virulence genes, 52 genes were predicted to be secretory 
proteins. It is believed that secretory proteins are the virulence factors in C. 
ureolyticus (Burgos-Portugal et al., 2012). Genome sequence of Mycobacterium 
abscessus from clinical isolates was another successful application of whole 
genome sequencing to unravel emerging pathogen‟s genome (Ripoll et al., 2009; 
Choo et al., 2014). In addition to causing severe soft tissue infection, the 
multidrug resistant characteristics of M. abscessus has become a significant 
challenge (Nessar et al., 2012). The genome sequence of M. abscessus revealed 
that phages were the driving components for the evolution of the species. 
Moreover, genome sequencing can be used to infer the pan-genome of M. 
abscessus was „opened‟ (Choo et al., 2014), referring to the possibility to receive 
external genes from the environment. With these examples of whole genome 
sequencing, this can be one of the approaches to the study of emerging pathogens. 
A combination of approaches, including whole genome sequencing, phenotypic 
test, susceptibility profile and virulence profile, is required for the establishment 
for linking genomic to biology. 
 
 
 
 
Chapter 1 
 23 
1.5. Achromobacter xylosoxidans as an emerging pathogen 
 
Achromobacter xylosoxidans was first described by (Yabuuchi & Oyama, 1971) 
as a Gram-negative bacteria presenting peritrichous pattern of flagella. 
Taxonomically, A. xylosoxidans is a member of the family Alcaligenaceae in the 
class β-proteobacteria. A. xylosoxidans has a close evolutionary relationship with 
Bordetella, which belong to the same family. When firstly described, A. 
xylosoxidans was only a member of the genus (Yabuuchi & Oyama, 1971). Until 
the present, the Genus is comprised of 19 species, including A. aegrifaciens, A. 
animicus, A. anxifer, A. arsenitoxydans, A. cycloclates, A. denitrificans, A. 
dolens, A. insolitus, A. insuavis, A. lysyl, A. marplatensis, A. mucicolens, A. 
piechaudii, A. pulmonis, A. ruhlandii, A. sediminum, A. spanius, A. spiritinus, 
and A. xylosoxidans. Nevertheless, A. xylosoxidans has the highest number of 
reports, clinically associated ones in particular, amongst the members of the 
Genus. 
 
A. xylosoxidans can be found in various environments including soil, hotspring, 
municipal waste (Zhang et al., 2007), and oil-polluted sea (Dave et al., 2013).  
However, the bacterium can be seen as clinical samples. The first report of 
clinical isolates of A. xylosoxidans was from the infection of the middle ear. The 
strain was isolated and characterised biochemically by Yabuuchi & Oyama 
(1971). Subsequent studies reported the collection of A. xylosoxidans from 
hospitalised patients and immune-compromised patients (Holmes, Snell & 
Lapage, 1977; Pien & Higa, 1978; Shigeta et al., 1978; Igra-Siegman, Chmel & 
Cobbs, 1980; Reverdy et al., 1984; Arroyo et al., 1987; Reina et al., 1988). A 
major challenge of A. xylosoxidans infection is the antibiotic resistance of the 
species. The first report of ear discharge isolates showed that they were resistant 
to penicillin, ampicillin, erythromycin, gentamycin, kanamycin, streptomycin 
and tetracycline (Yabuuchi & Oyama, 1971). Later, Bador et al. (2011, 2013) 
characterised intrinsic efflux pumps associated with antibiotic resistance. 
Moreover, a gene coding oxacillinase was identified as an intrinsic gene and used 
as an species identification test (Turton et al., 2011). The events of mobile 
genetic element in A. xylosoxidans have played a role in the acquisition of 
antibiotic resistance genes in the species, which worsened hospital-acquired 
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infections as the circulating pathogens can become drug-resistant strains (Shin et 
al., 2005; Sofianou et al., 2005; Yamamoto et al., 2012; Traglia et al., 2012). As 
a hospital-acquired infection-associated pathogen, several articles reported the 
outbreak of A. xylosoxidans in the hospital; for example, Reina et al. (1988) 
reported that contrast solution for computer tomography was contaminated by A. 
xylosoxidans. Tena et al. (2005) reported the persistent colonisation of A. 
xylosoxidans in intravascular catheter. Moreover, A. xylosoxidans has been 
considered an emerging pathogen in Cystic Fibrosis infection (Mahenthiralingam, 
2014). 
 
1.6. A. xylosoxidans as a Cystic Fibrosis pathogen 
 
Cystic Fibrosis (CF) is a disease caused by mutation of an ion channel called 
„Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)‟. The mutation 
of the channel leads to the inability to secrete Chloride ion, and then mucus in 
the lumen becomes thicker and difficult to be expelled (Davies & Rubin, 2007). 
The mutation of the channel affects wide range of organs, such as respiratory 
tract, sweat gland, liver, intestine, and pancreas. Multiple clinical manifestations, 
such as, male infertility, intestinal obstruction, diabetes mellitus and obstructive 
pulmonary disease, are shown (Cutting, 2014). CF lung infection is a hallmark of 
cause of death (O‟Sullivan & Freedman, 2009). The remained mucus in 
respiratory tract leads to serious clinical problems. The thickened mucus narrows 
the lumen of the tract, leading to airflow reduction during breathing. The 
unremoved mucus provides nourishing condition for bacterial colonisation P. 
aeruginosa has predominated CF infection; however, the prevalence of P. 
aeruginosa infection in CF decreased in the last decade (Lipuma, 2010). Other 
human pathogens, such as S. aureus and Burkholderia cepacia complex, also 
contribute to infesction in CF patients (Lipuma, 2010). Uncommon bacterial CF 
infection raises a challenge because less information is available.  
 
A. xylosoxidans is considered as an emerging pathogen in CF (Mahenthiralingam, 
2014). The prevalence of A. xylosoxidans infection ranges widely from 5% to 
30% of CF infections depending on individual CF centre (Raso et al., 2008; 
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Coburn et al., 2015). Transmission of A. xylosoxidans from environment to CF 
patients remains unclear. Nevertheless, person-to-person transmission has been 
reported from several CF centres (Raso et al., 2008; Magni et al., 2010; 
Amoureux et al., 2012; Hansen et al., 2013). The major impacts of A. 
xylosoxidans infections are the severity of infection and antibiotic resistance of 
the species. Many studies showed that A. xylosoxidans infection worsened lung 
function of patients (De Baets et al., 2007; Hansen et al., 2010). 
 
1.7. Complete genome sequence of the A. xylosoxidans genome 
 
Because next-generation sequencing technologies have rapidly improved over 
the last decade, they are faster, cheaper and more accessible (van Dijk et al., 
2014). Complete genome sequences reveal large amounts of interesting and 
important information about bacteria, such as metabolic pathways, resistance 
genes and virulence factors. The first complete genome of A. xylosoxidans strain 
A8 was published in 2011 (Strnad et al., 2011); however, MLST analysis shows 
that strain A8 is not placed in the A. xylosoxidans group (Spilker, Vandamme & 
LiPuma, 2012). The first complete genome of an A. xylosoxidans clinical isolate 
NH44784-1996 was composed of a total of 6,916,670 bp with 6,390 ORFs and 
67% of GC content (Jakobsen et al., 2013). The annotation revealed genes 
involved in anaerobic growth and biofilm formation. Moreover, as well as 
antibiotic-modifying enzymes, efflux transport systems were discovered in the 
genome and are expected to play an important role in major drug resistance 
mechanisms (Jakobsen et al., 2013; Bador et al., 2011, 2013). 
 
1.8. Aims and objectives 
 
At the beginning of this project, there was a need for effective and 
comprehensive analyses for the understanding of A. xylosoxidans. This work 
aims to compare methods for A. xylosoxidans identification and use comparative 
genome to analyse A. xylosoxidans. The comparative genomic study includes 
general genomic feature, antibiotic resistance, and virulence of the species. 
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1.8.1. The identification and strain typing of A. xylosoxidans (Chapter 3) 
 
Many identification methods indicate the differentiation of genus Achromobacter 
from other bacterial genus, including Burkholderia, Pseudomonas, and 
Bordetella. A wide range of procedures, from conventional biochemical 
approaches to molecular-based approaches, have been applied with an effort to 
indicate the species. The aim of this study was to compare the efficiency of 
multiple identifications on clinical isolates of A. xylosoxidans, and then, based on 
a current analysis, an appropriate algorithm for A. xylosoxidans identification 
was proposed. 
 
1.8.2. General feature of pan-genomic analysis of A. xylosoxidans 
(Chapter 4) 
 
The advances in whole genome sequencing technology allow researchers to 
discover the genetic component of bacterial genome. The aims of this study were 
to investigate the genomic characteristic and functional genome of A. 
xylosoxidans and to investigate the diversity of the clinical isolates of A. 
xylosoxidans obtained from the U.K. and Thailand. Twenty-five genomes of A. 
xylosoxidans isolates collected in this study were therefore sequenced using next-
generation sequencing. Genomic data was extracted to conduct comparative 
genomic analysis.  
 
1.8.3. Comparative analysis of antibiotic resistance in A. xylosoxidans 
(Chapter 5) 
 
Along with species identification, antibiotic resistance is another challenge that 
causes problems in clinical microbiology. This study aimed to extensive 
investigate genetic basis of antibiotic resistance in A. xylosoxidans. Class 
prediction analysis, along with antibiotic susceptibility profile, was applied to 
determine genes responsible for antibiotic resistance. Moreover, SMRT 
sequencing was used to investigate the presence of drug resistance-associated 
mobile genetic elements in the multidrug-resistant isolates. 
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1.8.4. The identification of virulence genes candidate in A. xylosoxidans 
(Chapter 6) 
 
Infection with A. xylosoxidans causes a broad range of severity in patients who 
have immune-compromised conditions. A study in animal model demonstrated 
detrimental outcome of A. xylosoxidans infection in immune deficient mouse. 
This study aimed to determine the virulence of A. xylosoxidans. A wax moth 
larvae Galleria mellonella infection model was used to measure the virulence of 
the isolates. The prediction of virulence determinants was performed via class-
predictive model to find the correlation between the presence of gene ortholgues 
and the virulence assessed by the infection model. 
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Chapter 2  
General methodology and isolate description 
 
2.1. Buffer for gel electrophoresis 
2.1.1. Tris-Acetate-EDTA buffer (TAE buffer) 
 
10X TAE buffer was prepared according to this following recipe 
 
1 L of 10X TAE buffer 
 
242g  Tris base   
57.1ml  Glacial Acetic Acid   
100ml  0.5M EDTA (pH8.0) 
 
All ingredients were dissolved and made up to 1L using deionised water. 
2.1.2. Tris-Borate-EDTA buffer (TBE buffer) 
 
10X TBE buffer was prepared according to this following recipe 
 
1 L of 10X TBE buffer 
 
108g  Tris base   
55g  Boric acid   
140ml   0.5M EDTA (pH8.0) 
 
All ingredients were dissolved and made up to 1L using deionised water. 
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2.2. Culture medium 
One of most widely used culture medium is Lysogeny broth (LB). The standard 
ingredients of LB are Tryptone, Yeast Extract, Sodium Chloride and distilled 
water (Gerhardt, 1994). LB provides nutrients for the maintaining non-fastidious 
bacteria in culture. Although Blood Agar were used to recover A. xylosoxidans 
from clinical samples (Yabuuchi & Oyama, 1971; Gómez-Cerezo et al., 2003; 
Tena et al., 2005; Gomila et al., 2014), haemolysis could not be detected in A. 
xylosoxidans (Otta et al., 2014). Nutrient Agar/broth was therefore an 
appropriate medium to grow and maintain A. xylosoxidans. Consequently, LB 
was selected as the standard culture medium in liquid and agar form for 
Achromobacter xylosoxidans culture.  
Recipe for 1L of LB (Gerhardt, 1994) 
10g Tryptone 
5g Yeast Extract 
10g Sodium Chloride 
15g Agar-agar (For agar only) 
All ingredients were measured and dissolved in 1L of distilled water. The 
mixture was autoclaved at 121°C for 15 minutes. 
2.3. Sample collection and culture 
 
In this study, comparative genomic analysis of A. xylosoxidans was conducted on 
bacteria from three different sources; reference strains, clinical isolates from the 
U.K. and clinical isolates from Bangkok. 
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2.3.1. Reference strains 
 
Six reference strains of bacteria in genus Achromobacter were purchased from 
Leibniz-Institut DSMZ, Germany and NCIMB, U.K. These strains were: 
 
a) Achromobacter xylosoxidans DSM 2402, an ear discharge isolate 
(Yabuuchi & Oyama, 1971) 
b) Achromobacter denitrificans DSM 30026, a soil isolate (Yabuuchi et al., 
1998) 
c) Achromobacter ruhlandii DSM 653, a soil isolate (Yabuuchi et al., 1998) 
d) Achromobacter piechaudii DSM 10342, a pharyngeal swab isolate 
(Yabuuchi et al., 1998) 
e) Achromobacter spanius DSM 23806, a human blood isolate (Coenye et al., 
2003) 
f) Achromobacter insolitus DSM 23807, a human wound isolate (Coenye et 
al., 2003) 
g) Achromobacter xylosoxidans NCIMB 11015, a soil isolate (Braker, 
Fesefeldt & Witzel, 1998) 
 
These reference strains of Achromobacter have been well identified and used in 
several studies. These isolates were cultured on LB from the freeze-dried stocks, 
and cloned before freezing at -80
o
C as glycerol stock aliquots.  
 
2.3.2. Bangkok strain collection 
 
Thai clinical isolates (Table 2.1) were collected from Ramathibodi hospital, a 
tertiary teaching hospital, in collaboration with Associate Professor Pitak 
Santanirand, Microbiology Unit, Department of Pathology, Faculty of Medicine, 
Ramathibodi hospital, Mahidol University. There were 14 isolates collecting 
between 2010 and 2012, see Table 2.1 for details. The collection of these 
samples was approved by the ethical review committee, Faculty of Medicine 
Ramathibodi Hospital, Mahidol University, Thailand (MURA 2009/1396/S8; ID 
03-52-93). After collection and identification, these strains were stored in Stuart 
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transfer medium and transferred to Institute of Infection and Global Health, 
University of Liverpool, Liverpool, U.K. 
 
Table 2.1: A list of Thai clinical isolates and the detail of collection 
 
Isolate 
code 
Site of isolation Type of specimen 
Date 
received 
R1 OPD (SURG) Sputum 31.3.2012 
R2 Ward (PED1) Gastrostomy 22.1.2012 
R3 ER Wound (Pus) 10.3.2012 
R4 ER Urine 2.4.2012 
R5 OPD (SURG) Sputum (tube) 31.3.2012 
R6 OPD (OBGYN) Urine 19.3.2012 
R7 ICU (SURG) Blood (Peripheral) 2.10.2011 
R8 ER Blood (Peripheral) 21.12.2010 
R9 Ward63 (SDMC) Sputum 12.4.2012 
R10 OPD (SURG) Wound (Pus) 27.2.2012 
R11 Ward (MED1) BAL 15.3.2012 
R12 OPD (SURG) Right Buttock 19.1.2012 
R13 ICU5 (SDMC) Sputum 14.4.2012 
R14 OPD (SURG) Sputum 21.1.2012 
 
OPD stands for out-patient clinic; ER for emergency room; ICU for intensive 
care unit; SURG for surgery unit; PED for paediatric unit; OBGYN for obstetric 
and gynaecology unit; MED for internal medicine unit; and SDMC for Somdej 
Bhradebaratana Medical Centre 
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2.3.3. British strain collection 
 
There were 17 isolates collected from multiple sites, mainly in Liverpool, 
between 2008 and 2012, see Table 2.2 for details. These clinical isolates will be 
called „Liverpool isolates‟ in this thesis. At the site of collection, they were 
identified using API20 NE kit before they were delivered to Institute of Infection 
and Global Health, University of Liverpool, Liverpool, U.K.  
 
Table 2.2: A list of Liverpool clinical isolates and the detail of collection 
Isolate 
code 
Location 
Specimen 
Type 
Date 
Received 
Clinical note 
L1 Liverpool Sputum 29.10.2011 COPD 
L2 Liverpool Blood culture 25.9.2010 Infected line 
L3 Liverpool Blood culture 29.7.2010 Catheterisation 
L4 Liverpool Blood culture 7.10.2010 Fever 
L5 Liverpool Blood culture 21.3.2009 Fever 
L6 Liverpool Blood culture 13.6.2008 Sepsis 
L7 London Eye discharge 25.7.2008 Eye infection 
L8 Liverpool Sputum 7.11.2011 COPD 
L9 Liverpool Blood culture 29.2.2012 CF 
L10 Liverpool Sputum 28.3.2012 Respiratory infection 
L11 Liverpool Sputum 28.3.2012 Bronchiectasis 
L12 Liverpool Node Tissue 18.4.2012 Lymphanenopathy 
L13 Liverpool No data 23.5.2012 NA 
L14 Liverpool Contact lens 23.5.2012 Keratitis 
L15 Liverpool Sputum 23.5.2012 Bronchiectasis 
L16 Liverpool Sputum 23.5.2012 COPD 
L17 Liverpool No data 20.5.2012 CF 
 
COPD stands for Chronic Obstructive Pulmonary Disease; CF for Cystic 
Fibrosis; NA for not applicable
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2.4. Culture and stock 
 
Stock cultures were made by plating a single colony of each Achromobacter 
isolate in LB agar and incubating the plates at 37°C overnight. A single colony of 
cultures was harvested from overnight incubation and re-suspended in 25% 
glycerol in LB. The 25% glycerol LB suspensions were stored at -80°C ready to 
use in this study. 
 
2.5. Growth of bacteria for experiments and genomic DNA 
 
Bacteria where plated directly from frozen stocks onto LB agar plates and 
incubated at 37°C overnight. A single colony from these overnight cultures was 
inoculated into liquid LB and shaken at 37°C overnight (18 h). Mid-logarithmic 
growth phase cultures were obtained by inoculating an overnight liquid culture to 
fresh LB, 1:1000 dilution and shaking for 6 h at 37°C until 0.5-0.6 OD600 was 
reached. These mid-log cultures where used for the majority of experiments, 
including DNA extraction. 
 
2.6. Genomic DNA purification and evaluation 
2.6.1. DNA purification 
 
The main objective of this project is to perform comparative genomic study of A. 
xylosoxidans from different sources, so the purification of genomic DNA from 
bacteria is the first step to disclosing the genetic information of A. xylosoxidans. 
There are a variety of DNA extraction methods used today, including 
phenol/chloroform, resin-based, and a membrane column methods. The 
phenol/chloroform preparation is widely used in molecular biology. However, 
both phenol and chloroform are corrosive chemicals, so handling with them 
should be done in a fume cupboard. According to health and safety, less harmful 
methods were used to purify DNA from bacteria in this project. Consequently, a 
resin-based purification was used for PCR reaction and a column-based 
purification was used for whole genome sequencing. 
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2.6.1.1. Single colony DNA extraction using 5% Chelex method 
 
A 5% working stock was made by adding 1 g of Chelex®-100 (Bio-Rad) was 
added to 20 ml of sterile molecular grade water. After vigorous mixing the 
mixture was aliquoted and stored at 4°C prior to use (maximum one month). A 
single colony of each A. xylosoxidans isolate was collected from LB plate and re-
suspended in a 5% Chelex® resin aliquot. After vortexing, samples were heated 
at 95 °C on a heat block for 5 min. The heated the mixture, was centrifuged at 
13,000 x g for 2 min. The DNA was collected by transferring the supernatant to a 
new sterile 1.5-μL microtube and stored at 4 °C overnight. 
 
2.6.1.2. Genomic DNA preparation using Membrane column-based 
preparation  
 
Genomic DNA preparation followed the “Gram-negative bacteria” protocol 
provided as part of the DNeasy Blood & Tissue kit (QIAGEN, U.K.). In brief, a 
one ml mid-log culture of A. xylosoxidans was pelleted by centrifuging at 5,000 x 
g for 10 min. The supernatant was discarded and 180 μL of buffer ATL was 
added to resuspend cell pellet, followed by 20 μL of Proteinase K and mixed by 
vortexing. After incubation for 1 h at 56°C the clear suspension was mixed with 
400 μL of pre-mixed buffer AL buffer, and transferred to a spin column provided 
and centrifuged for 1 min at 6,000 x g. Then washed with the AW1 and AW2 
according to the manufactories instructions. Finally, DNA was eluted with 100 
μL of sterile molecular grade water, incubated for 1 min prior to centrifugation at 
6,000 x g for 1 min. 
 
2.6.2. Quality control of DNA extraction 
 
DNA for molecular biology and genome sequencing needs to be quality 
controlled for purity, concentration and molecular weight.  
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2.6.2.1. DNA Purity  
 
The DNA extracted from an organism can be contaminated with a number of 
compounds, including RNA and protein. To validate the purity of DNA 
extractions, the spectrophotometric property of DNA, RNA and protein was 
measured to determine the contamination. Due to physical property of the 
substances, nucleic acids have a maximum absorbance at 260 nm and proteins 
have a maximum absorbance at 280 nm. Therefore, the ratio of absorbance at 
260 nm to absorbance at 280 nm is applied to validate DNA preparation. 
Normally, an acceptable ratio is 1.8-2.0, because this ratio is equivalent to less 
than 60 % protein in the preparation. In this study, light absorbance of DNA 
extracts were assessed using a Nanodrop™ spectrophotometer. Molecular grade 
water was used a blank to set absorbance at 260/280 nm to zero. The optical 
density of DNA extract was measured for 3 μL of the extract. 
 
2.6.2.2. Quantification of DNA concentration 
 
In this study, we used the commercial fluorescent dye assay, Qubit® dsDNA BR 
kit (Life Technology), which covers a range from 2-1,000 ng of DNA following 
the manufactures instructions. 
 
2.7. Whole Genome sequencing 
 
Sequencing of genomic DNA of Achormobacter isolates was performed using 
next-generation sequencing machines at the Centre for Genomic Research (CGR), 
University of Liverpool. All Achromobacter isolates were sequenced on the 
Illumina HiSeq 2000 platform, and three A. xylosoxidans strains, NCIMB 11015, 
R4 and R8, were also sequenced using the single-molecule, real-time PacBio 
RSII platform. All the library preparation and sequencing was performed by the 
CGR.  
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Chapter 3  
Comparison of methods for the identification and typing 
of Achromobacter xylosoxidans 
 
3.1. Introduction 
 
Methods for reliable species identification and strain typing are important for 
microbiological study, especially, clinical microbiology. Precise species 
identification of pathogens allows for the establishment of appropriate treatments 
and for the epidemiological study of the pathogens. However, the differentiation 
of bacterial species into strain level, called „strain typing‟, improves the 
understanding of strains responsible for the outbreaks (Bosch et al., 2010; Harris 
et al., 2013). The introductory part of this chapter will present currently available 
methods for species identification and strain typing. 
 
3.1.1. Identification of bacteria 
 
The identification of bacteria is the keystone that shapes the understanding of 
microbiology. The identification methods used in the clinical and 
epidemiological study should be accurate, as to enable the suitable treatment and 
infection prevention strategies. Methods for bacterial identification have been 
developed over the time. Conventional culture and phenotype-based methods of 
determination are still widely used as screening tests even though molecular 
methods, such as PCR amplification and gene sequencing (for example of 16S 
rDNA), have shown better sensitivity and accuracy in bacterial identification 
over culture-based methods and biochemical reaction-based methods. For 
example, MacConkey agar has been used as selective agar for non-fastigious 
Gram-negative bacteria. The presence of crystal violet and bile salts in 
MacConkey agar inhibit the growth of most of Gram-positive bacteria and 
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fastidious Gram-negative bacteria (Adams, 1967). However, outer membrane of 
non-fastidious Gram-negative bacteria does not allow crystal violet and bile salts 
to get into the cell. Therefore, only non-fastidious Gram-negative bacteria can 
grow on MacConkey agar (MacConkey, 1900). Moreover, the agar has been 
used as agar for lactose fermentating bacteria differentiation due to the presence 
of lactose and pH indicator in the agar.  
 
Biochemical analysis of bacteria is often able to identify the unique biochemical 
phenotypes associated with species of bacteria. However, such approaches are 
often limited in their ability to discriminate between strains of the same species. 
Therefore, bacterial identification has been improved by using molecular 
approaches: DNA-based methods and proteome-based methods.  
 
3.1.1.1. Bacterial identification using the 16S rDNA gene 
 
Since the advent of molecular techniques such as PCR amplification, molecular-
based identification has been developed and widely introduced as an important 
tool to characterise bacterial species. In particular, the DNA sequence of 16S 
rDNA genes has been used extensively for bacterial identification and 
phylogenetic analyses to study relationships between bacterial species (Weisburg 
et al., 1991). 
 
Compared to conventional phenotypic tests, which can often vary upon repetition 
and might lack sensitivity and sensitivity, 16S rDNA sequencing is more reliable. 
16S rDNA sequencing successfully identifies most common human pathogens 
which cannot be identified only by using conventional biochemistry (Woo et al., 
2001; Lau et al., 2002; Woo et al., 2008). In addition, PCR amplification coupled 
with 16S rDNA sequencing is able to find uncultivable pathogens of many 
important diseases, such as uncultivable Tropheryma whippeli, a causative 
pathogen of Whipple‟s disease (Relman et al., 1992).  
 
Some human infectious diseases are caused by emerging pathogens. The 
universal approach of 16S rDNA sequencing allows researchers not only to 
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diagnose causative known pathogens from clinical samples, but also to identify 
new species. The discovery of Ehrlichia chaffeensis, a causative pathogen in 
human ehrlichiosis exemplifies the application of 16S rDNA sequencing to 
identify emerging pathogens and discover new bacterial species because it is 
difficult to cultivate the pathogen from clinical samples (Anderson et al., 1991). 
 
3.1.1.2. Bacterial identification using MALDI-TOF mass spectrometry 
 
Matrix-Assisted Laser Desorption Ionisation Time-Of-Flight mass spectrometry 
(MALDI-TOF MS) has been successfully proposed as an alternative bacterial 
identification method. This technique applies the principle of mass spectrometry 
whereby the mass-to-charge ratio (m/z) of proteins is measured, and then used to 
generate spectral fingerprints, which vary between the bacteria (Fenselau & 
Demirev, 1975). Before the analysis, the sample is pre-mixed with a matrix that 
helps the sample absorbing the light (Croxatto, Prod‟hom & Greub, 2012). The 
sample can be either intact bacteria or bacterial protein extraction. The species 
identification is then performed by comparing those fingerprints to the database 
under certain growth conditions and sample preparation techniques. It is 
noteworthy to recognise that the spectral fingerprint can vary for the same isolate 
under different growing condition because different spectrum profiles can be 
affected by changes in growth conditions and growth medium (Carbonnelle et al., 
2011). Therefore, it is important to follow manufacturer‟s protocol, especially, 
type of culture media and incubation time. MALDI-TOF MS should be used with 
caution and as part of the evidence used for sample identification.    
 
MALDI-TOF MS is becoming a routine identification method in clinical 
microbiology and a recommended method for the identification of unusual 
organisms (Carbonnelle et al., 2011).  In addition, MALDI-TOF MS has been 
reported to improve the resolution and the quality of bacterial identification from 
clinical isolates (Fernández-Olmos et al., 2012). In comparison with other 
identification methods, mass spectrometry is claimed to be one of the most 
accurate and fast methods to diagnose the cause of infection (Schröttner et al., 
2014; Anderson et al., 2014). It has been reported that MALDI-TOF MS showed 
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a significant increase in the correctness of species identification in Cystic 
Fibrosis infection pathogens (Degand et al., 2008). In particular, the 
identification of non-fermenting Gram-negative bacteria from Cystic Fibrosis 
patients was improved. Nevertheless, MALDI-TOF MS cannot clearly identify 
uncommon or emerging pathogens because the limitation of the size of the 
spectral fingerprint database (Croxatto, Prod‟hom & Greub, 2012; AbdulWahab 
et al., 2015).  
 
MALDI-TOF MS technology has provided clinicians and researchers with a 
number of advantages compared to biochemical identification methods. In terms 
of cost-effectiveness, using MALDI-TOF MS significantly reduced cost and 
waste disposal, compared to using biochemical identification (Gaillot et al., 
2011). Moreover, using MALDI-TOF MS decreased time for identification, 
compared to standard biochemistry (Tan et al., 2012). Taken together, these 
studies suggest that MALDI-TOF is a better choice than biochemical 
identification, especially in the hospital setting. 
 
3.1.2. Bacterial strain typing 
 
Phenotypic and genotypic variations between bacteria can explain why bacteria 
with the same species behave differently. To define bacteria beyond the species 
level, especially for epidemiological benefit, strain typing is required. In the 
public health setting, bacterial strain typing can help clinicians to recognise 
particularly virulent strain types or strains that might be more difficult to counter; 
for example, E. faecium clonal complex 17 is associated with vancomycin 
resistance (Willems et al., 2005). Additionally, strain type information provides 
useful data when an outbreak happens (Mora et al., 2011), with the potential to 
unequivocally identify patient-to-patient spread and identify potential sources. 
 
Many bacterial typing systems are based on molecular or genomic characteristics 
of the bacteria. There are 2 main categories of DNA-based methods for 
discrimination at the sub-species level: DNA fingerprinting and DNA sequencing. 
Traditional typing using fingerprinting, exploits variations in the relative 
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positions of particular sequences within the bacterial chromosome.  For example, 
restriction enzyme digestion identifies variations in restriction sites and DNA 
amplification using arbitrary primers identifies variations in the relative positions 
of the sequences that the primers bind to.  
 
3.1.2.1. Bacterial typing using DNA fingerprint 
 
The most well-known restriction enzyme-based technique is pulsed field gel 
electrophoresis (PFGE), which involves the use of a rare-cutting restriction 
enzyme with subsequent band separation using a special electrophoretic 
technique (pulsed-field) to enable separation of large bands. The selection of 
restriction enzyme is the most essential step for PFGE (Goering, 2010). PFGE 
has high resolution and has been used for strain typing in many clinically 
important pathogens, such as Salmonella (Zou et al., 2013), S. aureus (Bosch et 
al., 2010), and P. aeruginosa (Fothergill et al., 2010). Although, PFGE generates 
the power of strain discrimination and provides epidemiological information of 
the species, PFGE is difficult to compare between laboratories and is time-
consuming. 
 
Similar to the restriction enzyme-based techniques, fingerprinting using DNA 
amplification is on the basis of the variation of genomic DNA sequences 
between strains. Instead of using restriction enzymes, amplicons are generated by 
selected PCR primers which are short and therefore bind in multiple places.  If 
two primers bind in the correct orientation in close enough proximity then an 
amplicon will be produced.  The amplicons that occur are visualised on an 
agarose gel as a DNA fingerprint.  Because the relative positions of primer-
binding sites differ between strains, variations will occur in the banding patterns 
obtained. Random amplification of polymorphic DNA (RAPD) is an example of 
the DNA amplification–based methods. The term „random amplification of 
polymorphic DNA‟ describes the random PCR products generated by short 
single oligonucleotide primers (< 10 bp) (Welsh & McClelland, 1990). In 
comparison to PFGE, RAPD does not require special electrophoresis; however, 
the resolution of RAPD is lower than that of PFGE (Kaur et al., 2009). The 
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choice of PCR primers is an important factor for typing using RAPD. Similar to 
PFGE, the limitation of this technique is its low reproducibility between 
laboratories because variations occur readily if there are slight differences in 
protocols, such as types of buffer, primers and running time, or the thermal 
cycler used (Sabat et al., 2013). Therefore, these fingerprint-based typing 
techniques can be used for a particular investigation. The standardisation and 
inter-laboratory reproducibility of fingerprint-based techniques is still necessary. 
 
3.1.2.2. Bacterial typing using DNA sequences 
 
DNA sequencing technologies have been developed and used by a large number 
of researchers. This typing is based on the similarity of DNA sequences and, 
consequently, the phylogenetic relationship of the strains. Typing using DNA 
sequence is considered more accurate than fingerprint-based methods because 
the sequence-based methods are using the comparison of DNA sequences, rather 
than DNA fragments or PCR amplicons (Li, Raoult & Fournier, 2009). The most 
commonly used DNA sequence-based typing method in genomic era is 
multilocus sequence typing (MLST) (Maiden et al., 1998). This technique uses 
the DNA sequences of multiple housekeeping genes (usually seven genes) to 
generate a typing scheme. For each gene, each new sequence is given a defined 
allelic number. The relationship and the strain type are assigned by the 
combination of gene alleles. Since gene sequences can be stored in digital format, 
Jolley and his colleagues have developed an MLST database, which is available 
at PubMLST site (http://pubmlst.org). Consequently, this database establishes the 
standardisatio of MLST. 
 
3.1.3. Identification and strain typing in A. xylosoxidans 
 
One of the problems associated with emerging human pathogens is that often 
there is a lack of information about antibiotic resistance, virulence genes and 
diagnostic markers. As an emerging pathogen causing various types of infections 
in patients, identification methods for A. xylosoxidans are limited. Since the first 
report about A. xylosoxidans isolates from clinical samples, conventional 
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biochemical methods have been the standard way to identify A. xylosoxidans 
(Yabuuchi & Oyama, 1971). Liu et al. (2002) introduced the use of partial 16S 
rDNA sequence-targeted PCR assays to identify A. xylosoxidans. However, this 
approach is not specific to A. xylosoxidans and positive PCR results can occur in 
the closely related species A. piechaudii, A. ruhlandii and A. denitrificans. More 
recently, the intrinsic BlaOXA-114 gene has been targeted as an alternative method 
for A. xylosoxidans identification. However, positive results were also present in 
A. ruhlandii (Turton et al., 2011). MALDI-TOF MS has shown the improvement 
of identification of A. xylosoxidans (Degand et al., 2008; Fernández-Olmos et al., 
2012), especially at the species level. Moreover, MALDI-TOF MS has 
demonstrated the ability to discriminate between A. xylosoxidans and other 
Achromobacter species (Gomila et al., 2014). 
 
Reliable typing methods for clinical isolates of A. xylosoxidans are required for 
epidemiological studies, in particular to monitor transmission of strains. Two of 
the most commonly used fingerprint-based typing strategies, PFGE and RAPD, 
have been applied to Achromobacter. Both PFGE and RAPD have been used to 
monitor the epidemiology of A. xylosoxidans (Amoureux et al., 2012, 2013; Kaur 
et al., 2009; Magni et al., 2010; Krzewinski et al., 2001). Typing using RAPD 
with primer 270 showed an association between RAPD profile of A. 
xylosoxidans and the severity of lung infection (decreased % FEV1) by A. 
xylosoxidans (Magni et al., 2010; Trancassini et al., 2014). The association 
between PFGE typing and severity of A. xylosoxidans infection has not been 
reported. DNA sequence-based typing has, recently, been introduced as a more 
precise and reliable typing method for Achromobacter. Spilker, Vandamme & 
LiPuma (2012) applied MLST to generate strain typing for the genus 
Achromobacter. The genes used in the Achromobacter MLST analysis are nusA, 
rpoB, eno, gltB, lepA, nuoL and nrdA. Apart from typing the strain, MLST can 
be used to identify new species; for example, A. xylosoxidans AXX-A was re-
named A. insuavis, based on MLST analysis (Spilker, Vandamme & LiPuma, 
2012; Vandamme et al., 2013) 
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3.1.4. Aims and objectives 
 
There are increasing numbers of clinical isolates being identified as members of 
the genus Achromobacter, with A. xylosoxidans being the most abundant species 
detected. In addition, A. xylosoxidans causes more serious infection than the 
other Achromobacter species cause. However, the currently available 
identification procedures remain problematic for the identification of members of 
Achromobacter. Therefore, highly sensitive and specific methods for the 
identification of A. xylosoxidans are essential in order to ensure that clinicians 
choose the correct treatment options. 
 
The aim of this study is to evaluate bacterial identification methods to find the 
most accurate and robust way to detect A. xylosoxidans amongst clinical isolates. 
A wide range of identification procedures will be compared: the determination of 
bacterial phenotype, 16S rDNA gene sequencing, and MALDI-TOF MS 
identification. Moreover, strain typing using RAPD-PCR and MLST are 
performed to study the relationships amongst the strains. 
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3.2. Material and methods 
 
The cultures of Achromobacter were made by directly plating stock culture on 
LB agar and incubating at 37°C overnight. Plates were labelled with the code of 
isolates as described in section 2.3.  
3.2.1. Biochemical property-based identification (Conventional method) 
 
In collaboration with Ramathibodi Hospital in Bangkok, Thailand, all of the Thai 
clinical isolates were identified using traditional microbiological procedure at 
Ramathibodi Hospital, by courtesy of Dr Pitak Santaniand. For clinical isolates 
from Liverpool, all of them were previously identified using API20 NE kit prior 
to this study. To standardise the identification of the isolates, all British isolates 
was subjected to conventional identification. 
 
Figure 3.1: The identification algorithm for A. xylosoxidans (adapted from 
Manual of Clinical Microbiology (Murray et al., 2007) 
 
The identification of A. xylosoxidans was carried out as shown in Figure 3.1 with 
further biochemical analysis described in Table 3.1. All isolates were cultured on 
MacConkey agar 
Pink colony ? 
Yes No 
Oxidase 
Negative Positive 
Indole 
Negative Positive 
Glucose fermentation 
Negative Positive 
Motility 
Yes No 
Follow Table 3.1 
Not A. xylosoxidans
Not A. xylosoxidans
Not A. xylosoxidans
Not A. xylosoxidans
Not A. xylosoxidans
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MacConkey agar to investigate whether they were Gram-negative bacteria as 
well as to determine if they were lactose fermenters. According to Yabuuchi 
(Yabuuchi & Oyama, 1971; Yabuuchi & Yano, 1981; Yabuuchi et al., 1998), A. 
xylosoxidans is a Gram-negative, motile, oxidase-positive, indole-negative, non 
lactose fermenting, glucose-fermenting, rod-shape bacterium with peritrichous 
flagellation. 
 
Table 3.1: A summary of expected phenotypes of A. xylosoxidans based on 
biochemical properties. This table is a summary of table in Manual of Clinical 
Microbiology (Murray et al., 2007). 
 
Biochemical reaction 
A. xylosoxidans 
(percent positive) 
Indole production* 0 
Motility* 100 
Sugar fermentation  
Lactose 0 
Sucrose 0 
Glucose 78 
Xylose 99 
Mannitol 0 
Maltose 0 
10% Glucose 100 
Simmons‟ Citrate 95 
Christensen's Urea 0 
Nitrate reduction 100 
Gas production from Nitrate 60 
Nitrite reduction
+ 
0 
Triple Sugar Iron (TSI) medium  
TSI slant, acid 0 
TSI buttom, acid 0 
TSI buttom, H2S 0 
Protein / Amino acid utilization  
Gelatin hydrolysis 0 
Aesculin hydrolysis 0 
Lysine decarboxylation 0 
Ornithine decarboxylation* 0 
 
* Using Motility-Indole-Ornithine medium 
+
 Nitrite reduction is performed in Nitrate reduction-negative and Gas production 
from Nitrate-negative isolates only 
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3.2.2. 16S rDNA sequencing 
 
The diversity of the 16S rDNA gene was determined by species-specific PCR 
amplification 16S rDNA, using the primers shown in Table 3.2. 
 
Table 3.2: 16S rDNA – based PCR primers used in this project (Liu et al., 
2002). AX-F1 and AX-B1 are specific to Achromobacter, whereas UFPL and 
URPL are universal primers for Kingdom Bacteria 
 
Primer Sequence (5‟  3‟) 
Product size 
(bp) 
AX-F1 GCAGGAAAGAAACGTCGCGGGT 
163 
AX-B1 ATTTCACATCTTTCTTTCCG 
   
UFPL AGTTTGATCCTGGCTCAG 
1,490 
URPL GGTTACCTTGTTACGACTT 
 
The PCR amplification was conducted in a total volume of 25 μL, containing 50 
ng of genomic DNA template, 2.5 pmoles of primers, 1.25 mmol of MgCl2, and 
12.5 μL of 2X Biomix Red (Bioline, U.K.). Amplification was performed using a 
Veriti thermal cycler (Life Technology, USA) with the following conditions: 
94°C for 1 min, followed by 35 cycles of 94°C for 1 min, 56°C for 45 s and 72°C 
for 1 min. Then, the mixture was heated to 72°C for 10 min in the final extension 
step. PCR products were visualised using 1% (w/v) agarose gel electrophoresis 
in TAE buffer (recipe described in section 2.1.1) at 100V for 45 min.  
 
Amplicons generated using the UFPL and URPL primers were isolated using the 
ISOLATE PCR & Gel kit (Bioline, U.K.) and quantified by Qubit (Invitrogen, 
U.K.). Finally, the sequencing of PCR products was executed using Sanger 
sequencing (GATC Biotech, Germany). After obtaining the partial sequence of 
the 16S rDNA gene, the chromatograms of the sequence were manually verified 
via Geneious version 6.1.7 (Biomatters Ltd, New Zealand). After editing the 
sequences, nucleotide sequence alignments were processed using the MUSCLE 
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algorithm in the Geneious version 6.1.7 (Biomatters Ltd, New Zealand). A 
phylogenetic tree was then constructed by maximum likelihood method using 
PhyML (Guindon, 2010) with 1,000 bootstrap replications. The tree was 
visualised using Figtree version 1.4.2 (http://tree.bio.ed.ac.uk/software/figtree). 
The partial sequences of 16S rDNA gene were used to search the database using 
BLAST  (http://blast.ncbi.nlm.nih.gov). The option „16S ribosomal RNA 
sequences (Bacteria and Archeae)‟ and „megablast‟ were selected for alignment 
database and for programme selection, respectively. 
 
3.2.3. Matrix- assisted Laser Desorption / Ionisation – Time – of –Flight 
Mass spectrophotometry (MALDI-TOF MS) 
 
A protein-based method to identify bacterial species was applied using MALDI-
TOF mass spectrometry on a MALDI-TOF Biotyper (Broker Daltonic, 
Germany). A single colony was suspended in 200 μL of molecular grade water. 
Then 900 μL of absolute ethanol was added into the mixture and the mixture was 
centrifuged at 13,000 x g for 2 min. After supernatant removal, the mixture was 
centrifuged at 13,000 x g for 2 min. The residual ethanol was removed from the 
tube and the sample was set to air-dry. The pellet was mixed with 40 μL of 70% 
(v/v) formic acid. After leaving at room temperature for 2 minutes, 40 μL of 
absolute acetonitrile was added to the mixture, and then the mixture was 
centrifuged at 13,000 x g for 2 min. One microlitre of the supernatant was 
transferred to a steel plate and the sample was allowed to air-dry. Finally, 1 μL of 
α-Cyano-4-hydroxycinnamic acid matrix was overlaid on the air-dried sample, 
and the steel plate was inserted into the MALDI-TOF to analyse the sample. The 
analysis was conducted using built-in Biotyper software by comparing obtained 
spectra with a reference database provived. Species identification was achieved 
using an identification score ≥ 2.00. 
 
3.2.4. Random amplification of polymorphic DNA (RAPD) PCR 
 
Bacterial DNA was prepared by as previously described in section 2.6.1.1. and 
the concentration of DNA was adjusted to 40 ng/μL. 
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In this study, primer 270 (Mahenthiralingam et al., 1996; Kaur et al., 2009) was 
used to reveal discriminatory variation between isolates. Primer 270 is a 10-mer 
long DNA sequence: TGCGCGCGGG. To perform RAPD – PCR, the mixture 
was prepared in total volume of 25 μL, containing 40 ng of gDNA template, 7.5 
pmol of primer 270 (Eurofin MWG), 1.25 μmol of MgCl2 (Promega, USA), 0.5 
μL of mixed dNTP (Promega, USA), 0.25 μL of GoTaq® DNA Polymerase 
(Promega, USA) and 2.5 μL of 10X Green GoTaq® flexi buffer (Promega, USA). 
PCR amplification was performed using Mastercycler® Thermal cycler 
(Eppendorf) using the following protocol, which was obtained from Kaur et al. 
(2009): 94°C for 15 minutes, then 4 cycles of 94°C for 5 minutes, 36°C for 5 
minutes and 72°C for 5 minutes, followed by 30 cycles of 94°C for 1 minute, 
36°C for 1 minute and 72°C for 1 minute, and 72°C for 10 minutes for the last 
step. The products were analysed using 1.5% (w/v) agarose gel electrophoresis in 
0.5X TBE buffer using 95 Volts for 2 hours. Hyperladder I (Bioline) molecular 
weight marker was included on the gel. Finally, the DNA fingerprint from RAPD 
was analysed using Gelcompare II software (Applied Maths, Belgium). 
3.2.5. Multi-locus sequence type (MLST) 
 
Sequence typing of A. xylosoxidans was performed based on the standard seven 
housekeeping genes; eno, gltB, lepA, nrdA, nuoL, nusA, and rpoB (Spilker, 
Vandamme & LiPuma, 2012). The gene sequences of isolates were obtained 
from whole genome sequencing information (Chapter 4) and the gene sequences 
of other Achromobacter were obtained from the Achromobacter MLST database 
(http://pubmlst.org/achromobacter). After concatenating gene sequences, 
multiple sequence alignment was performed using Geneious version 6.1.7 
(Biomatters Ltd, New Zealand) with MUSCLE and a maximum-likelihood 
phylogenetic tree was built on the alignment with 1,000 bootstrap replications. 
The analysis for population structure of Achromobacter isolates in this study was 
performed using eBURST algorithm (Feil et al., 2004) implemented in 
goeBURST version1.2.1 (Francisco et al., 2009). 
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3.3. Results 
 
In this study, seven reference strains (described in section 2.3.1) have been used 
as species control to evaluate identification methods.  
3.3.1. General phenotypic determination by conventional biochemical 
reactions 
 
Phenotypic tests were carried out on seven reference strains (representing six 
different species), 17 clinical isolates from Liverpool and 14 clinical isolates 
from Thailand. According to Figure 3.1, all Achromobacter species are motile 
non-lactose fermenting bacteria. This was confirmed for all of the isolates in this 
study. With respect to saccharolytic ability, the type strains of A. xylosoxidans, 
NCIMB 11015 and DSM 2402, could use only glucose and xylose as 
carbohydrate carbon source, whereas non-xylosoxidans type strains could not use 
any sugar tested as a carbon source (Table 3.3). All clinical isolates, except L3, 
L4, L7, L12 and L13, could ferment glucose and xylose. All strains could grow 
on Simmons‟ citrate medium. A. denitrificans, A. pichaudii, A. spanius, A. 
insolitus, except L3, L4, L7, L12 and L13 gave positive results on 10% (w/v) 
glucose medium. 
 
For Nitrogen utilising properties, most of clinical isolates including NCIMB 
11015 and DSM 2402 could convert Nitrate into Nitrite and convert Nitrite into 
Nitrogen gas, which is detected by gas in a Durham tube (Table 3.3). Non-
xylosoxidans type strains, L3, L4, L7 and L12 only converted Nitrate into Nitrite, 
which is detected by the appearance of red solution when alpha-naphthylamine 
and sulfanilic acid were added. The media of L13, L14 and L16 remained clear 
after the addition of alpha-naphthylamine and sulfanilic acid. However, with the 
addition of zinc powder, the solution with L13 became red, which means nitrate 
reduction is absence. The negative results of TSI agar and urea test indicated that 
all the isolates were aerobic bacteria with no expression of urease activity. The 
strains also showed inability to use Gelatin, Aesculin, Lysine and Ornithine as a 
carbon source (Table 3.3). 
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Considering the result of species identification, the phenotypic test assigned A. 
xylosoxidans to NCIMB 11015, DSM 2402, all Thai isolates and 12 British 
isolates. Some type strains were misidentified; A. insolitus and A. spanius were 
assigned A. denitrificans, and A. piechaudii and A. ruhlandii were assigned 
Achromobacter sp. (Table 3.3). Clinical isolates L3, L4, L7 and L12 were 
assigned A. denitrificans, and isolate L13 was assigned Advenella incenata, 
which is a relative of Achromobacter sp (Coenye et al., 2005).  
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Table 3.3:  Biochemical characteristic test on clinical Achromobacter isolates and Achromobacter type strains 
Chemical tested NCIMB 11015 DSM 2402 A. denitrificans A. ruhlandii A. piechaudii A. spanius A. insolitus 
Motility + + + + + + + 
Sugar fermentation        
Lactose - - - - - - - 
Sucrose - - - - - - - 
Glucose + + - + - - - 
Xylose + + - + - - - 
Mannitol - - - - - - - 
Maltose - - - - - - - 
10% glucose + + - + - - - 
Simmons' Citrate + + + + + + + 
Christensen's urea - - - - - - - 
Nitrate reduction +
*
 +
*
 +
$
 +
$
 +
$
 +
$
 +
$
 
Triple Sugar Iron (TSI)        
TSI slant, acid - - - - - - - 
TSI buttom, acid - - - - - - - 
TSI buttom, H2S - - - - - - - 
Protein utilisation        
Gelatin hydrolysis - - - - - - - 
Aesculin hydrolysis - - - - - - - 
Lysine decarboxylase - - - - - - - 
Ornithine decarboxylase - - - - - - - 
Result A. xylosoxidans A. xylosoxidans A. denitrificans Achromobacter sp. Achromobacter sp. A. denitrificans A. denitrificans 
$
 Positive when alpha-naphthylamine and sulfanilic acid added; 
*
 Nitrogen gas production from Nitrate reduction; 
#
 media remain clear when zinc powder added 
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Table 3.3:  Biochemical characteristic test on clinical Achromobacter isolates and Achromobacter type strains (Continued) 
Chemical tested L1 L2 L3 L4 L5 L6 L7 L8 L9 L10 L11 L12 L13 L14 L15 L16 L17 
Motility + + + + + + + + + + + + + + + + + 
Sugar fermentation                  
Lactose - - - - - - - - - - - - - - - - - 
Sucrose - - - - - - - - - - - - - - - - - 
Glucose + + - - + + - + + + + - - + + + + 
Xylose + + - - + + - + + + + - - + + + + 
Mannitol - - - - - - - - - - - - - - - - - 
Maltose - - - - - - - - - - - - - - - - - 
10% glucose + + - - + + - + + + + - - + + + + 
Simmons' Citrate + + + + + + + + + + + + + + + + + 
Christensen's urea - - - - - - - - - - - - - - - - - 
Nitrate reduction +
*
 +
*
 +
$ 
+
$
 +
*
 +
*
 +
$
 +
*
 +
*
 +
*
 +
*
 +
$
 - # +
*
 # +
*
 
Triple Sugar Iron (TSI)                  
TSI slant, acid - - - - - - - - - - - - - - - - - 
TSI buttom, acid - - - - - - - - - - - - - - - - - 
TSI buttom, H2S - - - - - - - - - - - - - - - - - 
Protein utilisation                  
Gelatin hydrolysis - - - - - - - - - - - - - - - - - 
Aesculin hydrolysis - - - - - - - - - - - - - - - - - 
Lysine decarboxylase - - - - - - - - - - - - - - - - - 
Ornithine decarboxylase  - - - - - - - - - - - - - - - - - 
Result AX AX AD AD AX AX AD AX AX AX AX AD AC AX AX AX AX 
$
 Positive when alpha-naphthylamine and sulfanilic acid added; 
*
 Nitrogen gas production from Nitrate reduction; 
#
 media remain clear when zinc powder is added 
AX stands for A. xylosoxidans; AD for A. denitrificans; AC for Advenella incenata; and L1-L17 for British isolates 1-17 
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Table 3.3:  Biochemical characteristic test on clinical Achromobacter isolates and Achromobacter type strains (Continued) 
Chemical tested R1 R2 R3 R4 R5 R6 R7 R8 R9 R10 R11 R12 R13 R14 
Motility + + + + + + + + + + + + + + 
Sugar fermentation               
Lactose - - - - - - - - - - - - - - 
Sucrose - - - - - - - - - - - - - - 
Glucose + + + + + + + + + + + + + + 
Xylose + + + + + + + + + + + + + + 
Mannitol - - - - - - - - - - - - - - 
Maltose - - - - - - - - - - - - - - 
10% glucose + + + + + + + + + + + + + + 
Simmons' Citrate + + + + + + + + + + + + + + 
Christensen's urea - - - - - - - - - - - - - - 
Nitrate reduction +
*
 +
*
 +
*
 +
*
 +
*
 +
*
 +
*
 +
*
 +
*
 +
*
 +
*
 +
*
 +
*
 +
*
 
Triple Sugar Iron (TSI)               
TSI slant, acid - - - - - - - - - - - - - - 
TSI buttom, acid - - - - - - - - - - - - - - 
TSI buttom, H2S - - - - - - - - - - - - - - 
Protein utilisation               
Gelatin hydrolysis - - - - - - - - - - - - - - 
Aesculin hydrolysis - - - - - - - - - - - - - - 
Lysine decarboxylase - - - - - - - - - - - - - - 
Ornithine decarboxylase  - - - - - - - - - - - - - - 
Result AX AX AX AX AX AX AX AX AX AX AX AX AX AX 
$
 Positive when alpha-naphthylamine and sulfanilic acid added; 
*
 Nitrogen gas production from Nitrate reduction; 
#
 media remain clear when zinc powder is added 
AX stands for A. xylosoxidans; and R1-14 for Thai isolates 1-14
  
5
4
 
C
h
ap
ter 3
 
 
Table 3.4: Summary of species identification using multiple approaches  
Isolate 
Biochemical 
properties 
API20NE 
16S rDNA 
PCR 
16S rDNA 
sequencing 
MALDI-TOF MLST (ID) MLST (ST) 
NCIMB 11015 AX N/A Positive AX AX AX 166 
DSM 2402 AX N/A Positive AX AX AX 20 
AD AD N/A Positive AD AD AD 102 
AI AD N/A Positive AI AI AI 99 
AP Achromobacter sp. N/A Positive AP AP AP 122 
AR Achromobacter sp. N/A Positive AR AR AR 30 
AS AD N/A Positive AS AS AS 112 
R1 AX N/A Positive AX AX AX 27 
R2 AX N/A Positive AX AX AX 196 
R3 AX N/A Positive AX AX AX 182 
R4 AX N/A Positive AX AX AX 183 
R5 AX N/A Positive AX AX AX 27 
R6 AX N/A Positive AX AX AX 180 
R7 AX N/A Positive AX AX AX 184 
R8 AX N/A Positive AX AX AX 185 
R9 AX N/A Positive AX AX AX 186 
R10 AX N/A Positive AIn AX AX 182 
R11 AX N/A Positive AX AX AX 187 
R12 AX N/A Positive AX AX AX 188 
R13 AX N/A Positive AX AX AX 189 
R14 AX N/A Positive AX AX AX 27 
N/A stands for Not applicable; AX for A. xylosoxidans; AD for A. denitrificans; AI for A. insolitus; AP for A. piechaudii; AR for A. ruhlandii; 
AS for A. spanius; AIn for A. insuavis; and R1-14 for Thai isolates 1-14 
  
5
5
 
C
h
ap
ter 3
 
 
Table 3.4: Summary of species identification using multiple approaches (Continued) 
 
Isolate 
Biochemical 
properties 
API20NE 
16S rDNA 
PCR 
16S rDNA 
sequencing 
MALDI-ToF MLST (ID) MLST (ST) 
L1 AX AX Positive AX AX AX 28 
L2 AX AX Positive AIn AX AIn 168 
L3 AD AX Positive AX A8 Achromobacter sp. ASp 169 
L4 AD AX Positive AP AR AP 170 
L5 AX AX Positive AX AX AX 171 
L6 AX AX Positive AX AX AX 28 
L7 AD AX Positive APu AR Genogroup19 172 
L8 AX AX Positive AX AX AX 175 
L9 AX AX Positive AX AX AM 174 
L10 AX AX Positive AX AX AX 173 
L11 AX AX Positive AX AX AX 176 
L12 AD AD Positive AM Poor ID ASp 177 
L13 AC AX Positive AS AP AS 178 
L14 AX AX Positive AX AX AX 179 
L15 AX AX Positive AX AX AX 176 
L16 AX AX Positive AX AX AX 180 
L17 AX AX Positive AX AX AX 175 
AX stands for A. xylosoxidans; AD for A. denitrificans; AI for A. insolitus; AP for A. piechaudii; AR for A. ruhlandii; AS for A. spanius; 
AC for Advonella incenata; APu for A. pulmonis; AM for A. marplatensis; Asp for A. spiritinus; and L1-L17 for British isolates 1-17
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3.3.2. Automated platform using API20NE and MALDI-TOF MS could 
not clearly identify Achromobacter species 
 
Using the API20 NE identification database, sixteen clinical strains from 
Liverpool were identified as A. xylosoxidans and L12 was identified as A. 
denitrificans (Table 3.4). Bruker biotyper MALDI-TOF MS assigned all 14 Thai 
isolates and 12 British isolates to A. xylosoxidans. Opposing to the identification 
by API20 NE, MALDI-TOF MS reported that five British isolates were not A. 
xylosoxidans. L4 and L7 were A. ruhlandii and L13 was A. piechaudii. L3 was 
identified as Achromobacter sp. and L12 were reported as „not reliable 
identification‟ by the Bruker biotyper database. The type strains of 
Achromobacter species were identified as their own type species using the 
MALDI-TOF MS Bruker biotyper database (Table 3.4). For Thai clinical strains, 
the MALDI-TOF MS assigned A. xylosoxidans to all isolates. 
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3.3.3. Genus-specific 16S ribosomal RNA-targeted identification 
 
The results of amplification using primers AX-F1 and AX-B1 revealed the 
presence of a 163-bp-long amplicon from all type strains  (Figure 3.2, Table 3.4). 
In the lane containing P. aeruginosa PAO1, there was no 163-bp long product 
but there were some DNA bands appearing on the top of the lane (PAO1, Figure 
3.2). These bands did not exist on the other gels (Figure 3.3A), so the bands 
could be the degraded DNA or non-specific amplicons. PCR products were 
obtained from all clinical isolates and the positive control strain, NCIMB 11015 
(Figure 3.3). Interestingly, the products were also detected from seven clinical 
isolates, L2, L3, L4, L7, L9, L12, and L13 (Table 3.4).  
 
 
 
Figure 3.2: A. xylosoxidans “specific” 16S rDNA gene PCR applied to type 
strains of the genus Achromobacter used in this study. Label: M1 stands for 
DNA marker - Hyperladder V; NCIMB 11015 for A. xylosoxidans NCIMB 
11015; PAO1 for P. aeruginosa PAO1; AD for A. denitrificans; AR for A. 
ruhlandii; AP for A. piechaudii; AS for A. spanius; AI for A. insolitus; DSM 
2402 for A. xylosoxidans DSM 2402; NEG for Negative control; and M2 for 
DNA marker - Hyperladder I 
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Figure 3.3: A. xylosoxidans “specific” 16S rDNA gene PCR applied to 
clinical Achromobacter isolates A) L1-L8, B) L9-L17 and C) R1-R14 using 
primers AX-F1 and AX-B1. Label: M1 stands for DNA marker - Hyperladder 
V; NCIMB 11015 for A. xylosoxidans NCIMB 11015; PA01 for P. aeruginosa 
PAO1; NEG for Negative control; M2 for DNA marker - Hyperladder I; L1-L17 
for British isolates 1-17; and R1-R14 for Thai isolates 1-14. 
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3.3.4. Random amplification of polymorphic DNA patterns showed intra-
hospital relationship of clinical isolates 
 
A total number of 38 strains of Achromobacter were typed using RAPD-PCR. 
With primer 270, the profile suggests the colonisation of the same strain in the 
patients (Figure 3.4). For Thai isolates, the RAPD profile revealed the similarity 
of isolates R1, R5 and R14 (black boxes in Figure 3.4). This similarity was 
explained by the fact that these isolates were from the same patient. For isolates 
from Liverpool, L2, L3, L4, L12 and L13 displayed RAPD profiles that were 
different from the other strains (Figure 3.4). L11 and L15, which were taken 
from the same patient, showed similar RAPD pattern (Red boxes in Figure 3.4). 
These demonstrated persistent colonisation of A. xylosoxidans. In addition, the 
profile presented a pair as examples of colonisation of similar strain in different 
patients; L8 and L17.  
 
With hierarchical clustering with UPGMA method in Gelcompare II, the analysis 
revealed non-xylosoxidans cluster (highlighted by orange box in Figure 3.5). 
This cluster consisted of A. denitrificans, A. insolitus, A. spanius, A. ruhlandii, 
L3, L12 and L13. However, some non-xylosoxidans strains and clinical isolates 
of A. xylosoxidans were clustered together, as indicated in a blue box in Figure 
3.6. Considering A. xylosoxidans clusters, the dendrogram demonstrated a close 
genomic relationship (80% similarity) of isolates R1, R5 and R14 (Green box in 
Figure 3.5). Liverpool isolates that had similar RAPD pattern were also clustered 
together; L8 and L17 (Yellow box in Figure 3.5) were 80% similarity and L11 
and L15 (Purple box in Figure 3.5) were 80% similarity. 
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3.3.5. Multilocus sequence typing analysis  
 
The multilocus sequence analysis (Figure 3.6) presented better resolution of 
species identification, in comparison with 16S rDNA phylogeny (Figure A2.1). 
Here, with the MLST phylogenetic tree, strain L7 was grouped with 
Achromobacter genogroup 19, and strain L9 was grouped with A. marplatensis. 
Also, the MLST phylogeny assigned species/genogroups to non-xylosoxidans 
isolates; L2 was genogroup 2b, L3 and L12 were A. spiritinus, L13 was A. 
spanius, and L4 was A. piechaudii (Figure A2.2). 
 
Considering a group of A. xylosoxidans on MLST phylogeny, some clinical 
isolates were assigned the same strain type; L8 and L17 were ST175, L11 and 
L15 were ST176, R1, R5 and R14 were ST27, and R3 and R10 were ST182 
(Table 3.4). As shown by MLST analysis, clinical isolates of A. xylosoxidans 
used in this study were diverse (A black dashed box, Figure 3.6). A population 
snapshot using eBURST algorithm revealed 14 groups. The largest groups 
contained 18 STs with ST 180 as a founder of the groups (Appendix Figure 
A2.3). None of them had „single locus variant‟ relationship.  
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Figure 3.4: Gel electrophoresis showing the RAPD profile of 31 clinical isolates of Achromobacter species. The typing is performed using 
primer 270. Each box indicated the similarity of RAPD profile by inspection. R1-R14 stands for Thai isolates; and L1-L17 for British isolates 
R1 L16L15L14L13L12L11L10L9L8L7L6L5L4L3L2L1R14R13R12R11R10R9R8R7R6R5R4R3R2 L17
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Figure 3.5: RAPD analysis of each Achromobacter isolates using primer 270. 
A dendrogram is constructed using UPGMA in Gelcompar II software. Label: 
R1-R14 stands for Thai isolates; L1-L17 for British isolates; AD for A. 
denitrificans; AR for A. ruhlandii; AP for A. piechaudii; AS for A. spanius; AI 
for A. insolitus; AXX for A. xylosoxidans DSM 2402; and AX11015 for A. 
xylosoxidans NCIMB 11015 
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Figure 3.6: MLST phylogenetic tree of all Achromobacter isolates based on 
seven housekeeping genes. R1-R14 are clinical isolates from Thailand; L1-L17 
are clinical isolates from the U.K.; DSM 2402 stands for A. xylosoxidans DSM 
2402; and AX11015 for A. xylosoxidans NCIMB 11015. Bootstrap values >50% 
are indicated. 
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3.4. Discussion 
 
3.4.1. Comparison of species identification methods 
 
Precise identification methods for A. xylosoxidans are essential for clinical 
microbiology due to epidemiological study and the increase in the prevalence of 
clinical isolates being reported as A. xylosoxidans. Here, multiple identification 
approaches, ranging from conventional phenotypic techniques to molecular 
techniques, were applied to reveal appropriate and robust identification methods. 
 
„A gold standard‟ of this study is determined by the ability to identify correct 
species from reference strains and by reviewing literatures. In the first place, the 
methods used to identify A. xylosoxidans were based on phenotypic or 
biochemical tests (Yabuuchi & Oyama, 1971). However, those methods were not 
robust enough for hospital‟s practice because the tests of bacterial phenotype 
need at least 24 hours for bacterial culture and a large panel of biochemical 
reaction. Therefore, molecular biology-based methods were taken into 
consideration. Of applied methods in this study, methods that correctly assign 
correct species to the reference strains are 16S rDNA sequence, MALDI-TOF 
MS, and MLST. Considering the identification of clinical isolates, 16S rDNA 
sequence shows the limitation to identify ambiguous clinical isolates. A recent 
study reveals that MALDI-TOF MS and MLST are methods that are able to 
identify and discriminate Achromobacter species in species and strain level. 
However, MALDI-TOF MS is limited to identify some clinical isolates in this 
study because of the small size of database. Therefore, MLST is considered a 
„gold standard‟ approach in this study. 
 
The comparison of biochemical phenotype-based approaches showed that 
manual biochemical reaction determination was better than API20 NE kit in 
terms of identification performance (Table 3.4). A previous study (Fernández-
Olmos et al., 2012) showed that API20 NE identified ten false positive A. 
xylosoxidans out of 66 strains (84.8% sensitivity), with respect to MLST 
identification. It also identified 25 false positive strains out of 59 strains as 
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Burkholderia cepacia complex (50.7% sensitivity). Here, in this study, with 
respect to identification by MLST, these approaches assigned the genus 
Achromobacter to all isolates. Taking the British isolates only, the phenotype-
based tests misidentified seven strains out of 17 strains (58.8% sensitivity). In 
order to identify A. xylosoxidans, the classic biochemical test identified five out 
of seven non-xylosoxidans Liverpool isolates (71.4% sensitivity), whereas the 
API20 NE could only identify one out of seven non-xylosoxidans Liverpool 
isolates (14.3% selectivity). The limitation of species identification by 
biochemical reaction-based approaches can be explained by the restricted 
number of biochemical reactions that allow for better differentiation 
Achromobacter species. Therefore, the approaches could be appropriate as an 
initial screening test, but identification at the species level would require the use 
of additional methods.  
 
Contrary to biochemical reaction-based approaches, the MALDI-TOF MS 
platform and 16S rDNA sequencing showed better performance on species 
identification. As shown in Table 3.4, these methods were able to differentiate A. 
xylosoxidans from other Achromobacter species. For five British isolates, L3, L4 
L7, L12, and L13, all three identification methods were in agreement that they 
were not A. xylosoxidans. Nonetheless, the identification for certain species is 
still ambiguous, as illustrated by inconsistent identification of seven British 
clinical isolates (Table 3.4). The ambiguity of Achromobacter identification 
using 16S rDNA sequence was also reported (Gomila et al., 2014). Considering 
available identification methods that have been used in hospital, MALDI-TOF 
MS has exhibited better performance to discriminate Achromobacter species 
with better sensitivity, compared to biochemical approach and 16S rDNA 
sequencing approach. Nevertheless, MALDI-TOF MS analyses are observed to 
be less accurate than MLST.  On account of working by matching the queried 
spectra to the database, this suggests that the size of the database is essential for 
MALDI-TOF MS (van Veen, Claas & Kuijper, 2010). 
 
As presented in this study, a combination of methods is required for accurate A. 
xylosoxidans identification (Gomila et al., 2014). Biochemical reaction-based 
panel were reliable enough for genus level, but not for species level, so the panel 
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can be used as a screening test prior to executing further identification. MALDI-
TOF, 16S rDNA sequencing and MLST demonstrated trustworthy identification. 
In clinical microbiology, a faster approach is preferred because early treatment to 
stop disease progression is important. In this respect, MALDI-TOF is better than 
the other methods because it is less time consuming. However, 16S rDNA 
sequencing and MLST identification could be supporting methods for strain-
level identification. 
 
3.4.2. Strain typing of Achromobacter members to study the global 
population 
 
In comparison with many bacterial pathogens, the global population of 
Achromobacter has been poorly characterised.  Several studies have reported the 
variation of A. xylosoxidans isolates and suggested that bacteria could spread out 
in various environments (Amoureux et al., 2012, 2013). This study focused on 
applied multiple typing approaches to help discriminate A. xylosoxidans from 
other Achromobacter and to investigate the clustering of A. xylosoxidans from 
different geographical background. 
 
The combination of DNA fingerprint typing and multilocus gene typing was 
applied to investigate species segregation and the epidemiology of A. 
xylosoxidans. In this study, RAPD fingerprinting and MLST were selected as 
strain typing methods because these methods are generally used in this species 
(Kaur et al., 2009; Magni et al., 2010; Spilker, Vandamme & LiPuma, 2012; 
Vandamme et al., 2013; Trancassini et al., 2014). Both RAPD fingerprinting and 
MLST analysis illustrated the ability to differentiate between A. xylosoxidans and 
non-xylosoxidans Achromobacter species, except that L1 was grouped with non-
xylosoxidans by RAPD (Figure 3.5). Considering only A. xylosoxidans, both 
typing methods could not group A. xylosoxidans isolates by their countries of 
origin (Figure 3.5 and Figure 3.6).  
 
By observing epidemiology of the isolates, the presence of similar genotypes of 
strains in different patients was observed in this study. Nevertheless, both the 
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RAPD typing and MLST demonstrated multiple genotypes of A. xylosoxidans, 
especially Thai strains (Figure 3.4). Both RAPD and MLST demonstrated 
multiple strain types of clinical isolates and the strains from both British and 
Thailand were not separated by geography.  
 
As shown in Figure 3.5 and Figure 3.6, there were two pairs of genetically 
similar strains; L11-L15 and L8-L17. For Thai strains, clonal strains were 
unsurprisingly found in strain R1, R5 and R14. British strain L11 and L15 were 
obtained from the same patient (two months apart), who had bronchiectasis, a 
disease with abnormally widened lung bronchi. Thai strain R1, R5 and R14 were 
also collected from the same patient (two months apart) who had pneumonia. 
These evidences represented long-termed colonisation of A. xylosoxidans, at least, 
over two months in a single patient with respiratory tract problems during 
intubation (Table 2.1). Interestingly, L8 and L17 were isolated from a non-Cystic 
Fibrosis patient with chronic obstructive pulmonary disease and a Cystic Fibrosis 
patient, respectively. It is still argued that how those patients be infected by 
similar strain type. It can be assumed that these patients contacted with the same 
environment so that they were infected with genetically-related strain of A. 
xylosoxidans.  
 
The diversity of A. xylosoxidans isolates demonstrates that the majority of 
infected patients acquire the pathogens from the environment. There is a 
possibility of persistent colonisation in patients with respiratory diseases 
(Kanellopoulou et al., 2004). Furthermore, these evidences suggest no 
geographic specificity of A. xylosoxidans with respect to the distribution of 
clonal types.  However, larger scale studies with samples from different clinical, 
environmental and geographical sources are needed to better understand and 
characterise the global population of this pathogen. This chapter demonstrated 
the determination of methods for identification of A. xylosoxidans. Molecular-
based approaches, including 16S rDNA and MLST, showed relationships 
between isolates. However, this did not explain entire genetic relationship 
between these isolates. This emphasised that the construction of whole genomic 
relationship was required.  
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3.5. Conclusion and future work 
 
The main purposes of this study were to demonstrate the ability of multiple 
bacterial identification approaches to identify emerging pathogens and to apply 
strain typing of clinical isolates of A. xylosoxidans in order to investigate 
geographical associations. Due to the fact that A. xylosoxidans is one of the most 
important emerging pathogens that cause severe diseases in Cystic Fibrosis 
patients and other immune-compromised patients, precise identification is 
required for epidemiological study and clinical work-up in order to deliver an 
appropriate treatment to the patients.  
 
 
 
Figure 3.7: The proposed algorithm for A. xylosoxidans identification from 
non-fermenting Gram-negative. Dashed boxes indicate approaches that are 
affected by the lack of advanced facilities such as MALDI-TOF MS and 
sequencing facility. 
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With respect to reference labs, the identifications in the reference labs are merely 
based on biochemical (conventional) tests. MALDI-TOF MS is used in particular 
samples, such as samples that cannot be clearly identified by means of 
conventional methods. A number of identification methods were compared in 
this study. On the basis of the results presented here, a pragmatic algorithm for A. 
xylosoxidans identification is suggested (Figure 3.7).  
 
Starting with non-fermenting Gram-negative bacteria from MacConkey agar, 
biochemical reaction-based methods, such as conventional tests and API20 NE 
can be used as screening tests due to their good performance in genus 
identification. For species identification, MALDI-TOF MS can be a main 
method to assign species to the isolates. The gene sequencing of 16S rDNA can 
be a supportive information for species identification. Finally, the intra-species 
discrimination can be conducted by additional methods, including MLST 
analysis and RAPD, which offer the potential to analyse within-species diversity.  
 
Theorically, utilising a single approach that can give a highly reliable result is the 
best practice in clinical and diagnostic microbiology but the ideal approach is 
still unavailable. Therefore, using multiple approaches is necessary for current 
situation because results from several methods can reciprocally support one 
another to define a final result.  However, some identification approachs, such as 
MALDI-TOF and DNA sequencing, cannot be used in a routine identification 
practice because some developing countries, such as Thailand, cannot afford 
those facilities for a routine purpose (They can afford for research purpose). 
Therefore, phenotypic identification remains a routine diagnostic practice in 
developing countries as the method still perform well in the identification of 
common pathogens, such as S. aereus, E. coli, and S. pneumoniae. Although the 
time-to-result of the phenotypic is approximately, at least, 48 hours, compared to 
its of MALDI-TOF which takes around 36 hours, the treatment is not affected 
because the treatment for infections, mostly, relies on antibiotic susceptibility of 
the pathogens. 
 
However, there is still in need for a better and more robust identification method 
for the healthcare unit where MALDI-TOF MS and sequencing facility are 
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unavailable because rapid and accurate diagnostic provides the opportunity to 
establish empirical treatment, especially for particular pathogens having intrinsic 
resistance. Likewise, correct species identification is important for 
microbiological research and epidemiology. Whole genome sequencing of all 
Achromobacter isolates will be conducted to achieve species identification and to 
pursue futher study. 
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Chapter 4  
Pan-genome analysis of Achromobacter xylosoxidans 
 
4.1. Introduction 
 
The previous analysis in Chapter 3 suggests that phylogenetic trees built using 
the 16S rDNA gene (Figure 3.4) and MLST genes (Figure 3.7) allow for 
Achromobacter species identification. However, sub-species level identification 
has not been clearly elucidated by those analyses. Further analysis of whole 
genome sequence data would enable a higher resolution of core phylogenomic 
analysis to be carried out, define the genome structure and pan-genome of A. 
xylosoxidans, and allow us to elucidate the molecular relationships between 
isolates. 
 
4.1.1. Comparative genomic analysis in pathogenic bacteria 
 
The use of comparative genomics to study bacterial evolution has revealed how 
bacteria undergo adaptation to survive in the host environment and how members 
of certain species from various niches can differ, particularly in genetic contents 
(Bentley & Parkhill, 2004). The comparative analysis of bacterial species is 
becoming important to reveal how a pathogen survives or causes diseases. For 
example, the pressure of host immune response pulses the adaptation of E. coli to 
be macrophage resistant strain, which is virulent to hosts (Miskinyte et al., 2013). 
The mutation of cis-regulatory element allows host-dependent pathogenic 
adaptation of Salmonella (Osborne et al., 2009). 
 
Since the first genome of a pathogenic bacterium, H. influenzae Rd, was 
published (Fleischmann et al., 1995), studies have used comparative genomic 
approaches to elucidate molecular and genetic factors that cause diseases in hosts. 
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One of the applications of comparative genomic analyses is to investigate the 
gain/loss of genes or genetic adaptations within the genomes of pathogens. An 
example that shows genetic adaptations leading to more virulent bacteria is seen 
in the discovery of extra plasmids in the Bacillus cereus group. Whilst the 
analysis showed that the genomes of B. cereus, an opportunistic pathogen that 
usually causes carbohydrate-related food-poisoning (Gilbert, Stringer & Peace, 
1974; Schoeni & Lee Wong, 2005), B. thuringiensis, a biological insecticide 
(Bravo et al., 2011), and B. anthracis, an anthrax-causing bacterium (Spencer, 
2003), are similar, some genes encoding invasion factors and the capsule were, 
surprisingly, not found in the B. anthracis and B. thuringiensis genomes. 
Subsequent whole genome sequencing enabled the analysis of the complete 
genomes of B. cereus, B. anthracis and B. thuringiensis revealing 85% similarity 
between these genomes. As a result of the analysis, species-specific genes were 
identified to allow differentiation between B. cereus and B. anthracis on a 
molecular level (Ivanova et al., 2003). Another example is the comparative 
genomic study of three pathogenic bacterial species in the genus Bordetella - B. 
pertussis, B. parapertussis and B. bronchiseptica. Adaptations in these species, 
in particular B. pertussis and B. parapertussis, occurred independently from each 
other and from their B. bronchiseptica-like ancestral, and the differences 
between the genomes of B. pertussis and B. parapertussis are regulated by the 
loss and the inactivation of the genes that results in different host-pathogen 
interaction (Parkhill et al., 2003). 
 
Comparative genomic analyses have also been used to demonstrate the 
adaptations that allow bacteria to survive in different environments. For example, 
the genomic study of Stenotrophomonas species illustrated host-specific genes 
(Alavi et al., 2014). Genes associated with plant growth promotion were found 
only in plant-associated S. rhizophila, not in S. maltophila, whereas genes 
associated with virulence in humans were found only in the pathogenic S. 
maltophila. However, there is no significant genomic difference between plant-
associated S. maltophila and pathogenic S. maltophila. In addition to 
determination of the genomes in different species, comparative genomics can 
shed the light on genomic difference between strains of the same species. For 
instance, lateral genetic transfers can mediate genetic variations in A. baumannii, 
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leading to antibiotic resistant phenotype of the species (Liu et al., 2014). 
Comparative analysis can also reveal genetic variation of the pathogen from 
similar area, as illustrated by genetic variation of Burkholderia pseudomallei, a 
pathogen that causes melioidosis, in a rice paddy in northeast Thailand 
(Wuthiekanun et al., 2009). Moreover, the significant change in genetic 
components of closely related species can be explored by comparative genome. 
For example, the pseudogenisation of gastroenteritis-associated genes in S. typhi 
serovars allows S. typhi to become human-specific strains and cause only 
systemic diseases, compared to S. enterica that have a broad host range and 
cause both gastroenteritis and systemic diseases (McClelland et al., 2004). Also, 
another example is the genomic reduction in the genome of B. mallei, compared 
to closely-related species B. pseudomallei, led to the lack of genetic diversity of 
B. mallei (Losada et al., 2010). All in all, these examples demonstrate the 
usefulness of comparative genomic analyses in understanding the biology of an 
organism. 
 
4.1.2. Genetic element transfer and recombination 
 
DNA can transfer between strains or species by three mechanisms: 
transformation, conjugation, and transduction (Frost et al., 2005). 
Transformation was the transfer of bacterial DNA between closely related 
species by means of taking free DNA from the environment (Thomas & Nielsen, 
2005). Inversely, another two mechanism require special tools to mediate DNA 
transfer. Conjugative transfer requires pairing organ called „Pilus‟ that provides a 
route to transfer DNA (plasmid or integrative conjugative element) from a „donor‟ 
cell to a „recipient‟ cell (Ou & Anderson, 1970; Burrus & Waldor, 2004). The 
last possible mechanism of genetic transfer is conduction. As a mediator to assist 
genetic transfer, a bacteriophage, a bacterial virus, uses a benefit from host‟s 
DNA replication machinery to replicate itself. As such, bacteriophages carry 
host‟s DNA and transfer it to other bacteria where bacteriophages infect 
(Canchaya et al., 2003). Once this has happened, DNA recombination events can 
occur. 
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Recombination can happen either at both the inter-species and intra-species level. 
Inter-species recombination is the exchange of genetic element that happens 
between species; for example, the recombination of glutamine synthetase and 
shikimate dehydrogenase genes between Neisseria meningitidis and other 
Neisseria species affects phylogenetic structure (Zhou, Bowler & Spratt, 1997). 
The effect of intra-species recombination varies between species but, mostly, 
their phylogenies are affected by the recombination (Feil et al., 2001). Several 
studies have shown that recombination has been involved in outbreaks in certain 
species. For example, genetic recombination significantly accelerates evolution 
and adaptation in Legionella pneumophila, and the recombination contributes to 
11-year outbreak in spain (Sánchez-Busó et al., 2014). Recombination also has 
the same effect on host adaptation in E. faecium to survive in hospital 
environment with the acquisition of cell wall biosynthesis genes and drug 
resistance genes allowing it to survive in a hospital environment (de Been et al., 
2013). In the case of antibiotic resistance and epidemiological problems, 
recombination has a vast impact, in particular, on the spread of drug-resistant 
bacteria in the community. A recent study has shown that the spread of S. 
pneumoniae in a refugee camp was driven by genetic recombination 
(Chewapreecha et al., 2014). In general, research into pneumococcal infections 
focuses on capsulated S. pneumoniae due to the virulence of the capsule 
(AlonsoDeVelasco et al., 1995; Kadioglu et al., 2008). Nevertheless, non-
capsulated strains of S. pneumoniae that are neglected by many researchers, 
contribute to the transfer of antibiotic resistance gene, as determined by high rate 
of exchange of genetic elements (Chewapreecha et al., 2014). Moreover, S. 
pneumoniae can obtain genetic element via transformation (Piotrowski, Luo & 
Morrison, 2009). 
 
4.1.3. Microbial pan-genomes 
 
An extension of a comparative genomic study is to investigate a comprehensive 
characteristic set of genomes, or „pan-genome‟, in a species. The study of pan-
genomes has elucidated the structure of bacterial species‟ genome beyond what 
is achievable by studying individual genome sequences. There is no absolute 
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definition of the term „pan-genome‟; however, a pioneering study by Tettelin et 
al. (2005) explained that the study of a pan-genome includes the determination of 
a core gene set and a disposable gene set with an explanation and extrapolation 
provided by a mathematical model. In the analysis of pan-genomes, a core 
genome is defined as „gene sets shared by all strains in the same species‟, and a 
dispensable/accessory/disposable genome includes „gene sets present in 2 or 
more strains, but not all, in the same species‟ and „gene sets specific to individual 
strains‟ (Tettelin et al., 2008). 
 
In practice, the estimation of pan-genome is based upon the level of protein 
sequence similarity or gene similarity that can be determined by using various 
methods, such as gene alignment (Tettelin et al., 2005), all-against-all BLAST 
searches (Jacobsen et al., 2011), Cluster of Orthologous Groups (COGs) 
databases (Conlan et al., 2012) and homology analyses (Soares et al., 2013). The 
number of genes added was taken from responsible added genomes. The 
extrapolation of the size of core genome and the size of strain-specific genomes 
follows an exponential decay (Tettelin et al., 2008): 
 
N = κe-n/τ + Ω 
 
Where N is the size of the pan-genome, n is the number of genomes compared, 
and κ, τ and Ω are free parameters. 
 
Heaps‟ law has been applied as a model for pan-genome estimation. In 
information retrieval, the principle of Heaps‟ law is used to count the number of 
unique characters/words or „attributes‟ in each document, or „entity‟, collected. 
According to Heaps‟ law, when more documents are collected, there will be 
some words that are repeated and some new words that are distinct (Egghe, 
2007). The relationship between the number of words/characters, T, and 
documents collected, A, is that T varies as A
γ; where γ is a constant and γ < 1. 
Likewise, in genome science, as more genomes are retrieved, it is more difficult 
to find new genes (Tettelin et al., 2008).  
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Heaps‟ law is applied to estimate the number of genes that will be found when a 
certain number of genomes are added (Tettelin et al., 2008), as follows: 
 
N = κ nγ 
 
Where N is the size of the pan-genome, n is the number of genomes compared, 
and κ and γ are free parameters. 
 
In addition to the pan-genome‟s size, one can address the fact that the number of 
new attributes and the number of entities added also follow Heaps‟ law (Tettelin 
et al., 2008). Therefore, the extrapolation of newly discovered genes can be used 
to explain the pan-genome with the following relationship: 
 
N = An
-α 
 
Where N is the number of new genes discovered, n is the number of genome 
added, and A and α are free parameters. 
 
Considering the relationship between the number of new genes discovered and 
the number of genomes added, when α > 1, the number of new genes decreases 
dramatically to reach zero. This means that the size of the pan-genome nearly 
approaches a stable number, resulting in it being a „closed-genome‟. On the other 
hand, when α ≤ 1, the number of new genes is still detectable. In other words, the 
pan-genome is still increasing in size and is an „opened pan-genome‟ (Tettelin et 
al., 2008). 
 
So far, pan-genome analysis has been performed in a number of pathogenic 
bacteria, for example, Streptococcus agalactiae (Tettelin et al., 2005), 
Haemophilus influenzae (Hogg et al., 2007), Neisseria meningitidis (Schoen et 
al., 2008), Escherichia coli (Rasko et al., 2008), Yersinia pestis (Eppinger et al., 
2010), Streptococcus pneumoniae (Donati et al., 2010), Bifidobacterium spp. 
(Bottacini et al., 2010), Elizabethkingia anophelis (Teo et al., 2014), Bacillus 
anthracis (Rouli et al., 2014), and Haemophilus parasuis (Howell et al., 2014). 
Chapter 4 
 77 
An example of a closed-genome organism is B. anthracis, which its core genome 
of which contributes to 99% of the whole genome, which suggests that B. 
anthracis is a pathogenic bacterium that does not need to retrieve external 
virulence genes (Rouli et al., 2014). S. pneumoniae is a clear example of an 
open-genome species. Its open pan-genome explains how the species can adapt 
and respond to the environment rapidly (Donati et al., 2010). It is a 
straightforward explanation that the adaptation of S. pneumoniae from non-
virulence to virulence was driven by the acquisition of capsule genes. 
 
4.1.4. Orthology and Paralogy of the genes 
 
Thousands of bacterial genomes have been sequenced; however, relatively few 
genes have been well studied and characterised to find their function. Homology, 
by definition, describes the relationship between genes that share a common 
origin. Genes with a homologous relationship are called homologous genes or 
homologues (Koonin, 2005). Orthology, meanwhile, defines the homologous 
relationship that emerges from a speciation event of compared species. Genes 
that have orthologous relationships are called orthologous genes or orthologues. 
Another extension of homology is paralogy. Paralogy is a form of homologous 
relationship that happens via duplication within a species. Genes that have 
paralogous relationships are called paralogous genes or paralogues. A classical 
example of paralogous genes can be seen in the presence of adult haemoglobin 
genes and foetal haemoglobin genes in humans (Hardison, 2012). Whereas 
orthologous genes have equivalent functions, paralogous genes often have 
different functions despite the fact that their mechanisms of action are similar. 
For instance, the oxygen entrapment of foetal haemoglobin is more rapid than the 
oxygen entrapment of adult haemoglobin (Berg, Tymoczko & Stryer, 2002).  
 
The use of orthologues and paralogues has been increasing and is becoming an 
important approach in genomics, especially in comparative genomic studies. A 
noticeable example of the application of orthologues/paralogues is a database 
called COGs (Tatusov, 1997) where large protein databases are collected and 
categorised into 25 sub-categories under four main categories. Recently, a 
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database called „evolutionary genealogy of genes: Non-supervised Orthologous 
Groups‟ (eggNOG) has been introduced as a comprehensive database for 
orthologous group identification (Jensen et al., 2008; Powell et al., 2014). 
Currently, the eggNOG database version 4.0 includes more than 11 million 
protein covering 3686 organisms. The eggNOG also applies COGs categories to 
the annotation. 
 
Besides database construction, orthologues/paralogues are also used to generate a 
core body in order to investigate shared genes and accessory genes amongst 
genomes analysed. For instance, they have been used to identify shared genes 
between Bifidobacterium spp. and other gut bacteria (Bottacini et al., 2010), a 
core genome for recombination analysis in E. faecium (de Been et al., 2013), a 
guide for gene annotation (Richardson & Watson, 2013) and a scaffold for whole 
genome phylogeny construction (Bertels et al., 2014). 
 
4.1.5. Comparative genomic analysis of the genus Achromobacter  
 
A recent comparative study of six genomes within the genus Achromobacter 
genomes revealed that Achromobacter has a large open-genome and a low 
recombination rate (Li et al., 2013). The genome size of members of genus 
Achromobacter is generally 6-7 Mbp with a GC content of 65-68%. Pan-genome 
analysis indicated that the size of the pan-genome is twice the average size of the 
genomes. This suggests the ability to be a reservoir and a donor for horizontal 
gene transfer. The size of the core genome is approximately half of the average 
genome size in the genus. Moreover, analysis of the core genome detected a low 
level of recombination in the core genome regions of Achromobacter.  
 
4.1.6. Data mining using random forest, an unsupervised learning 
machine 
 
The study of genome science is encouraged because of the development of 
genome sequencing technology and computational biology. However, the 
transformation of enlightened genome information into living organisms 
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phenotype is crucial. The establishment of the correlation between genome and 
biology is a challenge to genome scientists and biologists. To deal with large-
scale genomic data and biological expression, untrained or unsupervised machine 
learning principle has been applied to link genomic information to biology. 
Random Forest™ is one of the famous unsupervised learning algorithms that are 
used to operate data mining (Breiman, 2001). The theory behind Random 
Forest™ is that the machine constructs a binary tree using random input 
variables to from each daughter node. Then the algorithm groups the data based 
on the tree and classification indicated. The tree is re-drawn „n‟ times for 
bootstrap support purpose. The measurement of variable importance is a special 
feature of Random Forest™. Given an example of analysis in genotype-
phenotype association, input variables can be the presence of SNPs or genes in 
the genomes, and the classification can be phenotypes of interest. The machine 
randomly selects genes or SNPs to construct a binary tree, and, subsequently, 
group genomes with respect to the existence of variables and phenotypes. Finally, 
the variables are ranked on the basis of the purity of classification. In this study, 
Random forest™ was applied as a main data mining approach to correlate 
genomic information with phenotype information.  
 
4.1.7. Aims and objectives 
 
The complete genome sequence of A. xylosoxidans NH44784-1996 elucidated an 
understanding of the molecular and genetic content of A. xylosoxidans (Jakobsen 
et al., 2013). In addition, a subsequent analysis revealed better knowledge of 
potential antibiotic resistance genes in the species (Hu et al., 2015). However, a 
comprehensive analysis of the species, especially from diverse geographical 
sources, has not been carried out. Therefore, the first aim of this study is to 
investigate whether A. xylosoxidans strains from different continents are 
genetically different. In order to reveal the population structure of A. 
xylosoxidans isolates, next-generation sequencing technologies were utilised to 
sequence the genomes of the isolates and compare these new sequences to the 
recently published reference genome, A. xylosoxidans NH44784-1996. Gene 
orthology and phylogenetic relationships will be used as the main approaches to 
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compare these genome sequences to one another. Furthermore, a recombination 
analysis will be conducted to investigate whether recombination events affect the 
phylogenetic structure of A. xylosoxidans. By means of the comparative genomic 
analysis, the understanding of A. xylosoxidans in terms of the genetic 
relationships between its strains will be more enlightened. 
 
As well as its population structure, many genomic characteristics of A. 
xylosoxidans also remain unclear. According to a study by Hu et al. (2015), A. 
xylosoxidans genomes are likely to be receptive genomes because of the 
existence of mobile genetic elements in A. xylosoxidans genome. This indicates 
that the pathogens can exchange genetic elements with their surroundings. To 
unveil and investigate the genome structure of the species, an analysis of its pan-
genome will be pursued using newly sequenced genomes together with a 
reference genome. By doing so, an estimation of genes encoded by the entire A. 
xylosoxidans species, as well as an estimation of numbers of common genes, will 
be achievable to tell us whether genomes of A. xylosoxidans behave more like 
they are closed or open. 
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4.2. Materials and methods 
 
4.2.1. Genome mapping of sequence reads and genome assembly 
 
The first step in a comparative genomic analysis is to assess the similarity 
between sequence genomes and the reference genome. Here, the genomes of the 
38 strains, consisting of 31 clinical strains and seven reference strains, were 
sequenced using short-read sequencing on the Illumina HiSeq 2000. Adapters 
were trimmed from the sequenced reads using Cutadapt version 1.1 (Martin, 
2011) with an option – O 3 - that trimmed 3‟ ends of the reads that matched the 
adapters. Then, reads with base quality values below 20 were trimmed using 
Sickle version 1.200 (Joshi & Fass, 2011). Mapping of processed reads to the 
reference genome, A. xylosoxidans NH44784-1996, was performed using the 
Burrows-Wheeler Aligner (BWA) software version 0.5.9-r16 (Li & Durbin, 
2009), which uses the Burrows-Wheeler transformation to identify matches 
between reads and the reference sequence. Duplicated reads were removed using 
Picard version 1.85 (http://picard.sourceforge.net/), using the following 
command format: 
 
java -jar MarkDuplicates.jar ASSUME_SORTED=true 
MAX_FILE_HANDLES_FOR_READ_ENDS_MAP=1000 I=<original mapping 
file in BAM format> O=<duplication removed file in BAM format> 
REMOVE_DUPLICATES=true VALIDATION_STRINGENCY=LENIENT 
 
The mapping percentage of sequenced strains to the reference was obtained using 
the „flagstat‟ option in SAMtools version 0.1.18-r580 (Li & Durbin, 2009), 
enabled using the following command: 
 
samtools flagstat <alignment file in BAM format> 
 
Polymorphisms obtained from read mapping were extracted and were used to 
generate pseudoalignment using Snippy version 2.5 
(http://www.vicbioinformatics.com/software.snippy.shtml). A phylogenetic tree 
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was then constructed using PhyML version 3.1 to visualise a relationship of the 
strains using P. aeruginosa PAO1 as an outgroup.  
 
Prior to de novo assembly, k-mer values of sequence reads from each strain were 
estimated to attend optimum N50 values, using VelvetOptimizer version 2.2.5 
(Gladman & Seemann, 2008). The following command, testing k-mer values 
between19 and 89, is an example of commands used: 
 
Perl VelvetOptimiser.pl -s 19 -e 89 -f  ‘-fastq –shortPaired <1st read file> -
shortPaired2 <2
nd
 read file>’ 
 
These k-mer values obtained from this optimisation step were used in de novo 
assemblies to generate draft genomes of the strains. Genome assemblies, using 
the De Bruijin graph algorithm, were performed with Velvet version 1.2.07 
(Zerbino & Birney, 2008) using the following command format: 
 
velveth <output_file> <k-mer> -fastq -shortPaired <1
st
 read file> -shortPaired2 
<2
nd
 read file> 
 
velvetg 
 
In addition to the Velvet assembler, de novo genome assemblies were executed 
using Spades version 3.1.1 (Bankevich et al., 2012). Spades is another short read 
assembler that uses the De Bruijin graph algorithm but its advantage is that it can 
handle multiple k-mer values at the same time. De novo assemblies using Spades 
were computed using the following command format: 
 
spades.py -k <list of k-mer separated by comma > --careful --pe1-1 <1
st
 read 
file> --pe1-2 <2
nd
 read file> -o <output file> 
 
The list of k-mer values used in the above command was „51, 53, 55, 57, 59, 61, 
63, 65, 67, 69, 71, 73, 75, 77, 79, 81‟. 
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4.2.2. Gene annotation and functional assignment 
 
The next step in a comparative genomic analysis is to predict gene models within 
the draft genomes. Rapid annotation software, Prokka version 1.7.2, was used to 
predict and annotate genes within the draft genomes in this study (Seemann, 
2014). Firstly, Prokka predicted coding sequences in the draft genomes using 
„Prodigal‟ (Hyatt et al., 2010). Prodigal‟s algorithm looks for all open reading 
frames then creates hexamers for each of these sequences. The score given to 
each gene is calculated from the hexamers‟ coding scores. After creating 
potential coding sequences, the software checks for ribosome-binding sites based 
on Shine-Dalgano sequences, as a means of analysing the likelihood that 
identified sequenced could be translated. Then, connections between nodes/genes 
that are calculated before a final set of results, comprised of amino acid 
sequences of encoded by each gene, are generated. In parallel, tRNA genes and 
rRNA operons were predicted using tRNAscan-SE (Schattner, Brooks & Lowe, 
2005) and RNAmmer (Lagesen et al., 2007), respectively. After the gene calling 
process, the genes were annotated with a customised database, namely „Gbbct‟, 
from which most updated bacterial genes from Genbank were obtained. Prokka 
was executed using the following command format: 
 
prokka –locustag <strain’s name> --outdir <output file> --prefix <strain’s 
name> --addgenes –-usegenus –genus Gbbct <contig file> 
 
The assignment of functional groups to genes was conducted by reciprocal 
protein BLAST comparison (Altschul et al., 1990) to a bacterial gene pool using 
the eggNOG database version 4.0 (Powell et al., 2014). The eggNOG classifies 
genes based upon Clusters of Orthologous Groups (COGs) (Tatusov, 1997). A 
command used to perform reciprocal BLAST searches against the eggNOG 
database is shown in Appendix 1.1. Functional annotation by eggNOG follows 
COGs categories categorised into 25 sub-categories under four main categories, 
as follows: 
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Table 4.1: Functional annotation defined by COGs. 
Category  Abbrev
iation 
Information 
storage and 
processing 
RNA processing and modification (A) 
Chromatin structure and dynamics (B) 
Translation, ribosomal structure and 
biogenesis (J) 
Transcription (K) 
Replication, recombination and repair (L) 
Cellular 
processes 
Cell cycle control, cell division and 
chromosome partitioning (D) 
Cell wall/membrane biogenesis (M) 
Cell motility (N) 
Posttranslational modification, protein 
turnover and chaperones (O) 
Signal transduction mechanisms (T) 
Intracellular trafficking, secretion and 
vesicular transport (U) 
Defense mechanisms (V) 
Extracellular structures (W) 
Cytoskeleton (Z) 
Metabolism Energy production and conversion (C) 
Amino acid transport and metabolism (E) 
Nucleotide transport and metabolism (F) 
Carbohydrate transport and metabolism (G) 
Coenzyme transport and metabolism (H) 
Lipid transport and metabolism (I) 
Inorganic ion transport and metabolism (P) 
Secondary metabolites transport and 
metabolism (Q) 
Poorly 
characterised 
General function prediction (R) 
Function unknown (S) 
 
4.2.3. Comparative genomic analysis 
 
Of the „A. xylosoxidans‟ strains isolated for this project, the results of MLST 
analysis (Figure 3.7) and genome mapping suggested that only 25 were A. 
xylosoxidans – NCIMB 11015, DSM 2402, L1, L5, L8, L10, L11, L14, L15, L16, 
L17, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14. As such, 
only 26 genomes, including NH44784-1996, of A. xylosoxidans strains were used 
in the comparative genomic analysis.  
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The annotated proteins from these 26 A. xylosoxidans genomes were clustered 
into groups using an all-versus-all BLAST search with the Markov Cluster 
Algorithm (MCL) implemented in OrthoMCL version 1.4 (Li, Stoeckert & Roos, 
2003). The following command format was used: 
 
perl orthomcl.pl --mode 1 --fa_files <list of strains’ genes, separated by 
commas> 
 
OrthoMCL‟s output, showing gene orthologous groups, was parsed into a matrix 
showing the presence/absence of each orthologous group in each genome using 
in-house scripts (Shown in Appendix 1.2). The occurrence of the gene families 
was shown in binary format (1 = presence; 0 = absence). With the table 
representing strains in columns and orthologous groups in rows, core orthologous 
groups were defined as the groups that were present in every genome, and 
accessory orthologous groups were defined as the groups that were present in 
some genomes but not all. 
 
To investigate the strains as clusters, based on the occurrence of gene 
orthologues, the table showing strains and OrthoMCL‟s output was subjected to 
hierarchical clustering and heat mapping using the „gplots‟ package implemented 
in the R statistical package, version 3.1.2 (Team, 2014). In the cluster analysis, 
the distance calculation method and clustering method were „binary‟ and 
„complete‟, respectively, as per the following R command lines: 
 
dist<- as.matrix(dist(tab, method="binary")) 
heatmap.2(dist.bin) 
 
4.2.4. Pan-genome analysis 
 
A mathematical model was applied to predict the sizes of the pan-genome and 
core genome through extrapolation. Randomly selected gene families were used 
to simulate how the number of genes increased and decreased when genomes 
were added. One thousand permutations were applied on the simulation to ensure 
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that there was no bias when genes were picked. The medians were used as 
central tendency to estimate least-squares fit. 
The pan-genome analysis was performed by the addition of 26 genomes of A. 
xylosoxidans. The regression analysis for the pan genome and new genes 
discovered was executed by fitting a power model (Heaps‟ law) to the median of 
the data (Tettelin et al., 2008): 
 
N = κ nγ 
 
Where N is the size of the pan genome, n is the number of genomes, and κ and γ 
are free parameters. 
 
The core genome analysis was performed by adding 26 genomes. The regression 
analysis for the core genome was executed by fitting an exponential model to the 
median of the data: 
 
N = κ e-n/τ + Ω 
 
Where N is the size of the pan-genome, n is the number of genome, and κ, τ and 
Ω are free parameters (Conlan et al., 2012). 
 
Additional analysis of newly discovered genes was conducted in order to support 
an evidence of a pan-genome. The analysis was performed with the addition of A. 
xylosoxidans genomes and the number of new genes with each addition was 
estimated. The median of the number of new genes was fitted to a power model 
as per following formula: 
 
N = An
-α 
 
Where N is the number of new genes discovered, n is the number of genome 
added, and A and α are free parameters. 
 
Pan-genome and core genome extrapolation were both conducted in R with 
scripts and command lines courtesy of Dr. Jennifer Kelly (Appendix 1.3). 
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4.2.5. Phylogenetic tree construction 
 
Phylogenetic relationships between the A. xylosoxidans strains were estimated 
using the core genome. In this study, the core genome was defined as the gene 
sets in the OrthoMCL output that contained exactly one gene from each strain. 
The corresponding nucleotide sequences were extracted using in-house Perl 
scripts and were aligned using MUSCLE (Edgar, 2004) with the following 
command type: 
 
muscle -in <input file> -out <output file> 
 
All gaps in the alignment were then stripped using trimAl software (Capella-
Gutiérrez, Silla-Martínez & Gabaldón, 2009) with and option - „–gt 1‟ - that 
removes all columns with gaps from the alignments. The format of the Trimal 
command line used is follows: 
 
Trimal –in <input alignment file(gaps intact)> -out <output file(gaps removed)> 
-gt 1 
 
After alignment concatenation, a phylogenetic tree was constructed using Mr. 
Bayes version 3.2.3, which uses Bayesian inference tree construction with a 
Markov Chain Monte Carlo (MCMC) algorithm to estimate posterior probability 
(Ronquist & Huelsenbeck, 2003). A generalised time reversible substitution 
model with 100,000 generations and ten sampling frequencies was used in the 
MCMC analysis. A phylogenetic tree was also constructed using a maximum-
likelihood model, with 1,000 bootstrap values, in PhyML version 3.1 (Guindon 
et al., 2010). The phylogenetic trees were viewed in FigTree version 1.4.2 
(http://tree.bio.ed.ac.uk/software/figtree). 
 
4.2.6. Recombination detection 
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Recombination can accelerate bacterial evolution; however, recombined 
sequences can interfere with bacterial phylogeny. To identify recombination 
signals in the core genome of A. xylosoxidans, multiple softwares, including a 
Neighbor-Net phylogeny investigation, Pairwise Homology Index test (PHI) tests 
and Bayesian inference-based analyses in ClonalFrame (Didelot & Falush, 2007), 
BratNextGen (Marttinen et al., 2012) and ClonalFrameML (Didelot & Wilson, 
2015), were applied. 
 
The estimation of core genome alignment began with the Neighbor-Net 
phylogenetic tree construction and PHI test. These processes were performed 
using SplitTree (Bryant & Moulton, 2004). Following the detection of a 
significant recombination event using the PHI test, a recombination analysis was 
executed with ClonalFrame first. The software uses a MCMC algorithm together 
with Bayesian inference model to identify homologous recombination. 
Unfortunately, the analysis ran for nearly a month without finishing, so the 
analysis was stopped and performed using another software. BratNextGen was 
used to detect recombination in the core genome alignment. The principle of 
BratNextGen is to apply a Bayesian inference model to investigate homologous 
recombination in the genome alignment. 
 
Although BratNextGen and ClonalFrame both use Bayesian inference models, 
BratNextGen is believed to be able to handle large datasets, such as whole 
genomes, better than ClonalFrame, which is more suitable for smaller datasets, 
such as MLST analyses. Initially, all default parameters were used in the analysis 
but this did not allow for clustering in BratNextGen‟s output tree. We sent a 
query to Dr. Pekka Martinen, an author and co-creator of the BratNextGen 
software. He advised setting the alpha-parameter to „1‟ when working with a 
diverse collection of strains. Hence, the analysis subsequently used default 
settings apart from the alpha value, which was set to „1‟. The test of the 
significance of recombination signal-containing regions was executed with 100 
permutations on a computer cluster. A threshold of 5% was set as a significant 
level for each suspicious region. Furthermore, ClonalFrameML, new 
recombination analysis software that uses maximum-likelihood algorithm, was 
applied to search for recombination in the core genome of A. xylosoxidans.  
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4.2.7. Variable classification using Random Forest™ 
 
A matrix of gene occurrence of A. xylosoxidans isolates was used as an input for 
the analysis. Random Forest™ was conducted using „randomForest‟ package, 
implemented in R. The best „mtry‟ parameter was pre-optimised using a built-in 
command „tuneRF‟. The analysis was performed with following parameters: 
ntree = 5,000 and pre-optimised „mtry‟. The input was prepared as a matrix 
presenting the occurrence of the genes in each genome and phenotypes of each 
genome. The result of the analysis was visualised using a command „varImpPlot‟, 
which orders variables by variable importance score and shows the variables in a 
plot format. 
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4.3. Results 
 
4.3.1. Genome mapping 
 
All sequence reads from 38 Achromobacter isolates were mapped against a 
published reference genome, A. xylosoxidans NH44784-1996, using BWA. 
Twelve strains that were found not to be A. xylosoxidans through MLST analysis 
(Figure 3.7), consisting of five non-xylosoxidans reference strains and seven 
clinical isolates from the U.K. In these twelve strains, less than 80% of reads 
successfully mapped to the reference genome. The mapping percentage of strain 
L6 was also less than 80% (Appendix Table A2.1).  
 
Three A. xylosoxidans strains mapped to the genome of strain NH44784-1996 
(Appendix Table A2.1), with mapping percentages higher than 90.0%. In 17 
other strains, 85.0 to 89.9% of reads mapped to the reference strain. Sequenced 
reads from strain L1 reached the highest mapping percentage at 96.1%. The 
lowest mapping percentage was 80.8%, achieved for reads from L15. Two type 
strains, NCIMB 11015 and DSM 2402, mapped to the reference genome with 
85.6% and 84.7% of their reads, respectively. 
 
Reads from the Illumina sequencing platform were mapped to the newly 
sequenced genome of A. xylosoxidans strain NCIMB 11015, generated by the 
Pacific Bioscience platform (Appendix Table A2.1; Appendix 5). Self-mapping 
of strain NCIMB 11015 showed that 99.68% of the Illumina reads mapped, 
which is the highest of all of the strains tested. This self-mapping evaluated the 
quality of sequencing platform. The lowest percentage of a strain‟s reads to map 
to strain NCIMB 11015 was 76.1%, as seen in strain L15. Nine strains were 
mapped with percentages in between 85.0 and 89.9%. Thirteen strains fell in the 
range of 80.0 – 84.9%. In two strains, less than 80% of reads mapped to strain 
NCIMB 11015. 
 
 
 
Chapter 4 
 91 
 
Figure 4.1: A maximum-likelihood phylogenetic tree constructed from 2,470 
core genome SNPs using PhyML version 3.1. P. aeruginosa PAO1 is an 
outgroup. Strains L1-L17 are clinical isolates from the U.K. (mainly Liverpool). 
Strains R1-R14 are clinical isolates from Bangkok, Thailand. NCIMB 11015 
stands for A. xylosoxidans NCIMB 11015 and DSM 2402 stands for A. 
xylosoxidans DSM 2402. Bootstrap values more than 50% were indicated. 
 
Phylogenetic analysis of core SNPs presented a reliable cluster that contains A. 
piechaudii, A. spanius, L3, L4, L12, and L13 (>90% bootstrap supports). Some 
non-xylosoxidans Achromobacter species, A. denitrificans, A. insolitus, A. 
ruhlandii, and L7, were clustered closely to A. xylosoxidans. However, strains L2, 
L9, and, particularly, L6, which was ambiguously identified by multiple 
approaches (refer to Chapter 3), were clustered separately from the A. 
xylosoxidans‟s cluster with moderate confidence (>60% bootstrap value) (Figure 
4.1). Taken all together, this suggested that L6 was not considered to be an A. 
xylosoxidans strain. These 13 strains were excluded from this study. Therefore, 
only 25 isolates‟ genomes – 14 Thai isolates, 9 British isolates, and 2 reference 
strains – were used in subsequent analyses in this study. The nine British isolates 
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will be renamed „Liverpool‟ isolates in this thesis, as all of them were from 
Liverpool. 
 
Table 4.2: Short-read assembly statistics for all 25 A. xylosoxidans isolates 
used in this study, including pre-optimised k-mer values, numbers of contigs, 
sizes of largest contigs, N50 values, coverage values and the total sizes of 
contigs. Assemblies were performed using Velvet assembler version 1.2.07. 
 
Strain 
Assembly Information 
K-mer Contigs 
Largest 
Contig (bp) 
N50 
(bp) 
Coverage Total (bp) 
NCIMB 11015 61 720 53,541 8,063 > 100X 6,288,311 
DSM 2402 65 695 94,834 29,946 > 100X 6,788,478 
L1 69 418 180,149 53,488 > 100X 6,777,785 
L5 59 2,245 88,090 13,937 > 100X 6,480,710 
L8 73 904 150,975 22,877 > 100X 6,754,552 
L10 69 1,061 124,477 24,316 > 100X 6,842,075 
L11 75 806 144,777 24,225 > 100X 6,763,626 
L14 63 1,852 117,346 16,809 > 100X 6,574,805 
L15 67 2,381 61,892 7,605 > 100X 6,726,584 
L16 73 917 105,215 22,497 > 100X 6,742,623 
L17 67 891 153,800 32,174 > 100X 6,808,965 
R1 63 1,106 96,079 25,454 > 100X 6,831,430 
R2 65 1,148 117,644 21,480 > 100X 6,426,085 
R3 57 2,650 45,043 5,996 > 100X 6,391,477 
R4 61 1,627 83,204 10,449 > 100X 6,521,510 
R5 57 1,468 138,145 13,767 > 100X 6,789,429 
R6 61 1,946 84,664 9,768 > 100X 6,554,317 
R7 65 2,380 49,203 6,457 > 100X 6,604,764 
R8 63 2,006 43,169 8,471 > 100X 6,590,525 
R9 63 2,537 48,754 6,275 > 100X 6,269,108 
R10 61 2,319 40,301 6,943 > 100X 6,408,088 
R11 65 961 117,063 17,165 > 100X 6,361,925 
R12 65 1,044 106,951 18,417 > 100X 6,341,870 
R13 67 1,285 148,572 12,642 > 100X 6,443,125 
R14 67 1,153 114,801 14,264 > 100X 6,783,140 
Mean - 1,461 100,348 17,459 - 6,594,612 
S.D. - 672 40,240 11,026 - 190,068 
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Table 4.3: Short-read assembly statistics for all 25 A. xylosoxidans isolates 
used in this study, including numbers of contigs, sizes of largest contigs, N50 
values, coverage values and the total sizes of contigs. Assemblies were 
performed using Spades assembler version 3.1.1. 
 
Strain 
Assembly Information 
Contigs 
Largest 
Contig (bp) 
N50 (bp) Coverage Total (bp) 
NCIMB 11015 860 141,469 17,424 > 100X 6,489,821 
DSM 2402 127 685,532 130,241 > 100X 6,802,447 
L1 77 1,037,584 629,784 > 100X 6,793,720 
L5 191 508,865 92,693 > 100X 6,470,420 
L8 110 625,007 196,476 > 100X 6,771,819 
L10 151 714,992 170,117 > 100X 6,859,600 
L11 114 581,453 178,548 > 100X 6,790,401 
L14 156 335,678 126,442 > 100X 6,571,402 
L15 287 435,904 60,726 > 100X 6,801,183 
L16 142 525,536 130,061 > 100X 6,765,818 
L17 102 753,594 241,184 > 100X 6,815,184 
R1 184 445,795 130,265 > 100X 6,924,972 
R2 133 462,894 135,643 > 100X 6,453,898 
R3 1,132 107,851 11,612 > 100X 6,483,870 
R4 544 199,593 29,940 > 100X 6,577,466 
R5 480 222,108 32,361 > 100X 6,827,548 
R6 520 241,447 27,501 > 100X 6,605,589 
R7 908 153,959 16,343 > 100X 6,750,977 
R8 593 153,097 25,188 > 100X 6,670,944 
R9 603 103,277 25,145 > 100X 6,395,077 
R10 783 143,979 18,672 > 100X 6,498,797 
R11 281 257,991 52,469 > 100X 6,394,985 
R12 255 233,326 64,934 > 100X 6,375,895 
R13 328 397,578 48,338 > 100X 6,573,511 
R14 346 236,334 47,456 > 100X 6,849,323 
Mean 376 388,194 105,583 - 6,652,587 
S.D. 296 244,132 127,413 - 172,543 
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4.3.2. Genome assembly and general characteristics of A. xylosoxidans 
genome 
 
Short read assemblies of 25 A. xylosoxidans strains were performed using Velvet 
version 1.2.07, with pre-optimisation performed using VelvetOptimizer version 
2.2.5 (Table 4.2) and Spades assembler version 3.1.1 (Table 4.3). With Velvet, 
the average assembled length of each genome sequenced was 6.6 Mb with a 
standard deviation of 0.2 Mb. The number of contigs varied from 418 – 2,650 
contigs with an average of 1,461 contigs and a standard deviation of 672. The 
average N50 value was 17,459. The size of the largest contig in each assembly 
was, on average, 100,348 bp. Spades performed better than Velvet. With Spades 
the total size of the genomes assembled was, on average, 6.7 Mb with a standard 
deviation of 0.2 Mb. The mean of the number of contigs assembled was 376 
contigs, which is less than was seen in of Velvet‟s assemblies. The average N50 
value was higher, with 105,583 bp. The average size of the largest contigs was 
approximately four times that seen in Velvet‟s assemblies. The result suggested a 
better performance by the Spades assembler in terms of contigs‟ sizes and N50 
values. 
 
In terms of gene prediction, genome assemblies from the Velvet had an average 
GC content and standard deviation value of 67.5% and 0.16%, respectively 
(Table 4.4). The lowest GC content was 67.33%, which belonged to R5, and the 
highest GC content was 67.88%, which belonged to R8. An average of 6,094 
coding sequences (CDS), with approximately 38 tRNA genes and 3 rRNA 
operons, was predicted in the draft genomes. In genome assemblies output by 
Spades assembler (Table 4.4), the average GC content was 67.54% and the 
standard deviation was 2%. The lowest and the highest GC content values were 
62.04% and 69.88%, respectively. Prokka software was used to predict an 
average of 6,052 CDS with 63 tRNA genes and 3 rRNA operons.  
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Table 4.4: Genome features of all A. xylosoxidans isolates, including GC 
content, number of predicted CDS, number of predicted tRNA sequences 
and number of predicted rRNA sequences. These features were obtained from 
Prokka version 1.7.2. 
 
Strain 
Velvet assembler Spades assembler 
%GC CDS  tRNA rRNA %GC CDS  tRNA rRNA 
NCIMB 11015 67.49 5,871 33 3 69.23 5,915 65 3 
DSM 2402 67.39 6,140 37 2 67.26 6,150 60 2 
L1 67.47 6,251 31 3 62.04 6,225 54 3 
L5 67.67 5,919 38 2 67.42 5,823 61 2 
L8 67.55 6,139 38 3 64.44 6,111 61 3 
L10 67.57 6,263 41 2 64.57 6,256 62 2 
L11 67.37 6,277 41 3 65.56 6,232 59 3 
L14 67.57 6,055 32 3 66.55 5,962 62 3 
L15 67.33 6,414 33 3 68.19 6,264 61 3 
L16 67.35 6,142 33 3 65.21 6,101 65 3 
L17 67.45 6,150 45 3 64.97 6,153 59 3 
R1 67.36 6,246 45 3 66.69 6,271 68 3 
R2 67.80 5,836 40 3 67.01 5,778 66 3 
R3 67.48 6,039 31 3 69.57 5,993 61 3 
R4 67.65 6,041 29 3 69.10 5,988 65 3 
R5 67.33 6,254 40 3 68.69 6,198 68 3 
R6 67.55 6,099 42 3 69.12 6,041 69 3 
R7 67.53 6,273 39 3 69.88 6,215 67 3 
R8 67.52 6,206 27 3 69.01 6,124 64 3 
R9 67.78 5,921 28 3 69.72 5,787 64 3 
R10 67.66 6,003 32 3 69.88 5,935 63 3 
R11 67.75 5,828 34 2 68.36 5,816 60 2 
R12 67.88 5,816 40 3 68.09 5,771 65 3 
R13 67.70 5,943 36 3 69.20 5,974 64 3 
R14 67.37 6,215 38 3 68.70 6,210 68 3 
Mean 67.54 6,094 38 3 67.54 6,052 63 3 
S.D. 0.16 167.08 9 0 2 169.23 4 0 
Minimum 67.33 5,816 27 2 62.04 5,771 54 2 
Maximum 67.88 6,414 45 3 69.88 6,271 69 3 
Range - 598 18 1 - 500 15 1 
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Statistical analyses performed using Student‟s t-test showed a non-significant 
difference between the number of predicted CDS in Velvet assemblies and 
Spades assemblies (Student‟s t-test; P=0.383), but the number of tRNA genes 
predicted in Spades assemblies was significantly higher than in Velvet 
assemblies (Student‟s t-test; P=8.01E-25). The analysis suggested that Spades 
assembler performed better in assembling short reads by constructing larger and 
fewer contigs and a greater number of tRNA genes, which was comparable to the 
genome of strain NH44784-1996 (53 tRNAs). As a result, genome assemblies 
from the Spades assembler were used in subsequent analyses in this study. 
However, GC content of strain L1 from Spades assembler was the lowest 
(62.04%). The analysis of L1‟s reads which did not map to the genome of 
NH44784-1996 revealed the presence of the components of bacteriophage. This 
can cause low GC content in genome assembly of strain L1. Therefore, the 
genome of L1 would be used in further analysis with the caveat that the assembly 
had low GC content and the presence of phage‟s components. 
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4.3.3. Pan-genome analysis 
 
To determine a broad picture of the genome, a pan-genome was applied and 
fitted to a mathematical model in R. The pan-genome of A. xylosoxidans was 
determined by sequentially adding the whole gene sets of each genome and 
fitting them to a power model following Heaps‟ law. At the beginning of the 
curve (Figure 4.2), the median number of orthologues from a randomly picked 
genome was approximately 6,000 orthologues. The median increased when 
genomes were added until it reached a maximum point. A fitted curve (Figure 
4.2) predicted that the genome size of A. xylosoxidans reached 14,394 
orthologous groups when 26 genomes were added. This was approximately 2.4 
times the median of a single genome‟s size and 4 times the core genome‟s size. 
With the power law‟s (Heaps‟ law) estimation, the data fitted the power law with 
an exponent in the following model:  
 
 
N = 5571.59 x n
0.291315
 (F1,24 =1802; R
2
 = 0.99; p-value < 2.2e-16) 
 
Where N = the size of the pan-genome and n = the number of genomes.  
With R
2
 at 0.99, this model was able to explain 99% of the data, so the model 
could predict the size of the core genome. 
 
By considering newly discovered orthologues, the number of unique orthologues 
found in each genome was 920 orthologous groups on average (Figure 4.3). With 
every single genome added, the number of new genes decreased and the total 
reached 242 genes when the 25
th
 genome was added. With power law model 
fitted to medians, the curve of new genes followed a decreasing power law 
explained in the following equation:  
 
N = 838.6 x n
-0.38568
 (F1,23=1351; R
2
 = 0.98; p-value < 2.2e-16) 
 
Where N = the number of unique orthologous genes added and n = the number of 
genomes added. According to the R
2
-value, this model covered 98% of the data. 
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Figure 4.2: Boxplot showing the mathematical extrapolation curve of the A. 
xylosoxidans pan-genome. The analysis shows that the number of orthologues 
increases with the number of genomes added. The red line is a least squares fit of 
the power law to the median values. According to the power law, N = κ nγ, so γ > 
0 suggests an open-genome species. 
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Figure 4.3: Boxplot showing the power model of new orthologues found with 
the additional of multiple A. xylosoxidans strains‟ genomes. The red line is a 
least squares fit of the power law to median values. According to the power law, 
N = κ n-α, so α ≤ 1 suggests an open-genome species. 
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4.3.4. Core genome analysis 
 
The next questions to be answered concerned the size of the core genome and the 
functions to which the core genome contributed. As previously described, there 
were 3,764 commonly shared gene families recognised as the core orthologues of 
the A. xylosoxidans genome. The three largest orthologous groups consisted of 
154 genes, 92 genes and 75 genes, respectively, from 26 genomes; they were 
RND-type efflux-coding genes, Acr-family proteins and dipeptide transport ATP 
binding proteins, respectively.  
 
Using a mathematical approach, the result was, as expected, that the core 
genome‟s size decreased with each genome added. The median of the randomly 
selected first genome was approximately 6,000 orthologues and it sharply 
decreased to 5,000 when the second genome was added (Figure 4.4). The median 
number of gene orthologues then gradually reduced until it nearly reached an 
asymptote (a blue dashed line in Figure 4.4). The estimation of the exponential 
model with a least squares fit method showed that the curve reached a minimal 
value of 3,654 orthologous groups, which was approximately half of the genome 
in one genome, following this equation:  
 
N = (1720.05 x e
-0.10030 x n
) +3,654 (F1,24=970; R
2
 = 0.98; p-value < 2.2e-16) 
 
Where N = the number of orthologues in the core genome and n = the number of 
genomes added.  
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Figure 4.4: Boxplot showing the least squares fit curve of the A. xylosoxidans 
core genome. The analysis shows that the number of orthologues decreases with 
the number of genomes added. The red line is a least squares fit of the 
exponential law N = κ e-n/τ + Ω, with the correlation value, R2 = 0.98. This 
estimates that the size of the core genome of A. xylosoxidans is approximately 
half of the size of the whole genome. 
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4.3.5. Core genome single nucleotide polymorphisms (SNPs) and 
phylogeny 
 
The relationships between strains were investigated using phylogenetic trees 
constructed using core genes using two different algorithms: Bayesian inference 
(Figure 4.5) and Maximum-likelihood (Figure 4.6). Of the 3,764 core 
orthologous groups, 3,737 groups were considered core genes in this study due to 
exactly one gene representing one genome in each orthologous group. After 
stripping gaps and concatenating core genes, this resulted in 2.6 Mbp. 
 
There were similarities in the phylogenetic relationships amongst A. 
xylosoxidans in both trees. Phylogenetic analysis revealed two major clades - 
clade I and clade II (Figure 4.5 and 4.6) - with no specific geographical 
correlation. In clade I, there was a Thai-specific cluster (R2, R3, R7, R8, R9, R10 
and R13), which was closely related to a Liverpool isolate, L10. There was also a 
close evolutionary relationship between three Liverpool isolates, which were 
from patients with different conditions - were L8 and L14 (non-CF) and L17 
(CF) (Table 2.2). In clade II, isolates from the same patient (R1, R5 and R14) 
clustered together, demonstrating a close relationship with a non-CF Liverpool 
isolate, L1, and the reference genome, NH44784-1996. Strain NCIMB 11015 
was positioned as a separate sub-clade in clade I. In terms of functional 
distribution of the core genome, there is no difference in the gene functions 
presented in these clades (Figures A2.2 and A2.3). 
 
The Bayesian inference tree showed better statistical support than the Maximum-
likelihood tree. The posterior probability value was better than the bootstrap 
value in the mid-rooted tree. The posterior probability values were more than 0.8 
and most of them were 1.0 in the Bayesian inference tree (Figure 4.5). Most of 
the bootstrap supports were more than 70%, except for two values, which were 
50% and 67%, in Clade I (Figure 4.6). An analysis of new genes discovered in 
each clade revealed that clade I seemed to be more open than clade II, as 
indicated by the extrapolation of new genes discovered in each clade (Appendix 
Figure A2.5). 
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In total, 105,298 positions out of 2,602,900 bp (4.05% of core genome) were 
identified as core genome SNPs. The proportion of polymorphic sites was, on 
average, 4.05% which means that 1 SNPs exists in every 25 bp. By looking at 
clade specifically, a total of 85,651 SNPs and 57,692 SNPs were identified 
within Clade I and Clade II, respectively. 
 
 
Figure 4.5: Bayesian inference mid-rooted phylogenetic tree based on 3,736 
core genes from 26 genomes of A. xylosoxidans included in this study. 
Phylogenetic clades I and II are indicated. Strain nomenclature indicates the 
origins of clinical isolates; „L‟ strains are from Liverpool and „R‟ strains are from 
Thailand. NCIMB 11015 stands for A. xylosoxidans NCIMB 11015; DSM 2402 
for A. xylosoxidans DSM 2402; and NH44784-1996 for A. xylosoxidans 
NH44784-1996. All posterior probability values are higher than 0.8.  
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Figure 4.6: Maximum-likelihood mid-rooted phylogenetic tree based on 
3,736 core genes from 26 genomes of A. xylosoxidans included in this study. 
Phylogenetic clades I and II are indicated. Strain nomenclature indicates the 
origins of the clinical isolates; „L‟ strains are from Liverpool and „R‟ strains are 
from Thailand. NCIMB 11015 stands for A. xylosoxidans NCIMB 11015; DSM 
2402 for A. xylosoxidans DSM 2402; and NH44784-1996 for A. xylosoxidans 
NH44784-1996. Bootstrap values more than 50% were indicated. 
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4.3.6. Comparative genomic analysis 
 
For the purpose of a comparative genomic analysis, 26 genomes of A. 
xylosoxidans strains, including 25 recently sequenced genomes and the 
NH44784-1996 genome, were compared to one another using orthologous 
analysis performed by OrthoMCL software. This generated a total of 8,762 
OrthoMCL groups with 3,764 groups seen in all 26 genomes. These groups were 
defined as „core orthologues‟. The number of genes unique to each isolates was 
approximately 119 genes per genome (Appendix Table A2.2). The largest of 
OrthoMCL‟s output groups was comprised of 154 genes from 26 A. xylosoxidans 
genomes, which are encoded a RND-type efflux pump inner membrane subunit. 
Interestingly, these efflux pumps are associated with drug resistance in A. 
xylosoxidans, which will be discussed in Chapter 5.  
 
The determination of the functions of the core genes using Clusters of 
Orthologous Groups (COGs) suggested that approximately 31% of the core 
genes were assigned generalised and poorly-characterised functions, with most 
being labelled as „hypothetical protein‟ (Table 4.5; Figure 4.7). Apart from genes 
with unknown roles, the core genes employed functions related to adaptation to 
the environment, including roles such as amino acid transport/metabolism 
(12.57%), inorganic ion transportation/metabolism (6.16%) and energy 
production (5.95%), and housekeeping functions such as transcription (9.65%).  
 
For accessory orthologues (Appendix Table A2.3; Figure 4.7), 38% were 
assigned to functional categories. The most abundant group was associated with 
transcription, which made up 6.34% of the genome. The second most abundant 
was associated with amino acid metabolism, comprising 5.41% of the genome. 
Orthologues in the category „inorganic ion transport/metabolism‟ represented 
4.16% of the genome. 
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Figure 4.7: Functional annotation of core orthologous genes and accessory 
orthologous genes in A. xylosoxidans. Genes called by Prokka version 1.7.2 
were entered into the eggNOG database, which annotated functions based upon 
Clusters of Orthologous Groups (COGs) categories. 
 
4.3.7. Recombination 
 
Recombination events are common in bacteria. It is one of the processes that 
drive genetic evolution in bacterial populations. Starting with the core genome 
phylogeny (Figure 4.6), a PHI test and Neighbor-Net tree implemented in 
SplitTree (Figure 4.8A) detected significant levels of recombination in A. 
xylosoxidans. Recombination-detecting programs, ClonalFrame, BratNextGen 
and ClonalFrameML, were applied to SNPs alignments extracted from the 
sequence alignment of the core genes. ClonalFrame did not yield any results. For 
BratNextGen, no clustering resulted from the analysis when default parameters 
were used. With the alpha-parameter set to 1, as suggested by Dr. Pekka 
Martinen, recombination was seen to have happened everywhere across the core 
genome (Figure 4.9). Recombinant fragments detected by the software were 
removed from the core genome alignment. The phylogenetic tree then was re-
built based upon recombination-filtered alignments (Figure A2.6); however the 
recombination in the alignments was still detected by SplitTree and the PHI test 
Core orthologues
Accessory orthologues
Gene distribution based on eggNOG functional annotation
0 10 20 30 40 50 60
Feature percentage (%)
F
u
n
c
ti
o
n
a
l 
c
a
te
g
o
ry
(A) RNA processing and modification 
(B) Chromatin structure and dynamics 
(J) Translation 
(K) Transcription 
(L) Replication, recombination, repair 
(D) Cell cycle control, mitosis, meiosis 
(M) Cell wall/membrane biogenesis  
(N) Cell motility 
(O) Posttranslational modification, protein turnover, chaperones 
(T) Signal transduction mechanisms 
(U) Intracellular trafficking, secretion 
(V) Defense mechanism  
(W) Extracellular structures 
(Z) Cytoskeleton 
(C) Energy production, conversion
(E) Amino acid transport, metabolism 
(F) Nucleotide transport, metabolism
(G) Carbohydrate transport, metabolism 
(H) Coenzyme transport, metabolism 
(I) Lipid transport, metabolism 
(P) Inorganic ion transport, metabolism 
(Q) Secondary metabolites 
(R) General function prediction 
(S) Function unknown 
Chapter 4 
 107 
(Figure 4.8B). Furthermore, recombination analysis using ClonalframeML 
revealed a complicated 4,978 recombination events spreading through out the 
core genes of A. xylosoxidans (Appendix Figure A6.1). 
 
Figure 4.8: SplitTree‟s Neighbor-Net phylogenetic based upon SNP 
identified on 3,737 core genes, showing the net-like connection of core SNPs 
of 26 genomes of A. xylosoxidans A) before recombination sites were filtered 
out and B) after recombination sites were filtered out by BratNextGen. 
Strain nomenclature indicates the origins of clinical isolates: „L‟ strains are 
clinical isolates from Liverpool; „R‟ strains are clinical isolates from Thailand; 
NCIMB 11015 stands for A. xylosoxidans NCIMB 11015; DSM 2402 for A. 
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xylosoxidans DSM 2402; and NH44784-1996 for A. xylosoxidans NH44784-
1996. 
 
Figure 4.9:  Recombination detection across the core genome of A. 
xylosoxidans performed using BratNextGen. The dendrogram on the left-
hand side represents PSA (Proportion of shared ancestry), analysed by 
bratNextGen where alpha = 1. The colour of each block on the plot represents 
recombinant sequences received from strains/clusters corresponding with the 
colours on the dendrogram. Strain nomenclature indicates the origin of clinical 
isolates; „L‟ strains are clinical isolates from Liverpool; „R‟ strains are clinical 
isolates from Thailand; NCIMB 11015 stands for A. xylosoxidans NCIMB 
11015; DSM 2402 for A. xylosoxidans DSM 2402; and NH44784-1996 for A. 
xylosoxidans NH44784-1996. 
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To confirm that the recombination detection software works with other genomic 
data, BratNextGen was applied to Bartonella hensalae genomes. As presented in 
Appendix Figure A6.2, BratNextGen revealed possible recombination events in 
21 B. hensalae genomes when an alpha-parameter of 1 was used. Of the 809 
genes affected by recombination events, 51 genes were virulence-associated 
genes, encoding such proteins as those involved in adhesion, a hemin-binding 
protein and the type IV secretion system, which have been reported as major 
virulence genes in host-specific species/strains (Chen, 2004; Engel et al., 2011). 
 
4.3.8. Cluster analysis 
 
To assess the phylogenomic variation and adaptation in A. xylosoxidans, the 
occurrence of accessory genes was investigated. The clustering analysis inferring 
the presence/absence of 4,998 orthologous groups of accessory genes clearly 
illustrated two major groups, namely clade A and clade B (Figure 4.10).  
 
As shown in Figure 4.10, clade A included the majority of strains used in this 
study: NCIMB 11015, DSM 2402, L1, L5, L8, L10, L14, L16, L17, R1, R2, R4, 
R5, R6, R8, R11, R12, R13, R14 and NH44784-1996. Clade B was comprised of 
six strains: L11, L15, R3, R7, R9 and R10. Clade B included strains that were 
grouped by their country of origin - R3, R7, R9 and R10, all of Thai origins were 
grouped together, and L11 and L15, both of Liverpool origins, formed a single 
group. 
 
Of the 4,998 gene families, 1,067 orthologues were found to be unique to clade 
A and 384 orthologues were unique to clade B. Using Random Forest™ to 
investigate lineage-differentiating genes, comparative analysis suggested that 
ORTHOMCL5083 and ORTHOMCL5053, which encode a putative Acetyl-CoA 
synthetase (ADP-forming) alpha and beta chains and major facilitator 
superfamily MFS 1, respectively, were statistically significant factors associated 
with the formation of Clade A (Figure 4.11). When the tables were analysed, 
these two orthologous groups were present in all members of clade B, except 
R13, whereas none of the clade II contained these orthologous groups. 
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Further investigations into clade A (Figure 4.10) revealed that the clade could be 
divided into three sub-clades, which were named A1, A2 and A3. Binary table 
inspection showed that there were no clade A3-specific orthologous groups, but 
there were 15 orthologous groups that existed in all strains in clade A except R1, 
R5 and R14. Between clade A1 and A2, Random forest™ revealed that 
ORTHOMCL5667, ORTHOMCL5174 and ORTHOMCL5393, each of which is 
annotated as „hypothetical protein‟, were statistically involved in differentiation 
between clade A1 and clade A2 due to greatly mean decreased accuracy scores 
and mean decreased Gini scores (Figure 4.12). By determining an individual 
orthologous group, ORTHOMCL5667 was present in all of clade A2‟s strains 
and L14 (Clade A1 in Figure 4.11), whereas ORTHOMCL5174 and 
ORTHOMCL5393 existed in both clade A1 and A3. Therefore, only 
ORTHOMCL5667 was statistically reliable as a gene family that differentiated 
clade A2 from clade A3. 
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Figure 4.10: A hierarchical heatmap illustrating the clustering of A. xylosoxidans strains based on the occurrence of the orthologous 
groups of 26 A. xylosoxidans genomes in this study. Condition of patients (CF versus non-CF) and country of origin of isolates are included. 
Clade A and clade B are indicated. Strain nomenclature indicates the origin of clinical isolates: „L‟ strains are clinical isolates from Liverpool; 
„R‟ strains are clinical isolates from Thailand; NCIMB 11015 stands for A. xylosoxidans NCIMB 11015; DSM 2402 for A. xylosoxidans DSM 
2402; and NH44784-1996 for A. xylosoxidans NH44784-1996. 
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Figure 4.11: A plot of outstanding results from a Random Forest™ 
classification of orthologues that were associated with clade A and clade B 
differentiation in Figure 4.9. The analysis shows that genes in 
ORTHOMCL5083 and ORTHOMCL5053 were associated with the 
differentiation between clade A and clade B. The X-axes indicate the level of 
importance. The Y-axes show the list of orthologues. 
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Figure 4.12: A plot of outstanding results from a Random Forest™ 
classification of orthologues that were associated with sub-differentiation of 
clade A in Figure 4.9. The analysis shows that genes in ORTHOMCL5667 were 
associated with the differentiation of sub-clades in clade A. The X-axes indicate 
the level of importance. The Y-axes show the list of orthologues. 
 
4.3.9. Comparison of core genome phylogeny and accessory genome 
clustering 
 
By comparing a core genome-derived phylogenetic tree with an accessory genes-
based clustering (Figure 4.13), a tangle-gram showed the similarities in strain 
clusters between the core genome phylogeny and hierarchical clusters of 
accessory orthologues. Five pairs of genomes, which were from different sources, 
clustered together; they were strains NH44784-1996 and L1, L5 and R11, L8 and 
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L17, AX DSM 2402 and L16, and R3 and R10. Isolates from the same patient 
clustered together; they were R1, R5 and R14, and L11 and L15 (highlighted by 
a red box and red lines in Figure 4.13). The comparison of clinical isolates from 
the same patients, as well as the comparison of clinical isolates from a CF patient 
with a strain from a non-CF patient was performed. Isolates from the same 
patients were L11 and L15, and R1, R5 and R14. The clinical isolates from non-
CF patient was L1, compared with the clinical isolates from a CF patient, strain 
NH44784-1999. 
 
In the comparison of A. xylosoxidans genomes collected from the same patient 
from Liverpool, L11 and L15, 5,761 gene families were shared between these 
two strains and only two SNPs existed in the core genomes between them. There 
were 667 genes that were unique to one of the strain. For Thai strains from the 
same patients, R1, R5 and R14, there were 5,745 shared gene orthologues 
(90.5%) with three SNPs in the core genome, with 602 genes unique to one of 
the strains. 
 
In total, 5,651 gene families were conserved between strains L1 and NH44784-
1996, and 107 SNPs were identified in their core genomes. A total of 577 genes 
were unique to either of them. With the exception of genes defined as „poorly 
characterised‟ (~63%), different genes in L1 were involved in amino acid 
metabolism/transportation and fatty acid metabolism/transportation, and genes 
that were not present in NH44784-1996 were associated with carbohydrate 
metabolism/transportation. 
 
A comparison of a strain from a non-CF patient, L17, and a strain from a CF 
patient, L8, showed a close relationship between these strains. Conserved gene 
families between these strains numbered 5,734 gene families. The alignment of 
the core genomes revealed 40 nucleotide variations between the strains. 
Considering the accessory genome only, the CF strain possessed more phage-
related genes and inorganic ion-related genes than L8. 
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Figure 4.13: A tangle-gram tree to compare core genome phylogeny (left) and accessory genome clustering (right). The red boxes and 
red lines indicate genomes that are closely related to one other according to both core genome analysis and accessory genome analysis. 
Strain nomenclature indicates the origins of clinical isolates: „L‟ strains are clinical isolates from Liverpool; „R‟ strains are clinical isolates from 
Thailand; NCIMB 11015 stands for A. xylosoxidans NCIMB 11015; DSM 2402 for A. xylosoxidans DSM 2402; and NH44784-1996 for A. 
xylosoxidans NH44784-1996. 
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4.4. Discussion 
 
A. xylosoxidans is an emerging pathogen causing infections in Cystic Fibrosis 
patients (Dunne & Maisch, 1995; Krzewinski et al., 2001; Liu et al., 2002; 
Ferroni et al., 2002; Gibson, Burns & Ramsey, 2003; Van Daele et al., 2005; 
Rønne Hansen et al., 2006; De Baets et al., 2007; Spicuzza et al., 2009; Pereira 
et al., 2011; Ciofu, Hansen & Høiby, 2013; Mahenthiralingam, 2014). A. 
xylosoxidans can also cause problems in non-CF infections (Yabuuchi & Oyama, 
1971; Holmes, Snell & Lapage, 1977), including, opportunistic infection (Igra-
Siegman, Chmel & Cobbs, 1980; Giacoia, 1990; Reverdy et al., 1984; Arroyo et 
al., 1987; Gómez-Cerezo et al., 2003; Tena et al., 2005). So far, there have been 
a number of studies focusing on different kinds of infection caused by A. 
xylosoxidans (Adam et al., 2013; Tatro et al., 2013; Lee et al., 2014; Tena et al., 
2014; Otta et al., 2014). Despite the fact that previous works demonstrated 
comparative analysis of the members of genus Achromobacter (Li et al., 2013) 
and antibiotic resistance genes in A. xylosoxidans (Hu et al., 2015), a 
comprehensively comparative analysis of A. xylosoxidans genomes has not yet 
been performed.  A. xylosoxidans from a teaching hospital in Thailand and 
clinical sites in Liverpool have been used here in a comparative genomic analysis 
of the species to obtain comprehensive information about the genetic diversity of 
A. xylosoxidans from different areas, and obtain a better understanding of the A. 
xylosoxidans pan-genome. 
 
4.4.1. Phylogenetic relationships reveal global characteristics of A. 
xylosoxidans 
 
This is the first study to conduct comparative genomic analysis of A. 
xylosoxidans strains from different locations. A phylogenetic analysis of A. 
xylosoxidans (Figure 4.6 and Figure 4.7) suggests a global and diverse 
population structure of A. xylosoxidans, as implied by the absence of 
geographical location-specific clades. Heatmap clustering based on accessory 
genomes also presents non-specific clades amongst these genomes. Interestingly, 
some genomes from different locations are paired together, including those of 
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strains NH44784-1996 and L1, L5 and R11, L8 and L17, and DSM 2402 and 
L16. This grouping of genomes by core genome phylogeny and disposable 
genomes is also in agreement with strain typing performed using RAPD (Figure 
3.6) and MLST (Figure 3.7). These finding suggests that geographical feature of 
does not reflect genomic structure of A. xylosoxidans. This is not in agreement 
with other species. Genomic analyses in human pathigens, such as V. cholerae 
and C. fetus, illustrate that geographical identity and niche specificity of the 
pathogens can be influenced by genomic structure, mobile genetic elements in 
particular (Dutilh et al., 2014; Kienesberger et al., 2014). 
 
Also, this can suggest the global distribution of A. xylosoxidans in the 
environments (Bador et al., 2013). It is noteworthy that compromised patients 
will probably be infected by bacteria from the environment. Moreover, the 
complication regarding the epidemiology of the species would be seen during 
outbreak, as there is no geographical specificity. The global diversity 
characteristic is also present in other pathogens. For example, similar frequencies 
of clonal complex of S. aureus were seen in French and Algerian isolates. This 
similarity was probably driven by the migration of population between these two 
countries (Ruimy et al., 2009). Considering A. xylosoxidans, the global diversity 
of the isolates can be occurred by the migration of population between Thailand 
and the U.K. However, the greater number and the more diversity of sites of A. 
xylosoxidans isolates are required for further investigation. 
 
4.4.2. The possibility of genetic recombination in A. xylosoxidans 
 
Recombination is a key driver that causes a huge leap of evolution in bacteria 
because bacteria can exchange genetic fragments with one other. This potentially 
leads to a significant change in the bacteria, enabling more rapid evolution than 
can be achieved by the small changes that arise due to single mutations during 
replication (Boinett & Cain, 2014). Also, recombination can be associated with 
important phenotypes such as antibiotic resistance if the recombination involves 
transfer of drug resistance genes (Hanage et al., 2009; Croucher et al., 2014). 
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In a previous study of six Achromobacter genomes (Li et al., 2013), a low rate of 
recombination between different species of genus Achromobacter was detected; 
however, this could have been underestimated due to the diversity of genomes 
used in the study. Recombination analysis is a problem in this study. Analysis 
using a Neighbor-Net-derived phylogenetic tree and a PHI test in SplitTree 
revealed significant levels of recombination signals within the core genome 
alignment. However, ClonalFrame could not reveal recombination segments 
within the core genome. It is important to note that ClonalFrame is suitable for 
alignments of small regions/genes such as MLST analysis (Didelot & Falush, 
2007), rather than large data sets, such as the core genome‟s alignment. 
BratNextGen is a program that is able to detect and identify recombination in 
various bacteria including Streptococcus pneumoniae (Marttinen et al., 2012; 
Croucher et al., 2013; Chewapreecha et al., 2014), Staphylococcus aureus 
(Castillo-Ramírez et al., 2012), Escherichia coli (McNally et al., 2013) and 
Enterococcus faecium (de Been et al., 2013). In this study, the software did 
detect significant recombined fragments but it could not resolve recombination 
hotspots across 26 A. xylosoxidans genomes. Howell et al. (2014) experienced 
similar limitations when performing a recombination analysis using 
BratNextGen with Haemophilus parasuis genomes. Taking all of the above into 
consideration, it seems that there was evidence of recombination in the A. 
xylosoxidans genomes; however, genetic regions affected by recombination were 
not clearly identified by softwares used in this study (BratNextGen and 
ClonalFrame ML). Another recombination software (Gubbins) will be 
considered. Taking all above into account, the selection of the diversity of the 
samples (genomes) and using multiple softwares are important for recombination 
analysis in bacteria. 
 
Moreover, it has an influence on virulence and drug resistance. Together with 
this evidence and these implications, it appears that recombination guides A. 
xylosoxidans to acquired and antimicrobial drug-resistant phenotype, which will 
be discussed in Chapter 5. 
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4.4.3. Pan-genome characteristic correlates with receivable characteristic 
of A. xylosoxidans 
 
Li et al. (2013) revealed that pan-genome of six genomes of members of genus 
Achromobacter is opened; however, they did not focus on A. xylosoxidans. The 
prediction of the pan-genome was in agreement with the open genome 
characteristic. In addition, with Heaps‟ law, the model of new genes acquired 
supported the open-genome, which implies continued exchange of genes 
between the gene pool of the species and environment (Tettelin et al., 2008). 
Interestingly, pairwise comparison of clinical isolates obtained from the same 
patients revealed the difference between the isolates. Considering core-genome 
phylogeny and the heatmap of the existence of accessory genome, L11 was 
closely related to L15, and R1, R5 and R14 were closely related to one another. 
However, there was approximately 10% difference between them. This can be 
also explained by the open pan-genome characteristic of the species (Figure 4.2 
and Figure 4.3). This is in agreement with the evidence of genetic recombination. 
Examples of factors that drives genetic exchange in bacteria are mobile gene 
element transfer (Hu et al., 2015; Chen et al., 2014) and bacteriophage-related 
gene transfer (Wittmann et al., 2014). Previous studies report that genetic 
exchange occurring in A. xylosoxidans contributes to antibiotic resistance, such 
as genes encoding carbapenemase (Yamamoto et al., 2012; Hu et al., 2015). This 
is a problem that needs to be concerned in A. xylosoxidans infection.  
 
When considereing the genomic characteristics and pathogenicity of a species, 
pathogens with a closed-genome are assumed to be real pathogens because they 
do not need any virulence genes from other species (Rouli et al., 2014). 
Pathogens with open-genome, on the other hand, are likely to adapt from 
commensal strains or non-pathogenic bacteria to survive in the human body 
(Table 4.5). Bacillus anthracis is an example of a pathogen with a closed-
genome (Rouli et al., 2014). Its core genome covers approximately 99% of the 
whole genome‟s size. This study‟s pan-genome analysis considers B. anthracis 
an absolute pathogen due to the stability of the genome. Here, with its open-
genome, A. xylosoxidans would have the ability to exchange its genetic materials 
with surrounding pathogens. In other words, A. xylosoxidans can receive 
Chapter 4 
 120 
virulence genes or antibiotic resistance genes, and it can donate those genes to 
surrounding organisms. This suggests that this organism could have a major 
impact upon public health in the future by acting as a genetic reservoir. 
 
 
 
Table 4.5: Examples of pan-genome analyses on different organisms 
Pan-genome Organism 
Opened Streptococcus agalactiae (Tettelin et al., 2005) 
 Haemophilus influenzae (Hogg et al., 2007) 
 Escherichia coli (Rasko et al., 2008) 
 Streptococcus pneumoniae (Donati et al., 2010) 
 Enterococcus faecium (Qin et al., 2012) 
 Streptococcus mutans (Song et al., 2013) 
Closed Salmonella (Jacobsen et al., 2011) 
  Bacillus antracis (Rouli et al., 2014) 
 
4.4.4. Antibiotic resistance associated efflux pumps are abundant as the 
largest OrthoMCL‟s output in A. xylosoxidans 
 
One of the most concerning problems caused by A. xylosoxidans infections is the 
species‟ multidrug resistance. Whilst antimicrobial resistance is an important 
factor for clinicians when treatment is needed, an in-depth study of association 
between antimicrobial resistance phenotypes and corresponding genes is, perhaps, 
useful in studying resistance mechanisms to particular drugs. Several studies 
reveal that multidrug resistance in bacteria can possibly be regulated by 
horizontal gene transfer. However, A. xylosoxidans strains exhibit natural drug 
resistance due to their intrinsic resistance genes, for examples, OXA-114 beta-
lactamase (Doi et al., 2008) and RND-type efflux pumps (Bador et al., 2011, 
2013). In a similar way to previous studies where members of the genus 
Achromobacter, especially A. xylosoxidans, were found to possess multiple 
numbers of efflux pumps, the analysis of orthologous genes here showed that A. 
xylosoxidans strains possess high numbers of genes encoding efflux pumps 
within their genomes. The RND-type efflux pump ranks as the largest gene 
group amongst efflux pumps and amongst all genes in A. xylosoxidans (Hu et al., 
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2015). This is in accordance with this study, which showed that an orthologous 
groups consisting of the inner membrane subunit of the RND-type efflux pump – 
CmeB - is the largest protein group across 26 genomes of A. xylosoxidans. The 
RND-type efflux system is comprised of three parts: the inner membrane protein, 
the outer membrane protein, and an accessory protein or membrane fusion 
protein (Nikaido, 2011).  In previous studies, Bador et al. (2011, 2013) indicated 
two efflux systems, AxyABM and AxyXY-OprZ, which are associated with 
antibiotic resistance in Achromobacter species. In the same manner, this analysis 
addressed two RND-type transport systems, which are homologous to AxyABM 
and AxyXY-OprZ. Further analysis and detail of antibiotic resistance in A. 
xylosoxidans will be further discussed in Chapter 5.  
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4.5. Conclusions and future work 
 
This chapter has demonstrated a comparative analysis of A. xylosoxidans 
genomes from different sources. In this study, next-generation sequencing 
technologies, combined with bioinformatics tools, were used to investigate the 
population structure and genomic characteristics of A. xylosoxidans. 
 
Analysis of 25 newly sequenced genomes of A. xylosoxidans together with a 
publicly available reference genome, A. xylosoxidans NH44784-1996, showed a 
global relationship between strains. Isolates from different geographical sources 
(Thailand and Liverpool) did not cluster by either the core genome or the 
accessory genome, agreeing with analysis based on MLST typing (Figure 3.7) 
and suggesting that there are no distinct geographical associations with particular 
genotypes. Nonetheless, the limitations of this study are the number of samples 
collected and the range of sampling locations. Further study will benefit from 
expanding the range of isolates, in terms of number and location, in order to 
achieve a comparative genomic analysis of A. xylosoxidans. 
 
The study of the core-genome suggested that 3,763 gene families (approximately 
half of the genome‟s size) are conserved within the species. The analysis of new 
genes obtained, together with the pan-genome, allows for this Achromobacter 
species to be described as having an open-genome, which indicates the 
possibility of genetic exchange, such as recombination and mobile genetic 
elements, within the species or with different species. Furthermore, in silico 
analysis of recombination across the genomes of 26 strains of A. xylosoxidans 
using SNPs from the core gene alignment indicated that a recombination event 
occurred in these A. xylosoxidans genomes. Nevertheless, affected recombination 
regions were not successfully detected due to the large diversity of the genomes. 
This, therefore, guides us to perform additional work on recombination analysis 
within the core genome‟s clades or within regions from whence isolates were 
obtained. Moreover, comparative genomic analysis focused on antibiotic 
resistance and pathogenicity of A. xylosoxidans is required. 
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Chapter 5  
The genetics and phenotype of antibiotic resistance in 
Achromobacter xylosoxidans 
 
5.1. Introduction 
 
5.1.1. General overview of antibiotics 
 
Antibiotics improve life expectancy and increase survival rates of patients, 
notably reducing the number of patients who die as a result of an infection 
following an operation. Dating back to 1941, when penicillin was first 
administered, antibiotics have been used to treat patients infected with bacteria, 
whilst research into antibiotic discovery and development has continued. 
Antibacterial agents work via four main mechanisms (Katzung, Masters & 
Trevor, 2009): 
 
1. Interrupting and inhibiting cell wall production 
2. Altering cell membrane permeability 
3. Interfering with protein synthesis 
4. Interfering with nucleic acid synthesis 
 
The first mode of action is that the agent interrupts bacterial cell wall production 
by binding to the protein that elongates the cell wall structure or by directly 
binding to cell wall components. Without a cell wall, bacteria will become 
shrivelled in hypertonic solutions or be lysed in hypotonic solutions. Agents 
acting in this manner include the beta-lactams and glycopeptides. Beta-lactam is 
the most famous group of antibiotics, widely used across the world due to the 
spectrum of drugs available. The chemical structure of the beta-lactams mimics 
the structure of D-alanyl-D-alanine (Figure 5.1). Beta-lactam agents inhibit cell 
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wall synthesis by competitively binding to the D-alanyl-D-alanine transpeptidase 
enzyme or penicillin-binding proteins (Kong, Schneper & Mathee, 2010). This 
results in no cross-linking between murein polymers, thus weakening the cell 
wall. Examples of groups of drugs in this category are penicillin, cephalosporin 
and carbapenem.  
 
 
Figure 5.1: Chemical structures of penicillin (a beta-lactam antibiotic) and 
D-alanyl-D-alanine (cell wall component). This demonstrates the similarity of 
–CO-N- group in both chemicals. The beta-lactam ring is highlighted in red. 
 
The synthesis of bacterial cell walls is not interrupted only by the inhibition of 
the enzyme that processes the biosynthesis but also by interference with 
biosynthesis molecules. Glycopeptide antibiotics act to inhibit the cross-links 
between murein molecules by attaching directly to the D-alanyl-D-alanine 
moiety of murein molecules. This attachment results in the cell‟s inability to tie 
the cell wall. Vancomycin is an example of a glycopeptide antibiotic. 
 
The second mechanism of action is to interrupt and change membrane 
permeability so as to allow water or other antibiotics to get into, and kill bacteria. 
Drugs in this group should contain a hydrophobic group as well as a hydrophilic 
group that makes the chemicals insert themselves within the cell membrane and 
disrupt the membrane‟s structure and permeability. In other words, the agents 
behave as a detergent. Polymyxin and colistin exemplify drugs employing this 
mode of action. 
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The third mode of action seen in drugs is to interrupt or to inhibit cellular protein 
biosynthesis. Proteins are the main components that drive cellular functions and 
keep cells alive. Therefore, inhibiting protein biosynthesis can stop bacteria from 
growing and/or can kill them. Chemicals in this category include aminoglycoside, 
chloramphenicol, tetracycline and macrolide. These agents take part in protein 
synthesis inhibition by (1) preventing the formation of an initiation complex and 
inducing incorrect translation (aminoglycoside), (2) preventing the sitting of 
amino-acyl tRNA (tetracycline), (3) preventing the formation of a peptide bond 
(chloramphenicol) and (4) inhibiting translocation of the ribosome (macrolide) 
(Figure 5.2). 
 
Figure 5.2: A diagram to show an mRNA-ribosome complex and target sites 
for multiple antibiotics. Dashed boxes illustrate the binding sites at which the 
indicated antibiotics act. 
 
The fourth way that antibiotics work is to interfere with nucleic acid synthesis, 
which ultimately halts bacterial division and reproduction. There are two major 
drug targets related to nucleic acid synthesis: the folate biosynthesis pathway and 
the DNA replication process.  
 
Tetrahydrofolate is essential to nucleotide biosynthesis and methionine 
biosynthesis in bacteria. Briefly, tetrahydrofolate acts as a methyl group carrier 
and provides methyl groups for the biochemical synthesis of many molecules 
mRNA
Ribosome
tRNA
A siteP siteE site
Macrolide
Tetracycline
Aminoglycoside
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including purines, pyrimidines and methionine (Figure 5.3). Dihydropteroate 
synthase and dihydrofolate reductase are key enzymes in folate metabolism, 
which does not take place in humans, and they are inhibited by sulfamethoxazole 
and trimethoprim, respectively (Figure 5.3).  
 
Figure 5.3: Tetrahydrofolate biosynthesis pathway in prokaryotic organisms. 
The diagram shows two enzymes that are inhibited by the two antibiotics: 
sulfamethoxazole and trimethoprim. The inhibition of these enzymes leads to a 
shortage of substrates for nucleotide and methionine biosynthesis in prokaryotic 
organisms. 
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DNA replication is another target for antimicrobial agents. During DNA 
replication, the movement of the replication induces the formation of positive-
supercoils downstream to the replication site. However, negative-supercoils are 
preferred during the DNA replication. The topology of DNA is changed from 
positive-supercoils into negative-supercoils by DNA topoisomerase (Witz & 
Stasiak, 2010). The reaction happens at the binding pocket of topoisomerase and 
involves cutting, unwinding and rejoining of the DNA strands, allowing DNA 
replication to continue. The function of DNA topoisomerase can be inhibited by 
agents in category fluoroquinolones (Drlica, 1999). Fluoroquinolone antibiotics, 
including ciprofloxacin and levofloxacin, target the enzyme by binding to the 
pocket. As a result, DNA replication is interrupted by improper topoisomer of 
the DNA supercoils, leading to the inhibition of bacterial growth. 
 
5.1.2. Antibiotic resistance in Gram-negative pathogenic bacteria 
 
Clinical use of antibiotics dates back to the time when penicillin was discovered 
by Sir Alexander Fleming and was first synthesised by Sir Howard Florey. Since 
then, natural products, semi-synthetic substances and synthetic substances have 
been developed and trialled. Antibiotics have become a major weapon in dealing 
with bacterial infections. However, pathogens have become less susceptible 
and/or resistant to antibiotic agents. An increase in an antibiotic‟s use is a driving 
force in causing the emergence of drug-resistant bacteria. The Infectious 
Diseases Society of America has monitored six resistant bacteria referred to as 
„ESKAPE‟: E. faecium, S. aureus, K. pneumoniae, A. baumanii, P. aeruginosa 
and Enterobacter species. Although S. aureus has attracted attention from 
researchers and clinicians around the world with the eagerness to invest money 
in research into methicillin-resistant S.aureus (Boucher et al., 2009), other 
pathogens, in particular Gram-negative bacteria, are more problematic, especially 
in hospitals. WHO Antimicrobial resistance global surveillance 2014 reports that 
antibiotic resistance was noticed in several common pathogens including E. coli, 
S. pneumoniae and Salmonella species 
(http://www.who.int/drugresistance/documents/surveillancereport/en/). 
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In Gram-negative bacteria, there are four main mechanisms that drive drug 
resistance (Torres, Villegas & Quinn, 2007):  
 
1. Enzyme modification that involves a chemical reaction that changes 
the molecular structure of the chemical, resulting in loss of drug 
function 
2. Efflux transport system that pumps substances, such as antibiotics, 
out of organisms 
3. Membrane permeability change due to the mutation of porin protein 
4. Mutated drug target, which results in inability to bind to the target 
 
Enzymatic modification is the process by which an enzyme modifies the 
structure of an antibiotic through various chemical reactions, for example, 
hydrolysis and acetylation. A good example of a resistance-associated hydrolytic 
enzyme is beta-lactamase. It has become well known since it was first described 
in environmental isolates (Abraham & Chain). Interestingly, in Gram-negative 
bacteria, it is a major factor that contributes towards beta-lactam resistance 
because it resides in the periplasmic space, which the agent reaches before 
moving into the cytoplasm. Currently, beta-lactamases are grouped into 4 
categories – A, B, C and D - based on similarities in their amino acid sequences 
(Bush, 2010). Acetylation is another mechanism that can alter and inactivate 
antibiotics, involving the addition of an acetyl group to an antibiotic that results 
in the inactivation of the agent. A noticeable example of an acetylating enzyme is 
aminoglycoside acetyltransferase, which adds an acetyl group to aminoglycoside 
resulting in an inactivated agent (Dowding, 1979). 
 
Pumping out is another mechanism that decreases the accumulation of foreign 
substances by forcing them to leave the cell. Efflux pumps contribute towards 
this role. In pathogenic bacteria, five families of antibiotic resistance-associated 
efflux pumps are defined: major facilitator (MF), multidrug and toxic efflux 
(MATE), resistance nodulation division (RND), small multidrug resistance 
(SMR) and ATP-binding cassette (ABC) (Webber, 2002; Sun, Deng & Yan, 
2014). Normally, pumping mechanisms alone rarely have a significant effect 
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upon MIC; however, an overexpression of, particularly, intrinsic efflux pumps 
may bestow upon a multidrug resistance mechanism (Webber, 2002). 
 
Cellular permeability is regulated by the presence of porins, membrane proteins 
that act as filters in cells. Many antibiotics penetrate cells via these channels. 
Some antibiotics have their own specific channels; for example, carbapenem 
enters cells via the OprD porin only. The mutation of these membrane proteins 
causes decreased influx of antibiotics into bacterial cells. Moreover, reduced 
numbers of porins and reduced permeability of porins indicate resistance in 
strains as seen, in HMP-AB in A. baumannii (Gribun et al., 2003). 
 
The last possible antibiotic resistance mechanism is the modification of drug 
targets. This modification is due to individual mutations or mutated genes 
acquired from other bacteria. Resistance-causing mutations can arise in any drug 
target inside a bacterial cell including, penicillin-binding protein, dihydropteroate 
synthase and topoisomerase. The mutation of a penicillin-binding protein is the 
most well-known example of target modification due to the evolution of 
methicillin-resistant S. aureus (Hartman & Tomasz, 1984). The mutation of drug 
target can be transferred from animal pathogens to human pathogens. For 
example, fluoroquinolone resistant Campylobacter induced by extensive use of 
fluoroquinolone in poultry was transferred from chicken to human, leading to 
fluoroquinolone resistant Camplylobacter in human (Endtz et al., 1991).   
 
5.1.3. The transfer of antibiotic resistance via integron 
 
The exchange of genes allows bacteria to evolve and to adapt to certain 
environments. Even within the same species, bacteria can behave differently on 
account of the expression of obtained genetic elements (Ochman, Lawrence & 
Groisman, 2000). Horrizontal Gene Transfer (HGT), also known as Lateral Gene 
Transfer, is a form of genetic transfer that does not happen via reproduction, but 
occurs as genetic elements move from one bacterium to another bacterium 
(Stokes & Gillings, 2011). HGT has a remarkable impact on the evolution and 
adaptation of bacteria because it increases the chance of a phenotype change 
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more than the accumulation of single mutations does. Antibiotic resistance is a 
phenotype that is influenced by genetic exchange. As a result of exchange, 
different antibiotic susceptible profile can be present in the same species (Maiden, 
1998). 
 
A specific type of genetic element transfer involves integrons. The integron is a 
genetic element that enhances gene transfer using its internal cassette. In general, 
the structure of an integron contains three parts: the integrase gene, a 
recombination site, and a gene cassette (Figure 5.4). 
 
Figure 5.4: The general structure of integron. A diagram presents the structure 
of integron. The first part is 5‟ conserved sequence coding integrase. This is the 
class determinant of the integron, depending on the class of integrase (class 1 – 
class 5). The second part consists of gene cassettes obtained from the 
environment, catalysed by integrase. The last part is 3‟ conserved sequence, 
which is varied in different integrons. 
 
A single integron can have more than one gene cassette (Stalder et al., 2012). 
There are five classes of integron defined, based on the homology of the amino 
acid sequences of integrase genes. Class 1 integrons are the best-known type due 
to their being extensive studied. This integron class is evolutionarily related to 
Tn402. Interestingly, the integron is widely associated with antibiotic resistance 
transfer in bacteria and its sequence is highly conserved (Stalder et al., 2012). 
The conserved sequence at the 5‟ end (5‟-CS) of the element is used to determine 
the presence of the integron in bacteria (Gillings et al., 2009). The structure of 
3‟-CS is comprised of a quaternary ammonium compound transporter gene 
(qacEΔ), and sulfonamide-resistance dihydropteroate synthase (sul1). The former 
is associated with quaternary ammonium compound resistance and the latter is 
associated with sulfonamide resistance (Paulsen et al., 1993). As this type of 
integron, containing qacEΔ and sul1, is commonly found in clinical samples, 
Int Cassette 1
3’-CS5’-CS
Cassette n
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some authors call it „clinical class 1 integron‟ (Gillings et al., 2009). The second 
class of integron, class 2 integrons, is believed to be in association with Tn7. The 
conserved sequence of class 2 integrons is comprised of antibiotic resistance 
genes such as trimethoprim-resistant dihydrofolate reductase (dfrA1) and 
streptomycin-resistant aminoglycoside adenyltransferase (aadA1) (Hansson et al., 
2002). The third class of integron has been recognised not to have an impact on 
clinical microbiology (Rowe-Magnus & Mazel, 2002; Stalder et al., 2012). 
However, recent studies reveal that class 3 integrons have a role in the dispersion 
of antibiotic resistance (Barraud et al., 2013; Kargar et al., 2014). Another two 
classes of integron have not been frequently identified, however the literatures 
suggest that they are associated with the development of antibiotic resistance in 
genus Vibrio (Sørum, Roberts & Crosa, 1992; Hochhut et al., 2001). 
 
There are a number of studies reporting that integrons, especially class 1 
integrons, carry antibiotic resistance genes. Class 1 integrons are disseminating 
in the environment. Furthermore, the class 1 integrons that do not carry antibiotic 
resistance gene cassettes are often found in environmental bacteria, 
Betaproteobacteria in particular (Gillings et al., 2008). In addition to the 
aforementioned 3‟-CS that contains antibiotic resistance genes, the integron can 
carry resistance genes on its gene cassette. The gene cassette is able to carry 
various kinds of antibiotic resistance genes and most of them are aminoglycoside 
resistance-related genes and beta-lactamase genes (Rowe-Magnus & Mazel, 
2002; Partridge et al., 2009; Zhao & Hu, 2011).  
 
5.1.4. Antibiotic resistance in Achromobacter xylosoxidans 
 
The colonisation of A. xylosoxidans in immune-compromised patients is notable 
as its antibiotic resistance causes difficulties in using antibiotics to treat those 
patients. Since A. xylosoxidans was identified by Yabuuchi and Ohyama 
(Yabuuchi & Oyama, 1971), it has been recognised as a penicillin and 
aminoglycoside resistant pathogen. Reduced susceptibility to cephalosporin in A. 
xylosoxidans has also been reported in clinical isolates (Pien & Higa, 1978; 
Shigeta et al., 1978). The molecular mechanism of cephalosporin and 
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aminoglycoside resistance is regulated by resistance-nodulation-cell division 
(RND)-type efflux pump systems. The AxyABM pump is associated with 
cephalosporin and fluoroquinolone resistance (Bador et al., 2011) and the 
AxyXY-OprZ pump is associated with aminoglycoside resistance (Bador et al., 
2013). The whole genome sequence of strain NH44784-1996 displays several 
antibiotic resistance-associated genes, for example, beta-lactamase, efflux pump 
systems and modifying enzymes (Jakobsen et al., 2013). In addition, a 
comprehensive analysis of resistance genes in a Chinese strain of A. xylosoxidans 
is in agreement with previous works in finding that beta-lactamases, efflux 
pumps and modifying enzymes are intact and resistance to the aforementioned 
antibiotics - penicillin, aminoglycoside and cephalosporin - is an intrinsic 
phenotype (Hu et al., 2015). Cases of resistance to other agents in A. 
xylosoxidans, including carbapenems, have been described as acquired properties 
whereby the resistance genes are transferred to the pathogen via resistance genes 
that are carried by mobile genetic elements (Riccio et al., 2001; Shin et al., 2005; 
Neuwirth et al., 2006; Di Pilato, Pollini & Rossolini, 2014; Chen et al., 2014; Hu 
et al., 2015). 
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5.1.5. Aims and objectives 
 
Antibiotic resistance is considered a major problem in bacterial infections 
worldwide. Drug resistance patterns in A. xylosoxidans are interesting and 
challenging because few resistance phenotypes are considered to be intrinsic. 
Therefore, both disc diffusion and MIC will be conducted to investigate 
resistance in A. xylosoxidans.  
 
According to Hu et al. (2015), several genes associated with antibiotic resistance, 
including beta-lactamase and efflux transport systems, were found in the A. 
xylosoxidans genomes. The whole genome sequences available for all strains 
used in this study will be used to predict putative genes that are associated with 
drug resistance. Statistical prediction will also be used to search for associations 
between an antibiotic resistance phenotype and related genes. 
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5.2. Material and Methods 
 
5.2.1. Antibiotic susceptibility test 
 
Antibiotic susceptibility and resistance was tested in 25 A. xylosoxidans isolates 
following guidelines for disc diffusion produced by the British Society for 
Antimicrobial Chemotherapy (BSAC). Antimicrobial discs were purchased from 
Thermo Scientific Inc. and the MAST Group. A list of the antibiotics used in this 
study is shown in Table 5.1. Single isolates were grown on LB agar and 
resuspended in sterile distilled water until the turbidity of the suspensions 
reached 0.5 McFarland. Each bacterial suspension was spread radially on the 
surface of Iso-Sensitest agar. Four to six discs were applied to each agar plate 
using a disc dispenser. All plates were incubated at 37°C overnight. Resulting 
inhibition zones were measured using a caliper. The interpretation of the zone 
was conducted follow BSAC standards for Enterobacteriaceae. 
 
Further investigation using minimum inhibitory concentration (MIC) was carried 
out on Thai strains only due to their highly resistant phenotype. MIC 
determination was performed on a standard MIC plate, which was purchased 
from TREK Sensititre (Sigma Scientific), at the Clinical Microbiology Unit, 
Department of Pathology, Ramathibodi Hospital, Bangkok, Thailand, by 
courtesy of Dr. Pitak Santanirand. Mid-log phase cultures were used to inoculate 
into antibiotic-containing plate, each of which was labeled with the name and 
concentration of the antibiotic. After an overnight incubation at 37°C, the 
resulting MICs end-points were determined by inspection. 
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Table 5.1: A list of antimicrobial agents tested to determine the susceptibility of A. xylosoxidans. The agents are separated into chemical 
groups. Modes of action and known resistance mechanisms are shown. 
 
Group Generic name 
3-letter 
abbreviation 
Mode of action 
Possible resistance 
mechanism 
Beta-lactam     
Inhibit cell wall 
biosynthesis by 
binding 
transpeptidase or 
penicillin-binding 
proteins 
  
- Enzyme modification 
- Efflux pump 
- Change in cell 
membrane 
permeability 
- Mutation in drug target 
 
  
Aminopenicillin 
Amplicillin AMP 
Amoxicillin/Clavulanic acid AMC 
Ureidopenicillin Piperacillin/Tazobactam TZP 
Cephalosporin 
Cefuroxime CXM 
Cefotaxime CTX 
Ceftazidime CAZ 
Ceftriaxone CRO 
Cefepime FEP 
Carbapenem 
Imipenem IPM 
Meropenem MEM 
Ertapenem ETP 
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Table 5.1: A list of antimicrobial agents tested to determine the susceptibility of A. xylosoxidans. The agents are separated into chemical 
groups. Modes of action and known resistance mechanisms are shown. (Continued) 
 
Group Generic name 
3-letter 
abbreviatio
n 
Mode of action Possible resistance mechanism 
Aminoglycoside 
Gentamicin GEN Inhibit protein synthesis -       Enzyme modification 
Amikacin AMK   -       Efflux pump 
Glycylcycline Tigecycline TGC Inhibit protein synthesis -       Efflux pump 
Folate biosysthesis 
inhibitor 
Sulfamethoxazole/ 
Trimethoprim 
SXT 
Inhibit DNA replication 
through tetrahydrofolic 
synthesis 
-       Mutation in drug target 
Fluoroquinolone 
Ciprofloxacin CIP Inhibit DNA replication by 
binding with Topoisomerase 
-       Mutation in drug target 
Levofloxacin LEV -       Efflux pump 
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5.2.2. The determination of Beta-lactamase activity 
 
Beta-lactamase activity was tested using a common method - a nitrocefin assay. 
Nitrocefin is an antibiotic in the cephalosporin group, which is a sub-group of the 
beta-lactam antibiotics. Owing to the chromogenic properties of the drug, a 
normal form and a hydrolysed form have different visible colours and different 
UV absorbance properties. Nitrocefin is yellow and its wavelength of maximum 
absorbance is 390 nm, whilst the hydrolysed form is red and has a wavelength of 
maximum absorbance at 486 nm. 
 
The isolates were passed through antibiotic-free medium twice to ensure that 
beta-lactamases were at a basal level prior to being studied. Nitrocefin (Merck-
Millipore, Germany) was added at a final concentration of 51.6 µg/ml to mid-log 
grown cultures. Optimal density was measured at 390 nm and 486 nm every 
minute, for 25 minutes, using FLUOstar Omega (BMG biotech, Germany). The 
ratio OD486/OD390 was calculated for every time-point to determine the activity 
of the beta-lactamase over the time course. Three biological replicates were 
performed for each isolate. 
 
5.2.3. The use of an unsupervised learning machine to identify genes 
associated with a resistance phenotype 
 
Previous studies have highlighted that drug resistance in A. xylosoxidans is due 
to both intrinsic genes and acquired genes. The search for resistance genes in A. 
xylosoxidans was performed using BLAST-based methods. The genomes of 25 
isolates, newly sequenced for this study, were used in resistance genes analysis. 
Firstly, all genes, which were called and were annotated using Prokka version 
1.7.2, were put through a reciprocal protein BLAST search against the 
Comprehensive Antibiotic Resistance Database (CARD) (McArthur et al., 2013) 
with a threshold of 1e-5. Secondly, top hits from the reciprocal BLAST were 
validated by BLAST searches against the conserved domain database (CDD) and 
were manually curated to retrieve consistent results. Then, the resulting genes 
were assigned to previously performed OrthoMCL‟s output. 
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A matrix showing the occurrence of resistance genes, combined with drug 
susceptibility, was subjected to classification using the unsupervised learning 
algorithm, Random Forest™. Initially, Random Forest™ classification was 
performed using a web-based service called PhenoLink (Bayjanov et al., 2012). 
The limitation of PhenoLink is the smallest number of genomes that contain the 
studied variable is „three‟. The analysis was, therefore, conducted on a stand-
alone computer. The Random Forest™ package in R software was used as an 
alternative. The „randomforest‟ package in R required two sets of data to be 
subjected to the analysis. The former was a dataset of resistance-associated genes 
only, which consisted of 64 groups from ORTHOMCL, and the latter was a 
whole genome dataset, which consisted of 8,762 of ORTHOMCL‟s groups and 
was used in order to validate the performance of the algorithm. The 
implementation followed the instruction described in Chapter 4 
  
5.2.4. Whole genome sequencing using SMRT technology 
 
To investigate the localisation of resistance genes-carrying integron, the genome 
of A. xylosoxidans R4 and R8 was re-sequenced using single molecule real time 
(SMRT) sequencing on Pacific Bioscience RS platform at CGR, and assembled 
sequenced reads into complete genome sequence using the HGAP software 
(Chin C-S, 2013). The annotation of the genomes was performed using Prokka 
version 1.7.2 (Seemann, 2014). 
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5.3. Results 
 
5.3.1. Susceptibility phenotype 
 
Resistance to antibiotics was preliminarily determined by disc diffusion 
following decision criteria provided by the BSAC. According to previous studies 
(Bador et al., 2011, 2013), resistance to cephalosporins and aminoglycosides is 
intrinsic and is regulated by efflux transport systems. As summarised in Table 
5.2, all isolates were less susceptible to cephalosporins, including cefuroxime 
(CXM), cefotaxime (CTX) and ceftriaxone (CRO); however, all isolates except 
R4 and R8 were still susceptible to ceftazidime (CAZ) and cefipime (FEP). Also, 
aminoglycosides, including gentamicin (GEN) and amikacin (AMK) were unable 
to inhibit the growth of the isolates (Table 5.2). Consequently, these confirmed 
innate resistance of A. xylosoxidans to certain groups of antibiotics. 
 
When tested with aminopenicillin antibiotics, including amplicillin (AMP) and 
co-amoxiclav (AMC), and ureidopenicillins, including piperacillin/tazobactam 
(TZP), isolates from Liverpool consistently sensitive to the agents, whereas 
isolates from Thailand were less responsive. Strains R4 and R8 expressed 
resistance to amoxicillin, even with the addition of clavulanic acid, a beta-
lactamase inhibitor. Considering the type strains, as expected, soil strain NCIMB 
11015 responded to amoxicillin and co-amoxiclav, but clinical strain DSM 2402 
did not. All isolates, except R8, were responsive to the action of 
piperacillin/tazobactam (Table 5.2). 
 
Carbapenem, which is one of the most effective beta-lactam sub-groups against 
many Gram-negative pathogens, acted efficiently against A. xylosoxidans in this 
study (Table 5.2). Nevertheless, two Thai clinical isolates, R4 and R8, displayed 
high resistance to all of the carbapenem antibiotics used in this study, including 
imipenem (IPM), meropenem (MEM) and ertapenem (ETP). 
 
Tigecycline (TGC), a glycylcycline that was launched to the market in 2005, is a 
new generation of tetracycline, which acts by preventing amino acyl tRNA from 
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sitting on ribosomes. As shown in Table 5.2, tigecycline was the only drug that is 
still active against A. xylosoxidans isolates, although strains DSM 2402, R7 and 
R8 were less sensitive to the drug. 
 
Most clinical isolates from Liverpool and lab strains demonstrated susceptibility 
to fluoroquinolones, but isolates from Thailand and a clinical type strain from 
Japan were less susceptible to drugs in this category. Of the Liverpool strains 
(Table 5.2), L15 and L16 were less sensitive to ciprofloxacin (CIP), a second-
generation agent, but they were still responsive to the activity of levofloxacin 
(LEV), a third-generation agent. Strains from East Asia were less susceptible to 
CIP, whereas they were still susceptible to LEV. Strains DSM 2402 and R8 were 
the only strains that were resistant to LEV. Strain R6 was only the strain that was 
susceptible to the fluoroquinolones (Table 5.2). This evidence suggested that A. 
xylosoxidans in East Asia, Thailand in particular is resistant to fluoroquinolones.  
 
The last group of antibiotics tested in this study was the combination of folic acid 
biosynthesis inhibitors, sulfamethoxazole and trimethoprim (SXT). Both Thai 
and Liverpool isolates were susceptible to the action of SXT (Table 5.2). With 
consistent susceptibility, strains R4 and R8 did not respond to the bactericidal 
activity of the agents. The environmental strain NCIMB 11015 was susceptible 
to the agents, yet the clinical strain DSM 2402 was not. 
 
These preliminary results show that clinical isolates from Thailand demonstrated 
greater antibiotic resistance than clinical isolates from Liverpool did. Two Thai 
isolates, R4 and R8, were multidrug resistant strains because these two isolates 
showed resistance to almost all of tested antibiotics. This is in agreement with 
previous studies (Bador et al., 2011, 2013; Hu et al., 2015), which found that the 
resistance to cephalosporin and aminoglycoside is an intrinsic property. TZP and 
SXT, common clinically-used antimicrobial agents, were still active against A. 
xylosoxidans strains, except R4 and R8. Due to the limitations of disc diffusion, 
which could not illustrate the dosage of each antibiotic that inhibits the growth of 
bacteria, further investigation into the inhibitory doses of antibiotics was 
conducted on the group of Thai clinical isolates.  
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The determination of MICs was carried out for isolates from Thailand only, in 
order to quantify levels of resistance. As shown in Table 5.3, susceptibility of 
Thai isolates was consistent with results from the disc diffusion method in which 
the strains were less susceptible to cephalosporins and aminoglycosides. CAZ 
was the only cephalosporin used in this study that was able to inhibit the growth 
of Thai strains of A. xylosoxidans. The aminoglycosides were less effective 
against A. xylosoxidans. This was in agreement with previous studies (Bador et 
al., 2011, 2013), reaffirming the resistance of A. xylosoxidans to cephalosporins 
and aminoglycosides. 
 
Whilst MICs for aminopenicillins and carbapenems fell into the susceptible 
category in most Thai isolates, strain R4 and strain R8 showed resistance to those 
antimicrobial agents (Table 5.3). These two strains were suspected of expressing 
an extended-spectrum beta-lactamase that is able to hydrolyse carbapenem 
antibiotics. Therefore, further investigation into the presence of the beta-
lactamase enzyme in Thai isolates should be conducted to reveal the underlying 
mechanism of extended-spectrum beta-lactam resistance. 
 
The determination of MICs for fluoroquinolones gave a result that is consistent 
with the disc diffusion method, suggesting that Thai isolates developed resistance 
to CIP but are still susceptible to LEV (Table 5.2 and Table 5.3). Regarding 
susceptibility to LEV, R1, R4 and R5 remained responsive to the drug whilst the 
others were less susceptible and resistant to the drug (Table 5.3). Of the 
Levofloxacin-resistant group, strain R8 had the highest MIC (Appendix Table 
A3.4), which meant that R8 would probably have a unique mechanism, which 
will be discussed in the section entitled „Other resistance-associated proteins‟. 
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Table 5.2: Resistance in A. xylosoxidans to commonly-used antibiotics, tested using disc diffusion. The table presents an interpretation of 
susceptibility, determined using cut-off levels based on BSAC guidelines. The susceptibility interpretation is illustrated as „Resistant (R, 
Red)‟, „Intermediate (I, Yellow)‟ and „Susceptible (S, Green)‟. NCIMB 11015 stands for A. xylosoxidans NCIMB 11014; DSM 2402 for A. 
xylosoxidans DSM 2402, and L-strains are Liverpool‟s clinical isolates. 
 
Isolates AMP AMC TZP CXM CTX CAZ CRO FEP IPM MEM ETP LEV CIP GEN AMK SXT TGC 
NCIMB 11015 S S S R R S R I S S S S S R I S S 
DSM 2402 R R S R R S R R S S S R R R R R R 
L1 S S S R R S R I S S S S S R I S S 
L5 S S S R R S R R S S S S S R R S S 
L8 S S S R R S R R S S I S S I I S S 
L10 S S S R R S R I S S S S S R I S S 
L11 S S S R R S S I S S S S S S S S S 
L14 S S S R R S R R S S S S S R S S S 
L15 S S S R R S I S S S S S R R S S S 
L16 S S S R R S R R S S S I R R R S S 
L17 S S S R R S R R S S S S S S S S S 
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Table 5.2: Resistance in A. xylosoxidans to commonly-used antibiotics, tested using disc diffusion. The table presents an interpretation of 
susceptibility, determined using cut-off levels based on BSAC guidelines. The susceptibility interpretation is illustrated as „Resistant (R, 
Red)‟, „Intermediate (I, Yellow)‟ and „Susceptible (S, Green)‟. R-strains are Thai clinical isolates. (Continued) 
 
Isolates AMP AMC TZP CXM CTX CAZ CRO FEP IPM MEM ETP LEV CIP GEN AMK SXT TGC 
R1 I I S R R S R I S S S S I R R S S 
R2 S S S R R S R S S S S S I R R S S 
R3 I S S R R S R I S S S S I R R S S 
R4 R R S R R R R R I R R S I R R R S 
R5 I I S R R S R I S S S S I R R S S 
R6 S S S R R S S R S S S S S R S S S 
R7 S S S R R S I R S S S S R R R S I 
R8 R R R R R R R R R R R R R R R R I 
R9 S S S R I S I S S S S S I R I S S 
R10 I S S R R S R I S S S S R R R S S 
R11 S S S R R S R R S S S S S R S S S 
R12 S S S R R S R S S S S S I R I S S 
R13 I S S R R S R I I S S I R R R S S 
R14 I S S R R S R I S S S S I R R S S 
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Table 5.3: Interpretation of susceptibility in Thai isolates of A. xylosoxidans to antimicrobial agents based upon determination of the 
minimum inhibitory concentration (MIC). The susceptibility interpretation is illustrated as „Resistant (R, Red)‟, „Intermediate (I, 
Yellow)‟ and „Susceptible (S, Green)‟. R-strains are Thai clinical isolates. 
 
Isolates AMP AMC TZP CXM CTX CAZ CRO FEP IPM MEM ETP CIP LEV GEN AMK SXT TGC 
R1 R S S R R I R R I S S R S R R S S 
R2 S S S R R I R R S S S R R R R S S 
R3 S S S R R I R R S S S R I R R S S 
R4 R R S R R R R R I R R I S R R R S 
R5 R S S R R I R R I S S R S R R S S 
R6 S S S R R S R I S S S R I I I S S 
R7 S S S R R I R R S S S R R R R S S 
R8 R R R R R R R R R R R R R R R R S 
R9 S S S R R I R R S S S R I R R S S 
R10 S S S R R I R R S S S R I R R S S 
R11 S S S R R I R R S S S R R R R S S 
R12 S S S R R I R R S S S R R R R S S 
R13 R R S R R I R R S S S R R R R S S 
R14 R S S R R I R R I S S R I R R S S 
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The carbapenem-hydrolysing beta-lactamase, or carbapenemase, is a versatile 
beta-lactamase that is able to hydrolyse various groups of beta-lactam antibiotics, 
such as the penicillins, cephalosporins and carbapenems. As such, the 
investigation of the effect of carbapenemase upon clinical isolates is essential for 
clinicians to select an antibiotic of choice. The investigation into the beta-
lactamase‟s activity was investigated using a nitrocefin assay. After incubating 
cultures with nitrocefin for 25 minutes, visible colour changes of the suspensions 
were inspected as illustrated in Appendix Figure A3.1. The colour of nitrocefin 
in R4 and R8 cultures changed from yellow (native form) to red (hydrolysed 
form).  
 
In most of the isolates tested, except R4, R8 and R13, the conversion of 
nitrocefin progressed slowly. The ratio, OD486/OD390, changed from 
approximately 0.5 to 0.6 (Figure 5.5). Strain R13 slowly transformed nitrocefin 
into a hydrolysed form. Its ratio slowly shifted from 0.4 to 0.9 in 25 minutes. 
Interestingly, 2 Thai MDR strains demonstrated a high rate of nitrocefin 
hydrolysis. The colour of the suspensions in R4‟s and R8‟s wells changed 
immediately when nitrocefin was put into the wells. The ratio of optical density 
of strain R4 dramatically increased in the first minute after incubation and it 
levelled off at approximately 1.1 until the taking of measurements stopped. The 
ratio of optical density of strain R8 rose at a constant rate until it reached 1.1 at 
the point that the taking of measurements stopped. 
 
Using the ratios at the end of the measurement-taking, an ANOVA test revealed 
a significant difference between the ratios seen for the strains (F2,39 = 50.5; p < 
0.001). A post-hoc test using Tukey HSD showed significant differences 
between strain R4 and the others (p < 0.001), and between R8 and the others (p < 
0.001), as presented in Figure 5.6. This suggested that the performances of the 
beta-lactamases of R4 and R8 were more vigorous than those of the other strains. 
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Figure 5.5: Changes in OD486/OD390 ratios for clinical Thai isolates of A. 
xylosoxidans after incubation with nitrocefin for 25 minutes. The X-axis 
indicates the length of incubation after the addition of nitrocefin. The Y-axis 
indicates the change of OD486/OD390 ratios for each isolate. R1-R14 
nomenclature represents Thai clinical isolates 1-14.  
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Figure 5.6: The changes in OD486/OD390 ratios in carbapenem-resistant 
clinical Thai A. xylosoxidans strains R4 and R8, compared to susceptible 
strains, after incubation with Nitrocefin for 25 minutes. Optical density of 
each strain was obtained from 3 independent experiments. Means of the ratio 
changes for strain R4 and strain R8 are significantly different (Tukey‟s HSD, p-
value < 0.01) 
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5.3.2. Antibiotic resistance-associated genes 
 
Following a protein BLAST search against CARD and orthologous gene 
grouping, a total number of 1,303 resistance genes, taken from 26 genomes, were 
grouped into 64 groups, based on their amino acid sequence similarity, using 
OrthoMCL (Appendix Table A3.6). The largest group was ORTHOMCL0, 
which consisted of 154 genes from 26 genomes, and it was annotated as „RND 
efflux system, inner membrane transporter CmeB‟. The second largest group, 
ORTHOMCL1, contained 87 genes from 26 genomes and its annotation was 
„AcrB/AcrD/AcrF family protein‟. The third largest was ORTHOMCL2, which 
consisted of 30 genes from 25 genomes. These 3 groups were the only groups 
that contained more than one gene from one genome.  
 
5.3.3. Phylogenetic tree of conserved antibiotic resistance genes 
 
As shown in Table 5.4, comparative genomic analysis revealed that 31 groups of 
putative drug resistance genes were commonly shared across A. xylosoxidans; 
seven were beta-lactamases, 17 were efflux pumps, and seven were resistance-
associated proteins (Table 5.4). 
 
Phylogenetic relationships using a maximum-likelihood algorithm (Figure 5.7), 
described the clustering of strains, bearing similarities to the core genome 
phylogeny (Figure 4.5, Figure 4.6). To investigate the relationship between the 
core genome phylogeny and conserved antibiotic resistance phylogeny, a 
tanglegram tree (Figure A3.2) suggested that the conserved resistance phylogeny 
partially explains the core phylogeny. In other words, conserved antibiotic 
resistance gene phylogeny could not represent core genome phylogeny. 
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Table 5.4: Antibiotic resistance-associated genes that have been identified as 
conserved genes in the genomes of 26 strains of A. xylosoxidans 
 
 
Reference  
gene ID 
Gene annotation 
B
et
a-
la
ct
am
as
e
 
YP_008033064.1 Beta lactamase class C and other penicillin binding proteins 
YP_008032142.1 Beta lactamase class C and other penicillin binding proteins 
YP_008032848.1  Beta lactamase AmpC 
YP_008031641.1 Beta lactamase 
YP_008028833.1 Metallo beta lactamase family protein, putative 
YP_008031922.1 Metallo beta lactamase superfamily protein 
ADO14463.1 Oxacillinase OXA-114 
E
ff
lu
x
 t
ra
n
sp
o
rt
 s
y
st
em
 
R
N
D
 e
ff
lu
x
 
YP_008029803.1 RND efflux system, inner membrane transporter CmeB 
YP_008031292.1 RND efflux system, inner membrane transporter CmeB 
YP_008033424.1 RND efflux system, inner membrane transporter CmeB 
YP_008029804.1 RND efflux system, membrane fusion protein CmeA 
YP_008027730.1 RND efflux system, membrane fusion protein CmeA 
YP_008031291.1 RND efflux system, membrane fusion protein CmeA 
YP_008033423.1 RND efflux system, outer membrane lipoprotein CmeC 
YP_008028521.1 RND multidrug efflux transporter; Acriflavine resistance protein 
YP_008027735.1 RND multidrug efflux transporter; Acriflavine resistance protein 
YP_008030766.1 
Inner membrane component of tripartite multidrug resistance 
system 
A
B
C
 e
ff
lu
x
 
YP_008033182.1 ABC transporter, ATP binding permease protein 
YP_008031007.1 Lipid A export ATP binding permease protein MsbA 
YP_008027505.1 Lipid A export ATP binding permease protein MsbA 
YP_008027185.1 Lipid A export ATP binding permease protein MsbA 
YP_008028300.1 Macrolide export ATP binding permease protein MacB 
YP_008031184.1 Transport ATP binding protein CydCD 
M
F
S
 
YP_008031014.1 Fosmidomycin resistance protein 
O
th
er
 
YP_008033356.1 Transcriptional regulatory protein OmpR 
R
es
is
ta
n
ce
-a
ss
o
ci
at
ed
 
en
zy
m
e 
CKH34743.1 Chloramphenicol acetyltransferase 
YP_008031014.1 Fosmidomycin resistance protein 
CKH16534.1 Topoisomerase IV subunit B 
YP_008030648.1 Dihydropteroate synthase 
AIR49201.1 DNA gyrase subunit B 
CKH08160.1 DNA gyrase subunit A 
YP_008028255.1 Aminoglycoside-N
3
-acetyltransferase 
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Figure 5.7: Phylogenetic trees based on antibiotic resistance-associated 
genes that are conserved across 26 genomes of A. xylosoxidans. Maximum-
likelihood tree constructed with 1,000 bootstrap repeats. Bootstrap values more 
than 50% were indicated. NH44784-1996 stands for A. xylosoxidans NH44784-
1996; NCIMB 11015 for A. xylosoxidans NCIMB 11015; DSM 2402 for A. 
xylosoxidans DSM 2402. L-strains are Liverpool‟s clinical isolates and R-strains 
are Thai clinical isolates. 
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5.3.4. Efflux pumps 
 
A group of efflux transport systems in A. xylosoxidans was identified as the 
largest group of resistance-associated genes, including 18 intrinsic genes (Table 
5.4) and 28 acquired genes (Table 5.5 and Appendix Table A3.7). Amongst the 
eighteen pump-associated intrinsic genes identified, ten were associated with 
resistance nodulation cell division (RND) pumps, six were ATP-binding cassette 
(ABC) pumps, one was a major facilitator superfamily (MFS) pump and one was 
a porin regulator OmpR (Table 5.5).  
 
The first group of known antibiotic resistance-associated RND efflux system was 
CmeABC, which is consisted of CmeA (Reference gene id: YP_008027730.1), a 
membrane fusion protein, CmeB (Reference gene id: YP_008027731.1), an inner 
membrane transporter, and CmeC (Reference gene id: YP_008027732.1), an 
outer membrane protein. Only CmeA was found across all 26 strains (Table 5.4). 
The CmeB subunit and CmeC subunit were present in 23 strains and 25 strains, 
respectively (Appendix Table A3.8). The absence of the CmeB and CmeC genes 
in some strains was probably due to an error during the assembly or sequencing 
processes. 
 
This CmeC efflux pump system shared 96.9% similarity with the AxyXY-OprZ 
RND-type pump in A. xylosoxidans AXX-A (renamed A. insuavis AXX-A) 
(Appendix Figure A3.3). Bador et al. (2013) described the AxyXY-OprZ operon 
as being involved in resistance to carbapenems, aminoglycosides and 
fluoroquinolones.  
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Table 5.5: Antibiotic resistance-associated genes that have been identified as 
acquired genes in the genomes of 26 strains of A. xylosoxidans 
 
  
Reference  
gene ID 
Gene annotation 
B
et
a-
la
ct
am
as
e
 AHY18660.1 IMP-14 metallo beta lactamase 
YP_008027752.1 Beta lactamase 
YP_008029689.1  Beta lactamase 
AIR52250.1 Beta lactamase domain containing protein 
CDI94943.1 Beta lactamase domain containing protein 
YP_008031839.1 Metallo beta lactamase family protein, RNA specific 
E
ff
lu
x
 t
ra
n
sp
o
rt
 s
y
st
em
 
R
N
D
 
WP_020925327.1 AcrB/AcrD/AcrF family protein 
YP_008028715.1 AcrB/AcrD/AcrF family protein 
WP_013393781.1 Acriflavine resistance protein B 
YP_008027731.1 RND efflux system, inner membrane transporter CmeB  
YP_008033425.1 RND efflux system, membrane fusion protein CmeA 
YP_008028035.1 RND efflux system, membrane fusion protein CmeA 
YP_008027732.1 RND efflux system, outer membrane lipoprotein CmeC 
YP_008032982.1 RND efflux system, outer membrane lipoprotein CmeC 
YP_008027734.1 RND efflux system, outer membrane lipoprotein CmeC 
YP_008029977.1 RND efflux system, outer membrane lipoprotein CmeC 
YP_008031293.1 RND efflux system, outer membrane lipoprotein CmeC  
YP_008032981.1 RND multidrug efflux transporter; Acriflavine resistance protein 
WP_020925545.1 Cobalt-zinc-cadmium resistance protein CzcA 
CKG72640.1 Cation efflux system protein CzcA 
YP_008032003.1 RND multidrug efflux transporter; Acriflavine resistance protein  
YP_008033107.1 
Inner membrane component of tripartite multidrug resistance 
system 
YP_008030767.1 
Membrane fusion component of tripartite multidrug resistance 
system 
A
B
C
 
CKG97466.1 Iron import ATP-binding/permease protein IrtB 
YP_008030221.1 
Putative ABC iron siderophore transporter, fused permease and 
ATPase domains 
CKH86978.1 Putative multidrug export ATP-binding/permease protein SAV1866 
YP_008032049.1 Cyclolysin secretion ATP binding protein 
YP_008031197.1 Transport ATP binding protein CydCD 
M
F
S
 
YP_008028726.1 MFS permease 
AKE04698.1 MFS Transporter 
CKI18085.1 Spectinomycin/tetracycline efflux pump 
YP_008031167.1 Tetracycline efflux protein TetA 
O
th
er
 
WP_019396923.1 Cation transporter 
ADP16465.1 Periplasmic linker protein 2 
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Table 5.5: Antibiotic resistance-associated genes that have been identified as 
acquired genes in the genomes of 26 strains of A. xylosoxidans (Continued) 
 
  
Reference  
gene ID 
Gene annotation 
R
es
is
ta
n
ce
-a
ss
o
ci
at
ed
 e
n
zy
m
e YP_008029342.1 Translation elongation factor Tu 
YP_008029360.1 Translation elongation factor G 
YP_008029349.1 DNA directed RNA polymerase beta subunit 
YP_008030789.1 Topoisomerase IV subunit A 
YP_008031164.1 Putative streptomycin phosphotransferase 
AHY18660.1 Dihydropteroate synthase 
BAN89135.1 Streptomycin-6-kinase 
AIA53578.1 3'-kinase 
AHY18660.1 Aminoglycoside-N
6
-acetyltransferase 
 
 
A breakdown analysis of this AxyXY-OprZ-homologous CmeABC efflux pump 
revealed the cluster of pumps that is associated with this level of drug resistance. 
Determining that the CmeB subunit is a functional subunit of the pump, a 
phylogenetic tree of CmeB genes showed a cluster that consists of CmeB genes 
from strains L11, L15, and R11 (Figure 5.8), which are strains that exhibit low 
levels of aminoglycoside resistance (Appendix Table A3.2). Moreover, analysis 
of the pan-genome of antibiotic resistance in genus Achromobacter emphasised 
the association between this pump and aminoglycoside resistance in 
Achromobacter as the genes encoding CmeABC efflux were not present in A. 
piechaudii and A. spanius. Interestingly, the CmeABC efflux pump genes were 
present in the aminoglycoside-susceptible Achromobacter species, A. insolitus 
and A. ruhlandii, but they were clustered distantly from the genes from 
aminoglycoside-resistant Achromobacter species (Figure 5.9). Phylogenetic 
relationships revealed that the aminoglycoside resistance in genus 
Achromobacter has developed from a susceptible phenotype to resistant 
phenotype.  
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Figure 5.8: A Neighbour-Joining phylogenetic tree based on aminoglycoside-
resistance-associated CmeB in A. xylosoxidans. The tree was constructed with 
1,000 bootstrap repeats. The tree is constructed NCIMB 11015 stands for A. 
xylosoxidans NCIMB 11015; DSM 2402 for A. xylosoxidans DSM 2402; 
NH44784-1996 for A. xylosoxidans NH44784-1996; R-strains are Thai clinical 
isolates; and L-strains are Liverpool‟s clinical isolates. Bootstrap values more 
than 75% were indicated. 
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Figure 5.9: A Neighbour-Joining phylogenetic tree based on aminoglycoside-
resistance-associated CmeB in genus Achromobacter. NCIMB 11015 stands 
for A. xylosoxidans NCIMB 11015; NH44784-1996 for A. xylosoxidans 
NH44784-1996; and R-strains are Thai clinical isolates. Bootstrap values > 50% 
were indicated. 
 
In addition, another paralogue of these known efflux transport systems, 
CmeABC, was made of CmeA (Reference gene id: YP_008031291.1), CmeB 
(Reference gene id: YP_008031292.1) and CmeC (Reference gene id: 
YP_008031293.1). Both CmeA and CmeB were conserved across 26 genomes in 
this study (Appendix Table A3.9). This CmeABC shared 98.4% homology with 
the AxyABM efflux pump in A. insuavis AXX-A (Bador et al., 2011)(Appendix 
Figure A3.4). This pump plays an important role in cephalosporin and 
fluoroquinolone resistance. The presence of this efflux system in A. xylosoxidans 
was in agreement with the antibiotic resistance profiles of the isolates, as 
illustrated in Table 5.2 and 5.3. Likewise, this efflux pump was associated with 
cephalosporin resistance in other Achromobacter species.  
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The group containing an acriflavine resistance protein was another group of 
RND efflux pumps found in A. xylosoxidans (Table 5.4 and 5.5). Two copies of 
acriflavine resistance proteins were expressed in the core genome of A. 
xylosoxidans. Acriflavine resistance associated genes were also identified in 
accessory resistance genes (Table 5.5). In E. coli, Acriflavine resistance protein 
B (AcrB) is an essential factor for the survival of the bacteria. AcrB gathers with 
2 other proteins, AcrA and TolC (multifunctional channel), to form a complex 
efflux system, AcrAB-TolC. This efflux pump plays an important role in 
protecting E.coli from organic solvents such as nonane (Tsukagoshi & Aono, 
2000). In the comparative genomic analysis of this study, AcrB and TolC were 
present in the genome but the relationship between them was not observed in 
strains used in this study as well as in strain NH44784-1996 (Jakobsen et al., 
2013). 
 
Eleven ATP-binding cassette (ABC) efflux pumps were identified across 26 
genomes of A. xylosoxidans: six intrinsic genes (Table 5.4) and five acquired 
genes (Table 5.5). The majority of the intrinsic ABC pumps were involved in 
macrolide resistance. Two macrolide-resistance groups were intrinsically present 
in A. xylosoxidans: the Lipid A exporter and the macrolide exporter MacB. The 
main function of the MsbA protein is to export Lipid A, which is a part of the 
lipopolysaccharide (LPS), to outside of the cells. The interaction between this 
pump and some antibiotics, such as macrolides, has resulted in drug resistance 
(Woebking et al., 2005). Interestingly, MsbA has two binding sites, which can 
interact with Lipid A and drugs separately (Siarheyeva & Sharom, 2009). The 
macrolide-specific exporter is a transmembrane protein that extrudes macrolide 
antibiotics from cells, in cooperation with MacB and TolC (Kobayashi, Nishino 
& Yamaguchi, 2001).   
 
The only MFS–containing efflux pump presented as intrinsic was the 
fosmidomycin resistance protein. A study by Fujisaki et al. (1996) revealed that 
this protein has an effect on fosmidomycin resistance in E. coli. Fosmidomycin is 
an inhibitor of 2-C-methyl-D-erythritol-4-phosphate (MEP), which is an enzyme 
in the first step of the non-mevalonate pathway of isoprenoid biosynthesis. This 
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pathway is important in some human pathogens, such as A. baumannii, P. 
aeruginosa (Eberl et al., 2003) and A. xylosoxidans (from this analysis). The 
presence of the fosmidomycin resistance protein in A. xylosoxidans suggests that 
the bacteria have the potential to be fosmidomycin-resistant. 
 
In total, four groups of efflux pumps containing MFS were expressed, as 
acquired genes, by A. xylosoxidans. Two tetracycline-associated efflux pumps - 
spectinomycin/tetracycline efflux and Tetracycline efflux protein tetA - were 
identified; however, spectinomycin and tetracycline were not used in this study. 
The presence of these MFS efflux pumps was not related to tigecylcine 
resistance. 
 
5.3.5. Beta-lactamase 
 
Since it has been reported that A. xylosoxidans is resistant to multiple antibiotics, 
especially antibiotics in the beta-lactam group, genes associated with beta-lactam 
resistance were identified using CARD and validated using the NCBI database. 
A total of 13 beta-lactamase orthologous groups were revealed by OrthoMCL. 
Seven out of these thirteen groups were conserved across 26 A. xylosoxidans 
genomes (Table 5.4).  
 
These conserved beta-lactamase genes consisted of three groups of class C beta-
lactamase (one AmpC beta-lactamase and two general class C beta-lactamases), 
two groups of metallo-beta-lactamase, one group of class D beta-lactamase, and 
one group of non-specified beta-lactamase (Table 5.4). Only the class D beta-
lactamase, or oxacillinase-114, group has been well identified and biochemically 
characterised in A. xylosoxidans (Turton et al., 2011). Finding these intrinsic 
beta-lactamase genes ascertained that resistance to beta-lactam antibiotics is 
intrinsic in A. xylosoxidans.  
 
Acquired beta-lactamases were composed of six beta-lactamase genes. There 
were two beta-lactamase domain-containing proteins, one metallo-beta-lactamase, 
one class A beta-lactamase, one unclassified beta-lactamase and one RNA-
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specific metallo-beta-lactamase. The class A beta-lactamase is usually present in 
Gram-negative bacteria and is a target for many beta-lactamase inhibitors, 
including clavulanic acid and tazobactam.  
 
Resistance to aminopenicillin antibiotics was observed in these 25 strains of A. 
xylosoxidans. Of 74 annotated resistance-associated genes in the species, 
Random Forest™ ranked a beta-lactamase gene (reference gene id: 
YP_008027752.1) first with the highest values in both mean decreased accuracy 
score and mean decreased Gini score (Figure 5.10). This protein was annotated 
as a Class A beta-lactamase. Most beta-lactamase inhibitors target class A beta-
lactamases. This gene was found in strains that less susceptible to 
aminopenicillin: L1, R1, R3, and R5. With reference to Table 5.2 and Table 5.3, 
the addition of clavulanic acid made aminopenicillin work more effectively than 
aminopenicillin alone. This indicated an association between this selected beta-
lactamase and aminopenicillin resistance. 
 
Figure 5.10: A variable importance plot based on Random Forest™ 
classification of AMP susceptibility in 25 isolates of A. xylosoxidans, showing 
the importance of each orthologue. The x-axes indicate the level of importance. 
The Y-axes show the list of orthologues. 
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An interesting finding was that the metallo-beta-lactamase found only in R4 and 
R8 shared 100% similarity to an IMP-14 metallo-beta-lactamase found in an A. 
baumannii isolate from the same hospital (Appendix Figure A3.5). Strains R4 
and R8 were the only strains that were resistant to carbapenems (Table 5.2 and 
Table 5.3). This suggested that the finding of IMP-14 metallo-beta-lactamase 
would be associated with the resistance to carbapenems in strains R4 and R8. 
 
To investigate the presence of a carbapenemase gene in Thai MDR A. 
xylosoxidans genomes, found to be unique when the genomes were compared to 
the reference genome, reads from the MDR strains that did not map to the 
reference were assembled. The assembled reads that did not map to the reference 
genome showed that an IMP-14-metallo-beta-lactamase gene was present in the 
genomes of R4 and R8, whereas it was not present on the reference genome or 
the genomes of the other strains. When nucleotide sequences were viewed, the 
gene was found to be surrounded by other genes, such as integrase, and 
conserved sequences, such as attI and attC, that constitute an integron. In 
addition, this structure was detected in the whole genome assemblies of R4 and 
R8. 
 
With Pacific Biosciences‟ single molecular real-time sequencing technology, the 
resistance gene-carrying integron was found in the genomes of R4 and R8. It 
consisted of antibiotic resistance genes and conserved sequences (Genbank 
accession no. KJ406505-KJ406506) (Figure 5.11). This integron was only found 
in strains R4 and R8, not featuring in other Thai MDR strains (Figure 5.11). 
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Figure 5.11: The insertion of a 40kb-long class 1 integron into the chromosome of Thai A. xylosoxidans strains R4 and R8. The class 1 
integron consists of conserved genes for integron structure: Int, qacΔE and sul1. Genes in the cassette are blaOXA-114 and aac(6’). The 
dendrogram shows the phylogenetic relationships of Thai A. xylosoxidans isolates based on a MLST scheme. R1-R14 are Thai clinical isolates. 
Int stands for Integrase; blaIMP-14a for IMP-14a metallo-beta-lactamase; aac for aminoglycoside acetyltransferase; qacEΔ for quaternary 
ammonium compound transporter; and sul1 for sulfonamide-resistance dihydropteroate synthase. 
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The gene cassette in the integron was composed of the following genes: int - 
blaOXA-114 - aac(6’) – qacΔE – sul1. This kind of structure has been previously 
reported in Thailand (Piyakul, Tiyawisutsri & Boonbumrung, 2012). A 
comparative study revealed that the nucleotide sequences of the integrons found 
in R4 and R8 shared 100% similarity (Appendix Figure A3.5). Interestingly, the 
alignment of the BlaOXA-114 and Aac(6‟) genes was detected, with 99.9% and 
100% identity, in P. aeruginosa in 2004 (Genbank accession no.GQ302617, 
unpublished data) and A. baumannii in 2005, respectively (Kansakar et al., 2011) 
(Appendix Figure A3.5). These isolates were from the same teaching hospital, 
Ramathibodi hospital, as MDR strains of A. xylosoxidans. Since strains R4 and 
R8 were collected in 2012 and 2010, respectively, this study suggested that this 
integron had been well conserved over eight years. In addition, the integron was 
normally merged into, and carried by, a plasmid, but this integron was inserted 
into the chromosome instead (Figure 5.11). 
 
 
Figure 5.12: A variable importance plot based on Random Forest™ 
classification of carbapenem susceptibility in 25 isolates of A. xylosoxidans, 
showing the importance of each orthologue. The X-axes indicate the level of 
importance. The Y-axes show the list of orthologues. 
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Random Forest™ selected and ranked five orthologues: IMP-14-metallo-beta-
lactamase, Streptomycin-6-kinase, Aminoglycoside-N
6
-acetyltransferase, MFS 
permease (or Tetracycline resistance protein) and 3‟-kinase (or Streptomycin 
resistance protein B) (Figure 5.12). These genes were present in two MDR 
strains from Thailand only. These orthologues had close mean decreased 
accuracy scores and mean decreased Gini scores. Interestingly, these five 
orthologues were also obtained from the analyses using susceptible profiles to 
other carbapenems. With the whole genome as an input, these orthologues were 
made up the top five rankings based on mean decreased importance scores and 
mean decreased Gini scores. Regarding the biological function of these genes, 
only IMP-14-metallo-beta-lactamase, which exhibits a carbapenemase function, 
contributed to carbapenem resistance, whereas the other genes had other 
functions related to antibiotic resistance. The physical relationships between 
IMP-14-metallo-beta-lactamase, Aminoglycoside-N
6
-acetyltransferase and 3‟-
kinase (or Streptomycin resistance protein B) in those two Thai MDR strains 
(Figure 5.11) allowed us to ascertain the statistical relationships between the 
genes (Figure 5.12). 
 
5.3.6. Other resistance-associated proteins 
 
Apart from major resistance genes, efflux pumps and beta-lactamases, other 
enzymes related to drug resistance were identified using the protein BLAST 
against CARD and the NCBI database. As presented in Table 5.4, seven 
orthologous groups containing resistance-associated proteins were conserved 
across 26 genomes. Four out of these seven orthologous groups were enzymes 
that are normally present in prokaryotic organisms: dihydropteroate synthase, an 
enzyme in folic acid biosynthesis pathway, and topoisomerases II (DNA Gyrase) 
and IV - enzymes that relieve strain on the DNA string. The rest of the intrinsic 
resistance-associated enzymes were a fosmidomycin resistance protein, 
chloramphenicol acetyltransferase and aminoglycoside acetyltransferase. These 
could be directly involved in drug resistance due to their functions. 
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5.3.6.1. Dihydropteroate synthase 
 
Dihydropteroate synthase is an enzyme occurring in the folic acid biosynthesis 
pathway, which is important in living organisms. It is a target of a sulfonamide 
drug called sulfamethoxazole (McCullough & Maren, 1973). The mutation of 
this enzyme causes bacteria to become resistant to sulfonamide antibiotics. Even 
though this gene was found to be conserved across A. xylosoxidans (Table 5.4), 
resistance to sulfamethoxazole was not detected in any of the A. xylosoxidans 
isolates (Table 5.2 and 5.3) except for DSM 2402, R4 and R8, which were less 
susceptible to sulfamethoxazole. Another dihydropteroate synthase, in addition 
to those found in the groups of intrinsic genes, was detected in the 
sulfamethoxazole-resistant strains.  
 
Figure 5.13: A variable importance plot based on Random Forest™ 
classification of sulfamethoxazole/trimethoprim susceptibility in 25 isolates 
of A. xylosoxidans, showing the importance of each orthologue. The X-axes 
indicate the level of importance. The Y-axes show the list of orthologues. 
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Random Forest™ ranked dihydropteroate synthase orthologues the first amongst 
74 resistance gene candidates. As shown in Figure 5.13, this orthologue was 
found to have the highest mean decreased accuracy score (Score = 25.5) and 
mean decreased Gini score (Score = 1.17), which means that it is important in 
classification with high purity. 
 
 
Figure 5.14: A Neighbor-Joining phylogenetic tree showing genetic 
relationships between dihydropteroate synthase genes in A. xylosoxidans. A 
green box indicates housekeeping dihydropteroate synthase genes, which are 
important in folic acid biosynthesis in bacteria. An orange box indicates 
resistance-related dihydropteroate synthase genes, which are identified in SXT-
resistant strains. NH44784-1996 stands for A. xylosoxidans NH44784-1996, 
NCIMB 11015 for A. xylosoxidans NCIMB 11015; DSM 2402 for A. 
xylosoxidans DSM 2402; L-strains are Liverpool’s clinical isolates; and R-strains 
are Thai clinical isolates. The suffix ‘R’ signifies a gene that contributes towards 
trimethoprim resistance. Bootstrap values more than 50% were indicated. 
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As shown in Figure 5.14, a Neighbor-Joining phylogenetic tree of 
dihydropteroate synthase genes found in 26 A. xylosoxidans genomes illustrated 
two main clades of genes: clade A (highlighted in green) and clade B 
(highlighted in orange). Clade A consisted of dihydropteroate synthase genes 
from core genomes, whereas clade B consisted of genes from non-core genomes, 
which represents lateral transfer of the genes. The presence of resistance-
associated dihydropteroate synthases (clade B in Figure 5.14) was related to SXT 
resistance in those strains. It could be implied that the resistance to 
sulfamethoxazole in A. xylosoxidans in this study was not caused by the mutation 
of conserved dihydropteroate synthase, but by resistance genes acquired from 
external sources. 
 
5.3.6.2. Topoisomerase 
 
Topoisomerase is a group of enzymes that unwind DNA strands so as to reduce 
strain on the strands when the DNA strings are taken apart in replication process. 
Since the enzyme is a target of fluoroquinolone antibiotics (Aldred, Kerns & 
Osheroff, 2014), a mutation in the enzyme is considered one of the 
fluoroquinolone resistance mechanisms. The fluoroquinolone resistance-
determining region (QRDR) is a region of the enzyme that interacts with 
fluoroquinolone. The QRDR is determined by two amino acid residues, Serine at 
position 83 and Aspartic acid at position 87 in topoisomerase II subunit A. 
Several studies have shown that mutations mostly happen near the QRDR 
(Heddle & Maxwell, 2002; Aldred, Kerns & Osheroff, 2014), as shown in Table 
5.6. This region is a part of a binding pocket for both DNA and quinolone 
antibiotics. 
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Table 5.6: Amino acid substitutions in subunit A of the topoisomerase II 
enzyme, which is associated with fluoroquinolone resistance (Friedman, Lu & 
Drlica, 2001). 
 
Amino acid 
position 
Native Substitute 
67 Alanine (A) Serine (S) 
51 Alanine (A) Valine (V) 
81 Glycine (G) Cysteine (C) 
82 Cysteine (C) Alanine (A) 
83
* 
Serine (S) Leucine (L) 
83
*
 Serine (S) Tryptophan (W) 
84 Alanine (A) Proline (P) 
87
*
 Aspartate (D) Asparagine (N) 
87
*
 Aspartate (D) Tyrosine (Y) 
106 Glutamine (Q) Histidine (H) 
  * Quinolone resistance-determining region position 
 
As seen in Table 5.2 and Table 5.3, the strains were less susceptible to 
fluoroquinolone due to the presence of either intrinsic mutations or other genes 
that cause resistance. As described in the section entitled, „Efflux pump‟, the 
presence of intrinsic RND-type efflux pumps that are associated with 
fluoroquinolone resistance in the genome of A. xylosoxidans could explain an 
innate resistance in this species (Bador et al., 2013). 
 
Here, all genes encoding topoisomerase IV, except for topoisomerase IV subunit 
A, was found as conserved resistance genes. The loss of topoisomerase IV 
subunit A in strains R9 and R10 was probably due to an error in sequencing or a 
natural absence but it did affect their susceptibility to fluoroquinolone. A 
multiple sequence alignment was performed using genes encoding subunit A of 
topoisomerase II in A. xylosoxidans (Appendix Figure A3.6A), a region which 
commonly determines fluoroquinolone resistance in Gram-negative bacteria 
(Redgrave, 2014). It showed no significant amino acid substitutions that lead to 
fluoroquinolone resistance (Hallett & Maxwell, 1991; Jalal et al., 2000), except 
in R8 (marked by an asterisk in Appendix Figure A3.6A). The substitution 
involved the replacement of Aspartic acid (D) with Asparagine (N) at amino acid 
position 87, which is a part of the QRDR. As expected, the mutation of the 
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QRDR changed the polarity of a binding site (from acidic to basic), which could 
affect the binding of fluoroquinolone in the pocket. It finally resulted in a 
remarkably high MIC of LEV in R8 (Appendix Table A3.4). Even though the 
fluoroquinolons resistance was described by the presence of the efflux pump, 
AxyABM, this demonstrated that the mutation in topoisomerase II contributed 
towards a more resistant phenotype with higher amount of fluoroquinolone. 
 
5.3.6.3. Modifying enzymes 
 
Chloramphenicol acetyltransferase is an enzyme that inactivates the 
chloramphenicol antibiotic by adding an acetyl group to the chloramphenicol 
molecule (Murray, 1997). This enzyme was detected as one of the core resistance 
genes in this analysis (Table 5.4). The identification of chloramphenicol 
acetyltransferase genes in A. xylosoxidans was reported in the complete genome 
of A. xylosoxidans strain NH44784-1996, which had a chloramphenicol-resistant 
phenotype (Jakobsen et al., 2013). On the other hand, the gene was also detected 
in chloramphenicol-susceptible strains (Hu et al., 2015). 
 
Aminoglycoside acetyltransferase is an enzyme that modifies the structure of 
aminoglycosides by adding acetyl groups to aminoglycosides. This modification 
results in an activation of the antibiotics, which makes the bacteria resistant to 
aminoglycosides (Ramirez & Tolmasky, 2010). Orthologues of the 
aminoglycoside-N
3
-acetyltransferase were conserved across 26 genomes. 
Therefore, the finding of this conserved gene, together with the expression of 
efflux pumps previously mentioned on the genomes suggests an innate resistance 
to aminoglycosides in A. xylosoxidans. Moreover, a novel aminoglycoside 
acetyltransferase, aminoglycoside-N
6
-acetyltransferase, was detected in 
multidrug-resistant (MDR) A. xylosoxidans strains, R4 and R8. After further 
investigation into the genomes of the MDR strains, the aminoglycoside-N
6
-
acetyltransferase was located on their genomes. It was found to be surrounded by 
genes such as integrase and conserved sequences (a diagram of the gene cassette 
is shown in Figure 5.11) such as attI and attC sites, which are generally found in 
the integron. Several studies have revealed that a gene encoding aminoglycoside 
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acetyltransferase was a part of a resistant gene-carrying integron (Zhao & Hu, 
2011; Traglia et al., 2012; Di Pilato, Pollini & Rossolini, 2014; Touati et al., 
2013; Chen et al., 2014).  
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5.4. Discussion 
 
Antibiotic resistance has been considered a major problem due to the difficulty to 
select antibiotics to eliminate those resistant bacteria. A. xylosoxidans is a 
bacterium that is famous for its multi-drug resistance (Hu et al., 2015). A study 
on antibiotic resistance in A. xylosoxidans, looking at both phenotypic attributes 
and genetic attributes, revealed both intrinsic resistance and acquired resistance 
on its chromosome. In addition, a comparative study of the resistance phenotype 
and the genome of A. xylosoxidans identified acquired resistance that is regulated 
by mobile genetic elements. 
 
Table 5.7: A summary table presenting drug resistance mechanisms 
identified in A. xylosoxidans in this study (categorised by resistance types - 
intrinsic and acquired) 
 
  
Groups of 
antibiotic 
Possible mechanism of resistance 
Intrinsic 
Aminopenicillin 
Cephalosporin 
- CmeABC (AxyABM homologue) 
- Beta lactamase 
 Aminoglycoside 
- CmeABC (AxyXY-OprZ homologue) 
- Aminoglycoside-N
3
-acetyltransferase 
 Fluoroquinolone 
- CmeABC (both AxyABM and AxyXY-OprZ 
homologue) 
- Mutation of QRDR of the subunit A of DNA 
gyrase 
Acquired Aminoglycoside - Aminoglycoside-N
6
-acetyltransferase 
 Carbapenem - IMP-14 metallo-beta-lactamase 
 Aminopenicillin - Class A beta-lactamase 
  Folate inhibitor - Drug resistant dihydropteroate synthase 
 
 
5.4.1. Intrinsic antibiotic resistance and associated genes 
 
Innate resistance in A. xylosoxidans was characterised by the presence of an 
OXA-114 beta-lactamase (Doi et al., 2008) and an RND-type efflux pump 
(Bador et al., 2011, 2013). OXA-114 beta-lactamase is the only beta-lactamase 
that has been identified and well characterised. In this study, seven orthologues 
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of a commonly shared beta-lactamase were identified across 26 A. xylosoxidans 
genomes (Table 5.4). This agrees, to a certain degree, with previous studies, 
which reported that there were at least five beta-lactamase enzymes found in A. 
xylosoxidans ATCC 27061 (Hu et al., 2015) and ten beta-lactamases found in A. 
xylosoxidans NH44784-1996 (Jakobsen et al., 2013). It is believed that these 
beta-lactamases mainly contributed to the resistance to beta-lactam in these A. 
xylosoxidans strains (Table 5.7). 
 
As well as beta-lactamase genes, a number of efflux pumps were identified as 
intrinsic resistance genes. There are five families of efflux pumps associated with 
antibiotic resistance mechanisms in bacteria (Webber, 2002): major facilitator, 
multidrug and toxic effect, RND, small multidrug resistance and ATP-binding 
cassette. Comparative genomics of resistance genes in genus Achromobacter 
revealed that the number of MDR pumps ranges from 40 to 53 genes, depending 
on the species. Despite the fact that MDR efflux systems in genus 
Achromobacter have been studied, the RND-type pump is the only efflux pump 
that is well identified, including AxyABM and AxyXY-OprZ (Bador et al., 2011, 
2013). These pumps are associated with resistance to fluoroquinolones, 
cephalosporins and aminoglycosides (Table 5.7). In the same manner, 45 
resistance pump-related genes were discovered in the complete genome of A. 
xylosoxidans NH44784-1996 (Jakobsen et al., 2013) and 38 resistance pump-
related genes were identified in the genome of A. xylosoxidans ATCC 27061 (Hu 
et al., 2015). In keeping with previous studies, RND-type efflux pumps were the 
largest groups of genes found in A. xylosoxidans in this study (see Chapter 4). 
With orthologous grouping and resistance gene re-annotation, 18 common drug 
resistance-related families were detected across 26 A. xylosoxidans genomes 
(Table 5.4). 
 
Our evidence that AxyXY-OprZ homologues are absent in aminoglycoside-
susceptible Achromobacter species (Figure 5.9) strongly supports the theory that 
an AxyXY-OprZ homologue contributes towards aminoglycoside resistance in A. 
xylosoxidans. Consequently, it can be assumed that the presence of these intrinsic 
efflux transport systems may affect the innate resistance of multiple antibiotics 
(Table 5.7). An RND-type efflux transport system contains three main subunits: 
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an inner membrane protein (for example, CmeB and AxyY), an outer membrane-
integrated channel (such as CmeC and OprZ), and an adaptor/accessory protein 
(for example, CmeA and AxyX) (Nikaido, 2011). The inner membrane protein is 
the most essential part of the system because this subunit plays a role in binding 
drug molecules and expelling them from the cell. The adaptor protein has a 
minimal role in drug resistance. Nevertheless, evidence shows that different 
adaptor proteins affect the compatibility of the drug and the inner membrane 
protein (Krishnamoorthy, Tikhonova & Zgurskaya, 2008). The last part of the 
system is the outer membrane channel. The channel provides the gateway for the 
expelled molecule (Blair & Piddock, 2009). Comparative analysis of the 
structure of the channel shows that the different channel molecules have similar 
gross structures whilst their sequences are different (Federici et al., 2005). As 
mentioned above, the inner membrane protein is, therefore, crucial to the 
resistance mechanism of the RND pump system.  
 
The innate presence of drug resistance enzyme modification enhances drug 
resistance ability in the strains. In addition to expressing CmeABC efflux 
transport systems that pump out aminoglycosides, A. xylosoxidans have an 
aminoglycoside-N
3
-acetyltransferase (Table 5.7), which confers aminoglycoside 
resistance (Davies & O‟Connor, 1978). However, this conserved 
acetyltransferase enzyme probably has a non-significant effect on 
aminoglycoside resistance in A. xylosoxidans, compared to the efflux pump. This 
is demonstrated by the existence of strains that lack an AxyXY-OprZ homologue 
pump and are aminoglycoside-susceptible despite having an acetyltransferase in 
their genome. 
 
5.4.2. Acquired resistance 
 
In addition to core resistance genes, acquired resistance-associated genes were 
also identified in the genomes of 2 Thai MDR A. xylosoxidans strains. As shown 
in Table 5.2 and Table 5.3, resistance to carbapenems was unique to strain R4 
and strain R8. Yamamoto et al. (2012) have reported carbapenem-resistance in A. 
xylosoxidans possessing a class 1 integron that carries IMP-1 and IMP-19 
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metallo-beta-lactamase. This study is the first to report the detection of a class 1 
integron carrying IMP-14 metallo-beta-lactamase from Thai strains of A. 
xylosoxidans (Table 5.7). IMP-14 was detected in Thai clinical strains of P. 
aeruginosa (Genbank accession no. GQ302617, unpublished data) and A. 
baumannii in 2005 (Kansakar et al., 2011). These two species were clinical 
isolates from the same hospital from whence two MDR A. xylosoxidans isolates 
were collected. This suggests the appearance of horizontal gene transfer in this 
species. 
 
When compared to the gene cassette found in P. aeruginosa and A. baumannii 
(Appendix Figure A3.5), the structure of the integron - including an integrase, an 
aminoglycoside-N
6
-acetyltransferase, a sulfamethoxazole-resistance 
dihydropteroate synthetase (Table 5.7) and a conserved sequence - demonstrates 
high percentage similarity (99.9% and 100%). This evidences the local 
transmission and the preservation of the genetic element across the species. 
Interestingly, the integron was intact on the chromosome, which is consistent 
with the finding that A. xylosoxidans can harbour mobile genetic elements on its 
chromosome (Hu et al., 2015). Taken together with the fact that, as discussed in 
Chapter 4, the A. xylosoxidans genome is open, this may shed the light on why 
the genome of A. xylosoxidans is likely to be receivable and likely to be a 
reservoir of resistance genes. 
 
5.4.3. Beta-lactam resistance 
 
In general, A. xylosoxidans is recognised as a species that is resistant to several 
antibiotics, especially beta-lactam antibiotics. The mechanism for developing 
beta-lactam resistance could be the production of beta-lactamase, the expression 
of efflux transporter and the production of modified drug targets. The presence of 
a number of beta-lactamase genes was shown by previous studies (Jakobsen et 
al., 2013; Hu et al., 2015). The discovery of an intrinsic class D beta-lactamase, 
oxacillinase-114, in the species proved that beta-lactam resistance in A. 
xylosoxidans is innate and gene expression is not induced (Doi et al., 2008). 
Moreover, the presence of a metallo-beta-lactamase is acquired and transferred 
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via a genetic element (Sofianou et al., 2005; Neuwirth et al., 2006; Di Pilato, 
Pollini & Rossolini, 2014). In the comparative analysis in this study, the IMP-14-
metallo-beta-lactamase was revealed in the strains with less susceptible to 
carbapenems (Table 5.2, Table 5.3, Figure 5.5 and Figure 5.6). The presence of a 
class A beta-lactamase could explain the resistance to aminopenicillin in A. 
xylosoxidans (Table 5.7). 
 
In addition, an efflux pump associated with resistance to cephalosporin was 
indicated in the genome of A. xylosoxidans. Inactivation of these two RND-type 
efflux pump genes, AxyABM and AxyXY-OprZ, resulted in a decrease in 
cephalosporin MIC values (Bador et al., 2011, 2013). In agreement with previous 
studies, RND-type efflux pump genes were also identified as intrinsic resistance 
genes of the strains (Table 5.4). These findings suggested that the beta-lactam 
resistance mechanism in A. xylosoxidans would be due to both beta-lactamases 
and efflux pumps.  
 
5.4.4. Aminoglycoside resistance 
 
Aminoglycoside is an antibiotic that is commonly used against various pathogens, 
including Gram-negative bacteria. A. xylosoxidans has been shown to be 
aminoglycoside resistant (Yabuuchi & Oyama, 1971; Pien & Higa, 1978; Shigeta 
et al., 1978; Giacoia, 1990; Bador et al., 2011, 2013). The mechanisms leading 
to aminoglycoside resistance are the modification of the drug by enzymes, the 
transportation of the drug out of a cell by a pump, and the modification of the 
drug target. An RND-type efflux transporter, AxyXY-OprZ (Table 5.7), is the 
only aminoglycoside resistance-associated protein that has been well 
characterised and identified in Achromobacter species (Bador et al., 2013). The 
analysis in this study also presented that an AxyXY-OprZ homologous pump 
could not be identified in aminoglycoside-susceptible species. Moreover, the 
presence of AxyXY-OprZ homologous CmeABC in less-aminoglycoside 
susceptible strains supported the evidence that the efflux pump was strongly 
associated with an aminoglycoside-resistant phenotype. This leads to the 
implication of using these genes as a screening test for aminoglycoside resistance. 
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A drug-modifying enzyme, aminoglycoside acetyltransferase, is an enzyme 
believed to have a role in aminoglycoside resistance by structurally inactivating 
agents (Wright, 1999). It has been reported that the existence of this modifying 
enzyme is associated with aminoglycoside resistance in E. coli and Klebsiella 
spp. (Haldorsen et al., 2014). Isolates used in this study contain this enzyme in 
their core genome and MDR isolates contain an extra gene encoding 
aminoglycoside acetlyltransferase on an integron (Table 5.7, Figure 5.11). The 
comprehensive analysis showed that a CmeABC pump, with a high identity to 
AxyXY-OprZ, and an aminoglycoside acetyltransferase were present in the 
intrinsic resistance gene set of isolates, suggesting that aminoglycoside resistance 
is an innate ability of A. xylosoxidans. 
 
5.4.5. Fluoroquinolone resistance 
 
Agents in the fluoroquinolone class are some of the most widely clinically-used 
antibiotics due to their broad spectrum. Bador et al. (Bador et al., 2011) has 
described AxyABM as an efflux pump that has a role in multidrug resistance in 
A. xylosoxidans AXX-A. This is the only mechanism that has been identified that 
can explain the fluoroquinolone resistance mechanism in genus Achromobacter. 
Genes that have close homology to the efflux system‟s genes were identified as 
intrinsic resistance genes of A. xylosoxidans.  
 
The mutation of DNA Topoisomerase effects a massive change in MIC 
(Redgrave et al., 2014) in E. coli.  In Gram-negative bacteria, the mutation in the 
QRDR in DNA Topoisomerase subunit A is used to indicate resistance to 
fluroquinolone (Heddle & Maxwell, 2002). In this study, the mutation in the 
QRDR region (Appendix Figure A3.6) explains the higher resistance to 
fluoroquinolones seen in A. xylosoxidans strain R8. 
 
5.4.6. Sulfamethoxazole-trimethoprim resistance 
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Sulfamethoxazole-trimethoprim is a combination of agents that is potent in 
treating a broad range of pathogens, especially in urinary tract infections or in 
systemic infections (Huovinen et al., 1995; Eliopoulos & Huovinen, 2001).  Due 
to the mechanism of action and spectrum of activity, this combination is 
extensively used as a first line drug against urinary tract infections. For 
Achromobacter infections, this agent is usually effective against the pathogen 
(Derber et al., 2011; Atalay et al., 2012; Sheng et al., 2013; Tena et al., 2014). 
Resistance to SXT occurs mostly due to mutations in dihydropteroate synthase 
and dihydrofolate reductase, respectively. In agreement with previous studies, 
two groups of dihydropteroate synthase were identified here (Figure 5.14). 
Physically, this gene locates on the class 1 integron that is carrying IMP-14-
metallo-beta-lactamase (Figure 5.11 and Figure 5.12). Some studies have shown 
sulfamethoxazole resistance to be passed between strains and species in a 
horizontal transfer event via a class 1 integron (Antunes et al., 2005; Blahna, 
2006). Altogether, it is reasonable to propose that sulfamethoxazole-
trimethoprim resistance is acquired in A. xylosoxidans because of its open pan-
genome (as discussed in Chapter 4). 
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5.5. Conclusions and future work 
 
Here, a present study has illustrated the use of whole genome sequencing and 
bioinformatics tools to predict and reveal antibiotic resistance genes associated 
with a susceptibility profile. The susceptibility of isolates of A. xylosoxidans 
reveals that resistance to aminoglycosides, fluoroquinolones and cephalosporins 
are inherent phenotypes in A. xylosoxidans, as indicated by the presence of RND-
type efflux pump genes and beta-lactamase genes. Fluoroquinolone resistance 
could be explained by the presence of a fluoroquinolone-associated efflux pump. 
Abnormally high resistance (high MIC) to fluoroquinolones is caused by a 
mutation of the QRDR. On account of the presence of the AxyXY-OprZ 
homologous efflux system in strains less susceptible to aminoglycosides, the 
presence of this pump, especially its inner membrane protein, could potentially 
be used as a screening marker for aminoglycoside resistance. 
 
The pump system genes and beta-lactamase genes were included in accessory 
genes. Additionally, an extra metallo-beta-lactamase gene and resistant 
dihydropteroate synthase gene were found on a class 1 integron that has firmly 
merged into a chromosome of an open-genome species. According to the 
structure of the class 1 integron, the co-resistance to trimethoprim, 
aminoglycosides, and beta-lactamases could have lead to the presence of the 
integron in the isolates. 
 
Using extensive bioinformatics analysis, Random Forest™ was able to select 
carbapenemase genes. The detection of these genes led us to a further 
investigation and the discovery of the chromosomally-lodged integron. This 
demonstrated the efficiency of an unsupervised-learning machine in linking 
biological information to computationally predicted information.  
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Chapter 6  
Identifying virulence genes used by Achromobacter 
xylosoxidans in an infection model 
 
6.1. Introduction 
 
6.1.1. Virulence in bacterial infection 
 
In the environment bacteria are often found as part of bacterial communities and 
the human body is no exception. There are many examples of bacterial 
communities associated with humans, which are referred to a microbiomes. The 
relationship between microbiomes and their hosts can be often defined as 
„commensalism‟, where the microbes gain benefit from the host without 
affecting the host‟s fitness. Interactions can also be „mutualism‟, where both host 
and microbes gain benefit from each other, as exemplified by gut microbes that 
synthesise vitamin for their host (LeBlanc et al., 2013). Conversely, there are 
also pathogenic relationships where microbes detrimentally affect the fitness of 
the host. 
 
Bacteria are evolving in the contact with the host and both partners can be 
expected to evolve strategies for co-existence. This can result in an “arms race” 
between the host and the microbe as each tries to overcome the others defences 
or infection strategies (Brown et al., 2006). If the bacteria can overcome host 
defence, it is considered virulent colonisation of the bacteria. By etymology, 
virulence derives from Latin words virulentus (full of poison): virus (poison) and 
lentus (fullness) (Casadevall & Pirofski, 2001). Virulence is also defined as „the 
capacity of a microorganism to infect and damage a host‟ (Lipsitch & Moxon, 
1997). The important mechanisms of virulence are toxicity, attachment, 
aggressiveness and immunity avoidance (Casadevall & Pirofski, 2001).  
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Toxicity is determined as the ability to produce a substance that causes damage 
to host tissue. The substance is called a „toxin‟. The toxin can be categorised into 
two main groups: endotoxin and exotoxin. Endotoxin is a structure that is 
commonly present as a part of bacterial cell wall and is released after the death of 
the microbes. Lipopolysaccharide (LPS) is the endotoxin of Gram-negative 
bacteria and techoic acid and peptidoglycan are the endotoxin of Gram-positive 
bacteria. The molecules are recognised by toll-like receptor (TLR) moleules, 
which are present in most of innate immune cells. LPS is recognised by TLR-4 
(Erridge, Bennett-Guerrero & Poxton, 2002), whereas Techoic acid and 
peptidoglycan are recognised by TLR-2 (Schwandner et al., 1999). This leads to 
the production of inflammatory cytokines (e.g. interleukin-1 and interleukin-12) 
that orchestrate inflammatory response in host (Miller, Ernst & Bader, 2005). 
Inversely, exotoxin, sometimes called „true toxin‟, is defined as the toxic 
substance that is secreted by a living microorganism (Casadevall & Pirofski, 
2001). The effect of exotoxin leads to several detrimental infections; for example, 
Cholera toxin of V. cholerae and Staphylococcal toxic shock syndrome toxin-1 
of S. aureus. 
Attachment is also considered as a characteristic of virulence. The attachment of 
bacteria to host tissues, in particular, epithelial surface, is an essential process for 
some species to cause disease. For example, the firm adherence of uropathogenic 
E. coli to urinary tract using P and type I fimbria protects the bacteria from 
shedding by urine flow (Melican et al., 2011). This gives an advantage to 
bacteria to remain their colonisation, leading to the inflammation of urinary tract 
system. Nevertheless, not all bacteria attached to host‟s tissue are virulence. 
Commensal bacteria in human gastrointestinal tract adhere to mucosal surface as 
a protective layer to prevent the attachment of non-commensal bacteria 
(Tlaskalová-Hogenová et al., 2011). 
Aggressiveness is the ability to invade and reproduce in the host. This attribute 
of virulence refers to any mechanism that promotes bacterial survival in the host 
and, subsequently, leads to the damage to host (Casadevall & Pirofski, 2001). 
Most of the mechanisms that contribute to the aggressiveness of the bacteria are 
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to invade or avoid host‟s immune response. The production of polysaccharide 
capsule is the example of immune avoidance mechanism. The polysaccharide 
capsule produced by some species, such as S. pneumoniae, inhibits host‟s 
immunity by means of inhibiting complements and phagocytosis (Hyams et al., 
2010). This helps bacteria to survive and, subsequently, damage the host using 
other virulence factors, such as hyaluronidase in S. pneumoniae (Kadioglu et al., 
2008).  
One important parameter determining the pathogenicity of the bacteria is the 
ability to grow and to reproduce in the host. It is called a „fitness‟ of pathogen. 
Both host and pathogen try to retain their fitness by overcoming one another. For 
example, host increases body‟s temperature to suppress the reproduction of the 
bacteria and the bacteria try to avoid thermoregulator by rapidly killing the host 
(Elliot, Blanford & Thomas, 2002). Therefore, the pathogen needs to produce the 
factor that makes them dominate host‟s fitness. 
Virulence factor is defined as the factor that helps bacteria to retain their 
virulence, and the virulence is weakened when the factor is diminished 
(Casadevall & Pirofski, 2000). According to the attributes of bacterial virulence 
described above, the virulence factor, therefore, promotes those abilities in the 
host. Nonetheless, the concept of virulence of the pathogen is dependent on the 
susceptibility of the host. Therefore, this defines a term „pathogen‟ as an 
organism that can colonise a host and can cause diseases (Brown et al., 2006).  
The genes used by A. xylosoxidans in pathogenic infection are currently 
unknown. There is limited knowledge of the virulence factor produced by A. 
xylosoxidans. It has been recognised that the bacteria is opportunistic infection, 
determined by in vivo experiment (Hyodo, Katahira & Shigeta, 1982), and the 
bacteria secretes heat-stable inflammatory factor, determined by in vitro 
experiment (Mantovani et al., 2010). 
 
6.1.2. Infection models 
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Animal models of infection are important tools for experimental immunologists 
and microbiologists to understand defense mechanisms of immune systems and 
how pathogens avoid the host‟s immune system. Whole organism models include 
several levels of organisation and complexity e.g. organisms, organs, tissues and 
culture. According to different level of infection model, the whole body can 
provide a better understanding of how a pathogen behave during infections and 
cause disease. Moreover, organisms with close relationship to human can 
demonstrate host response better. For human diseases, mammal models such as 
mouse, pig, rabbit and ape, are relevant as their genetics, physiology and immune 
systems can have direct parallels humans (Hedges, 2002; Hunter, 2008). In 
addition, genetic manipulation and engineering of mammals can provide 
researchers with the genetic tools to understand the role of genes with a human 
homolog. 
 
The mouse model is a very important for scientific research, including the study 
of infectious diseases. Mice share about 70% of amino acids sequences with 
humans (Emes, 2003), so molecular mechanisms in mice often have human 
homologs and vice versa. A number of studies to understand human immune 
responses have been conducted in mice (Buer & Balling, 2003). Despite 
similarities between mice and humans it is often necessary to use genetic 
modification to determine particular process. There are a number of mutant mice 
available to support study in immunity and infection.  
 
Prior to the utilisation of animal infection model, the principle of 3Rs should be 
considered. The 3Rs are the framework developed for animal use in scientific 
research. 3Rs consist of (1) replacement, (2) reduction, and (3) refinement 
(https://www.nc3rs.org.uk/the-3rs). Firstly, replacement means to avoid animal 
use or to replace vertebrate animal model with another model, including human 
tissue, established cell line, immature animal, and computer model. An example 
of replacement in infection model is the replacement of mouse by G. mellonella 
in P. aeruginosa infection (Jander, Rahme & Ausubel, 2000). Secondly, 
reduction refers to reduce the number of animals used in the experiment. This 
can be done by comprehensively designed experiments, sharing information 
between groups, and using advanced data collection technology. For example, 
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green fluorescent protein-tagged bacteria can be used to show both mortality of 
the animal and in vivo distribution of the bacteria in a single experiment (Park et 
al., 2012). Lastly, refinement is important in the studies that the use of animal 
model is unavoidable. This issue involves animal husbandry and welfare, which 
affect the quality of life of animal (Morton, 1998). Good welfare allows animals 
not to be stressed, resulting in interpretable result with a reduced number of 
animals used (Baker et al., 2011). Above all, cost effectiveness of the model is 
an issue to be considered. Mammalian models are more expensive than non-
mammalian model, however, mammalian models can provide researchers with 
more comprehensive data. The 3Rs framework provides the researchers with 
guideline and ethical issue to consider the use of animal model in the scientific 
experiment. 
 
Following the principle of 3Rs, if the use of animal model is unavaoidable, the 
replacement is regarded as the most important issue. To investigate the 
pathogenicity of the pathogen, systemic infection model, such as animal, remains 
important. The replacement of mammalian model by non-mammalian model is 
under consideration. Non-mammalian models are an important alternative for 
infection and immunology. These models can be used directly as infection 
models, but also for initial screens of large bacterial strain panels, prior to 
performing smaller scale mammalian model tests. Non-mammalians are non-
sentient organisms. Furthermore, they have demonstrated the potential to replace 
mammalian model in various studies. Non-mammals models include, the 
nematode Caenorhabditis elegans, the fruit fly Drosophila melanogaster and the 
zebrafish Danio rerio. 
 
C. elegans was the first non-mammalian model used to study infectious diseases. 
It has often been used as a test for virulence in clinical strains and in screening 
tests for antibiotic treatments. Owing to lack of adaptive immune response, the 
nematode provides a good model for observing innate immune responses. For 
example, in E. faecalis infection, the immune response of the nematodes 
demonstrated the importance of reactive oxygen species as a defence mechanism 
(Chávez et al., 2007), which are similar to the response shown by human 
phagocytic cells.  
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The fruit fly is a well-known model for human genetics and cancer studies. 
Based on its behavior, the fly consumes rotten fruit, which contains many 
bacteria, so the fly produces number of antimicrobial agent into the gut in order 
to defend against those bacteria. In addition, the anatomy of the gut and immune 
signaling pathways have some conserved features with humans, so D. 
melanogaster can be used as a model for human gut infection (Apidianakis & 
Rahme, 2011). Flies have also been used to study Gram-positive bacterial 
infections, such as S. aureus (Needham et al., 2004) due to the presence of 
Peptidoglycan-specific Pattern-recognition Receptor (Pili-Floury et al., 2004).  
 
The zebrafish is an important model for the study of embryology in medical 
research. The zebrafish has both innate and adaptive immune systems. For innate 
immunity, the phagocytes and, interestingly, Toll-like receptors play a role 
similar to immune response in human (Phelan, Mellon & Kim, 2005). Enzymes 
involved in adaptive immune system (Willett, Cherry & Steiner, 1997), as well 
as B cells (Danilova & Steiner, 2002) and T cells (Danilova et al., 2004), were 
found in the fish. Humoral immune response is also conserved between zebrafish 
and human. With exposure to pathogens, inflammatory cytokines, such as 
interleukin-1 and tumor-necrosis factor are produced to respond to infection in 
zebrafish (Pressley et al., 2005). It is agreed that the zebrafish is an effective 
model for infection and immunology study.  
 
All of human pathogens are able to grow well at 37 °C, which is the 
physiological temperature in human. However, optimal temperature of the all 
aforementioned organisms are below 37 °C. Substituted pathogens are often used 
to study the course of infection in those models, as exemplified by the use of M. 
marinarum in the Zebra fish to imitate human tuberculosis from M. tuberculosis 
(Meeker & Trede, 2008). Non-mammalian model being able to grow at 37 °C is  
considered an appropriate model to demonstrate in vivo infection. 
 
6.1.3. The use of G. mellonella as an infection model in infection biology 
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The wax moth larvae, G. mellonella, provides experimental biologists with a 
convenient model, compared to other models. There are a number of advantages 
in using G. mellonella as an infection model. 
 
1. The larvae is relatively large (2-4 cm). The size of animal is large 
enough for a researcher to hold and perform the experiment: For 
example, bacteria can be injected into the larvae via its left proleg to 
mimic bacteraemia, and antimicrobial injected to test drug‟s efficacy. 
2. Haemolymph of the worm contains phagocytes, which its action is 
similar to human phagocytes, such as they produce radical oxygen 
species to combat foreign organisms (Bergin et al., 2005). 
3. The worm can be cultured at 37°C. This is important when 
considering its use as model for human infection, because human 
pathogens can be grown at 37 °C. 
 
The use of this larvae as an infection model has been increasing in recent years. 
Many important human pathogens have been tested using G. mellonella model. 
A study in P. aeruginosa illustrated a power of G. mellonella that is positively 
correlated with P. aeruginosa experiment in mice (Jander, Rahme & Ausubel, 
2000). Virulence of different strains were tested in B. cepacia complex (Seed & 
Dennis, 2008), E. faecium (Lebreton et al., 2011) and Uropathogenic E. coli 
(Alghoribi et al., 2014). Moreover, G. mellonella has also been used to reveal the 
efficacy of antibiotic against pathogens, such as A. baumannii (Peleg et al., 2009; 
Hornsey et al., 2013) and B. pseudomallei (Thomas et al., 2013). These provide 
evidence that G. mellonella is an appropriate infection model and an alternative 
to a mouse model, when considering the 3Rs. 
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6.1.4. Aims and objectives 
 
A. xylosoxidans is often described in a clinical context as an opportunistic 
pathogen, and a clinical strain has been shown to be lethal in immune-
compromised mice (Hyodo, Katahira & Shigeta, 1982). However, there is no 
information about the relative virulence of A. xylosoxidans strains and no 
candidate virulence genes have been described.  
 
The aim of this study is to investigate whether the larvae of the great moth (G. 
mellonella) could be used as an infection model for A. xylosoxidans. To 
specifically investigate whether there is difference between virulence 
determinants of the clinical strains (e.g. DSM 2402) and virulence determinants 
of environmental strains (e.g. NCIMB 11015). In addition to assess the relative 
virulence of A. xylosoxidans strains and use Random Forest™ data mining 
approach to determine the genetic bases of the any observed differences in 
virulence. 
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6.2. Material and methods 
 
In order to investigate the virulence amongst A. xylosoxidans isolates, infections 
were performed in the G. mellonella model. 
 
6.2.1. Determination of LD50 of type strains, NCIMB 11015 and DSM 
2402, in G. mellonella infection model 
 
Firstly, the difference in virulence between environmental strain, NCIMB 11015, 
and clinical lab strain, DSM 2402, were determined using lethal dose -50 (LD50) 
of each strain. Prior to experiment, larvae were divided into four groups; two 
controls: non-injection, mock infection, and two experimental infections of 
strains NCIMB 11015 and DSM 2402. Each group contains 32 worms and was 
replicated three times. Overnight LB cultures of the NCIMB 11015 and DSM 
2402 strains, were inoculated into LB broth, grown until they reached an optical 
density at 600 nm of 0.3 to 0.4 (approximately 1x10
8
 cells/ml). Then the cultures 
were centrifuged at maximum speed and resuspended in phosphate buffer saline 
(PBS) twice prior to inoculating into larvae. This was used as a stock inoculum, 
approximately 1x10
8
 cells/ml, to setup dilutions of cells for the experiments. 
 
Randomly selected larvae were injected with 10 μl of previously prepared 
inocula using a 50 – μl Hamilton syringe. The injection was achieved via the last 
left proleg of the larvae. The larvae were injected with three different amounts of 
bacteria, 10
4
 cells, 10
5
 cells and 10
6
 cells of each bacterial strain. After injection, 
the larvae were kept in 24-well plates (one larva per well) and were incubated at 
37°C. Two control groups were included in this experiment, which were larvae 
injected with PBS (mock infection) and larvae with no injection in order to 
assure that larvae did not die of trauma from injection. The number of dead 
larvae was scored every 12 hours for 96 hours. Larvae were considered „death‟ 
when they did not respond to physical stimulation and the physical appearance 
became melanised (Peleg et al., 2009). Survival of larvae was assessed using 
Kaplan-Meier survival curves and Log-rank test in survival package in R version 
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3.1.2. Finally, The LD50 was calculated from a regression plot between the 
percentage of death and logarithmic value of number of bacteria.  
 
6.2.2. Determination of virulence of clinical isolates of A. xylosoxidans in 
G. mellonella 
 
All clinical isolates were prepared as previously described above to produce a 
final suspension in PBS of 1x10
8
 cells/ml. Larvae were inoculated with 10 μl of 
bacterial suspension, approximately 1x10
6
 cells, and placed in 24-well plate. Ten 
worms for each strain, replicated three times. After the injection, larvae were 
incubated at 37°C and the status of the larvae were assessed every 12 hours until 
96 hours after injection. Larvae were considered „death‟ when they did not 
respond to physical stimulation and became melanised (Miyata et al., 2003). 
Survival of larvae was assessed using Kaplan-Meier survival curves and Log-
rank test using the survival package in R version 3.1.2. 
 
6.2.3. Virulence genes prediction 
 
To predict potential virulence factors a reciprocal protein BLASTP was 
performed for each strain predicted proteome against the Virulence Factor 
Database (VFDB) (Chen, 2012). BLASTP searching was done with a threshold 
at 1e-5. The top reciprocal BLASTP hits were validated by PSIBLAST against 
CDD and were curated to ensure consistent results. Resulting genes were 
assigned back to their OrthoMCL orthologous clusters (Chapter 5) according to 
gene accession. Finally, OrthoMCL orthologous clusters were transformed into a 
matrix showing the presence/absence of orthologous groups in each strain. 
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6.2.4. Phenotype-associated virulence genes prediction 
 
Two sets of genomic data were prepared as inputs for the algorithm. The former 
was constructed based on VFDB-riched orthologues, and the latter was 
constructed based on whole genome orthologues. Both inputs for the gene 
searching were prepared as matrices showing the presence/absence of the 
orthologues across 25 genomes of tested A. xylosoxidans. The rate of kill (fast 
and slow) was used as a category for Random Forest™ classification. Both 
matrices were subjected to classification process using Random forest™ in R 
statistic software. The implementation was previously described in Chapter 4.  
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6.3. Results 
 
6.3.1. Determination of LD50 of type strains, NCIMB 11015 and DSM 
2402, in G. mellonella infection model 
 
The suitability of G. mellonella as an A. xylosoxidans infection model was 
assessed using two type strains.  A bacterial titre of 10
6
 cells for NCIMB 11015 
caused 50% mortality within 24 hours and 100% mortality within 36 hours 
(Figure 6.1). The same titre for the DSM 2402 strain caused 65 % mortality after 
36 hours and 100% mortality within 48 hours (Figure 6.1). The LD50 of the two 
strains shows a significant difference with a mean of 71,969 and 146,757 cells of 
NCIMB 11015 and DSM 2402, respectively (Student‟s t-test; t = -6.0066; p < 
0.05) (Figure A4.1). The effect of reducing the inoculum dose was to reduce the 
rate of larval mortality, and a positive correlation was observed between larval 
mortality and injected bacterial titre (Figure 6.1). The control larval groups of 
mock infection and no injection remained alive till the end of the observation 
period. 
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Figure 6.1: Virulence of type strains of A. xylosoxidans. A) Kaplan-Meier 
survival curve of G. mellonella after treatment with different concentration of A. 
xylosoxidans strains NCIMB 11015 and DSM 2402. X-axis indicates time after 
injection. Y-axis indicates the percentage of larval survival. B) A linear 
regression graph plotted between the percentage of killed larvae and 
log10(Inoculum dose) from A. xylosoxidans strain NCIMB 11015 (black line and 
black square) and strain DSM 2402 (dash line and open-circle). 
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6.3.2. Virulence of clinical strains in the Galleria mellonella model 
 
Virulence of clinical strains was determined in G. mellonella larvae over a 96 
hours post injection. Based on the experiment described in section 6.3.1, it was 
expected that A. xylosoxidans strains would kill at different rates.   
 
Based on the observed differences in Time to Death (TD) at 24 h, the strains 
were put in two groups (Figure 6.2A). Fast, ≥80% mortality within 24 h and slow 
<80% mortality within 24 h see Table 6.1. Moreover, the strains were also 
separated into 2 groups by UPGMA hierarchical clustering (Figure 6.3B). 
 
Table 6.1: Summary table showing groups of strains categorised by time-to-
death of G. mellonella (Referring to Figure 6.2). NCIMB 11015 stands for A. 
xylosoxidans NCIMB 11015; DSM 2402 for A. xylosoxidans DSM 2402. L-
strain for Liverpool‟s clinical isolates; and R-strain for Thai clinical isolates.  
 
Killing group 
Strain 
Type Liverpool Thai 
Fast ≥80% TD<24 h 
NCIMB 
11015 
L1 L5 L10 
R1 R2 R3 R5 
R6 R7 R8 R9 
R10 R11 R12 
R14 
Non-fast <80% TD <24h  DSM 2402 
L8 L11 L14 
R4 R13 L15 L16 
L17 
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Figure 6.2: Grouping of A. xylosoxidans isolates by time-to-death (TD) of the 
larvae. A) Differential virulence of A. xylosoxidans in G. mellonella model. Data 
were collected after 24 hour post-injection B) Hierarchical clustering of the 
isolates based on TD using UPGMA method, implemented in R. NCIMB 11015, 
stands for A. xylosoxidans NCIMB 11015; DSM 2402 for A. xylosoxidans DSM 
2402; L-strain for Liverpool‟s clinical isolates; and R-strain for Thai clinical 
isolates. 
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6.3.3. Candidate prediction using the VFDB-enriched data set 
 
The VFDB database hits to A. xylosoxidans revealed 238 gene clusters 
containing 4,549 genes (Appendix Table A4.1). Of these orthologous clusters, 76 
clusters were shared across all genomes and the most abundant candidates were 
general secretion pathway protein E, accounting for 50 genes from 25 genomes. 
Moreover, conserved virulence-associated genes included genes coding flagella 
biosynthesis, genes coding lipid A and genes involved in capsule biosynthesis 
(Appendix Table A4.1).  
 
Cluster analysis of the candidate virulence factor genes revealed some local 
clustering of strains from the same virulence category (Appendix Figure A4.3), 
for example, fast strain R3, R7 R9, R10; slower strains such as L11, L15 and 
R13. However, there was little indication of global virulence factor associated 
with the rate of larval mortality. Interestingly, the heatmap‟s dendrogram was 
consistent with core genome phylogeny (Appendix Figure A4.3) and some 
clinical isolates were genetically related to each other; for example, L11 was 
related to L15, and L5 was related to R11. 
 
Figure 6.3: A variable importance plot obtained from Random Forest™ 
classification on virulence of 25 isolates of A. xylosoxidans in G. mellonella 
shows the importance of each orthologue based on VFDB-enriched data set. 
A) Orthologs ranked by their „mean decreased accuracy‟ score. B) Orthologous 
ranked by their „mean decreased Gini‟ score. The x-axes indicate the level of 
importance. The Y-axes show the list of orthologs. 
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The use of Random Forest™ classification-based algorithm to identify gene 
candidate that had the highest importance score. The classification extracted 
three orthologues that had high mean decreased accuracy score and mean 
decreased Gini score. These orthologues were genes encoding UDP-N-
acetylglucosamine-2-epimerase, transposase and type III secretion system 
protein PscD (As shown in Figure 6.3).   
 
When these genes were considered in the context of the cluster analysis, no 
strong correlation with rate of larval mortality was observed. However these 
three genes did correlate with the local clustering discussed above. For example 
the fast strain cluster R3, R7 R9, R10 all contained type III secretion system 
protein PscD. It is also evident that most fast strain contained the same PscD 
gene (Figure 6.4). The PscD was not found on conserved orthologues. UDP-N-
acetylglucosamine-2-epimerase was present in most of Fast groups (11/16), and 
it was not present in any slow strain (Figure 6.4). When investigating gene 
orthologues of these isolates, the epimerase were found as both conserved genes 
and acquired genes. Interestingly, none of fast strain contains the transposase, 
whereas five out of nine of slow strains contain the transposase.  
 
Figure 6.4: The presence of significant Random Forest™ (RF)‟s gene groups 
in A. xylosoxidans isolates. Upper panel indicates RF‟s output from whole 
genome data set. Lower panels indicate RF‟s output from VFDB-enriched data 
set. NCIMB 11015 stands for A. xylosoxidans NCIMB 11015; DSM 2402 for A. 
xylosoxidans DSM 2402; L-strain for Liverpool‟s clinical isolates; and R-strain 
for Thai clinical isolates. 
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6.3.4. Candidate prediction from whole genome data set 
 
The use of Random Forest™ classification-based algorithm to identify gene 
candidate from the whole genome data sets was able to classify one gene that had 
correlation with fast larval mortality with a high mean decreased accuracy score 
and mean decreased Gini score (Figure 6.5). This gene had 80% homology to α/β 
-hydrolase domain-containing protein from P. aeruginosa. This gene was found 
in 15 (out of 16) fast-killing strains but was also found in one (out of nine) of the 
slower-killing strains (Figure 6.4). The investigation into the secondary structure 
of the hydrolase revealed that this protein consisted of α-helices and β-pleated 
sheet structure (Figure A4.2). The analysis for subcellular localisation of the 
protein showed that this protein could be cytoplasmic protein. 
 
 
Figure 6.5: A variable importance plot obtained from Random Forest™ 
classification on the virulence of 25 isolates of A. xylosoxidans in G. 
mellonella model shows the importance of each orthologue based on whole 
genome data set. The X-axes indicate the level of importance. The Y-axes show 
the list of OrthoMCL‟s groups. 
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6.4. Discussion 
 
This is the first study to assess the virulence of A. xylosoxidans in G. mellonella. 
Compared to the other animal models for infectious diseases, G. mellonella hold 
many advantages, such as lower in cost. When ethic of animal research 
considered, using G. mellnella attains the 3Rs. Additionally, its immune response 
is similar to innate immune response in mammals. Nitric oxide production in 
insect haemocyte is similar to the process in human neutrophil (Bergin et al., 
2005). This suggests that G. mellonella can be an alternative model to examine A. 
xylosoxidans infection in this study. 
 
6.4.1. G. mellonella as an infection model for A. xylosoxidans 
 
Preliminary result showed the difference of virulence of A. xylosoxidans type 
strain, as determined by the number of dead insects. The killing of the insects is 
dose-dependent (Aperis et al., 2007). The experiment demonstrated that A. 
xylosoxidans could establish the infection and could kill the larvae. The larvae 
could remain undamaged at low inoculum and died at higher inoculum. The 
lethality of the bacteria was different, as determined by the measurement of LD50. 
The soil reference strain (NCIMB 11015) was more virulent that the clinical 
reference strain (DSM 2402) in the insect model. Insects have been used to test 
the pathogenicity and virulence of human pathogens. C. elegans (Ewbank & 
Zugasti, 2011) and D. melanogaster (Dionne & Schneider, 2008) are well-known 
insect infection models. Insects, including C. elegans, D. melanogaster, and G. 
mellonella, and mice were used for P. aeruginosa infection model and they 
showed good performance to represent human infection (Tan, Mahajan-Miklos 
& Ausubel, 1999; Jander, Rahme & Ausubel, 2000; D‟Argenio et al., 2001). 
However, insect models are preferred, when considering 3Rs. The most 
important advantage of G. mellonella over C. elegans and D. melanogaster is 
that the great moth larvae can be cultured at 37°C. Taking these observations 
together, it suggests that G. mellonella can be used as an infection model for A. 
xylosoxidans. 
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6.4.2. Virulence of clinical isolates of A. xylosoxidans 
 
Virulence, by definition, is the measurement of the pathogenicity of the bacteria, 
which, mostly, refers to the ability to cause diseases in the hosts. Using wax 
moth larvae as a model, injected larvae died of infection whereas non-injected 
larvae and mock injection larvae did not. This suggests that the bacteria have 
virulence in the larvae of G. mellonella. The difference between the virulence of 
these strains is probably because of the expression of virulence factors. Gram-
negative bacteria posses lipopolysaccharide molecule that induces immune 
response in innate immune cells that ends up with inflammatory process and 
septicaemia in human (Mogensen, 2009). However, Montovani et al. showed 
that the virulence of A. xylosoxidans was not due to lipopolysaccharide molecule 
(Mantovani, Levy & Yano, 2012). On account of being a soil bacterium, A. 
xylosixidans can be a natural pathogen for G. mellonella. Therefore, a further 
investigation using a known G. mellonella pathogen will be conducted to 
evaluate the pathogenicity of A. xylosoxidans. 
 
As a result of the killing assay, most of Thai isolates exhibited rapid killing by 
kill more than 80 per cent of the larvae by 24 hours (Figure 6.2). This is similar 
to the soil type strain. Considering groups of strains by killing rate, the majority 
of fast-killing strains are strains from Thailand and the majority of slow-killing 
strains are strains from the UK (Figure 6.2). It can be assumed that strains from 
different geographical background require different growing conditions such as 
temperature. Therefore, a further investigation will be conducted by varying 
incubating temperature of killing assay in G. mellonella model. 
 
Subsequently, the hierarchical cluster of virulence genes taken from each strain 
did not indicate geographical specificity of the strains (Figure A4.3). 
Furthermore, the cluster revealed groups of fast killers and non-fast killers. As 
seen in the killing assays, all bacterial isolates are detrimental to the larvae. The 
factors that cause the variation in time-to-death of the larvae can be different 
growth rate of the bacteria and different level of virulence factors. Different 
growth rate of the bacteria can influence time-to-death of the larvae due to 
difference in the number of bacteria inside the larvae at particular time point. In 
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other words, bacteria having faster rate of growth can generate a higher number 
of bacterial cell, when the same amount of time spent, compared to the bacteria 
having slower growth rate. Subsequently, the fast growing bacteria can cause 
mortality faster than the slow growing bacteria.  
 
As discussed in Chapter 4 that genome of the species is open, this points to the 
idea that the difference in virulence of each strain can be due to different 
virulence genes, which are received from various sources. The evidence of 
horizontal transferred genes in A. xylosoxidans is explained by the detection of 
mobile element genes, such as integrase (As discussed in Chapter 5), and by the 
presence of recombination in the species (As discussed in Chapter 4). In other 
species, lateral gene transfer is considered a tool to exchange virulence genes. 
For instance, the transfer of Shiga toxin-encoding gene into the E. coli via phage, 
and they become Shiga-toxin-producing E. coli strains (Muniesa et al., 2000). 
 
On account of being an emerging and opportunistic pathogen, a few 
investigations of virulence of A. xylosoxidans have been conducted. A. 
xylosoxidans is recognised for its low virulence in healthy individual. This study 
presented the invasion of A. xylosoxidans that ended up with the death of the 
larvae. The result in this study is in connection with that explained by Hyodo, 
Katahira & Shigeta (1982) that A. xylosoxidans successfully infects and kills 
immune-compromised mouse. The investigation also detects the distribution of A. 
xylosoxidans throughout the body of mouse, except for the liver. These 
emphasise the low virulence of A. xylosoxidans.  
6.4.3. Potential virulence genes in A. xylosoxidans based on G. mellonella 
infection model 
 
The virulence factors of A. xylosoxidans have not been extensively investigated. 
(Mantovani, Levy & Yano (2012) detected secretory heat-stable cytotoxic factor 
from the supernatant of A. xylosoxidans. The factor was seen to induce the 
production of interleukin-6 and interleukin-8, when treating lung cell line. 
Subsequently, these interleukins caused the inflammation of lung epithelial cells 
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in in vitro investigation. There is only a single study to investigate virulence 
factor of A. xylosoxidans. 
 
There are a number of bacterial virulence-associated genes identified as 
conserved genes of A. xylosoxidans. The most prominent genes are gene coding 
flagella, capsule, and LPS. These are conventional bacterial virulence 
deteminants (Casadevall & Pirofski, 2001). However, A. xylosoxidans isolates in 
this study demonstrated variable larval killing ability. The prediction of virulence 
determinant mediating this differential virulence of A. xylosoxidans was 
therefore conducted. 
 
To identify virulence factor candidates, Random Forest™, together with whole 
genome data set and VFDB-matched data set, nominated virulence gene 
candidates. For whole genome dataset, the predictive model ranked hydrolase 
and hypothetical proteins as statistically virulence-associated genes. For VFDB-
enriched dataset, the predictive model ranked UDP-N-acetlyglucosamine 2-
epimerase, PscD homologous type 3 secretion system export protein, transposase 
and hypothetical proteins as statistically virulence-associated genes. Determining 
biological roles of the candidates, hydrolase, PscD homologous gene, and UDP-
N-acetlyglucosamine 2-epimerase were considered potential candidates for the 
virulence determinants of A. xylosoxidans in G. mellonella model. The putative 
functions of hypothetical proteins remain unclear and there is a need for further 
studies. 
 
6.4.3.1. α/β-hydrolase fold-containing protein 
 
Gene coding α/β-hydrolase fold-containing protein was found as a strong 
candidate with the highest score assigned by Random Forest™ classifying model. 
The α/β-hydrolase fold is commonly found as a major part of hydrolytic enzymes, 
such as esterase, lipase and peroxidase (Nardini & Dijkstra, 1999). This domain 
serves as a catalyst of several biochemical reactions. A number of bacterial 
proteins contain this domain have been reported as important factors for 
homeostasis. For example, rsbQ gene encoding α/β-hydrolase domain-containing 
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protein is essential for energy stress response mechanism in B. subtilis (Brody, 
Vijay & Price, 2001). Another example of α/β-hydrolase-containing protein is 
2,4-dioxygenase, which catalyses quinolone degradation in catechol metabolism 
(Fischer, Künne & Fetzner, 1999). The virulence-associated hydrolase-
containing proteins have been reported. For instance, the α/β-hydrolase domain 
was identified in CFTR inhibitory factor (Cif) from A. baumannii (Bahl et al., 
2014). Cif acts by inhibiting the expression of CFTR channel to the apical 
surface of broncho-epithelial layer, so this resembles the characteristic of 
pulmonary CF (Swiatecka-Urban et al., 2006). A virulence factor BioH from 
Francisella, a causing pathogen of Tularaemia, also contains the hydrolase fold 
(Feng et al., 2014). These support the potential of α/β-hydrolase-containing 
protein found in this study to be a virulence factor; however, an actual role of the 
protein in A. xylosoxidans has not been elucidated yet. 
 
6.4.3.2. Type III secretion export protein PscD is a potential virulence 
protein 
 
For gene candidates obtained from VFDB-enriched data sets, PscD is considered 
as the most virulence-associated gene. The analysis revealed that PscD-
homogous gene is correlated with virulence in the larvae model (Figure 6.4). 
PscD is a forkhead-associated fold-containing protein and, interestingly, is 
homologous to inner membrane subunit of type 3 secretion system (T3SS), such 
as YscD in Yersinia enterocolitica, EscD in E. coli O157:H7, and CT664 in 
Chlamydia trachomatis (Pallen, Beatson & Bailey, 2005). The T3SS is a 
membrane-integrated transporter having a needle-like structure (Radics, 
Königsmaier & Marlovits, 2014). Once, the T3SS is inserted into host cell, an 
effector molecule is transported through the secretory apparatus directly to the 
host cell. Previous studies demonstrated the importance of PscD and YscD in 
virulence of these pathogens. In Yersinia, YscD is essential for the secretion of 
effector protein YopM (Plano & Straley, 1995). In P. aeruginosa, PscD is 
reported to associate with pathogenesis of the infection in great moth model 
(Miyata et al., 2003) and in zebrafish model (Clatworthy et al., 2009). This 
observation will probably support the secretory heat-stable protein that causes 
inflammation in lung epithelial cell line (Mantovani, Levy & Yano, 2012). 
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Many pathogens use the T3SS to adhere to host cells. For instance, 
enteropathogenic and enterohaemorrhagic E. coli use T3SS to inject Tir protein, 
which forms a complex with host‟s cytoskeleton, thus attaching to host cell 
(Frankel, 2001). Following the attachament to the host cell, the T3SS provides 
pathogens with a tunnel for virulence protein transfer. The T3SS-dependent 
virulence proteins damage host cells in two main ways:  damaging cytoplasmic 
process and disrupting cell-to-cell adjacent. The examples of these mechanisms 
are P. aeruginosa‟s cytotoxic protein ExoU (Sato et al., 2003) and 
enteropathogenic E. coli‟s tight junction-disrupting protein EspG (Tomson et al., 
2005). The actual importance and role of PscD protein in A. xylosoxidans will be 
further investigated. 
 
6.4.3.3. Capsule is a potential virulence factor in insect model. 
 
UDP-N-acetlyglucosamine 2-epimerase is an essential enzyme in polysaccharide 
capsule production. The deletion of this gene in E. coli strain K1 causes a 
problem in capsule biosynthesis (Vann et al., 2004). There were two genes 
encoding the epimerase on A. xylosoxidans genomes. One was included in 
conserved gene sets and the other was included in accessory gene sets. An extra 
existence of gene encoding UDP-N-acetlyglucosamine 2-epimerase is also 
identified in other species. For example, the duplication of UDP-N-
acetlyglucosamine 2-epimerase is reported in S. aureus with functional 
redundancy (Kiser et al., 1999). 
 
The polysaccharide capsule is the basic structure found in many pathogenic 
bacteria, such as S. pneumoniae (Kadioglu et al., 2008) and P. aeruginosa 
(Pollack, 1984). The compositions of capsules are different in each species. For 
example, the capsule of P. aeruginosa consists of alginic acid (Jain & Ohman, 
2005), while capsular component of S. pneumoniae are diverse (Bentley et al., 
2006). However, the function of capsule is similar that is to protect bacterial cells 
from external environment, especially host‟s immune responses, such as 
opsonophagocytosis, so as to survive inside the host‟s body (Wilson, 2002; 
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Hyams et al., 2010). Furthermore, the presence of capsule makes host recruit 
more immune cells to the site of infection to eliminate the pathogens, leading to 
reactive immunopathogenic response, which is an over-inflammatory response to 
host tissue (Wilson, 2002). Considering the characteristic of virulence, the 
capsule increases bacterial survival, which subsequently ends up with the 
inflammation and damage of host. Therefore, the enzyme involved in capsule 
biosynthesis can be considered as a virulence-associated gene in A. xylosoxidans. 
The mechanism how the capsule manipulates the virulence in G. mellonella 
remains undiscovered. 
 
6.4.3.4. Transposase: An interference of virulence in G. mellonella 
 
This study revealed the possibility of the interruption of bacterial virulence by 
the insertion of the transposon into the genomes. Mobile genetic element has a 
significant role in the diversification of bacteria. Transposase is one of the 
components of the mobile element called „transposon‟ (Frost et al., 2005). The 
mobilisation of transposon follows a pattern of „cut-and-paste‟ (Muñoz-López & 
García-Pérez, 2010) and the mobilisation can be promoted by transformation 
(Domingues et al., 2012), refering to an open pan-genome characteristic of the 
isolates (As discussed in chapter 4). It is assumed that the presence of the 
obtained transposase gene in low-virulence strain can be aasociated with the 
elimination of virulence gene by the insertion of transposon. However, this can 
happen by chance. Therefore, an additional study to investigate the importance of 
transposase gene in the virulence of A. xylosoxidans infection should be 
conducted. 
6.5. Conclusion and Future work 
 
The findings of this study demonstrate the integration of laboratory-based 
experiments and bioinformatic analysis in order to investigate virulence of 
emerging pathogens. The study displayed that G. mellonella is suitable for a 
model to study A. xylosoxidans infection. The model is convenient and easy to 
handle with due to its inexpensive cost. The larvae model can also be a 
replacement for mammalian model, when reviewing the principles of 3Rs. 
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The finding presented herein reveals the difference in virulence of A. xylosxidans 
with the use of G. mellonella. The investigation shows that environmental strain, 
NCIMB 11015, is more virulent than clinical strain, DSM 2402. However, some 
Thai clinical isolates demonstrate aggressive larvae killing. The combination of 
bioinformatic approaches, whole genome sequence and the killing of larvae has 
identified α/β-hydrolase-containing protein from whole genome data set, and 
UPD-N-acetylglucosamin-2-epimerase and T3SS protein PscD from virulence 
gene-enriched data. The best candidate is α/β-hydrolase-containing on account of 
its biological function and its existence in the isolates. 
 
The limitations of this study are that the number of bacteria was not determined 
after the larval infection and the distribution of bacteria inside the larvae was not 
conducted. Moreover, the assay at different temperatures has been performed yet. 
The cellular mechanism of A. xylosoxidans in G. mellonella model is still 
questioned. Nevertheless, The presence of these genes encourages the eagerness 
to conduct in-depth study of those candidates and the virulence using more 
comprehensive methods such as single molecule sequencing to determine the 
presence of transposon on the genome and mutagenesis of α/β-hydrolase-
containing protein, epimerase and PscD to observe the virulence in infection 
model.  
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Chapter 7  
General discussion  
 
This study attempted to apply a wide range of methods in biology to understand 
A. xylosoxidans on multiple levels – species identification, pan-genome analysis, 
antibiotic susceptibility, and virulence. This study also sought to explore the 
functional and comparative genomic perspective of the antibiotic resistance and 
virulence of A. xylosoxidans. As A. xylosoxidans has been increasingly identified 
from clinical sites, CF centres in particular, and has been perceived as an 
opportunistic pathogen, investigating genomic attribute, as well as a factor that is 
possibly responsible for antibiotic resistance or virulence of the pathogen, may 
allow relevant authorities to establish an appropriate treatment and infection 
control, especially in the hospital. This study led to the discussion of these 
following topics: 
1. Is A. xylosoxidans an emerging pathogen? 
2. How does the study of microbial pan-genome explain the events of 
hospital-acquired infections and antibiotic resistance in bacteria ? 
3. Do whole genome sequencing and bioinformatics help to understand 
emerging pathogens? 
 
7.1. Is A. xylosoxidans an emerging pathogen? 
 
The empirical data to answer this question are summarised by the demonstration 
of phylogenetic relationships between isolates. The phylogenetic relationships 
constructed using different sets of genes, including core genes set, antibiotic 
resistance-associated genes and virulence-associated genes, revealed the diverse 
population structure of A. xylosoxidans, as stated in Chapter 3, 4, 5, and 6. The 
genome analyses demonstrated no significant differentiation between clinical 
isolates and an environmental isolate. Moreover, most of the clinical isolates in 
this study were collected from patients with underlying conditions, for example, 
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CF, COPD, and cardiovascular and metabolic diseases. Patients with these 
diseases are likely to be susceptible to infections.  
 
Emerging pathogens, by definition, are microorganisms that can colonise and 
cause diseases to hosts with these three possible mechanisms: new hosts, new 
phenotypes and new area (Engering, Hogerwerf & Slingenbergh, 2013). 
Opportunistic pathogens, organisms that can cause infection, takes advantage 
over abnormal conditions of host such as chronic diseases, persistent infection by 
other pathogen, and ageing (Brown, Cornforth & Mideo, 2012). Previous studies 
revealed that most of the cases with A. xylosoxidans infection have underlying 
diseases (Kanellopoulou et al., 2004; Rønne Hansen et al., 2006; De Baets et al., 
2007; Amoureux et al., 2012; Mantovani, Levy & Yano, 2012; Trancassini et al., 
2014). The collection of isolates in this study supported the theories of emerging 
and opportunistic pathogen as those clinical isolates were collected from patients 
with chronic diseases and from hospitalised patients. The patients with 
underlying diseases are prone to be susceptible to infection, so they can be 
infected with bacteria that inhabit the environment. Following the hospitalisation, 
patients can bring those environmental bacteria to the hospital, which allows the 
circulation of the bacteria in the hospital. Those bacteria can cause serious 
hospital-acquired infection if they are resistant to antibiotics.  
 
As an emerging pathogen, the availability of robust methods for A. xylosoxidans 
identification is restricted. An accurate identification of the pathogens of 
hospital-acquired infection is required in order to give an appropriate treatment 
for the infection. There is a use of multiple approaches for the species 
identification of emerging pathogens (Dong et al., 2008; Emerson et al., 2008). 
Focusing merely on A. xylosoxidans, several studies have suggested various 
approaches such as 16S rDNA-directed PCR (Liu et al., 2002) and MLST 
(Spilker, Vandamme & LiPuma, 2012). This study demonstrated the limitation of 
single identification method to identify A. xylosoxidans. The analysis, therefore, 
proposed that the hierarchical combination of identification would be a suitable 
approach for A. xylosoxidans identification. This strongly suggests that multiple 
identification methods are essential for the identification of bacteria, especially 
for the uncommon and emerging pathogenic bacteria. 
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Despite the fact that using multiple identification approaches may improve the 
accuracy of species identification for emerging pathogens, facilities for the 
identification, such as a sequencer and MALDI-TOF, are unavailable in 
community hospitals, especially hospitals in developing countries including 
Thailand. Phenotypic test is widely used in those hospitals and the test provides 
healthcare providers with reliable results for well-known human pathogens, not 
for emerging pathogens. Therefore, patients infected by emerging pathogens 
have to be transferred to research-led hospitals, where advanced facilities are 
available. A precise identification is essential for the epidemiological study of 
the pathogens; however, giving an appropriate treatment is more clinically 
important. This makes antibiotic susceptible profile and the identification of 
antibiotic resistance genes become more important than species identification in 
clinical practice. Hence, antibiotic susceptible test should be available and 
performed in all hospitals, primary unit in particular, to shape the administration 
of an appropriate treatment for the infection. The species identification, which is 
second important, can be performed afterward by hospitals or institutes having 
the advanced facilities. This strategy may result in an improvement in treatment 
and epidemiology of the infections. 
 
7.2. How does the study of microbial pan-genome explain the events of 
hospital-acquired infections and antibiotic resistance in bacteria? 
 
The analyses of pan-genome and antibiotic resistance of A. xylosoxidans enabled 
us to understand the genomic characteristics that have major impacts on hospital-
associated infection. One of the important problems of hospital-associated 
pathogens is antibiotic resistance (Struelens, 1998), specifically in Gram-
negative bacteria (Lynch, Clark & Zhanel, 2013). The antibiotic resistance of A. 
xylosoxidans has been recognised as intrinsic phenotypes (Bador et al., 2011, 
2013; Hu et al., 2015). Similar to previous studies (Bador et al., 2011, 2013), this 
study revealed natural antibiotic resistance to aminoglycosides, fluroquinolones 
and cephalosporins, in association with the presence of RND-type efflux pumps.  
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The analyses of genomic characteristic also revealed the capability of A. 
xylosoxidans to obtain antibiotic resistance genes from external sources, as 
explained by the open pan-genome and evidenced by the presence of integron. 
Bacteria with open-genome have shown dynamic property of the genomes 
(Medini et al., 2005). The open pan-genome also refers to continuous exchange 
of genes between bacteria in order to survive in new environment. Regarding 
hospital-associated infections, bacteria with open pan-genome carry a prominent 
feature that can transfer antibiotic resistance genes and obtain virulence genes 
from the environment. Open pan-genome characteristic can be seen in several 
pathogenic bacteria, including S. pneumoniae, S. agalactiae, E. coli, and E. 
faecium. Common features determined by the opened genome of those pathogens 
are the ability to exchange their genetic with environements, as demonstrated by 
the retrieval of antibiotic resistance genes in S. pneumoniae and the retrieval of 
virulence genes in E. coli. On the other hands, close pan-genome can be 
observed in some pathogenic bacteria, such as Bordetella species. The core-
genome of Bordetella contributed to >95% of the genome, in which virulence 
genes are already included. The high conservation of Bordetella genome can be a 
consequence of sporulation, providing preventive shells for the genome from 
harsh environments.  
 
The population structure of the species reveals the diversification of the isolates, 
as presented by no geography-specific isolates based on the analysis of either 
core genome or accessory genome. A similar population structure, which is 
diverse, was seen in the genomic analysis of Haemophilus parasuis, 
demonstrated by mixed MLST and BAPS population structure analysis (Howell, 
2014). However, the population structure of A. xylosoxidans in this study does 
not clearly represent the actual population structure of the species because the 
number of isolates/genomes included may not reach the level that geographical 
specificity can be discriminated.     
 
A. xylosoxidans is also well-known for the potential to obtain additional 
resistance via horizontal gene transfers (Traglia et al., 2012; Di Pilato, Pollini & 
Rossolini, 2014; Chen et al., 2014; Wittmann et al., 2014). The existence of 
lateral genetic transfers may lead to unusual and harmful features: antibiotic 
Chapter 7 
 207 
resistance and virulence (Ochman, Lawrence & Groisman, 2000). Under the 
pressure of antibiotic uses in the hospistals, genetic elements help bacteria to 
survive, by providing antibiotic resistance genes (Rowe-Magnus & Mazel, 2002). 
The results in this study strengthened those findings by presenting the insertion 
of resistance-associated integron in highly resistant A. xylosoxidans isolates. This 
study also displayed the transfer of mobile genetic elements in the hospitals, as 
exemplified by the presence of identical integron in A. baumannii and in 
different strain-types of A. xylosoxidans. In some bacteria, the acquisition of 
external genetic elements is also important for the transformation from non-
virulent strains to virulent strains; for instance, the transformation of E. coli into 
Shiga toxin-producing E. coli by obtaining Stx1 gene-containing phages 
(Muniesa et al., 2000). The procurement of prophages that is associated with the 
enhanced competitiveness of the clone (Winstanley et al., 2009) also exemplifies 
the importance of lateral gene transfer to induce virulence in bacteria. 
 
The integration of genetic elements into bacterial genomes leads to genetic 
recombination, allowing for molecular evolution of bacteria (Smets & Barkay, 
2005). The recombination accelerates the evolution of the microorganisms faster 
than a single-nucleotide mutation due to the replacement of a large piece of DNA 
sequence, rather than a single nucleotide of an existing gene(Didelot et al., 2012; 
Boto, 2010). Recombination has a significant impact upon the population‟s 
structure of some pathogenic bacteria, including P. aeruginosa (Darch et al., 
2015), E. faecum (de Been et al., 2013), and S. aureus (Feil et al., 2003). In 
addition, the recombination contributes to the outbreak of L. pneumophila 
(Sánchez-Busó et al., 2014) and S. aureus (Castillo-Ramírez et al., 2011, 2012). 
Recently, genomic analysis has shown the low rate of recombination in genus 
Achromobacter. Inversely, the analysis presented herein the significant level of 
recombination on the core genomes, as evaluated by PHI test, BratNextGen and 
the non-congruent phylogenetic tree. The importance of bacterial recombination 
for hospital-associated infection is that the recombination drives the diversity of 
bacteria (Boinett & Cain, 2014). Therefore, it enhances the probability of the 
pathogens to survive since there is the diverse population of bacteria. If the 
events involve genes, which are detrimental to the host, including antibiotic 
resistance genes and genes coding virulence determinants, the recombined 
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bacteria will be more harmful, leading to serious infection in the hospital. In 
other words, the species that are naturally recombinant are likely to be a reservoir 
for those detrimental genes.  
 
Considering the diversity of the species, A. xylosoxidans seems to be a broad 
diverse species as there was no particular pathogenic sequence type. Inversely, 
other pathogens, such E. coli (Alghoribi et al., 2014) and E. faecium (de Been et 
al., 2013), have specific pathogenic sequence types or clonal. Importantly, with 
the open pan-genome of A. xylosoxidans, the pathogen can cause problems in 
hospital-acquired infections as it can habour and transfer virulence- or drug 
resitance-associated mobile genetic elements to other bacteria.  
 
Another principal contribution of this study has been moved forward to 
understand the antibiotic resistance problem. Since a hospital is recognised as a 
place where various antibiotic agents are extensively used, the inappropriate use 
of the antibiotic can induce the adaptation of bacteria - from susceptible strains to 
resistant strains. Importantly, empirical medication is often considered to treat 
infections. For example, aminoglycosides are usually used as empirical 
medication for Gram-negative infections. The investigation into the comparison 
between the antibiotic resistance susceptibility of clinical isolates of A. 
xylosoxidans and the environmental isolate of A. xylosoxidans revealed that Thai 
isolates were more resistant to antibiotics than British isolates. Considering the 
regulation of antibiotic use, medical prescription is always required to purchase 
antibiotics in the U.K. None of them is over-the-counter medicine. Therefore, the 
distribution of antibiotic is under inspection that reduces an inappropriate use of 
the agents. On the other hand, the regulation is poor-controlled in Thailand. The 
first possible contributor to this problem is the regulation for antibiotic 
prescription in Thailand. Some first-line antibiotics, such as amoxicillin, are 
over-the-counter medicines. They can be purchased without prescription from 
anywhere from chemists to local groceries. The second contributor is the 
medication compliance of Thai people. Most of Thai people stop taking 
medication when they feel that the symptoms are relieved (Personal 
communication with Dr. Ponpan Matangkasombut). The failure to complete the 
recommended course of antibiotic leads to the development of resistance strains 
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of bacteria. Antibiotic resistant bacteria, as a consequence of the failure, can be 
introduced to the hospital when those patients are hospitalised. It would seem 
sensible to determine the possession of antibiotic resistance associated genes in 
the communities, including hospitals and residential area, in order to investigate 
the evolution and the transmission of those genes. 
 
7.3. Does whole genome sequencing and bioinformatics help to 
understand emerging pathogens? 
 
Sequencing technologies and bioinformatics have become essential tools for a 
study of molecular microbiology. The improvement of facilities for whole 
genome sequencing has allowed for an increasing number of genome sequenced. 
In the latest publicly available Genbank information (September, 2015), there are 
over 20 million bacterial sequences, including uncultured bacteria (Figure 7.1). E. 
coli contributes to the most abundant bacterial nucleotide sequences (1,406,795 
deposited sequences, 6.95%). Clinically relevant species are the targets of 
sequencing, as illustrated by the top ten most sequenced species which are the 
causes of infection in human (Figure 7.1). Nucleotide sequencing has also been 
used as an unlocking tool for the investigation of emerging pathogens, such as M. 
abscessus (Choo et al., 2014), H. influenzae type f (Su et al., 2014), Vibrio 
furnissii (Lux, Lee & Love, 2014), and nosocomial pathogens including S. 
aureus (Harris et al., 2010; Price et al., 2014).  
 
 
Figure 7.1: Pie chart of bacterial sequences available on Genbank database 
in September, 2015. 
Uncultured bacterium 22.15%
Escherichia coli 6.95%
Staphylococcus aureus 4.98%
Streptococcus pneumoniae 4.33%
Mycobacterium tuberculosis 3.51% 
Salmonella enterica 3.23%
Pseudomonas aeruginosa 2.38%
Shigella sonnei 2.26%
Yersinia pestis 1.77%
Bordetella pertussis 1.61%
Acinetobacter baumannii 1.58%
All other taxa
Chapter 7 
 210 
This study applied whole genome sequencing to build up the understanding of A. 
xylosoxidans. The sequencing was, initially, performed on Illumina HiSeq 
platform, in which generated 150-bp paired-end reads. The critical step in 
genome sequencing approach is to obtain the best assembly, de novo assembly in 
particular. Statistical parameters have been used to evaluate the efficiency of the 
assemblers. N50 values are widely used to determine the quality of the 
assemblies. However, the investigation into the genome with the highest N50 is 
required to determine the quality of the assemblies in the event of repetitive 
sequences the can be ignored by the assemblers (Baker, 2012). The comparison 
of the efficiency of assembly between Velvet and Spades was performed. Spades 
assembler is likely to have a better ability (Bankevich et al., 2012), as 
determined by N50 values, the number of contigs and the size of the largest 
contigs. SMRT sequencing using PacBio platform has been introduced to 
achieve a single contig from the genome sequencing. The combination of 
Illumina‟s sequencing and PacBio‟s sequencing allows for complete genome 
sequences of bacteria such as B. subtilis (Kamada et al., 2014). Likewise, the 
sequencing using PacBio RS II platform, as well as Illumina platform, also 
revealed complete genome sequences of A. xylosoxidans. With a single contig, 
the localisation of antibiotic resistance-carrying integron on the genomes of 
antibiotic resistance isolates R4 and R8 can be achieved. 
 
In parallel with sequencing technologies, the number of software and database 
for genomic analyses has also been increasing. Apart from Genbank database 
(http://www.ncbi.nlm.nih.gov/genbank), several databases are established to 
provide information for the study of specific genus or species of bacteria, for 
example, the Pseudomonas Genome DB for Pseudomonas 
(http://www.pseudomonas.com) and EcoCyc for E. coli K-12 MG 1655 
(http://ecocyc.org). There are also databases for specific study such as PHAST 
for bacteriophage identification (http://phast.wishartlab.com) and PubMLST for 
MLST (http://pubmlst.org). For pathogenic bacteria specifically, the number of 
databases has enabled the comparative analysis of antibiotic resistance-
associated genes and virulence-associated genes. However, emerging pathogens 
and uncommon pathogens are not included in some databases such as VFDB 
(Chen, 2004). Therefore, the prediction of virulence genes of those uncommon 
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pathogens, such as Erysipelothrix rhusiopathiae (Kwok et al., 2014), is mostly 
performed by means of alternative approach based on sequence homology. 
Identifying virulence genes and antibiotic genes in emerging pathogens remains 
a main challenge.  
 
Data mining is vital for genomic analysis since whole genome sequence contains 
large size of information. The critical approach for genomic analysis is to explore 
the correlation and association between genetic information and biological 
information of the organisms. Several classification and correlation analyses 
have been developed and applied to examine genotype-phenotype correlation. 
This investigation executed unsupervised classifying approach, using Random 
Forest™, to find the association between phenotypes and whole genome data set. 
Random Forest™ algorithm has been implemented in several „omic‟ studies. As 
Random Forest™ can deal with large data set, it has been used as an approach to 
reduce the number of candidates for further analysis; for instance, the number of 
psychiatric disease-associated SNPs was narrowed by Random Forest™ (Lunetta 
et al., 2004). Nevertheless, with high-dimensional data set, the ability of Random 
Forest™ decreases (Winham et al., 2012).  This indicates that filtered data set is 
more suitable for Random Forest™. It is, therefore, noteworthy that results 
obtained from Random Forest™ are „statistically‟ important, and they are not 
always biologically important in the observed variables. The analysis for 
antibiotic resistance-associated genes demonstrated that Random Forest™ 
analysis resulted in genes that have been proved to play a role in antibiotic 
resistance. However, there is no obvious evidence to show that genes are 
statistically associated with virulence in G. mellonella model. Insight studies of 
the role of those genes will be necessary to pursue as a future research. 
 
7.4. Future work 
 
The study of the virulence of A. xylosoxidans identified genes important for the 
pathogenicity of the species using G. mellonella infection model. However, the 
assessment of the virulence of the candidates in in vivo experiments is still 
required. For further study, bacteria with knocked-out virulence gene candidates 
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will be tested using G. mellonella model to investigate whether those genes 
contribute to the pathogenicity of the bacterial. In parallel, the distribution of the 
pathogen will be examined using green fluorescent-tagged bacteria. Additional 
analysis can be conducted further in mouse model. Hyodo, Katahira & Shigeta 
(1982) demonstrated that adaptive immunity responsible for A. xylosoxidans 
infection in BALB/c mice. Further investigation can be conducted in CF mouse 
model using F508del-CFTR mice (Wilke et al., 2011). Considering the principles 
of 3Rs, investigating chronic infection in CF mouse model cannot be replaced by 
other non-mammalian model. The investigation in CF mouse model will be 
executed using signature-tagged mutagenesis as the approach can identify genes 
essential for the pathogenicity of the bacteria in tested animal model. Then the 
features of the virulence gene candidates will be studied in terms of roles in 
metabolic pathways, biological effects on hosts, and three-dimentional structure 
of the protein. These studies will pave the way for specific treatments, such as 
species-specific monoclonal antibody and passive immunisation.  
 
As the pathogen is well known for its multidrug resistance, a rapid detection for 
antibiotic resistance in pathogenic bacteria will improve the precision of 
antibiotic administration, without commencing treatment with non-specific 
empirical antibiotic. Therefore, the rapid identification for resistance genes will 
be developed to shorten time-to-result of currently used antibiogram. In addition, 
an inhibitor for RND-type efflux pumps will be invented as the activity of the 
RND-type efflux pumps play an important role in antibiotic resistance in severl 
human pathogenic bacteria, including A. xylosoxidans, A. baumannii, and P. 
aeruginosa. 
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Figure 7.2: A study flow diagram for the investigation of A. xylosoxidans  
 
7.5. Conclusion 
 
This study provides the comprehensive analysis of an emerging pathogen, A. 
xylosoxidans, using advanced genome sequencing technologies and 
bioinformatics (Figure 7.2). The study has also shown the limitation of (1) 
species identification for this emerging pathogen, and (2) the comparative 
genomic analysis with regards to antibiotic resistance and virulence in larval 
model. The scale of this investigation is applicable to the explanation for A. 
xylosoxidans in the local area. A large number of experimental observations and 
analyses are required to understand the event of A. xylosoxidans infection in a 
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broad level. There is, therefore, a need for larger collections of isolates and more 
various origins of isolates. The genomic study of other emerging nosocomial 
pathogens will offer a comprehensive situation of hospital-acquired infection, 
providing molecular evidences for public health policy maker to prevent an 
outbreak as well as antibiotic resistance in hospital setting. Finally, an animal 
infection model is required for the investigation of virulence. 
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Appendix 1 Scripts and Command lines used in this 
study 
 
1.1 Command line used to perform reciprocal BLAST and to parse 
functional assignment via eggNOG. A script is taken from FAS 
Center for System Biology, Harvard University 
(http://archive.sysbio.harvard.edu/csb/resources/computational/scri
ptome/UNIX/Protocols/Sequences.html) and edited for in-house use. 
 
blastall -p blastp -i <A file containing amino acid sequence of the strain> -d 
/pub16/pisut/PROJECTS/eggNOG/DB/aln_db/bactNOG/bactNOG.fasta -e 1e-10 
-b 3 -v 3 -a 16 -m 8 -o A_B 
 
blastall -p blastp -d < A file containing amino acid sequence of the strain > -i 
/pub16/pisut/PROJECTS/eggNOG/DB/aln_db/bactNOG/bactNOG.fasta -e 1e-10 
-b 3 -v 3 -a 16 -m 8 -o B_A 
 
perl -e '$name_col=0; $score_col=11; while(<>) {s/\r?\n//; @F=split /\t/, $_; ($n, 
$s) = @F[$name_col, $score_col]; if (! exists($max{$n})) {push @names, $n}; 
if (! exists($max{$n}) || $s > $max{$n}) {$max{$n} = $s; $best{$n} = ()}; if ($s 
== $max{$n}) {$best{$n} .= "$_\n"};} for $n (@names) {print $best{$n}}' A_B 
> A_B.best 
 
perl -e '$name_col=0; $score_col=11; while(<>) {s/\r?\n//; @F=split /\t/, $_; ($n, 
$s) = @F[$name_col, $score_col]; if (! exists($max{$n})) {push @names, $n}; 
if (! exists($max{$n}) || $s > $max{$n}) {$max{$n} = $s; $best{$n} = ()}; if ($s 
== $max{$n}) {$best{$n} .= "$_\n"};} for $n (@names) {print $best{$n}}' B_A 
> B_A.best 
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perl -e '$col1=1; $col2=0;' -e '($f1,$f2)=@ARGV; open(F1,$f1); while (<F1>) 
{s/\r?\n//; @F=split /\t/, $_; $line1{$F[$col1]} .= "$_\n"} open(F2,$f2); while 
(<F2>) {s/\r?\n//;@F=split /\t/, $_; if ($x = $line1{$F[$col2]}) {$x =~ 
s/\n/\t$_\n/g; print $x}}' A_B.best B_A.best > A_B_A 
 
perl -e '$colm=0; $coln=13; $count=0; while(<>) {s/\r?\n//; @F=split /\t/, $_; if 
($F[$colm] eq $F[$coln]) {print "$_\n"; $count++}} warn "\nChose $count lines 
out of $. where column $colm had same text as column $coln\n\n";' A_B_A > 
A_B_A.recip 
 
perl -e '@cols=(0, 1, 10, 11); while(<>) {s/\r?\n//; @F=split /\t/, $_; print 
join("\t", @F[@cols]), "\n"} warn "\nJoined columns ", join(", ", @cols), " for $. 
lines\n\n"' A_B_A.recip > RBHB.out 
 
cat RBHB.out | awk '{print $2}' > use.bbh.txt 
 
perl /pub16/pisut/PROJECTS/perl_scripts/str_match.pl use.bbh.txt 
/pub16/pisut/PROJECTS/eggNOG/DB/bactNOG.members.adjusted.txt  > 
eggNOG_prot.txt 
 
cat eggNOG_prot.txt | awk '{print $2}' > use.eggNOG_prot.txt 
 
perl /pub16/pisut/PROJECTS/perl_scripts/str_match.pl use.eggNOG_prot.txt 
/pub16/pisut/PROJECTS/eggNOG/DB/bactNOG.description.txt > descrip.txt 
 
perl /pub16/pisut/PROJECTS/perl_scripts/str_match.pl use.eggNOG_prot.txt 
/pub16/pisut/PROJECTS/eggNOG/DB/bactNOG.funccat.txt > COG.txt 
 
 
 
 
 
Appendices 
 258 
1.2 Commands used to parse OrthoMCL‟s output to generate a binary 
table presenting the presence/absence of genes in bacterial strains. 
Perl‟s and Pyhton‟s scripts are written with a help from Thomas 
Craig. 
 
1) Create fasta files with every protein used in clustering 
 
for i in *.gene.faa; do perl 
~/PROJECTS/orthomcl/from_jen/append_header_SA.pl $i > $i.append; done 
#append headers of fasta files to look like '>geneID(filename)' (which are similar 
to orthoMCL output) 
   
cat *.append > ALLfiles.append # concatenating all appended files together 
(make a new file containing all files) 
 
2) Generate a binary table using appended file and OrthoMCL‟s output 
  
./table_alt_cluster.py ALLfiles.append all_orthomcl.out > table.out 
 
1.3 Methods for Pan-genome and Core genome extrapolation 
 
1) Uploading code into R 
   
load("/Users/BEER/Desktop/AXresearch/Pan-
Core_Genome/For_Jen_Redesigned_code") 
 
2) Uploading the binary table generated using scripts in Appendix 1.2 
   
data<-as.matrix(read.table("binary table")) 
 
3) Run 'Wrapper' with 1,000 permutations (a command from the 
previously uploaded code) 
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Wrapper(data,1000) -> all_out_data 
 
4) Write CORE genes to a file 
   
all_out_data[,2,] -> CORE 
write.csv(CORE,"core.out ") 
 
5) Write PAN genes to a file 
   
all_out_data[,3,] -> PAN 
write.csv(PAN,"pan.out") 
 
6) Fitting core-genome and pan-genome to exponential model and 
power model, respectively 
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Appendix 2 Comparative Genomic analysis 
 
 
Figure A2.1: Phylogenetic tree based on maximum-likelihood analysis of 
16S rDNA gene sequences of Achromobacter isolates. B. pertussis was used as 
an outgroup. The tree is built on 1,000 bootstrap repeats. R1-R14 are Thai 
clinical isolates; L1-L17 are British clinical isolates; DSM2402 stands for A. 
xylosoxidans DSM 2402; and AX11015 for A. xylosoxidans NCIMB 11015. 
Bootstrap values >50% are indicated. 
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Figure A2.2: Phylogenetic tree of the Achromobacter species based on the 
analysis of MLST scheme. The tree is constructed by Maximum-likelihood with 
100 bootstrap repeats. Strains used in this study are presented in bold. Bordetella 
bronchisepticus and Bordetella pertussis are used as outgroup.  
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Figure A2.3: A population snapshot based on Achromobacter isolates used in 
this study. This shows the differentiation between A. xylosoxidans (forming a 
clonal complex) and non-xylosoxidans species (singletons). 
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Figure A2.4: Gene distribution on core genome of A. xylosoxidans presented 
in clade A and clade B on core genome phylogeny (Figure 4.5 and 4.6). X-
axis indicates the percentage of gene with respect to core genome. Y-axis 
indicates functional category based on eggNOG database. 
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Figure A2.5: Regression curve for new gene discovered with additional 
genomes in clade I (A) and clade II (B) of A. xylosoxidans. Extrapolated 
mathematical model is reported. 
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Table A2.1: The mapping percentage of sequence reads of bacterial strains 
used in this study to the genome of A. xylosoxidans NH44784-1996 (the 
second column) and to strain NCIMB 11015 (the third column). The genome 
mapping is performed using BWA version 0.5.9-r16 and mapping statistic is 
obtained using SAMtools version 0.1.18-r580. 
 
Strain 
Percentage of reads mapped to 
NH44784-1996 genome 
Percentage of reads mapped to 
NCIMB 11015 genome 
NCIMB 11015 85.56% 99.68%* 
DSM 2402 84.66% 83.31% 
L1 96.12% 83.72% 
L5 88.80% 86.87% 
L8 88.48% 82.92% 
L10 84.72% 80.89% 
L11 85.61% 80.80% 
L14 88.95% 85.33% 
L15 80.76% 76.10% 
L16 86.17% 83.80% 
L17 89.66% 82.87% 
R1 84.84% 79.63% 
R2 89.68% 86.92% 
R3 85.62% 82.78% 
R4 85.22% 85.37% 
R5 85.24% 80.48% 
R6 88.57% 84.45% 
R7 86.51% 81.47% 
R8 83.17% 80.55% 
R9 89.09% 87.23% 
R10 87.88% 85.05% 
R11 91.72% 89.32% 
R12 91.26% 89.15% 
R13 87.71% 85.70% 
R14 85.91% 81.17% 
Mean 87.28% 84.22% 
 
* Self-mapping of Illumina‟s reads to sequence obtained from PacBio RS II 
platform 
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Table A2.1: The mapping percentage of sequence reads of bacterial strains used 
in this study to the genome of A. xylosoxidans NH44784-1996 (the second 
column) and to strain NCIMB 11015 (the third column). The genome mapping is 
performed using BWA version 0.5.9-r16 and mapping statistic is obtained using 
SAMtools version 0.1.18-r580 (Continued) 
 
Strain 
Percentage of reads mapped to 
NH44784-1996 genome 
Percentage of reads mapped to 
NCIMB 11015 genome 
A. denitrificans 13.25% 13.33% 
A. insolitus 9.17% 8.97% 
A. piechaudii 13.25% 13.61% 
A. ruhlandii 53.80% 52.17% 
A. spanius 8.80% 7.11% 
L2 52.78% 53% 
L3 11.96% 10.43% 
L4 10.76% 9.22% 
L6 77.27% 74.19% 
L7 41.75% 40.81% 
L9 79.57% 78.07% 
L12 10.54% 9.43% 
L13 8.35% 8.07% 
Mean 30.10% 29.11% 
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Table A2.2: The number of genes unique to each A. xylosoxidans isolate used 
in this study. 
 
Isolates No. of genes 
NCIMB 11015 167 
DSM 2402 190 
NH44784-1996 141 
L1 101 
L5 140 
L8 100 
L10 174 
L11 82 
L14 115 
L15 96 
L16 129 
L17 115 
R1 89 
R2 97 
R3 91 
R4 145 
R5 87 
R6 141 
R7 135 
R8 180 
R9 99 
R10 91 
R11 99 
R12 99 
R13 105 
R14 85 
Mean 118.96 
Median 103 
S.D. 32.05 
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Table A2.3: The functional annotation of core orthologs and accessory 
orthologs of 26 genomes of A. xylosoxidans with respect to Cluster of 
Orthologous Group (COG) implemented using eggNOG database 
 
COGs function 
%Core 
orthologs 
%Accessory 
orthologs 
Information storage and processing     
(A) RNA processing and modification 0.03% 0.00% 
(B) Chromatin structure and dynamics 0.13% 0.00% 
(J) Translation 3.69% 0.74% 
(K) Transcription 9.64% 6.34% 
(L) Replication, recombination, repair 2.21% 3.34% 
Cellular processes 
  
(D) Cell cycle control, mitosis, meiosis 0.61% 0.34% 
(M) Cell wall/membrane biogenesis 4.91% 2.70% 
(N) Cell motility 0.90% 0.50% 
(O) Posttranslational modification, protein turnover, chaperones 3.53% 1.29% 
(T) Signal transduction mechanisms 3.40% 1.89% 
(U) Intracellular trafficking, secretion 1.25% 1.31% 
(V) Defense mechanisms 1.06% 1.15% 
(W) Extracellular structures 0% 0.00% 
(Z) Cytoskeleton 0% 0.00% 
Metabolism 
  
(C) Energy production, conversion 5.95% 3.80% 
(E) Amino acid transport, metabolism 12.57% 5.41% 
(F) Nucleotide transport, metabolism 1.41% 0.40% 
(G) Carbohydrate transport, metabolism 3.19% 1.37% 
(H) Coenzyme transport, metabolism 2.28% 0.64% 
(I) Lipid transport, metabolism 4.60% 1.87% 
(P) Inorganic ion transport, metabolism 6.16% 4.16% 
(Q) Secondary metabolites 1.78% 1.15% 
Poorly characterised 
  
(R) General function prediction 6.19% 4.06% 
(S) Function unknown 24.51% 57.53% 
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Appendix 3 Antibiotic resistance determination 
 
 
 
 
Figure A3.1: The detection of Beta-lactamase activity in A. xylosoxidans 
using Nitrocefin assay. The significant change of visible colour was observed in 
strain R4, R8 and NCIMB 11015 after incubation for 25 minutes, C stands for 
negative control; R1-R14 for Thai strains; NC for NCMIB11015; and DS for 
DSM2402 
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Figure A3.2: A tanglegram tree to show the association between the core genome phylogenetic tree (left panel) and an intrinsic antibiotic 
resistance phylogenetic tree (right panel). Red lines indicate consistent relationships between isolates in the phylogenetic trees based on core 
genes and conserved antibiotic resistance genes. NH44784-1996 stands for A. xylosoxidans NH44784-1996, NCIMB 11015 for A. xylosoxidans 
NCIMB 11015; DSM 2402 for A. xylosoxidans DSM 2402; L-strains are Liverpool’s clinical isolates; R-strains are Thai clinical isolates.
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Figure A3.3: Multiple sequence alignment of CmeABC genes and AxyXY-
OprZ 
 
CmeABC        1 MARFFIDRPVFAWVISLLIALVGLLSIRALPVAQYPDIAPPVVNIGASYPGASAKVVEEAVTAIIEREMNGAPGLMYTSS 
AxyXY-OprZ    1 MARFFIDRPVFAWVISLLIALVGLLSIRALPVAQYPDIAPPVVNIGASYPGASAKVVEEAVTAIIEREMNGAPGLMYTSS 
 
 
CmeABC       81 SSDSTGWASINLTFKQGTNPDIAAVEVQNRLKAVEPRLPESVRRDGVRVEKAADNIQLVVSLKSDGSLDDMQLGELAASN 
AxyXY-OprZ   81 SSDSTGWASINLTFKQGTNPDIAAVEVQNRLKAVEPRLPESVRRDGVRVEKAADNIQLVVSLKSDGSLDDMQLGELAASN 
 
 
CmeABC      161 VLQALRRVEGVGKVQSFGAEAAMRIWPDPAKLTALSLTPGDIVSALRSHNARVTIGELGNQAVPKDAPLNASIVAGESLH 
AxyXY-OprZ  161 VLQALRRVEGVGKVQSFGAEAAMRIWPDPAKLTALSLTPGDIVSALRSHNARVTIGELGNQAVPKDAPLNASIVAGESLH 
 
 
CmeABC      241 TPEQFANIPLRAQPDGATLRLKDVARVELGGTDYMYLSRVNGMTGTGLGIKLAPGSNAVETTRRIRETMRELAQYFPPGV 
AxyXY-OprZ  241 TPEQFANIPLRALPDGATLRLKDVARVELGGTDYMYLSRVNGLTGTGLGIKLAPGSNAVETTRRIRETMRELAQYFPPGV 
 
 
CmeABC      321 SWDIPYETSTFVEISIQKVLMTLLEAVALVFCVMYLFMQNLRATLIPTLVVPVALLGTLGVMLGLGYSINVLTMFGMVLA 
AxyXY-OprZ  321 TWDIPYETSTFVEISIKKVLMTLLEAVALVFCVMYLFMQNLRATLIPTLVVPVALLGTLGVMLGLGYSINVLTMFGMVLA 
 
 
CmeABC      401 IGILVDDAIVVVENVERIMAEEGLSPHDATVKAMGQISGAIVGITVVLVSVFVPMAFFDGAVGNIYRQFAVTLAVSIAFS 
AxyXY-OprZ  401 IGILVDDAIVVVENVERIMAEEGLSPHDATVKAMGQISGAIVGITVVLVSVFVPMAFFDGAVGNIYRQFAVTLAVSIAFS 
 
 
CmeABC      481 AFLALSLTPALCASLLKPIPAGHHEKRGFFGWFNRAFARLTTRYTARVAGVLARPVRFGLAYALVIGVAALLFARLPSSF 
AxyXY-OprZ  481 AFLALSLTPALCASLLKPVPAGHHEKRGFFGWFNRAFARLTTRYTARVAGVLARPVRFGLAYALVIGVAALLFARLPSSF 
 
 
CmeABC      561 LPDEDQGSFMAMVILPQGSPQAETMAVVKDVERYMMEHEPVQYVYSVNGFSQYGSGPNSAMFFVTLKDWKERRDASLHVD 
AxyXY-OprZ  561 LPDEDQGSFMAMVILPQGSPQAETMAVVKDVERYMMEHEPVQYVYSVNGFSQYGSGPNSAMFFVTLKDWKERRDASQHVD 
 
 
CmeABC      641 AVVKRINEAFADRKNLMVFALNSPPLPDLGSTSGFDFRLQDRGGLGYEALTQARQKLLAAAAEHPALTDVVFAGQEEAPQ 
AxyXY-OprZ  641 AVVKRINKAFADRKNLMVFALNSPPLPDLGSTSGFDFRLQDRGGLGYEALTQARQKLLAKAAEHPALTDVVFAGQEEAPQ 
 
 
CmeABC      721 LQLRIDRDKAQAMGVPIDEINTALAVMYGSDYIGDFMLNGQVRRVTVQADGKRRVDVDDISRLHVRNLQGQMVPLSAFAT 
AxyXY-OprZ  721 LQLRVDRDKAQAMGVPIDEINTALAVMYGSDYIGDFMLNGQVRRVMVQADGKRRVDVDDISRLHVRNLQGQMVPLSAFAT 
 
 
CmeABC      801 LKWSMGPPQLNRYNGFPSFTINGSAAPGHSSGEAMRAMEALAAELPRGIGFDWSGQSYEERLSGNQAPVLFALSVLIVFL 
AxyXY-OprZ  801 LTWSMGPPQLNRYNGFPSFTINGSAARGHSSGEAMRAMETLAAELPRGIGFDWSGQSYEERLSGNQAPVLFALSVLIVFL 
 
 
CmeABC      881 ALAALYESWSIPLAVILVVPLGVIGALLGVTVRGMPNDIYFKVGLIATIGLSAKNAILIVEVAKDLVRDGQGILSATLEA 
AxyXY-OprZ  881 ALAALYESWSIPLAVILVVPLGVIGALLGVTVRGMPNDIYFKVGLIATIGLSAKNAILIVEVAKDLVRDGQGILSATLEA 
 
 
CmeABC      961 ARLRLRPIVMTSLAFGVGVLPLALASGAASGAQAAIGTGVLGGIITATVLAVFLVPLFFLIVGRMVGMRARPARPTGREP 
AxyXY-OprZ  961 ARLRLRPIVMTSLAFGVGVLPLALATGAASGAQAAIGTGVLGGIITATVLAVFLVPLFFLIVGRMVGMRARPARPDGREP 
 
 
CmeABC     1041 LETTPMSHRVPLRTLAFVSVLLLVSACSKKEAPEAAKAPAEIGVIVAKATPTSVASELPGRLEPYREAEVRARVAGIVTR 
AxyXY-OprZ 1041 LETT-MTHRVPFRTLAFASVLVLVSACSKQEAPEAAKAPAEVGVIVARATPTAVASELPGRLEPYREAEVRARVAGIVTR 
 
 
CmeABC     1121 RLYEEGQEVARGAPLFQIDPAPLQAAYDSEAAALARAQANLSAAADKLRRYADLVSDRAISERDHAESVAEERQARAEVA 
AxyXY-OprZ 1120 RLYEEGQEVTRGTPLFQIDPAPLQAAYDSEAAALARAQANLSAAADKLRRYADLVSDRAISERDHAESVAQERQARAEVA 
 
 
CmeABC     1201 LAKANLQSARLRLEYARVTSPIDGRARRALVTEGALVGEGQATPLTVVQQLDPIYVNFSQPAAEVMQLQKQIRAGALEGV 
AxyXY-OprZ 1200 LAKANLQSARLRLEYARVTSPIDGRARRALVTEGALVGEGQATPLTVVQQLDPIYVNFSQPAAEVMQLQKQIRAGALQGV 
 
 
CmeABC     1281 APDKMRVRLLLPDGSEYGQGGTLSFADLAVDPGTDNVTMRALFDNPDRVLLPGMYVRVRLEQAVNRDTYLVPRDALLRNA 
AxyXY-OprZ 1280 APDKMRVRLLLPDGSEYGQGGTLSFADLAVDPGTDNVTMRALFANPGRELLPGMYVRVRLEQAVNRDTFLVPRNALLRNA 
 
 
CmeABC     1361 DGAHLLVAGDDGELRSVAVAAHRLLGPNWVITEGLEGGERVVVENAAQLAPGQKIKPVERAAPSAPVATAGNNEKRMKPV 
AxyXY-OprZ 1360 DGAHVLVAGDDGELRSVAVTAHRLLGPNWVVTEGLAGGERVVVENAAQLAPGQKIKPVERTAPSAPVATAGNNEKRMKPV 
 
 
CmeABC     1441 AMTLLALALSGCSLAPTYERPAAPMPARYDTPAQAGQATAPQDWRAYFNDPALQAWIAAALANNRDLRVAALRIEEARAL 
AxyXY-OprZ 1440 AMTLLALALSGCSLAPTHERPAAPVPAQYDTPAQPGQAAAPQDWRAYFNDPALQAWIAAALANNRDLRVAALRIEEARAL 
 
 
CmeABC     1521 YGVQQSERLPAIDASGEFSRGRFTEPGQSGTAVSSRYRAAVGITAFELDFFGRVRSLSDAALARYLVSEEAHRAATLALV 
AxyXY-OprZ 1520 YGVQQSERLPAIDASGEFSRGRATEPGQPRTPVSNRYRAAVGITAFELDFFGRVRSLSDAALARYLASEEAHRAATLALV 
 
 
CmeABC     1601 AETATAYFNQRSLAEQLRLTDSTLALREASLKLTQRRYDAGLETAIGLRTAQMLVESSRATRAELTREASLARHALGLLA 
AxyXY-OprZ 1600 AETATAYFNQRSLAEQLRLTDDTLALRETTLKLTQRRYDAGLETAIGLRTAQMLVESSRATRAELTREASLARHALGLLA 
 
 
CmeABC     1681 GDFALPLGVDPAPLESQSLTPLAAGLPSELLTRRPDLRQAEQALLAANADIGAARAAFFPSVQLTTDIGTTADRFSDLFS 
AxyXY-OprZ 1680 GDFALPLGVDPTPLESQSLTPLAAGLPSELLTRRPDLRQAEQALRAANADIGAARAAFFPSVQLTTDIGTTADRFSDLFS 
 
 
CmeABC     1761 GGTGGWSFAPRLTLPIFNAGRNRANLSLAETRKHIAVAQYEGSIQAAFRDVADALSARDALRDQIEAQRKVRDADRERQR 
AxyXY-OprZ 1760 GGTGGWSFAPRLTLPIFNAGRNRANLSLAETRKHIAVAQYEGSIQAAFRDVADALSARDALRDQIEAQRKVRDADRERQR 
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CmeABC     1841 LAERRYTRGVANYLEMLEAQRSLFESEQEYIRLQQRRLVNAVDLYKALGGWDDGKAPAS 
AxyXY-OprZ 1840 LAERRYARGVANYLEMLEAQRSLFESEQEFIRLQQRRLVNAVDLYKALGGWDDGSSPAS 
 
 
 
Figure A3.4: Multiple sequence alignment of CmeABC genes and AxyABM 
 
CmeABC    1 MAKFFIDRPVFAWVIAIVLMMAGALSILKLPVSQYPNIAPPAIGIAVTYPGASAQTVQDTVVQVIEQQMNGLDGLEYISS 
AxyAMB    1 MAKFFIDRPVFAWVIAIVLMMAGALSILKLPVSQYPNIAPPAIGIAVTYPGASAQTVQDTVVQVIEQQMNGLDGLEYISS 
 
 
CmeABC   81 ESNSDGSMSITLTFRQGTNPDTAQVQVQNKLSLAQPLLPQEVQQQGIRVTKATKNFLIVAGFVSTDGTMTKDDLADYVAS 
AxyAMB   81 ESNSDGSMSITLTFRQGTNPDTAQVQVQNKLSLAQPLLPQEVQQQGIRVTKATKNFLIVAGFVSTDGTMTKDDLADYVAS 
 
 
CmeABC  161 YVQDPISRTQGVGDFQLFGSQYAMRIWLDPAKLVNYGLTTVDVVNAIKEQNVQVSSGQLGGLPAVRGQQLNATIIGPSRL 
AxyAMB  161 YVQDPISRTQGVGDFQLFGSQYAMRIWLDPAKLVNYGLTTVDVVNAIKEQNVQVSSGQLGGLPAVRGQQLNATIIGPSRL 
 
 
CmeABC  241 EKPEDFGRILLKVNADGSQVRLANVARIELGGQTYAIDSYYNGKPASGLAIKLAPGANALDTAQAVRDTINNLKPYFPPG 
AxyAMB  241 ERPEDFGRILLKVNSDGSQVRLANVARIELGGQTYAIDSYYNGKPASGLAIKLAPGANALDTAQAVRDTINNLKPYFPPG 
 
 
CmeABC  321 MDVVYPYDTTPFVSLSIEEVFKTLVEAIILVFLVMYLFLQNFRATLIPTLAVPVVLLGTFGVLAAFGYSINTLTMFGMVL 
AxyAMB  321 MDVVYPYDTTPFVSLSIEEVFKTLVEAIILVFLVMYLFLQNFRATLIPTLAVPVVLLGTFGVLAAFGYSINTLTMFGMVL 
 
 
CmeABC  401 AIGLLVDDAIVVVENVERVMAEEGLTPKQATRKSMSQITGALIGIAMVLAAVFIPMAFFGGSTGVIYRQFSITIVSSMVL 
AxyAMB  401 AIGLLVDDAIVVVENVERVMAEEGLTPKQATRKSMTQITGALIGIAMVLAAVFIPMAFFGGSTGVIYRQFSITIVSSMVL 
 
 
CmeABC  481 SVIVAIVFTPALCATLLKPIPKGHHGTKRGFFGWFNRAFDRSSHGYANTVARGLGRTKRLMVVYLAIVIAMGWMFTRIPT 
AxyAMB  481 SVIVAIVFTPALCATLLKPIPKGHHGTKRGFFGWFNRSFDRSSHAYANTVARGLGRTKRLMVVYLAIVIAMGWLFTRIPT 
 
 
CmeABC  561 AFLPAEDQGILFAQIQTPAGATAERTKAVIDEATNYLLTEEKDAVTSVFAVNGFNFGGRGQNASILFIKLRDWEDRGDAK 
AxyAMB  561 AFLPAEDQGILFAQIQTPAGATAERTKAVIDEATNYLLTEEKDAVTSVFAVNGFNFGGRGQNASILFIKLRDWEDRGDAK 
 
 
CmeABC  641 LKAAAVAARANAHFRKTERDAMLFVVPPPSVMELGNVDGFDFQLMDRAGVGHEKLLAARNQLLGEAAQSKILQGVRPNGI 
AxyAMB  641 LKAAAVAARANAHFRKTERDAMLFVVPPPSVMELGNVDGFDFQLMDRAGVGHEKLLAARNQLLGEAAQSKILQGVRPNGI 
 
 
CmeABC  721 EDAPQYQLDIDREKARALGVAVSDINSTLSTAWGSSYVNDFIDRGRVKKVFAQGEASARMLPEDLDKWYVRNKDGDMVPF 
AxyAMB  721 EDAPQYQLDIDREKARALGVAVSDINSTLSTAWGSSYVNDFIDRGRVKKVFAQGEASARMLPDDLDKWYVRNKDGDMVPF 
 
 
CmeABC  801 SAFAKATWSFGPQKLNRYNGVPSYNIQGQAAPGYSSGAAMEEMERIASKLPVGVGFEWTGMSYEERLSGAQAPALYAISL 
AxyAMB  801 SAFAKATWSFGPQKLNRYNGVPSYNIQGQAAPGYSSGAAMDEMERIASKLPVGVGFEWTGMSYEERLSGAQAPALYAISL 
 
 
CmeABC  881 IVVFLCLAALYESWTIPSAVMLVVPLGIIGALGATMLRGLSNDVYFQVGLLTTIGLAAKNAILIVEFAKEHYEAGASLTE 
AxyAMB  881 IVVFLCLAALYESWTIPSAVMLVVPLGIIGALGATLLRGLSNDVYFQVGLLTTIGLAAKNAILIVEFAKEHYEAGASLTE 
 
 
CmeABC  961 SAIHAARQRLRPILMTSLAFILGVVPLAISSGAGSGSQNAIGTGVIGGMLTATFLAIFFVPAFFVIMLRLFKVERMSARR 
AxyAMB  961 SAIHAARQRLRPILMTSLAFILGVVPLAISSGAGSGSQNAIGTGVIGGMLTATFLAIFFVPAFFVIMLRLFKVERMSARR 
 
 
CmeABC 1041 DPHDPSANDAQDVSVEGKPQMNKKSAMWRGAAVVTLTASALTLAACGKKQEAPQAGKPQVTVVTLTTKPVSLTTELPGRT 
AxyAMB 1041 DPHDPSANDAQDVSVEGKPQMNKKSAMWRGAAVLTLTASALTLAACGKKQDAPQAGKPQVTVVTLTTKPVSLTTELPGRT 
 
 
CmeABC 1121 SPFRVAEVRPQVNGIVQKRLFTEGGEVKAGEQLYQIDPALYQASFDSQKAALARAQAQQKTAALLAERYKPLVATRAVSQ 
AxyAMB 1121 SPFRVAEVRPQVNGIVQKRLFTEGGEVKAGEQLYQIDPALYQASLDSQKAALARAQAQQKTAALLAERYKPLVATRAVSQ 
 
 
CmeABC 1201 QTYDNAVAARDQAVADVLSAKAALDTARINLVYTKVLSPISGIIGRSSVTEGALVTANQATALAAVQQIDPIYVDVTQSS 
AxyAMB 1201 QTYDNAVATRDQAVADVMSAKAALDTARINVVYTKVLSPIDGIIGRSAVTEGALVTANQATALAAVQQIDPIYVDVTQSS 
 
 
CmeABC 1281 VQLLRLQNALSSGQLKKAEGEQAALVTLTLEDGSQYTQQGKLQFSEVTVDPGTGSVTLRAVFPNPDRRLLPGMFVRARLV 
AxyAMB 1281 VQLLRLQNALSSGQLKKAEGEQAALVTLTLEDGSQYTQQGKLQFSEVTVDPGTGSVTLRAVFPNPDRRLLPGMFVRARLV 
 
 
CmeABC 1361 DGVAADGLLVPQRGVTRNQRGLPTALVVNAENKVELREIKTDRAIGDQWLVTDGLKAGEKVIVEGVQMVRPGVEVVATEA 
AxyAMB 1361 DGVAADGLLVPQRGVTRNQRGLPTALVVNAENKVELRELKTDRAIGDQWLVTDGLKAGEKVIVEGVQMVRPGVEVVATEA 
 
 
CmeABC 1441 SAKPAQQPQAGAAAAKQMKLQMRTLVSLSLAAALAGCSLAPTYERPDAPVSAAYPAGPAYKADAAGPVATADIGWRDFFA 
AxyAMB 1441 GAKPAQQPQAGAAAAKQMKLQMRTLVSLSLAAALAGCSLAPTYERPDAPVSSAYPAGPAYKADAAGAVATADIGWRDFFA 
 
 
CmeABC 1521 DPLLQQLIEQSLANNRDLRVAALNVEAARAQYRIQRADLLPSVGIAGKETAQRTPADLSPSGQASTSHNYQVGAALSSWE 
AxyAMB 1521 DPLLQQLIEQSLANNRDLRVAALNVEAARAQYRIQRADLLPSVGIAGKETAQRTPADLSPSGQASTSHNYQVGAALSSWE 
 
 
CmeABC 1601 LDLFGRIRSLSDKALESYLALDETRTATQLTLIAEVANAYLTLRADQELLSLTRDTLKSQDDSYKLTKQSYDQGLSTALD 
AxyAMB 1601 LDLFGRIRSLSDKALESYLALDETRTATQLTLIAEVANAYLTLRADQELLSLTRDTLKSQDDSYKLTKQSFDQGLSTALD 
 
 
CmeABC 1681 LSQAEVSLRTAQRNLSQYTRQAAQDRNALVLLVGQPLSPEISAALDDAVKLDDGMLPTALPAGLPSELLARRPDIRAAEH 
AxyAMB 1681 LSQAEVSLRTAQRNLSQYTRQAAQDRNALVLLVGQPLSPEISAALDNAVKLDDGMLPTALPAGLPSELLARRPDIRAAEH 
 
 
CmeABC 1761 QLKGANANIGAARAAFFPTISLTGNAGTASASLGGLFDAGSGAWSFVPQITVPIFAGGSLLAGLDLAKVQKNIQVAQYEK 
AxyAMB 1761 QLKGANANIGAARAAFFPTISLTGNAGTASASLGGLFDGGSGAWSFVPQITVPIFAGGSLLAGLDLAKVQKNIQVAQYEK 
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CmeABC 1841 TIQTGFREVADALAGRGTLDEQIQAQQLLVAANQRAYDLSEQRFRQGIDDYLTVLDSQRSLYTAQQALVDTRLSRLSNLV 
AxyAMB 1841 SIQTGFREVADALAGRGTLDEQIQAQQLLVAANQRAYDLSEQRFRQGIDDYLTVLDSQRSLYTAQQSLVDTRLSRLSNLV 
 
 
CmeABC 1921 TLYKVLGGGWTERTVTAAQPASDAAAAPGGQPG 
AxyAMB 1921 TLYKVLGGGWTERTVTAAQPAPGAAPAAAGQPG 
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Figure A3.5: Multiple sequence alignment of gene cassettes with the 
integron 
 
P.aeruginosa    1 GGAGCAGCAACGATGTTACGCAGCAGGGCAGTCGCCCTAAAACAAAGTTAGAAAAGGATAAGTATGAAAAAATTATTTGT 
R4              1 GGAGCAGCAACGATGTTACGCAGCAGGGCAGTCGCCCTAAAACAAAGTTAGAAAAGGATAAGTATGAAAAAATTATTTGT 
R8              1 GGAGCAGCAACGATGTTACGCAGCAGGGCAGTCGCCCTAAAACAAAGTTAGAAAAGGATAAGTATGAAAAAATTATTTGT 
Aci_16          1 GGAGCAGCAACGATGTTACGCAGCAGGGCAGTCGCCCTAAAACAAAGTTAGAAAAGGATAAGTATGAAAAAATTATTTGT 
RA-41520608     1 GGAGCAGCAACGATGTTACGCAGCAGGGCAGTCGCCCTAAAACAAAGTTAGAAAAGGATAAGTATGAAAAAATTATTTGT 
 
 
P.aeruginosa   81 TTTATGTGTATTCTTCTTCTGCAACATTGCAGTTGCAGAAGAATCTTTGCCTGATTTAAAAATTGAGAAGCTTGAAGAAG 
R4             81 TTTATGTGTATTCTTCTTCTGCAACATTGCAGTTGCAGAAGAATCTTTGCCTGATTTAAAAATTGAGAAGCTTGAAGAAG 
R8             81 TTTATGTGTATTCTTCTTCTGCAACATTGCAGTTGCAGAAGAATCTTTGCCTGATTTAAAAATTGAGAAGCTTGAAGAAG 
Aci_16         81 TTTATGTGTATTCTTCTTCTGCAACATTGCAGTTGCAGAAGAATCTTTGCCTGATTTAAAAATTGAGAAGCTTGAAGAAG 
RA-41520608    81 TTTATGTGTATTCTTCTTCTGCAACATTGCAGTTGCAGAAGAATCTTTGCCTGATTTAAAAATTGAGAAGCTTGAAGAAG 
 
 
P.aeruginosa  161 GCGTTTATGTTCATACTTCGTTTGAAGAAGTTAAAGGTTGGAGTGTGGTCACTAAACACGGTTTGGTGGTTCTTGTGAAA 
R4            161 GCGTTTATGTTCATACTTCGTTTGAAGAAGTTAAAGGTTGGAGTGTGGTCACTAAACACGGTTTGGTGGTTCTTGTGAAA 
R8            161 GCGTTTATGTTCATACTTCGTTTGAAGAAGTTAAAGGTTGGAGTGTGGTCACTAAACACGGTTTGGTGGTTCTTGTGAAA 
Aci_16        161 GCGTTTATGTTCATACTTCGTTTGAAGAAGTTAAAGGTTGGAGTGTGGTCACTAAACACGGTTTGGTGGTTCTTGTGAAA 
RA-41520608   161 GCGTTTATGTTCATACTTCGTTTGAAGAAGTTAAAGGTTGGAGTGTGGTCACTAAACACGGTTTGGTGGTTCTTGTGAAA 
 
 
P.aeruginosa  241 AATGACGCCTATCTGATTGATACTCCAATTACTGCTAAAGATACTGAAAAATTAGTCAATTGGTTTGTTGAGCGGGGCTA 
R4            241 AATGACGCCTATCTGATTGATACTCCAATTACTGCTAAAGATACTGAAAAATTAGTCAATTGGTTTGTTGAGCGGGGCTA 
R8            241 AATGACGCCTATCTGATTGATACTCCAATTACTGCTAAAGATACTGAAAAATTAGTCAATTGGTTTGTTGAGCGGGGCTA 
Aci_16        241 AATGACGCCTATCTGATTGATACTCCAATTACTGCTAAAGATACTGAAAAATTAGTCAATTGGTTTGTTGAGCGGGGCTA 
RA-41520608   241 AATGACGCCTATCTGATTGATACTCCAATTACTGCTAAAGATACTGAAAAATTAGTCAATTGGTTTGTTGAGCGGGGCTA 
 
 
P.aeruginosa  321 TAAAATCAAAGGCAGTATTTCAACACATTTCCATGGTGACAGTACGGCTGGAATAGAGTGGCTTAATTCTCAATCTATCC 
R4            321 TAAAATCAAAGGCAGTATTTCCACACATTTCCATGGTGACAGTACGGCTGGAATAGAGTGGCTTAATTCTCAATCTATCC 
R8            321 TAAAATCAAAGGCAGTATTTCCACACATTTCCATGGTGACAGTACGGCTGGAATAGAGTGGCTTAATTCTCAATCTATCC 
Aci_16        321 TAAAATCAAAGGCAGTATTTCCACACATTTCCATGGTGACAGTACGGCTGGAATAGAGTGGCTTAATTCTCAATCTATCC 
RA-41520608   321 TAAAATCAAAGGCAGTATTTCCACACATTTCCATGGTGACAGTACGGCTGGAATAGAGTGGCTTAATTCTCAATCTATCC 
 
 
P.aeruginosa  401 CCACATATGCTTCTGAATTAACAAATGAACTTCTTAAAAAAGACAATAAGGTACAAGCTAAACACTCTTTTAATGGGGTT 
R4            401 CCACATATGCTTCTGAATTAACAAATGAACTTCTTAAAAAAGACAATAAGGTACAAGCTAAACACTCTTTTAATGGGGTT 
R8            401 CCACATATGCTTCTGAATTAACAAATGAACTTCTTAAAAAAGACAATAAGGTACAAGCTAAACACTCTTTTAATGGGGTT 
Aci_16        401 CCACATATGCTTCTGAATTAACAAATGAACTTCTTAAAAAAGACAATAAGGTACAAGCTAAACACTCTTTTAATGGGGTT 
RA-41520608   401 CCACATATGCTTCTGAATTAACAAATGAACTTCTTAAAAAAGACAATAAGGTACAAGCTAAACACTCTTTTAATGGGGTT 
 
 
P.aeruginosa  481 AGTTATTCACTAATTAAAAACAAAATTGAAGTTTTTTATCCAGGCCCAGGGCACACTCAAGATAACGTAGTGGTTTGGTT 
R4            481 AGTTATTCACTAATTAAAAACAAAATTGAAGTTTTTTATCCAGGCCCAGGGCACACTCAAGATAACGTAGTGGTTTGGTT 
R8            481 AGTTATTCACTAATTAAAAACAAAATTGAAGTTTTTTATCCAGGCCCAGGGCACACTCAAGATAACGTAGTGGTTTGGTT 
Aci_16        481 AGTTATTCACTAATTAAAAACAAAATTGAAGTTTTTTATCCAGGCCCAGGGCACACTCAAGATAACGTAGTGGTTTGGTT 
RA-41520608   481 AGTTATTCACTAATTAAAAACAAAATTGAAGTTTTTTATCCAGGCCCAGGGCACACTCAAGATAACGTAGTGGTTTGGTT 
 
 
P.aeruginosa  561 ACCTGAAAAGAAAATTTTATTCGGTGGTTGCTTTGTTAAACCGGACGGTCTTGGCTATTTGGGGGACGCAAATTTAGAAG 
R4            561 ACCTGAAAAGAAAATTTTATTCGGTGGTTGCTTTGTTAAACCGGACGGTCTTGGCTATTTGGGGGACGCAAATTTAGAAG 
R8            561 ACCTGAAAAGAAAATTTTATTCGGTGGTTGCTTTGTTAAACCGGACGGTCTTGGCTATTTGGGGGACGCAAATTTAGAAG 
Aci_16        561 ACCTGAAAAGAAAATTTTATTCGGTGGTTGCTTTGTTAAACCGGACGGTCTTGGCTATTTGGGGGACGCAAATTTAGAAG 
RA-41520608   561 ACCTGAAAAGAAAATTTTATTCGGTGGTTGCTTTGTTAAACCGGACGGTCTTGGCTATTTGGGGGACGCAAATTTAGAAG 
 
 
P.aeruginosa  641 CTTGGCCAAAGTCCGCTAAAATATTAATGTCTAAATATGGTAAAGCAAAACTAGTTGTGTCGAGTCATAGTGATATTGGA 
R4            641 CTTGGCCAAAGTCCGCTAAAATATTAATGTCTAAATATGGTAAAGCAAAACTAGTTGTGTCGAGTCATAGTGATATTGGA 
R8            641 CTTGGCCAAAGTCCGCTAAAATATTAATGTCTAAATATGGTAAAGCAAAACTAGTTGTGTCGAGTCATAGTGATATTGGA 
Aci_16        641 CTTGGCCAAAGTCCGCTAAAATATTAATGTCTAAATATGGTAAAGCAAAACTAGTTGTGTCGAGTCATAGTGATATTGGA 
RA-41520608   641 CTTGGCCAAAGTCCGCTAAAATATTAATGTCTAAATATGGTAAAGCAAAACTAGTTGTGTCGAGTCATAGTGATATTGGA 
 
 
P.aeruginosa  721 GATGTATCACTCTTGAAACGTACATGGGAGCAGGCTGTTAAAGGGCTGAATGAAAGTAAAAAATCATCACAGCCAAGCGA 
R4            721 GATGTATCACTCTTGAAACGTACATGGGAGCAGGCTGTTAAAGGGCTGAATGAAAGTAAAAAATCATCACAGCCAAGCGA 
R8            721 GATGTATCACTCTTGAAACGTACATGGGAGCAGGCTGTTAAAGGGCTGAATGAAAGTAAAAAATCATCACAGCCAAGCGA 
Aci_16        721 GATGTATCACTCTTGAAACGTACATGGGAGCAGGCTGTTAAAGGGCTGAATGAAAGTAAAAAATCATCACAGCCAAGCGA 
RA-41520608   721 GATGTATCACTCTTGAAACGTACATGGGAGCAGGCTGTTAAAGGGCTGAATGAAAGTAAAAAATCATCACAGCCAAGCGA 
 
 
 
P.aeruginosa  801 CTAAATTTCTAACAAGGCGCTTCAGCACCGCGCACTTCGTGCGCTCGACAGTTCGTAAGCCGCTTTTTTGTGGTTTTGCT 
R4            801 CTAAATTTCTAACAAGGCGCTTCAGCACCGCGCACTTCGTGCGCTCGACAGTTCGTAAGCCGCTTTTTTGTGGTTTTGCT 
R8            801 CTAAATTTCTAACAAGGCGCTTCAGCACCGCGCACTTCGTGCGCTCGACAGTTCGTAAGCCGCTTTTTTGTGGTTTTGCT 
Aci_16        801 CTAAATTTCTAACAAGGCGCTTCAGCACCGCGCACTTCGTGCGCTCGACAGTTCGTAAGCCGCTTTTTTGTGGTTTTGCT 
RA-41520608   801 CTAAATTTCTAACAAGGCGCTTCAGCACCGCGCACTTCGTGCGCTCGACAGTTCGTAAGCCGCTTTTTTGTGGTTTTGCT 
 
 
P.aeruginosa  881 ACGCAAAAGGTTTCCACAAAAAATCAACTTACAAACTGCGGCTGAGCTTAACGTTAGAAGGCCCAGGCTATGCAGTACTC 
R4            881 ACGCAAAAGGTTTCCACAAAAAATCAACTTACAAACTGCGGCTGAGCTTAACGTTAGAAGGCCCAGGCTATGCAGTACTC 
R8            881 ACGCAAAAGGTTTCCACAAAAAATCAACTTACAAACTGCGGCTGAGCTTAACGTTAGAAGGCCCAGGCTATGCAGTACTC 
Aci_16        881 ACGCAAAAGGTTTCCACAAAAAATCAACTTACAAACTGCGGCTGAGCTTAACGTTAGAAGGCCCAGGCTATGCAGTACTC 
RA-41520608   881 ACGCAAAAGGTTTCCACAAAAAATCAACTTACAAACTGCGGCTGAGCTTAACGTTAGAAGGCCCAGGCTATGCAGTACTC 
 
 
P.aeruginosa  961 CATTCGCTCGGTTCGTGTTTCGGATACATCTGATTGGTTACGCCTTCGCAATCTCCTGTGGGAAGGGGATGACCACGAAA 
R4            961 CATTCGCTCGGTTCGTGTTTCGGATACATCTGATTGGTTACGCCTTCGCAATCTCCTGTGGGAAGGGGATGACCACGAAA 
R8            961 CATTCGCTCGGTTCGTGTTTCGGATACATCTGATTGGTTACGCCTTCGCAATCTCCTGTGGGAAGGGGATGACCACGAAA 
Aci_16        961 CATTCGCTCGGTTCGTGTTTCGGATACATCTGATTGGTTACGCCTTCGCAATCTCCTGTGGGAAGGGGATGACCACGAAA 
RA-41520608   961 CATTCGCTCGGTTCGTGTTTCGGATACATCTGATTGGTTACGCCTTCGCAATCTCCTGTGGGAAGGGGATGACCACGAAA 
 
 
P.aeruginosa 1041 CCGAGATCGCCCAGTTTTTCGCCGGAGCCCTGGCCGAGCCCAACGAAGTGCTGGTAGCCCATGATGATGCGGGGGCCGTT 
R4           1041 CCGAGATCGCCCAGTTTTTCGCCGGAGCCCTGGCCGAGCCCAACGAAGTGCTGGTAGCCCATGATGATGCGGGGGCCGTT 
R8           1041 CCGAGATCGCCCAGTTTTTCGCCGGAGCCCTGGCCGAGCCCAACGAAGTGCTGGTAGCCCATGATGATGCGGGGGCCGTT 
Aci_16       1041 CCGAGATCGCCCAGTTTTTCGCCGGAGCCCTGGCCGAGCCCAACGAAGTGCTGGTAGCCCATGATGATGCGGGGGCCGTT 
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RA-41520608  1041 CCGAGATCGCCCAGTTTTTCGCCGGAGCCCTGGCCGAGCCCAACGAAGTGCTGGTAGCCCATGATGATGCGGGGGCCGTT 
 
 
P.aeruginosa 1121 GTTGGGCATGTCGAGTTATCCATCCGCGAGGATGTCGCAGGGCTGGAGGGCATCAGAGCGGGCTATATCGAAGGCCTGTA 
R4           1121 GTTGGGCATGTCGAGTTATCCATCCGCGAGGATGTCGCAGGGCTGGAAGGCATCAGAGCGGGCTATATCGAAGGCCTGTA 
R8           1121 GTTGGGCATGTCGAGTTATCCATCCGCGAGGATGTCGCAGGGCTGGAAGGCATCAGAGCGGGCTATATCGAAGGCCTGTA 
Aci_16       1121 GTTGGGCATGTCGAGTTATCCATCCGCGAGGATGTCGCAGGGCTGGAAGGCATCAGAGCGGGCTATATCGAAGGCCTGTA 
RA-41520608  1121 GTTGGGCATGTCGAGTTATCCATCCGCGAGGATGTCGCAGGGCTGGAAGGCATCAGAGCGGGCTATATCGAAGGCCTGTA 
 
 
P.aeruginosa 1201 CATCGAGGAGGCCCATCGCTCGTCCAGCGTCGCGACGCAGTTACTACGGCACTCCGAGCAATGGGCCCAAAGTCAGGGAT 
R4           1201 CATCGAGGAGGCCCATCGCTCGTCCAGCGTCGCGACGCAGTTACTACGGCACTCCGAGCAATGGGCCCAAAGTCAGGGAT 
R8           1201 CATCGAGGAGGCCCATCGCTCGTCCAGCGTCGCGACGCAGTTACTACGGCACTCCGAGCAATGGGCCCAAAGTCAGGGAT 
Aci_16       1201 CATCGAGGAGGCCCATCGCTCGTCCAGCGTCGCGACGCAGTTACTACGGCACTCCGAGCAATGGGCCCAAAGTCAGGGAT 
RA-41520608  1201 CATCGAGGAGGCCCATCGCTCGTCCAGCGTCGCGACGCAGTTACTACGGCACTCCGAGCAATGGGCCCAAAGTCAGGGAT 
 
 
P.aeruginosa 1281 GCCGGGCGTTTGCATCGGATCGAGAGGATCGCCTGATCATCCATAAGCGGTTTTCTGTGAGTCCGCTTTCTAACCCTTCA 
R4           1281 GCCGGGCGTTTGCATCGGATCGAGAGGATCGCCTGATCATCCATAAGCGGTTTTCTGTGAGTCCGCTTTCTAACCCTTCA 
R8           1281 GCCGGGCGTTTGCATCGGATCGAGAGGATCGCCTGATCATCCATAAGCGGTTTTCTGTGAGTCCGCTTTCTAACCCTTCA 
Aci_16       1281 GCCGGGCGTTTGCATCGGATCGAGAGGATCGCCTGATCATCCATAAGCGGTTTTCTGTGAGTCCGCTTTCTAACCCTTCA 
RA-41520608  1281 GCCGGGCGTTTGCATCGGATCGAGAGGATCGCCTGATCATCCATAAGCGGTTTTCTGTGAGTCCGCTTTCTAACCCTTCA 
 
 
P.aeruginosa 1361 TTCCAGCGGACCGCCTTCGGCGGCCGCTGAATTT 
R4           1361 TTCCAGCGGACCGCCTTCGGCGGCCGCTGAATTT 
R8           1361 TTCCAGCGGACCGCCTTCGGCGGCCGCTGAATTT 
Aci_16       1361 TTCCAGCGGACCGCCTTCGGCGGCCGCTGAATTT 
RA-41520608  1361 TTCCAGCGGACCGCCTTCGGCGGCCGCTGAAT 
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Figure A3.6: Multiple sequence alignment to show amino acid sequence 
alignment of topoisomerase extracted from A. xylosoxidans; (A) DNA Gyrase 
subunit A, (B) DNA Gyrase subunit B, (C) Topoisomerase IV subunit A and (D) 
Topoisomerase IV subunit B. The substitution of amino acid at QRDR is marked 
by an asterisk. 
 
A) DNA Gyrase subunit A 
                           1                                  80 
NCIMB11015_00314    1 MDSFAKETLPVSLEEEMRRSYLDYAMSVIVGRALPDVRDGLKPVHRRVLYAMHELNNDWNRAYKKSARIVGDVIGKYHPH 
L1_03358            1 MDSFAKETLPVSLEEEMRRSYLDYAMSVIVGRALPDVRDGLKPVHRRVLYAMHELNNDWNRAYKKSARIVGDVIGKYHPH 
R10_03668           1 MDSFAKETLPVSLEEEMRRSYLDYAMSVIVGRALPDVRDGLKPVHRRVLYAMHELNNDWNRAYKKSARIVGDVIGKYHPH 
R3_01426            1 MDSFAKETLPVSLEEEMRRSYLDYAMSVIVGRALPDVRDGLKPVHRRVLYAMHELNNDWNRAYKKSARIVGDVIGKYHPH 
NH44784_1996        1 MDSFAKETLPVSLEEEMRRSYLDYAMSVIVGRALPDVRDGLKPVHRRVLYAMHELNNDWNRAYKKSARIVGDVIGKYHPH 
L16_00279           1 MDSFAKETLPVSLEEEMRRSYLDYAMSVIVGRALPDVRDGLKPVHRRVLYAMHELNNDWNRAYKKSARIVGDVIGKYHPH 
DSM2402_03744       1 MDSFAKETLPVSLEEEMRRSYLDYAMSVIVGRALPDVRDGLKPVHRRVLYAMHELNNDWNRAYKKSARIVGDVIGKYHPH 
L10_04633           1 MDSFAKETLPVSLEEEMRRSYLDYAMSVIVGRALPDVRDGLKPVHRRVLYAMHELNNDWNRAYKKSARIVGDVIGKYHPH 
L11_03975           1 MDSFAKETLPVSLEEEMRRSYLDYAMSVIVGRALPDVRDGLKPVHRRVLYAMHELNNDWNRAYKKSARIVGDVIGKYHPH 
L14_02140           1 MDSFAKETLPVSLEEEMRRSYLDYAMSVIVGRALPDVRDGLKPVHRRVLYAMHELNNDWNRAYKKSARIVGDVIGKYHPH 
L15_03364           1 MDSFAKETLPVSLEEEMRRSYLDYAMSVIVGRALPDVRDGLKPVHRRVLYAMHELNNDWNRAYKKSARIVGDVIGKYHPH 
L17_00812           1 MDSFAKETLPVSLEEEMRRSYLDYAMSVIVGRALPDVRDGLKPVHRRVLYAMHELNNDWNRAYKKSARIVGDVIGKYHPH 
L5_03801            1 MDSFAKETLPVSLEEEMRRSYLDYAMSVIVGRALPDVRDGLKPVHRRVLYAMHELNNDWNRAYKKSARIVGDVIGKYHPH 
L8_03080            1 MDSFAKETLPVSLEEEMRRSYLDYAMSVIVGRALPDVRDGLKPVHRRVLYAMHELNNDWNRAYKKSARIVGDVIGKYHPH 
R11_00266           1 MDSFAKETLPVSLEEEMRRSYLDYAMSVIVGRALPDVRDGLKPVHRRVLYAMHELNNDWNRAYKKSARIVGDVIGKYHPH 
R12_01916           1 MDSFAKETLPVSLEEEMRRSYLDYAMSVIVGRALPDVRDGLKPVHRRVLYAMHELNNDWNRAYKKSARIVGDVIGKYHPH 
R13_00732           1 MDSFAKETLPVSLEEEMRRSYLDYAMSVIVGRALPDVRDGLKPVHRRVLYAMHELNNDWNRAYKKSARIVGDVIGKYHPH 
R14_01680           1 MDSFAKETLPVSLEEEMRRSYLDYAMSVIVGRALPDVRDGLKPVHRRVLYAMHELNNDWNRAYKKSARIVGDVIGKYHPH 
R1_01507            1 MDSFAKETLPVSLEEEMRRSYLDYAMSVIVGRALPDVRDGLKPVHRRVLYAMHELNNDWNRAYKKSARIVGDVIGKYHPH 
R2_00884            1 MDSFAKETLPVSLEEEMRRSYLDYAMSVIVGRALPDVRDGLKPVHRRVLYAMHELNNDWNRAYKKSARIVGDVIGKYHPH 
R4_00307            1 MDSFAKETLPVSLEEEMRRSYLDYAMSVIVGRALPDVRDGLKPVHRRVLYAMHELNNDWNRAYKKSARIVGDVIGKYHPH 
R5_03246            1 MDSFAKETLPVSLEEEMRRSYLDYAMSVIVGRALPDVRDGLKPVHRRVLYAMHELNNDWNRAYKKSARIVGDVIGKYHPH 
R6_03779            1 MDSFAKETLPVSLEEEMRRSYLDYAMSVIVGRALPDVRDGLKPVHRRVLYAMHELNNDWNRAYKKSARIVGDVIGKYHPH 
R7_00393            1 MDSFAKETLPVSLEEEMRRSYLDYAMSVIVGRALPDVRDGLKPVHRRVLYAMHELNNDWNRAYKKSARIVGDVIGKYHPH 
R9_01704            1 MDSFAKETLPVSLEEEMRRSYLDYAMSVIVGRALPDVRDGLKPVHRRVLYAMHELNNDWNRAYKKSARIVGDVIGKYHPH 
R8_00369            1 MDSFAKETLPVSLEEEMRRSYLDYAMSVIVGRALPDVRDGLKPVHRRVLYAMHELNNDWNRAYKKSARIVGDVIGKYHPH 
 
  81         160 
NCIMB11015_00314   81 GDQSVYDTIVRMAQDFSMRYMLVDGQGNFGSIDGDNAAAMRYTEIRLAKIAHELLADIDQETVDFGPNYDGSEQEPLLLP 
L1_03358           81 GDQSVYDTIVRMAQDFSMRYMLVDGQGNFGSIDGDNAAAMRYTEIRLAKIAHELLADIDQETVDFGPNYDGSEQEPLLLP 
R10_03668          81 GDQSVYDTIVRMAQDFSMRYMLVDGQGNFGSIDGDNAAAMRYTEIRLAKIAHELLADIDQETVDFGPNYDGSEQEPLLLP 
R3_01426           81 GDQSVYDTIVRMAQDFSMRYMLVDGQGNFGSIDGDNAAAMRYTEIRLAKIAHELLADIDQETVDFGPNYDGSEQEPLLLP 
NH44784_1996       81 GDQSVYDTIVRMAQDFSMRYMLVDGQGNFGSIDGDNAAAMRYTEIRLAKIAHELLADIDQETVDFGPNYDGSEQEPLLLP 
L16_00279          81 GDQSVYDTIVRMAQDFSMRYMLVDGQGNFGSIDGDNAAAMRYTEIRLAKIAHELLADIDQETVDFGPNYDGSEQEPLLLP 
DSM2402_03744      81 GDQSVYDTIVRMAQDFSMRYMLVDGQGNFGSIDGDNAAAMRYTEIRLAKIAHELLADIDQETVDFGPNYDGSEQEPLLLP 
L10_04633          81 GDQSVYDTIVRMAQDFSMRYMLVDGQGNFGSIDGDNAAAMRYTEIRLAKIAHELLADIDQETVDFGPNYDGSEQEPLLLP 
L11_03975          81 GDQSVYDTIVRMAQDFSMRYMLVDGQGNFGSIDGDNAAAMRYTEIRLAKIAHELLADIDQETVDFGPNYDGSEQEPLLLP 
L14_02140          81 GDQSVYDTIVRMAQDFSMRYMLVDGQGNFGSIDGDNAAAMRYTEIRLAKIAHELLADIDQETVDFGPNYDGSEQEPLLLP 
L15_03364          81 GDQSVYDTIVRMAQDFSMRYMLVDGQGNFGSIDGDNAAAMRYTEIRLAKIAHELLADIDQETVDFGPNYDGSEQEPLLLP 
L17_00812          81 GDQSVYDTIVRMAQDFSMRYMLVDGQGNFGSIDGDNAAAMRYTEIRLAKIAHELLADIDQETVDFGPNYDGSEQEPLLLP 
L5_03801           81 GDQSVYDTIVRMAQDFSMRYMLVDGQGNFGSIDGDNAAAMRYTEIRLAKIAHELLADIDQETVDFGPNYDGSEQEPLLLP 
L8_03080           81 GDQSVYDTIVRMAQDFSMRYMLVDGQGNFGSIDGDNAAAMRYTEIRLAKIAHELLADIDQETVDFGPNYDGSEQEPLLLP 
R11_00266          81 GDQSVYDTIVRMAQDFSMRYMLVDGQGNFGSIDGDNAAAMRYTEIRLAKIAHELLADIDQETVDFGPNYDGSEQEPLLLP 
R12_01916          81 GDQSVYDTIVRMAQDFSMRYMLVDGQGNFGSIDGDNAAAMRYTEIRLAKIAHELLADIDQETVDFGPNYDGSEQEPLLLP 
R13_00732          81 GDQSVYDTIVRMAQDFSMRYMLVDGQGNFGSIDGDNAAAMRYTEIRLAKIAHELLADIDQETVDFGPNYDGSEQEPLLLP 
R14_01680          81 GDQSVYDTIVRMAQDFSMRYMLVDGQGNFGSIDGDNAAAMRYTEIRLAKIAHELLADIDQETVDFGPNYDGSEQEPLLLP 
R1_01507           81 GDQSVYDTIVRMAQDFSMRYMLVDGQGNFGSIDGDNAAAMRYTEIRLAKIAHELLADIDQETVDFGPNYDGSEQEPLLLP 
R2_00884           81 GDQSVYDTIVRMAQDFSMRYMLVDGQGNFGSIDGDNAAAMRYTEIRLAKIAHELLADIDQETVDFGPNYDGSEQEPLLLP 
R4_00307           81 GDQSVYDTIVRMAQDFSMRYMLVDGQGNFGSIDGDNAAAMRYTEIRLAKIAHELLADIDQETVDFGPNYDGSEQEPLLLP 
R5_03246           81 GDQSVYDTIVRMAQDFSMRYMLVDGQGNFGSIDGDNAAAMRYTEIRLAKIAHELLADIDQETVDFGPNYDGSEQEPLLLP 
R6_03779           81 GDQSVYDTIVRMAQDFSMRYMLVDGQGNFGSIDGDNAAAMRYTEIRLAKIAHELLADIDQETVDFGPNYDGSEQEPLLLP 
R7_00393           81 GDQSVYDTIVRMAQDFSMRYMLVDGQGNFGSIDGDNAAAMRYTEIRLAKIAHELLADIDQETVDFGPNYDGSEQEPLLLP 
R9_01704           81 GDQSVYDTIVRMAQDFSMRYMLVDGQGNFGSIDGDNAAAMRYTEIRLAKIAHELLADIDQETVDFGPNYDGSEQEPLLLP 
R8_00369           81 GDQSVYNTIVRMAQDFSMRYMLVDGQGNFGSIDGDNAAAMRYTEIRLAKIAHELLADIDQETVDFGPNYDGSEQEPLLLP 
                            * 
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          161        240 
NCIMB11015_00314  161 SRLPNLLVNGSSGIAVGMATNIPPHNLQEVVDGCLYCLRNPACSVDELMEIIPAPDFPTGGVIYGMSGVREGYRTGRGRV 
L1_03358          161 SRLPNLLVNGSSGIAVGMATNIPPHNLQEVVDGCLYCLRNPACSVDELMEIIPAPDFPTGGVIYGMSGVREGYRTGRGRV 
R10_03668         161 SRLPNLLVNGSSGIAVGMATNIPPHNLQEVVDGCLYCLRNPACSVDELMEIIPAPDFPTGGVIYGMSGVREGYRTGRGRV 
R3_01426          161 SRLPNLLVNGSSGIAVGMATNIPPHNLQEVVDGCLYCLRNPACSVDELMEIIPAPDFPTGGVIYGMSGVREGYRTGRGRV 
NH44784_1996      161 SRLPNLLVNGSSGIAVGMATNIPPHNLQEVVDGCLYCLRNPACSVDELMEIIPAPDFPTGGVIYGMSGVREGYRTGRGRV 
L16_00279         161 SRLPNLLVNGSSGIAVGMATNIPPHNLQEVVDGCLYCLRNPACSVDELMEIIPAPDFPTGGVIYGMSGVREGYRTGRGRV 
DSM2402_03744     161 SRLPNLLVNGSSGIAVGMATNIPPHNLQEVVDGCLYCLRNPACSVDELMEIIPAPDFPTGGVIYGMSGVREGYRTGRGRV 
L10_04633         161 SRLPNLLVNGSSGIAVGMATNIPPHNLQEVVDGCLYCLRNPACSVDELMEIIPAPDFPTGGVIYGMSGVREGYRTGRGRV 
L11_03975         161 SRLPNLLVNGSSGIAVGMATNIPPHNLQEVVDGCLYCLRNPACSVDELMEIIPAPDFPTGGVIYGMSGVREGYRTGRGRV 
L14_02140         161 SRLPNLLVNGSSGIAVGMATNIPPHNLQEVVDGCLYCLRNPACSVDELMEIIPAPDFPTGGVIYGMSGVREGYRTGRGRV 
L15_03364         161 SRLPNLLVNGSSGIAVGMATNIPPHNLQEVVDGCLYCLRNPACSVDELMEIIPAPDFPTGGVIYGMSGVREGYRTGRGRV 
L17_00812         161 SRLPNLLVNGSSGIAVGMATNIPPHNLQEVVDGCLYCLRNPACSVDELMEIIPAPDFPTGGVIYGMSGVREGYRTGRGRV 
L5_03801          161 SRLPNLLVNGSSGIAVGMATNIPPHNLQEVVDGCLYCLRNPACSVDELMEIIPAPDFPTGGVIYGMSGVREGYRTGRGRV 
L8_03080          161 SRLPNLLVNGSSGIAVGMATNIPPHNLQEVVDGCLYCLRNPACSVDELMEIIPAPDFPTGGVIYGMSGVREGYRTGRGRV 
R11_00266         161 SRLPNLLVNGSSGIAVGMATNIPPHNLQEVVDGCLYCLRNPACSVDELMEIIPAPDFPTGGVIYGMSGVREGYRTGRGRV 
R12_01916         161 SRLPNLLVNGSSGIAVGMATNIPPHNLQEVVDGCLYCLRNPACSVDELMEIIPAPDFPTGGVIYGMSGVREGYRTGRGRV 
R13_00732         161 SRLPNLLVNGSSGIAVGMATNIPPHNLQEVVDGCLYCLRNPACSVDELMEIIPAPDFPTGGVIYGMSGVREGYRTGRGRV 
R14_01680         161 SRLPNLLVNGSSGIAVGMATNIPPHNLQEVVDGCLYCLRNPACSVDELMEIIPAPDFPTGGVIYGMSGVREGYRTGRGRV 
R1_01507          161 SRLPNLLVNGSSGIAVGMATNIPPHNLQEVVDGCLYCLRNPACSVDELMEIIPAPDFPTGGVIYGMSGVREGYRTGRGRV 
R2_00884          161 SRLPNLLVNGSSGIAVGMATNIPPHNLQEVVDGCLYCLRNPACSVDELMEIIPAPDFPTGGVIYGMSGVREGYRTGRGRV 
R4_00307          161 SRLPNLLVNGSSGIAVGMATNIPPHNLQEVVDGCLYCLRNPACSVDELMEIIPAPDFPTGGVIYGMSGVREGYRTGRGRV 
R5_03246          161 SRLPNLLVNGSSGIAVGMATNIPPHNLQEVVDGCLYCLRNPACSVDELMEIIPAPDFPTGGVIYGMSGVREGYRTGRGRV 
R6_03779          161 SRLPNLLVNGSSGIAVGMATNIPPHNLQEVVDGCLYCLRNPACSVDELMEIIPAPDFPTGGVIYGMSGVREGYRTGRGRV 
R7_00393          161 SRLPNLLVNGSSGIAVGMATNIPPHNLQEVVDGCLYCLRNPACSVDELMEIIPAPDFPTGGVIYGMSGVREGYRTGRGRV 
R9_01704          161 SRLPNLLVNGSSGIAVGMATNIPPHNLQEVVDGCLYCLRNPACSVDELMEIIPAPDFPTGGVIYGMSGVREGYRTGRGRV 
R8_00369          161 SRLPNLLVNGSSGIAVGMATNIPPHNLQEVVDGCLYCLRNPACSVDELMEIIPAPDFPTGGVIYGMSGVREGYRTGRGRV 
 
  241        320 
NCIMB11015_00314  241 IMRAKTHFEDMEKGNRQAIVVDAIPYQVNKKTLQERIAELVNDKKIEGISDIRDESDKDGMRLVIELKRGEVPEVVLNNL 
L1_03358          241 IMRAKTHFEDMEKGNRQAIVVDAIPYQVNKKTLQERIAELVNDKKIEGISDIRDESDKDGMRLVIELKRGEVPEVVLNNL 
R10_03668         241 IMRAKTHFEDMEKGNRQAIVVDAIPYQVNKKTLQERIAELVNDKKIEGISDIRDESDKDGMRLVIELKRGEVPEVVLNNL 
R3_01426          241 IMRAKTHFEDMEKGNRQAIVVDAIPYQVNKKTLQERIAELVNDKKIEGISDIRDESDKDGMRLVIELKRGEVPEVVLNNL 
NH44784_1996      241 IMRAKTHFEDMEKGNRQAIVVDAIPYQVNKKTLQERIAELVNDKKIEGISDIRDESDKDGMRLVIELKRGEVPEVVLNNL 
L16_00279         241 IMRAKTHFEDMEKGNRQAIVVDAIPYQVNKKTLQERIAELVNDKKIEGISDIRDESDKDGMRLVIELKRGEVPEVVLNNL 
DSM2402_03744     241 IMRAKTHFEDMEKGNRQAIVVDAIPYQVNKKTLQERIAELVNDKKIEGISDIRDESDKDGMRLVIELKRGEVPEVVLNNL 
L10_04633         241 IMRAKTHFEDMEKGNRQAIVVDAIPYQVNKKTLQERIAELVNDKKIEGISDIRDESDKDGMRLVIELKRGEVPEVVLNNL 
L11_03975         241 IMRAKTHFEDMEKGNRQAIVVDAIPYQVNKKTLQERIAELVNDKKIEGISDIRDESDKDGMRLVIELKRGEVPEVVLNNL 
L14_02140         241 IMRAKTHFEDMEKGNRQAIVVDAIPYQVNKKTLQERIAELVNDKKIEGISDIRDESDKDGMRLVIELKRGEVPEVVLNNL 
L15_03364         241 IMRAKTHFEDMEKGNRQAIVVDAIPYQVNKKTLQERIAELVNDKKIEGISDIRDESDKDGMRLVIELKRGEVPEVVLNNL 
L17_00812         241 IMRAKTHFEDMEKGNRQAIVVDAIPYQVNKKTLQERIAELVNDKKIEGISDIRDESDKDGMRLVIELKRGEVPEVVLNNL 
L5_03801          241 IMRAKTHFEDMEKGNRQAIVVDAIPYQVNKKTLQERIAELVNDKKIEGISDIRDESDKDGMRLVIELKRGEVPEVVLNNL 
L8_03080          241 IMRAKTHFEDMEKGNRQAIVVDAIPYQVNKKTLQERIAELVNDKKIEGISDIRDESDKDGMRLVIELKRGEVPEVVLNNL 
R11_00266         241 IMRAKTHFEDMEKGNRQAIVVDAIPYQVNKKTLQERIAELVNDKKIEGISDIRDESDKDGMRLVIELKRGEVPEVVLNNL 
R12_01916         241 IMRAKTHFEDMEKGNRQAIVVDAIPYQVNKKTLQERIAELVNDKKIEGISDIRDESDKDGMRLVIELKRGEVPEVVLNNL 
R13_00732         241 IMRAKTHFEDMEKGNRQAIVVDAIPYQVNKKTLQERIAELVNDKKIEGISDIRDESDKDGMRLVIELKRGEVPEVVLNNL 
R14_01680         241 IMRAKTHFEDMEKGNRQAIVVDAIPYQVNKKTLQERIAELVNDKKIEGISDIRDESDKDGMRLVIELKRGEVPEVVLNNL 
R1_01507          241 IMRAKTHFEDMEKGNRQAIVVDAIPYQVNKKTLQERIAELVNDKKIEGISDIRDESDKDGMRLVIELKRGEVPEVVLNNL 
R2_00884          241 IMRAKTHFEDMEKGNRQAIVVDAIPYQVNKKTLQERIAELVNDKKIEGISDIRDESDKDGMRLVIELKRGEVPEVVLNNL 
R4_00307          241 IMRAKTHFEDMEKGNRQAIVVDAIPYQVNKKTLQERIAELVNDKKIEGISDIRDESDKDGMRLVIELKRGEVPEVVLNNL 
R5_03246          241 IMRAKTHFEDMEKGNRQAIVVDAIPYQVNKKTLQERIAELVNDKKIEGISDIRDESDKDGMRLVIELKRGEVPEVVLNNL 
R6_03779          241 IMRAKTHFEDMEKGNRQAIVVDAIPYQVNKKTLQERIAELVNDKKIEGISDIRDESDKDGMRLVIELKRGEVPEVVLNNL 
R7_00393          241 IMRAKTHFEDMEKGNRQAIVVDAIPYQVNKKTLQERIAELVNDKKIEGISDIRDESDKDGMRLVIELKRGEVPEVVLNNL 
R9_01704          241 IMRAKTHFEDMEKGNRQAIVVDAIPYQVNKKTLQERIAELVNDKKIEGISDIRDESDKDGMRLVIELKRGEVPEVVLNNL 
R8_00369          241 IMRAKTHFEDMEKGNRQAIVVDAIPYQVNKKTLQERIAELVNDKKIEGISDIRDESDKDGMRLVIELKRGEVPEVVLNNL 
 
  321        400 
NCIMB11015_00314  321 YKNTQLQDTFGMNLVALVDGQPRLLNLKQMIDYFLQHRREVVTRRTVFQLRKARERGHVLEGLAVALANIDDFIAIIKAA 
L1_03358          321 YKNTQLQDTFGMNLVALVDGQPRLLNLKQMIDYFLQHRREVVTRRTVFQLRKARERGHVLEGLAVALANIDDFIAIIKAA 
R10_03668         321 YKNTQLQDTFGMNLVALVDGQPRLLNLKQMIDYFLQHRREVVTRRTVFQLRKARERGHVLEGLAVALANIDDFIAIIKAA 
R3_01426          321 YKNTQLQDTFGMNLVALVDGQPRLLNLKQMIDYFLQHRREVVTRRTVFQLRKARERGHVLEGLAVALANIDDFIAIIKAA 
NH44784_1996      321 YKNTQLQDTFGMNLVALVDGQPRLLNLKQMIDYFLQHRREVVTRRTVFQLRKARERGHVLEGLAVALANIDDFIAIIKAA 
L16_00279         321 YKNTQLQDTFGMNLVALVDGQPRLLNLKQMIDYFLQHRREVVTRRTVFQLRKARERGHVLEGLAVALANIDDFIAIIKAA 
DSM2402_03744     321 YKNTQLQDTFGMNLVALVDGQPRLLNLKQMIDYFLQHRREVVTRRTVFQLRKARERGHVLEGLAVALANIDDFIAIIKAA 
L10_04633         321 YKNTQLQDTFGMNLVALVDGQPRLLNLKQMIDYFLQHRREVVTRRTVFQLRKARERGHVLEGLAVALANIDDFIAIIKAA 
L11_03975         321 YKNTQLQDTFGMNLVALVDGQPRLLNLKQMIDYFLQHRREVVTRRTVFQLRKARERGHVLEGLAVALANIDDFIAIIKAA 
L14_02140         321 YKNTQLQDTFGMNLVALVDGQPRLLNLKQMIDYFLQHRREVVTRRTVFQLRKARERGHVLEGLAVALANIDDFIAIIKAA 
L15_03364         321 YKNTQLQDTFGMNLVALVDGQPRLLNLKQMIDYFLQHRREVVTRRTVFQLRKARERGHVLEGLAVALANIDDFIAIIKAA 
L17_00812         321 YKNTQLQDTFGMNLVALVDGQPRLLNLKQMIDYFLQHRREVVTRRTVFQLRKARERGHVLEGLAVALANIDDFIAIIKAA 
L5_03801          321 YKNTQLQDTFGMNLVALVDGQPRLLNLKQMIDYFLQHRREVVTRRTVFQLRKARERGHVLEGLAVALANIDDFIAIIKAA 
L8_03080          321 YKNTQLQDTFGMNLVALVDGQPRLLNLKQMIDYFLQHRREVVTRRTVFQLRKARERGHVLEGLAVALANIDDFIAIIKAA 
R11_00266         321 YKNTQLQDTFGMNLVALVDGQPRLLNLKQMIDYFLQHRREVVTRRTVFQLRKARERGHVLEGLAVALANIDDFIAIIKAA 
R12_01916         321 YKNTQLQDTFGMNLVALVDGQPRLLNLKQMIDYFLQHRREVVTRRTVFQLRKARERGHVLEGLAVALANIDDFIAIIKAA 
R13_00732         321 YKNTQLQDTFGMNLVALVDGQPRLLNLKQMIDYFLQHRREVVTRRTVFQLRKARERGHVLEGLAVALANIDDFIAIIKAA 
R14_01680         321 YKNTQLQDTFGMNLVALVDGQPRLLNLKQMIDYFLQHRREVVTRRTVFQLRKARERGHVLEGLAVALANIDDFIAIIKAA 
R1_01507          321 YKNTQLQDTFGMNLVALVDGQPRLLNLKQMIDYFLQHRREVVTRRTVFQLRKARERGHVLEGLAVALANIDDFIAIIKAA 
R2_00884          321 YKNTQLQDTFGMNLVALVDGQPRLLNLKQMIDYFLQHRREVVTRRTVFQLRKARERGHVLEGLAVALANIDDFIAIIKAA 
R4_00307          321 YKNTQLQDTFGMNLVALVDGQPRLLNLKQMIDYFLQHRREVVTRRTVFQLRKARERGHVLEGLAVALANIDDFIAIIKAA 
R5_03246          321 YKNTQLQDTFGMNLVALVDGQPRLLNLKQMIDYFLQHRREVVTRRTVFQLRKARERGHVLEGLAVALANIDDFIAIIKAA 
R6_03779          321 YKNTQLQDTFGMNLVALVDGQPRLLNLKQMIDYFLQHRREVVTRRTVFQLRKARERGHVLEGLAVALANIDDFIAIIKAA 
R7_00393          321 YKNTQLQDTFGMNLVALVDGQPRLLNLKQMIDYFLQHRREVVTRRTVFQLRKARERGHVLEGLAVALANIDDFIAIIKAA 
R9_01704          321 YKNTQLQDTFGMNLVALVDGQPRLLNLKQMIDYFLQHRREVVTRRTVFQLRKARERGHVLEGLAVALANIDDFIAIIKAA 
R8_00369          321 YKNTQLQDTFGMNLVALVDGQPRLLNLKQMIDYFLQHRREVVTRRTVFQLRKARERGHVLEGLAVALANIDDFIAIIKAA 
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  401        480 
NCIMB11015_00314  401 PTPPVARQELMAKSWDSSLVREMLSRADGDTPGGRAAFRPDDLGAEFGLQGDGLYRLSDTQAQEILNMRLQRLTGLEQDK 
L1_03358          401 PTPPVARQELMAKSWDSSLVREMLSRADGDTPGGRAAFRPDDLGAEFGLQGDGLYRLSDTQAQEILNMRLQRLTGLEQDK 
R10_03668         401 PTPPVARQELMAKSWDSSLVREMLSRADGDTPGGRAAFRPDDLGAEFGLQGDGLYRLSDTQAQEILNMRLQRLTGLEQDK 
R3_01426          401 PTPPVARQELMAKSWDSSLVREMLSRADGDTPGGRAAFRPDDLGAEFGLQGDGLYRLSDTQAQEILNMRLQRLTGLEQDK 
NH44784_1996      401 PTPPVARQELMAKSWDSSLVREMLSRADGDTPGGRAAFRPDDLGAEFGLQGDGLYRLSDTQAQEILNMRLQRLTGLEQDK 
L16_00279         401 PTPPVARQELMAKSWDSSLVREMLSRADGDTPGGRAAFRPDDLGAEFGLQGDGLYRLSDTQAQEILNMRLQRLTGLEQDK 
DSM2402_03744     401 PTPPVARQELMAKSWDSSLVREMLSRADGDTPGGRAAFRPDDLGAEFGLQGDGLYRLSDTQAQEILNMRLQRLTGLEQDK 
L10_04633         401 PTPPVARQELMAKSWDSSLVREMLSRADGDTPGGRAAFRPDDLGAEFGLQGDGLYRLSDTQAQEILNMRLQRLTGLEQDK 
L11_03975         401 PTPPVARQELMAKSWDSSLVREMLSRADGDTPGGRAAFRPDDLGAEFGLQGDGLYRLSDTQAQEILNMRLQRLTGLEQDK 
L14_02140         401 PTPPVARQELMAKSWDSSLVREMLSRADGDTPGGRAAFRPDDLGAEFGLQGDGLYRLSDTQAQEILNMRLQRLTGLEQDK 
L15_03364         401 PTPPVARQELMAKSWDSSLVREMLSRADGDTPGGRAAFRPDDLGAEFGLQGDGLYRLSDTQAQEILNMRLQRLTGLEQDK 
L17_00812         401 PTPPVARQELMAKSWDSSLVREMLSRADGDTPGGRAAFRPDDLGAEFGLQGDGLYRLSDTQAQEILNMRLQRLTGLEQDK 
L5_03801          401 PTPPVARQELMAKSWDSSLVREMLSRADGDTPGGRAAFRPDDLGAEFGLQGDGLYRLSDTQAQEILNMRLQRLTGLEQDK 
L8_03080          401 PTPPVARQELMAKSWDSSLVREMLSRADGDTPGGRAAFRPDDLGAEFGLQGDGLYRLSDTQAQEILNMRLQRLTGLEQDK 
R11_00266         401 PTPPVARQELMAKSWDSSLVREMLSRADGDTPGGRAAFRPDDLGAEFGLQGDGLYRLSDTQAQEILNMRLQRLTGLEQDK 
R12_01916         401 PTPPVARQELMAKSWDSSLVREMLSRADGDTPGGRAAFRPDDLGAEFGLQGDGLYRLSDTQAQEILNMRLQRLTGLEQDK 
R13_00732         401 PTPPVARQELMAKSWDSSLVREMLSRADGDTPGGRAAFRPDDLGAEFGLQGDGLYRLSDTQAQEILNMRLQRLTGLEQDK 
R14_01680         401 PTPPVARQELMAKSWDSSLVREMLSRADGDTPGGRAAFRPDDLGAEFGLQGDGLYRLSDTQAQEILNMRLQRLTGLEQDK 
R1_01507          401 PTPPVARQELMAKSWDSSLVREMLSRADGDTPGGRAAFRPDDLGAEFGLQGDGLYRLSDTQAQEILNMRLQRLTGLEQDK 
R2_00884          401 PTPPVARQELMAKSWDSSLVREMLSRADGDTPGGRAAFRPDDLGAEFGLQGDGLYRLSDTQAQEILNMRLQRLTGLEQDK 
R4_00307          401 PTPPVARQELMAKSWDSSLVREMLSRADGDTPGGRAAFRPDDLGAEFGLQGDGLYRLSDTQAQEILNMRLQRLTGLEQDK 
R5_03246          401 PTPPVARQELMAKSWDSSLVREMLSRADGDTPGGRAAFRPDDLGAEFGLQGDGLYRLSDTQAQEILNMRLQRLTGLEQDK 
R6_03779          401 PTPPVARQELMAKSWDSSLVREMLSRADGDTPGGRAAFRPDDLGAEFGLQGDGLYRLSDTQAQEILNMRLQRLTGLEQDK 
R7_00393          401 PTPPVARQELMAKSWDSSLVREMLSRADGDTPGGRAAFRPDDLGAEFGLQGDGLYRLSDTQAQEILNMRLQRLTGLEQDK 
R9_01704          401 PTPPVARQELMAKSWDSSLVREMLSRADGDTPGGRAAFRPDDLGAEFGLQGDGLYRLSDTQAQEILNMRLQRLTGLEQDK 
R8_00369          401 PTPPVARQELMAKSWDSSLVREMLSRADGDTPGGRAAFRPDDLGAEFGLQGDGLYRLSDTQAQEILNMRLQRLTGLEQDK 
 
  481        560 
NCIMB11015_00314  481 IVGEYKDVMSAIADLLDILARPERITTIIGEELQAIKAEFSTGAKDTRRSEIELNATELDTEDLITPTDMVVTLSHGGYI 
L1_03358          481 IVGEYKDVMSAIADLLDILARPERITTIIGEELQAIKAEFSTGAKDTRRSEIELNATELDTEDLITPTDMVVTLSHGGYI 
R10_03668         481 IVGEYKDVMSAIADLLDILARPERITTIIGEELQAIKAEFSTGAKDTRRSEIELNATELDTEDLITPTDMVVTLSHGGYI 
R3_01426          481 IVGEYKDVMSAIADLLDILARPERITTIIGEELQAIKAEFSTGAKDTRRSEIELNATELDTEDLITPTDMVVTLSHGGYI 
NH44784_1996      481 IVGEYKDVMSAIADLLDILARPERITTIIGEELQAIKAEFSTGAKDTRRSEIELNATELDTEDLITPTDMVVTLSHGGYI 
L16_00279         481 IVGEYKDIMSTIADLLDILARPERITTIIGEELQAIKAEFSTGAKDTRRSEIELNATELDTEDLITPTDMVVTLSHGGYI 
DSM2402_03744     481 IVGEYKDIMSTIADLLDILARPERITTIIGEELQAIKAEFSTGAKDTRRSEIELNATELDTEDLITPTDMVVTLSHGGYI 
L10_04633         481 IVGEYKDIMSTIADLLDILARPERITTIIGEELQAIKAEFSTGAKDTRRSEIELNATELDTEDLITPTDMVVTLSHGGYI 
L11_03975         481 IVGEYKDIMSTIADLLDILARPERITTIIGEELQAIKAEFSTGAKDTRRSEIELNATELDTEDLITPTDMVVTLSHGGYI 
L14_02140         481 IVGEYKDIMSTIADLLDILARPERITTIIGEELQAIKAEFSTGAKDTRRSEIELNATELDTEDLITPTDMVVTLSHGGYI 
L15_03364         481 IVGEYKDIMSTIADLLDILARPERITTIIGEELQAIKAEFSTGAKDTRRSEIELNATELDTEDLITPTDMVVTLSHGGYI 
L17_00812         481 IVGEYKDIMSTIADLLDILARPERITTIIGEELQAIKAEFSTGAKDTRRSEIELNATELDTEDLITPTDMVVTLSHGGYI 
L5_03801          481 IVGEYKDIMSTIADLLDILARPERITTIIGEELQAIKAEFSTGAKDTRRSEIELNATELDTEDLITPTDMVVTLSHGGYI 
L8_03080          481 IVGEYKDIMSTIADLLDILARPERITTIIGEELQAIKAEFSTGAKDTRRSEIELNATELDTEDLITPTDMVVTLSHGGYI 
R11_00266         481 IVGEYKDIMSTIADLLDILARPERITTIIGEELQAIKAEFSTGAKDTRRSEIELNATELDTEDLITPTDMVVTLSHGGYI 
R12_01916         481 IVGEYKDIMSTIADLLDILARPERITTIIGEELQAIKAEFSTGAKDTRRSEIELNATELDTEDLITPTDMVVTLSHGGYI 
R13_00732         481 IVGEYKDIMSTIADLLDILARPERITTIIGEELQAIKAEFSTGAKDTRRSEIELNATELDTEDLITPTDMVVTLSHGGYI 
R14_01680         481 IVGEYKDIMSTIADLLDILARPERITTIIGEELQAIKAEFSTGAKDTRRSEIELNATELDTEDLITPTDMVVTLSHGGYI 
R1_01507          481 IVGEYKDIMSTIADLLDILARPERITTIIGEELQAIKAEFSTGAKDTRRSEIELNATELDTEDLITPTDMVVTLSHGGYI 
R2_00884          481 IVGEYKDIMSTIADLLDILARPERITTIIGEELQAIKAEFSTGAKDTRRSEIELNATELDTEDLITPTDMVVTLSHGGYI 
R4_00307          481 IVGEYKDIMSTIADLLDILARPERITTIIGEELQAIKAEFSTGAKDTRRSEIELNATELDTEDLITPTDMVVTLSHGGYI 
R5_03246          481 IVGEYKDIMSTIADLLDILARPERITTIIGEELQAIKAEFSTGAKDTRRSEIELNATELDTEDLITPTDMVVTLSHGGYI 
R6_03779          481 IVGEYKDIMSTIADLLDILARPERITTIIGEELQAIKAEFSTGAKDTRRSEIELNATELDTEDLITPTDMVVTLSHGGYI 
R7_00393          481 IVGEYKDIMSTIADLLDILARPERITTIIGEELQAIKAEFSTGAKDTRRSEIELNATELDTEDLITPTDMVVTLSHGGYI 
R9_01704          481 IVGEYKDIMSTIADLLDILARPERITTIIGEELQAIKAEFSTGAKDTRRSEIELNATELDTEDLITPTDMVVTLSHGGYI 
R8_00369          481 IVGEYKDIMSTIADLLDILARPERITTIIGEELQAIKAEFSTGAKDTRRSEIELNATELDTEDLITPTDMVVTLSHGGYI 
 
  561        640 
NCIMB11015_00314  561 KSQPLSEYRSQKRGGRGKQATAMKENDWIDQLFIANTHDFLLCFSNRGRVYWLKVWEVPQGTRNSRGKPIVNMFPLAEGE 
L1_03358          561 KSQPLSEYRSQKRGGRGKQATAMKENDWIDQLFIANTHDFLLCFSNRGRVYWLKVWEVPQGTRNSRGKPIVNMFPLAEGE 
R10_03668         561 KSQPLSEYRSQKRGGRGKQATAMKENDWIDQLFIANTHDFLLCFSNRGRVYWLKVWEVPQGTRNSRGKPIVNMFPLAEGE 
R3_01426          561 KSQPLSEYRSQKRGGRGKQATAMKENDWIDQLFIANTHDFLLCFSNRGRVYWLKVWEVPQGTRNSRGKPIVNMFPLAEGE 
NH44784_1996      561 KSQPLSEYRSQKRGGRGKQATAMKENDWIDQLFIANTHDFLLCFSNRGRVYWLKVWEVPQGTRNSRGKPIVNMFPLAEGE 
L16_00279         561 KSQPLSEYRSQKRGGRGKQATAMKENDWIDQLFIANTHDFLLCFSNRGRVYWLKVWEVPQGTRNSRGKPIVNMFPLAEGE 
DSM2402_03744     561 KSQPLSEYRSQKRGGRGKQATAMKENDWIDQLFIANTHDFLLCFSNRGRVYWLKVWEVPQGTRNSRGKPIVNMFPLAEGE 
L10_04633         561 KSQPLSEYRSQKRGGRGKQATAMKENDWIDQLFIANTHDFLLCFSNRGRVYWLKVWEVPQGTRNSRGKPIVNMFPLAEGE 
L11_03975         561 KSQPLSEYRSQKRGGRGKQATAMKENDWIDQLFIANTHDFLLCFSNRGRVYWLKVWEVPQGTRNSRGKPIVNMFPLAEGE 
L14_02140         561 KSQPLSEYRSQKRGGRGKQATAMKENDWIDQLFIANTHDFLLCFSNRGRVYWLKVWEVPQGTRNSRGKPIVNMFPLAEGE 
L15_03364         561 KSQPLSEYRSQKRGGRGKQATAMKENDWIDQLFIANTHDFLLCFSNRGRVYWLKVWEVPQGTRNSRGKPIVNMFPLAEGE 
L17_00812         561 KSQPLSEYRSQKRGGRGKQATAMKENDWIDQLFIANTHDFLLCFSNRGRVYWLKVWEVPQGTRNSRGKPIVNMFPLAEGE 
L5_03801          561 KSQPLSEYRSQKRGGRGKQATAMKENDWIDQLFIANTHDFLLCFSNRGRVYWLKVWEVPQGTRNSRGKPIVNMFPLAEGE 
L8_03080          561 KSQPLSEYRSQKRGGRGKQATAMKENDWIDQLFIANTHDFLLCFSNRGRVYWLKVWEVPQGTRNSRGKPIVNMFPLAEGE 
R11_00266         561 KSQPLSEYRSQKRGGRGKQATAMKENDWIDQLFIANTHDFLLCFSNRGRVYWLKVWEVPQGTRNSRGKPIVNMFPLAEGE 
R12_01916         561 KSQPLSEYRSQKRGGRGKQATAMKENDWIDQLFIANTHDFLLCFSNRGRVYWLKVWEVPQGTRNSRGKPIVNMFPLAEGE 
R13_00732         561 KSQPLSEYRSQKRGGRGKQATAMKENDWIDQLFIANTHDFLLCFSNRGRVYWLKVWEVPQGTRNSRGKPIVNMFPLAEGE 
R14_01680         561 KSQPLSEYRSQKRGGRGKQATAMKENDWIDQLFIANTHDFLLCFSNRGRVYWLKVWEVPQGTRNSRGKPIVNMFPLAEGE 
R1_01507          561 KSQPLSEYRSQKRGGRGKQATAMKENDWIDQLFIANTHDFLLCFSNRGRVYWLKVWEVPQGTRNSRGKPIVNMFPLAEGE 
R2_00884          561 KSQPLSEYRSQKRGGRGKQATAMKENDWIDQLFIANTHDFLLCFSNRGRVYWLKVWEVPQGTRNSRGKPIVNMFPLAEGE 
R4_00307          561 KSQPLSEYRSQKRGGRGKQATAMKENDWIDQLFIANTHDFLLCFSNRGRVYWLKVWEVPQGTRNSRGKPIVNMFPLAEGE 
R5_03246          561 KSQPLSEYRSQKRGGRGKQATAMKENDWIDQLFIANTHDFLLCFSNRGRVYWLKVWEVPQGTRNSRGKPIVNMFPLAEGE 
R6_03779          561 KSQPLSEYRSQKRGGRGKQATAMKENDWIDQLFIANTHDFLLCFSNRGRVYWLKVWEVPQGTRNSRGKPIVNMFPLAEGE 
R7_00393          561 KSQPLSEYRSQKRGGRGKQATAMKENDWIDQLFIANTHDFLLCFSNRGRVYWLKVWEVPQGTRNSRGKPIVNMFPLAEGE 
R9_01704          561 KSQPLSEYRSQKRGGRGKQATAMKENDWIDQLFIANTHDFLLCFSNRGRVYWLKVWEVPQGTRNSRGKPIVNMFPLAEGE 
R8_00369          561 KSQPLSEYRSQKRGGRGKQATAMKENDWIDQLFIANTHDFLLCFSNRGRVYWLKVWEVPQGTRNSRGKPIVNMFPLAEGE 
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  641        720 
NCIMB11015_00314  641 KITVVLPVKEFSEDHYVFMATSRGTVKKTPLSDFSNPRKAGIIAVDLDDGDYLIGADLTDGKHDVMLFSDAGKAVRFDEN 
L1_03358          641 KITVVLPVKEFSEDHYVFMATSRGTVKKTPLSDFSNPRKAGIIAVDLDDGDYLIGADLTDGKHDVMLFSDAGKAVRFDEN 
R10_03668         641 KITVVLPVKEFSEDHYVFMATSRGTVKKTPLSDFSNPRKAGIIAVDLDDGDYLIGADLTDGKHDVMLFSDAGKAVRFDEN 
R3_01426          641 KITVVLPVKEFSEDHYVFMATSRGTVKKTPLSDFSNPRKAGIIAVDLDDGDYLIGADLTDGKHDVMLFSDAGKAVRFDEN 
NH44784_1996      641 KITVVLPVKEFSEDHYVFMATSRGTVKKTPLSDFSNPRKAGIIAVDLDDGDYLIGADLTDGKHDVMLFSDAGKAVRFDEN 
L16_00279         641 KITVVLPVKEFSEDHYVFMATSRGTVKKTPLSDFSNPRKAGIIAVDLDDGDYLIGADLTDGKHDVMLFSDAGKAVRFDEN 
DSM2402_03744     641 KITVVLPVKEFSEDHYVFMATSRGTVKKTPLSDFSNPRKAGIIAVDLDDGDYLIGADLTDGKHDVMLFSDAGKAVRFDEN 
L10_04633         641 KITVVLPVKEFSEDHYVFMATSRGTVKKTPLSDFSNPRKAGIIAVDLDDGDYLIGADLTDGKHDVMLFSDAGKAVRFDEN 
L11_03975         641 KITVVLPVKEFSEDHYVFMATSRGTVKKTPLSDFSNPRKAGIIAVDLDDGDYLIGADLTDGKHDVMLFSDAGKAVRFDEN 
L14_02140         641 KITVVLPVKEFSEDHYVFMATSRGTVKKTPLSDFSNPRKAGIIAVDLDDGDYLIGADLTDGKHDVMLFSDAGKAVRFDEN 
L15_03364         641 KITVVLPVKEFSEDHYVFMATSRGTVKKTPLSDFSNPRKAGIIAVDLDDGDYLIGADLTDGKHDVMLFSDAGKAVRFDEN 
L17_00812         641 KITVVLPVKEFSEDHYVFMATSRGTVKKTPLSDFSNPRKAGIIAVDLDDGDYLIGADLTDGKHDVMLFSDAGKAVRFDEN 
L5_03801          641 KITVVLPVKEFSEDHYVFMATSRGTVKKTPLSDFSNPRKAGIIAVDLDDGDYLIGADLTDGKHDVMLFSDAGKAVRFDEN 
L8_03080          641 KITVVLPVKEFSEDHYVFMATSRGTVKKTPLSDFSNPRKAGIIAVDLDDGDYLIGADLTDGKHDVMLFSDAGKAVRFDEN 
R11_00266         641 KITVVLPVKEFSEDHYVFMATSRGTVKKTPLSDFSNPRKAGIIAVDLDDGDYLIGADLTDGKHDVMLFSDAGKAVRFDEN 
R12_01916         641 KITVVLPVKEFSEDHYVFMATSRGTVKKTPLSDFSNPRKAGIIAVDLDDGDYLIGADLTDGKHDVMLFSDAGKAVRFDEN 
R13_00732         641 KITVVLPVKEFSEDHYVFMATSRGTVKKTPLSDFSNPRKAGIIAVDLDDGDYLIGADLTDGKHDVMLFSDAGKAVRFDEN 
R14_01680         641 KITVVLPVKEFSEDHYVFMATSRGTVKKTPLSDFSNPRKAGIIAVDLDDGDYLIGADLTDGKHDVMLFSDAGKAVRFDEN 
R1_01507          641 KITVVLPVKEFSEDHYVFMATSRGTVKKTPLSDFSNPRKAGIIAVDLDDGDYLIGADLTDGKHDVMLFSDAGKAVRFDEN 
R2_00884          641 KITVVLPVKEFSEDHYVFMATSRGTVKKTPLSDFSNPRKAGIIAVDLDDGDYLIGADLTDGKHDVMLFSDAGKAVRFDEN 
R4_00307          641 KITVVLPVKEFSEDHYVFMATSRGTVKKTPLSDFSNPRKAGIIAVDLDDGDYLIGADLTDGKHDVMLFSDAGKAVRFDEN 
R5_03246          641 KITVVLPVKEFSEDHYVFMATSRGTVKKTPLSDFSNPRKAGIIAVDLDDGDYLIGADLTDGKHDVMLFSDAGKAVRFDEN 
R6_03779          641 KITVVLPVKEFSEDHYVFMATSRGTVKKTPLSDFSNPRKAGIIAVDLDDGDYLIGADLTDGKHDVMLFSDAGKAVRFDEN 
R7_00393          641 KITVVLPVKEFSEDHYVFMATSRGTVKKTPLSDFSNPRKAGIIAVDLDDGDYLIGADLTDGKHDVMLFSDAGKAVRFDEN 
R9_01704          641 KITVVLPVKEFSEDHYVFMATSRGTVKKTPLSDFSNPRKAGIIAVDLDDGDYLIGADLTDGKHDVMLFSDAGKAVRFDEN 
R8_00369          641 KITVVLPVKEFSEDHYVFMATSRGTVKKTPLSDFSNPRKAGIIAVDLDDGDYLIGADLTDGKHDVMLFSDAGKAVRFDEN 
 
  721        800 
NCIMB11015_00314  721 DVRPMGRNARGVRGMMLEDTQNVIALLVAGDETQSVLTATENGYGKRTPITEYTRHGRGTKGMIAIQTSSRNGKVVGAVL 
L1_03358          721 DVRPMGRNARGVRGMMLEDTQNVIALLVAGDETQSVLTATENGYGKRTPITEYTRHGRGTKGMIAIQTSSRNGKVVGAVL 
R10_03668         721 DVRPMGRNARGVRGMMLEDTQNVIALLVAGDETQSVLTATENGYGKRTPITEYTRHGRGTKGMIAIQTSSRNGKVVGAVL 
R3_01426          721 DVRPMGRNARGVRGMMLEDTQNVIALLVAGDETQSVLTATENGYGKRTPITEYTRHGRGTKGMIAIQTSSRNGKVVGAVL 
NH44784_1996      721 DVRPMGRNARGVRGMMLEDTQNVIALLVAGDETQSVLTATENGYGKRTPITEYTRHGRGTKGMIAIQTSSRNGKVVGAVL 
L16_00279         721 DVRPMGRNARGVRGMMLEDTQNVIALLVAGDETQSVLTATENGYGKRTPITEYTRHGRGTKGMIAIQTSSRNGKVVGAVL 
DSM2402_03744     721 DVRPMGRNARGVRGMMLEDTQNVIALLVAGDETQSVLTATENGYGKRTPITEYTRHGRGTKGMIAIQTSSRNGKVVGAVL 
L10_04633         721 DVRPMGRNARGVRGMMLEDTQNVIALLVAGDETQSVLTATENGYGKRTPITEYTRHGRGTKGMIAIQTSSRNGKVVGAVL 
L11_03975         721 DVRPMGRNARGVRGMMLEDTQNVIALLVAGDETQSVLTATENGYGKRTPITEYTRHGRGTKGMIAIQTSSRNGKVVGAVL 
L14_02140         721 DVRPMGRNARGVRGMMLEDTQNVIALLVAGDETQSVLTATENGYGKRTPITEYTRHGRGTKGMIAIQTSSRNGKVVGAVL 
L15_03364         721 DVRPMGRNARGVRGMMLEDTQNVIALLVAGDETQSVLTATENGYGKRTPITEYTRHGRGTKGMIAIQTSSRNGKVVGAVL 
L17_00812         721 DVRPMGRNARGVRGMMLEDTQNVIALLVAGDETQSVLTATENGYGKRTPITEYTRHGRGTKGMIAIQTSSRNGKVVGAVL 
L5_03801          721 DVRPMGRNARGVRGMMLEDTQNVIALLVAGDETQSVLTATENGYGKRTPITEYTRHGRGTKGMIAIQTSSRNGKVVGAVL 
L8_03080          721 DVRPMGRNARGVRGMMLEDTQNVIALLVAGDETQSVLTATENGYGKRTPITEYTRHGRGTKGMIAIQTSSRNGKVVGAVL 
R11_00266         721 DVRPMGRNARGVRGMMLEDTQNVIALLVAGDETQSVLTATENGYGKRTPITEYTRHGRGTKGMIAIQTSSRNGKVVGAVL 
R12_01916         721 DVRPMGRNARGVRGMMLEDTQNVIALLVAGDETQSVLTATENGYGKRTPITEYTRHGRGTKGMIAIQTSSRNGKVVGAVL 
R13_00732         721 DVRPMGRNARGVRGMMLEDTQNVIALLVAGDETQSVLTATENGYGKRTPITEYTRHGRGTKGMIAIQTSSRNGKVVGAVL 
R14_01680         721 DVRPMGRNARGVRGMMLEDTQNVIALLVAGDETQSVLTATENGYGKRTPITEYTRHGRGTKGMIAIQTSSRNGKVVGAVL 
R1_01507          721 DVRPMGRNARGVRGMMLEDTQNVIALLVAGDETQSVLTATENGYGKRTPITEYTRHGRGTKGMIAIQTSSRNGKVVGAVL 
R2_00884          721 DVRPMGRNARGVRGMMLEDTQNVIALLVAGDETQSVLTATENGYGKRTPITEYTRHGRGTKGMIAIQTSSRNGKVVGAVL 
R4_00307          721 DVRPMGRNARGVRGMMLEDTQNVIALLVAGDETQSVLTATENGYGKRTPITEYTRHGRGTKGMIAIQTSSRNGKVVGAVL 
R5_03246          721 DVRPMGRNARGVRGMMLEDTQNVIALLVAGDETQSVLTATENGYGKRTPITEYTRHGRGTKGMIAIQTSSRNGKVVGAVL 
R6_03779          721 DVRPMGRNARGVRGMMLEDTQNVIALLVAGDETQSVLTATENGYGKRTPITEYTRHGRGTKGMIAIQTSSRNGKVVGAVL 
R7_00393          721 DVRPMGRNARGVRGMMLEDTQNVIALLVAGDETQSVLTATENGYGKRTPITEYTRHGRGTKGMIAIQTSSRNGKVVGAVL 
R9_01704          721 DVRPMGRNARGVRGMMLEDTQNVIALLVAGDETQSVLTATENGYGKRTPITEYTRHGRGTKGMIAIQTSSRNGKVVGAVL 
R8_00369          721 DVRPMGRNARGVRGMMLEDTQNVIALLVAGDETQSVLTATENGYGKRTPITEYTRHGRGTKGMIAIQTSSRNGKVVGAVL 
 
  801        880 
NCIMB11015_00314  801 VMPSDEIMLITTGGVLVRTRVAEIREMGRATQGVTLINVDDGSSLSGVRRVVESDADDDSEDLDDGQEEGQEEGNGDAGA 
L1_03358          801 VMPSDEIMLITTGGVLVRTRVAEIREMGRATQGVTLINVDDGSSLSGVRRVVESDADDDSEDLDDGQEEGQEEGNGDAGA 
R10_03668         801 VMPSDEIMLITTGGVLVRTRVAEIREMGRATQGVTLINVDDGSSLSGVRRVVESDADDDSEDLDDGQEEGQEEGNGDAGA 
R3_01426          801 VMPSDEIMLITTGGVLVRTRVAEIREMGRATQGVTLINVDDGSSLSGVRRVVESDADDDSEDLDDGQEEGQEEGNGDAGA 
NH44784_1996      801 VMPSDEIMLITTGGVLVRTRVAEIREMGRATQGVTLINVDDGSSLSGVRRVVESDADDDSEDLDDGQEEGQEEGNGDAGA 
L16_00279         801 VMPSDEIMLITTGGVLVRTRVAEIREMGRATQGVTLINVDDGSSLSGVRRVVESDADDDSEDLDDGQEEGQEEGNGDAGA 
DSM2402_03744     801 VMPSDEIMLITTGGVLVRTRVAEIREMGRATQGVTLINVDDGSSLSGVRRVVESDADDDSEDLDDGQEEGQEEGNGDAGA 
L10_04633         801 VMPSDEIMLITTGGVLVRTRVAEIREMGRATQGVTLINVDDGSSLSGVRRVVESDADDDSEDLDDGQEEGQEEGNGDAGA 
L11_03975         801 VMPSDEIMLITTGGVLVRTRVAEIREMGRATQGVTLINVDDGSSLSGVRRVVESDADDDSEDLDDGQEEGQEEGNGDAGA 
L14_02140         801 VMPSDEIMLITTGGVLVRTRVAEIREMGRATQGVTLINVDDGSSLSGVRRVVESDADDDSEDLDDGQEEGQEEGNGDAGA 
L15_03364         801 VMPSDEIMLITTGGVLVRTRVAEIREMGRATQGVTLINVDDGSSLSGVRRVVESDADDDSEDLDDGQEEGQEEGNGDAGA 
L17_00812         801 VMPSDEIMLITTGGVLVRTRVAEIREMGRATQGVTLINVDDGSSLSGVRRVVESDADDDSEDLDDGQEEGQEEGNGDAGA 
L5_03801          801 VMPSDEIMLITTGGVLVRTRVAEIREMGRATQGVTLINVDDGSSLSGVRRVVESDADDDSEDLDDGQEEGQEEGNGDAGA 
L8_03080          801 VMPSDEIMLITTGGVLVRTRVAEIREMGRATQGVTLINVDDGSSLSGVRRVVESDADDDSEDLDDGQEEGQEEGNGDAGA 
R11_00266         801 VMPSDEIMLITTGGVLVRTRVAEIREMGRATQGVTLINVDDGSSLSGVRRVVESDADDDSEDLDDGQEEGQEEGNGDAGA 
R12_01916         801 VMPSDEIMLITTGGVLVRTRVAEIREMGRATQGVTLINVDDGSSLSGVRRVVESDADDDSEDLDDGQEEGQEEGNGDAGA 
R13_00732         801 VMPSDEIMLITTGGVLVRTRVAEIREMGRATQGVTLINVDDGSSLSGVRRVVESDADDDSEDLDDGQEEGQEEGNGDAGA 
R14_01680         801 VMPSDEIMLITTGGVLVRTRVAEIREMGRATQGVTLINVDDGSSLSGVRRVVESDADDDSEDLDDGQEEGQEEGNGDAGA 
R1_01507          801 VMPSDEIMLITTGGVLVRTRVAEIREMGRATQGVTLINVDDGSSLSGVRRVVESDADDDSEDLDDGQEEGQEEGNGDAGA 
R2_00884          801 VMPSDEIMLITTGGVLVRTRVAEIREMGRATQGVTLINVDDGSSLSGVRRVVESDADDDSEDLDDGQEEGQEEGNGDAGA 
R4_00307          801 VMPSDEIMLITTGGVLVRTRVAEIREMGRATQGVTLINVDDGSSLSGVRRVVESDADDDSEDLDDGQEEGQEEGNGDAGA 
R5_03246          801 VMPSDEIMLITTGGVLVRTRVAEIREMGRATQGVTLINVDDGSSLSGVRRVVESDADDDSEDLDDGQEEGQEEGNGDAGA 
R6_03779          801 VMPSDEIMLITTGGVLVRTRVAEIREMGRATQGVTLINVDDGSSLSGVRRVVESDADDDSEDLDDGQEEGQEEGNGDAGA 
R7_00393          801 VMPSDEIMLITTGGVLVRTRVAEIREMGRATQGVTLINVDDGSSLSGVRRVVESDADDDSEDLDDGQEEGQEEGNGDAGA 
R9_01704          801 VMPSDEIMLITTGGVLVRTRVAEIREMGRATQGVTLINVDDGSSLSGVRRVVESDADDDSEDLDDGQEEGQEEGNGDAGA 
R8_00369          801 VMPSDEIMLITTGGVLVRTRVAEIREMGRATQGVTLINVDDGSSLSGVRRVVESDADDDSEDLDDGQEEGQEEGNGDAGA 
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  881 889 
NCIMB11015_00314  881 TDSTEPTEQ 
L1_03358          881 TDSTEPTEQ 
R10_03668         881 TDSTEPTEQ 
R3_01426          881 TDSTEPTEQ 
NH44784_1996      881 TDSTEPTEQ 
L16_00279         881 MDSTEPTEQ 
DSM2402_03744     881 TDSTEPTEQ 
L10_04633         881 TDSTEPTEQ 
L11_03975         881 TDSTEPTEQ 
L14_02140         881 TDSTEPTEQ 
L15_03364         881 TDSTEPTEQ 
L17_00812         881 TDSTEPTEQ 
L5_03801          881 TDSTEPTEQ 
L8_03080          881 TDSTEPTEQ 
R11_00266         881 TDSTEPTEQ 
R12_01916         881 TDSTEPTEQ 
R13_00732         881 TDSTEPTEQ 
R14_01680         881 TDSTEPTEQ 
R1_01507          881 TDSTEPTEQ 
R2_00884          881 TDSTEPTEQ 
R4_00307          881 TDSTEPTEQ 
R5_03246          881 TDSTEPTEQ 
R6_03779          881 TDSTEPTEQ 
R7_00393          881 TDSTEPTEQ 
R9_01704          881 TDSTEPTEQ 
R8_00369          881 TDSTEPTEQ 
 
B) DNA Gyrase subunit B 
 
  1        80 
L5_03504            1 MSDQQNTTPENGGYGADSIKMLKGLEAVRKRPGMYIGDTSDGTGLHHMVFEVVDNAIDEALAGYCDDIVVTIHTDNSISV 
R11_03913           1 MSDQQNTTPENGGYGADSIKMLKGLEAVRKRPGMYIGDTSDGTGLHHMVFEVVDNAIDEALAGYCDDIVVTIHTDNSISV 
DSM2402_04205       1 MSDQQNTTPENGGYGADSIKMLKGLEAVRKRPGMYIGDTSDGTGLHHMVFEVVDNAIDEALAGYCDDIVVTIHTDNSISV 
L10_03108           1 MSDQQNTTPENGGYGADSIKMLKGLEAVRKRPGMYIGDTSDGTGLHHMVFEVVDNAIDEALAGYCDDIVVTIHTDNSISV 
L11_01822           1 MSDQQNTTPENGGYGADSIKMLKGLEAVRKRPGMYIGDTSDGTGLHHMVFEVVDNAIDEALAGYCDDIVVTIHTDNSISV 
L14_04214           1 MSDQQNTTPENGGYGADSIKMLKGLEAVRKRPGMYIGDTSDGTGLHHMVFEVVDNAIDEALAGYCDDIVVTIHTDNSISV 
L15_02710           1 MSDQQNTTPENGGYGADSIKMLKGLEAVRKRPGMYIGDTSDGTGLHHMVFEVVDNAIDEALAGYCDDIVVTIHTDNSISV 
L16_01630           1 MSDQQNTTPENGGYGADSIKMLKGLEAVRKRPGMYIGDTSDGTGLHHMVFEVVDNAIDEALAGYCDDIVVTIHTDNSISV 
L17_02230           1 MSDQQNTTPENGGYGADSIKMLKGLEAVRKRPGMYIGDTSDGTGLHHMVFEVVDNAIDEALAGYCDDIVVTIHTDNSISV 
L1_00569            1 MSDQQNTTPENGGYGADSIKMLKGLEAVRKRPGMYIGDTSDGTGLHHMVFEVVDNAIDEALAGYCDDIVVTIHTDNSISV 
L8_02109            1 MSDQQNTTPENGGYGADSIKMLKGLEAVRKRPGMYIGDTSDGTGLHHMVFEVVDNAIDEALAGYCDDIVVTIHTDNSISV 
R10_02546           1 MSDQQNTTPENGGYGADSIKMLKGLEAVRKRPGMYIGDTSDGTGLHHMVFEVVDNAIDEALAGYCDDIVVTIHTDNSISV 
R12_04117           1 MSDQQNTTPENGGYGADSIKMLKGLEAVRKRPGMYIGDTSDGTGLHHMVFEVVDNAIDEALAGYCDDIVVTIHTDNSISV 
R13_03776           1 MSDQQNTTPENGGYGADSIKMLKGLEAVRKRPGMYIGDTSDGTGLHHMVFEVVDNAIDEALAGYCDDIVVTIHTDNSISV 
R14_04290           1 MSDQQNTTPENGGYGADSIKMLKGLEAVRKRPGMYIGDTSDGTGLHHMVFEVVDNAIDEALAGYCDDIVVTIHTDNSISV 
R1_04574            1 MSDQQNTTPENGGYGADSIKMLKGLEAVRKRPGMYIGDTSDGTGLHHMVFEVVDNAIDEALAGYCDDIVVTIHTDNSISV 
R2_00592            1 MSDQQNTTPENGGYGADSIKMLKGLEAVRKRPGMYIGDTSDGTGLHHMVFEVVDNAIDEALAGYCDDIVVTIHTDNSISV 
R3_02923            1 MSDQQNTTPENGGYGADSIKMLKGLEAVRKRPGMYIGDTSDGTGLHHMVFEVVDNAIDEALAGYCDDIVVTIHTDNSISV 
R4_01893            1 MSDQQNTTPENGGYGADSIKMLKGLEAVRKRPGMYIGDTSDGTGLHHMVFEVVDNAIDEALAGYCDDIVVTIHTDNSISV 
R5_01403            1 MSDQQNTTPENGGYGADSIKMLKGLEAVRKRPGMYIGDTSDGTGLHHMVFEVVDNAIDEALAGYCDDIVVTIHTDNSISV 
R6_03122            1 MSDQQNTTPENGGYGADSIKMLKGLEAVRKRPGMYIGDTSDGTGLHHMVFEVVDNAIDEALAGYCDDIVVTIHTDNSISV 
R7_03015            1 MSDQQNTTPENGGYGADSIKMLKGLEAVRKRPGMYIGDTSDGTGLHHMVFEVVDNAIDEALAGYCDDIVVTIHTDNSISV 
R8_01986            1 MSDQQNTTPENGGYGADSIKMLKGLEAVRKRPGMYIGDTSDGTGLHHMVFEVVDNAIDEALAGYCDDIVVTIHTDNSISV 
R9_00581            1 MSDQQNTTPENGGYGADSIKMLKGLEAVRKRPGMYIGDTSDGTGLHHMVFEVVDNAIDEALAGYCDDIVVTIHTDNSISV 
NH44784_1996        1 MSDQQNTTPENGGYGADSIKMLKGLEAVRKRPGMYIGDTSDGTGLHHMVFEVVDNAIDEALAGYCDDIVVTIHTDNSISV 
NCIMB11015_01803    1 MSDQQNTTPENGGYGADSIKMLKGLEAVRKRPGMYIGDTSDGTGLHHMVFEVVDNAIDEALAGYCDDIVVTIHTDNSISV 
 
  81        160 
L5_03504           81 TDNGRGIPTDIHKDDEFHRSAAEIVMTELHAGGKFDQNSYKVSGGLHGVGVSCVNALSEWLRLTIRRNGEVHQMEFRQGE 
R11_03913          81 TDNGRGIPTDIHKDDEFHRSAAEIVMTELHAGGKFDQNSYKVSGGLHGVGVSCVNALSEWLRLTIRRNGEVHQMEFRQGE 
DSM2402_04205      81 TDNGRGIPTDIHKDDEFHRSAAEIVMTELHAGGKFDQNSYKVSGGLHGVGVSCVNALSEWLRLTIRRNGEVHQMEFRQGE 
L10_03108          81 TDNGRGIPTDIHKDDEFHRSAAEIVMTELHAGGKFDQNSYKVSGGLHGVGVSCVNALSEWLRLTIRRNGEVHQMEFRQGE 
L11_01822          81 TDNGRGIPTDIHKDDEFHRSAAEIVMTELHAGGKFDQNSYKVSGGLHGVGVSCVNALSEWLRLTIRRNGEVHQMEFRQGE 
L14_04214          81 TDNGRGIPTDIHKDDEFHRSAAEIVMTELHAGGKFDQNSYKVSGGLHGVGVSCVNALSEWLRLTIRRNGEVHQMEFRQGE 
L15_02710          81 TDNGRGIPTDIHKDDEFHRSAAEIVMTELHAGGKFDQNSYKVSGGLHGVGVSCVNALSEWLRLTIRRNGEVHQMEFRQGE 
L16_01630          81 TDNGRGIPTDIHKDDEFHRSAAEIVMTELHAGGKFDQNSYKVSGGLHGVGVSCVNALSEWLRLTIRRNGEVHQMEFRQGE 
L17_02230          81 TDNGRGIPTDIHKDDEFHRSAAEIVMTELHAGGKFDQNSYKVSGGLHGVGVSCVNALSEWLRLTIRRNGEVHQMEFRQGE 
L1_00569           81 TDNGRGIPTDIHKDDEFHRSAAEIVMTELHAGGKFDQNSYKVSGGLHGVGVSCVNALSEWLRLTIRRNGEVHQMEFRQGE 
L8_02109           81 TDNGRGIPTDIHKDDEFHRSAAEIVMTELHAGGKFDQNSYKVSGGLHGVGVSCVNALSEWLRLTIRRNGEVHQMEFRQGE 
R10_02546          81 TDNGRGIPTDIHKDDEFHRSAAEIVMTELHAGGKFDQNSYKVSGGLHGVGVSCVNALSEWLRLTIRRNGEVHQMEFRQGE 
R12_04117          81 TDNGRGIPTDIHKDDEFHRSAAEIVMTELHAGGKFDQNSYKVSGGLHGVGVSCVNALSEWLRLTIRRNGEVHQMEFRQGE 
R13_03776          81 TDNGRGIPTDIHKDDEFHRSAAEIVMTELHAGGKFDQNSYKVSGGLHGVGVSCVNALSEWLRLTIRRNGEVHQMEFRQGE 
R14_04290          81 TDNGRGIPTDIHKDDEFHRSAAEIVMTELHAGGKFDQNSYKVSGGLHGVGVSCVNALSEWLRLTIRRNGEVHQMEFRQGE 
R1_04574           81 TDNGRGIPTDIHKDDEFHRSAAEIVMTELHAGGKFDQNSYKVSGGLHGVGVSCVNALSEWLRLTIRRNGEVHQMEFRQGE 
R2_00592           81 TDNGRGIPTDIHKDDEFHRSAAEIVMTELHAGGKFDQNSYKVSGGLHGVGVSCVNALSEWLRLTIRRNGEVHQMEFRQGE 
R3_02923           81 TDNGRGIPTDIHKDDEFHRSAAEIVMTELHAGGKFDQNSYKVSGGLHGVGVSCVNALSEWLRLTIRRNGEVHQMEFRQGE 
R4_01893           81 TDNGRGIPTDIHKDDEFHRSAAEIVMTELHAGGKFDQNSYKVSGGLHGVGVSCVNALSEWLRLTIRRNGEVHQMEFRQGE 
R5_01403           81 TDNGRGIPTDIHKDDEFHRSAAEIVMTELHAGGKFDQNSYKVSGGLHGVGVSCVNALSEWLRLTIRRNGEVHQMEFRQGE 
R6_03122           81 TDNGRGIPTDIHKDDEFHRSAAEIVMTELHAGGKFDQNSYKVSGGLHGVGVSCVNALSEWLRLTIRRNGEVHQMEFRQGE 
R7_03015           81 TDNGRGIPTDIHKDDEFHRSAAEIVMTELHAGGKFDQNSYKVSGGLHGVGVSCVNALSEWLRLTIRRNGEVHQMEFRQGE 
R8_01986           81 TDNGRGIPTDIHKDDEFHRSAAEIVMTELHAGGKFDQNSYKVSGGLHGVGVSCVNALSEWLRLTIRRNGEVHQMEFRQGE 
R9_00581           81 TDNGRGIPTDIHKDDEFHRSAAEIVMTELHAGGKFDQNSYKVSGGLHGVGVSCVNALSEWLRLTIRRNGEVHQMEFRQGE 
NH44784_1996       81 TDNGRGIPTDIHKDDEFHRSAAEIVMTELHAGGKFDQNSYKVSGGLHGVGVSCVNALSEWLRLTIRRNGEVHQMEFRQGE 
NCIMB11015_01803   81 TDNGRGIPTDIHKDDEFHRSAAEIVMTELHAGGKFDQNSYKVSGGLHGVGVSCVNALSEWLRLTIRRNGEVHQMEFRQGE 
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  161        240 
L5_03504          161 RVAPLAVTGTTDKRGTEVRFLADPIIFTNVEYHYEILSKRLRELSFLNNGVKIRLIDQRQGKEENFAFSGGVKGFVEYIN 
R11_03913         161 RVAPLAVTGTTDKRGTEVRFLADPIIFTNVEYHYEILSKRLRELSFLNNGVKIRLIDQRQGKEENFAFSGGVKGFVEYIN 
DSM2402_04205     161 RVAPLAVTGTTDKRGTEVRFLADPIIFTNVEYHYEILSKRLRELSFLNNGVKIRLIDQRQGKEENFAFSGGVKGFVEYIN 
L10_03108         161 RVAPLAVTGTTDKRGTEVRFLADPIIFTNVEYHYEILSKRLRELSFLNNGVKIRLIDQRQGKEENFAFSGGVKGFVEYIN 
L11_01822         161 RVAPLAVTGTTDKRGTEVRFLADPIIFTNVEYHYEILSKRLRELSFLNNGVKIRLIDQRQGKEENFAFSGGVKGFVEYIN 
L14_04214         161 RVAPLAVTGTTDKRGTEVRFLADPIIFTNVEYHYEILSKRLRELSFLNNGVKIRLIDQRQGKEENFAFSGGVKGFVEYIN 
L15_02710         161 RVAPLAVTGTTDKRGTEVRFLADPIIFTNVEYHYEILSKRLRELSFLNNGVKIRLIDQRQGKEENFAFSGGVKGFVEYIN 
L16_01630         161 RVAPLAVTGTTDKRGTEVRFLADPIIFTNVEYHYEILSKRLRELSFLNNGVKIRLIDQRQGKEENFAFSGGVKGFVEYIN 
L17_02230         161 RVAPLAVTGTTDKRGTEVRFLADPIIFTNVEYHYEILSKRLRELSFLNNGVKIRLIDQRQGKEENFAFSGGVKGFVEYIN 
L1_00569          161 RVAPLAVTGTTDKRGTEVRFLADPIIFTNVEYHYEILSKRLRELSFLNNGVKIRLIDQRQGKEENFAFSGGVKGFVEYIN 
L8_02109          161 RVAPLAVTGTTDKRGTEVRFLADPIIFTNVEYHYEILSKRLRELSFLNNGVKIRLIDQRQGKEENFAFSGGVKGFVEYIN 
R10_02546         161 RVAPLAVTGTTDKRGTEVRFLADPIIFTNVEYHYEILSKRLRELSFLNNGVKIRLIDQRQGKEENFAFSGGVKGFVEYIN 
R12_04117         161 RVAPLAVTGTTDKRGTEVRFLADPIIFTNVEYHYEILSKRLRELSFLNNGVKIRLIDQRQGKEENFAFSGGVKGFVEYIN 
R13_03776         161 RVAPLAVTGTTDKRGTEVRFLADPIIFTNVEYHYEILSKRLRELSFLNNGVKIRLIDQRQGKEENFAFSGGVKGFVEYIN 
R14_04290         161 RVAPLAVTGTTDKRGTEVRFLADPIIFTNVEYHYEILSKRLRELSFLNNGVKIRLIDQRQGKEENFAFSGGVKGFVEYIN 
R1_04574          161 RVAPLAVTGTTDKRGTEVRFLADPIIFTNVEYHYEILSKRLRELSFLNNGVKIRLIDQRQGKEENFAFSGGVKGFVEYIN 
R2_00592          161 RVAPLAVTGTTDKRGTEVRFLADPIIFTNVEYHYEILSKRLRELSFLNNGVKIRLIDQRQGKEENFAFSGGVKGFVEYIN 
R3_02923          161 RVAPLAVTGTTDKRGTEVRFLADPIIFTNVEYHYEILSKRLRELSFLNNGVKIRLIDQRQGKEENFAFSGGVKGFVEYIN 
R4_01893          161 RVAPLAVTGTTDKRGTEVRFLADPIIFTNVEYHYEILSKRLRELSFLNNGVKIRLIDQRQGKEENFAFSGGVKGFVEYIN 
R5_01403          161 RVAPLAVTGTTDKRGTEVRFLADPIIFTNVEYHYEILSKRLRELSFLNNGVKIRLIDQRQGKEENFAFSGGVKGFVEYIN 
R6_03122          161 RVAPLAVTGTTDKRGTEVRFLADPIIFTNVEYHYEILSKRLRELSFLNNGVKIRLIDQRQGKEENFAFSGGVKGFVEYIN 
R7_03015          161 RVAPLAVTGTTDKRGTEVRFLADPIIFTNVEYHYEILSKRLRELSFLNNGVKIRLIDQRQGKEENFAFSGGVKGFVEYIN 
R8_01986          161 RVAPLAVTGTTDKRGTEVRFLADPIIFTNVEYHYEILSKRLRELSFLNNGVKIRLIDQRQGKEENFAFSGGVKGFVEYIN 
R9_00581          161 RVAPLAVTGTTDKRGTEVRFLADPIIFTNVEYHYEILSKRLRELSFLNNGVKIRLIDQRQGKEENFAFSGGVKGFVEYIN 
NH44784_1996      161 RVAPLAVTGTTDKRGTEVRFLADPIIFTNVEYHYEILSKRLRELSFLNNGVKIRLIDQRQGKEENFAFSGGVKGFVEYIN 
NCIMB11015_01803  161 RVAPLAVTGTTDKRGTEVRFLADPIIFTNVEYHYEILSKRLRELSFLNNGVKIRLIDQRQGKEENFAFSGGVKGFVEYIN 
 
  241        320 
L5_03504          241 RAKTVLHPNVFSVTTESTAGGVPVGVEVAMQWNDSYSESVLCFTNNIPQRDGGSHLTGLRAAMTRIINKYITDNELAKKA 
R11_03913         241 RAKTVLHPNVFSVTTESTAGGVPVGVEVAMQWNDSYSESVLCFTNNIPQRDGGSHLTGLRAAMTRIINKYITDNELAKKA 
DSM2402_04205     241 RAKTVLHPNVFSVTTESTAGGVPVGVEVAMQWNDSYSESVLCFTNNIPQRDGGSHLTGLRAAMTRIINKYITDNELAKKA 
L10_03108         241 RAKTVLHPNVFSVTTESTAGGVPVGVEVAMQWNDSYSESVLCFTNNIPQRDGGSHLTGLRAAMTRIINKYITDNELAKKA 
L11_01822         241 RAKTVLHPNVFSVTTESTAGGVPVGVEVAMQWNDSYSESVLCFTNNIPQRDGGSHLTGLRAAMTRIINKYITDNELAKKA 
L14_04214         241 RAKTVLHPNVFSVTTESTAGGVPVGVEVAMQWNDSYSESVLCFTNNIPQRDGGSHLTGLRAAMTRIINKYITDNELAKKA 
L15_02710         241 RAKTVLHPNVFSVTTESTAGGVPVGVEVAMQWNDSYSESVLCFTNNIPQRDGGSHLTGLRAAMTRIINKYITDNELAKKA 
L16_01630         241 RAKTVLHPNVFSVTTESTAGGVPVGVEVAMQWNDSYSESVLCFTNNIPQRDGGSHLTGLRAAMTRIINKYITDNELAKKA 
L17_02230         241 RAKTVLHPNVFSVTTESTAGGVPVGVEVAMQWNDSYSESVLCFTNNIPQRDGGSHLTGLRAAMTRIINKYITDNELAKKA 
L1_00569          241 RAKTVLHPNVFSVTTESTAGGVPVGVEVAMQWNDSYSESVLCFTNNIPQRDGGSHLTGLRAAMTRIINKYITDNELAKKA 
L8_02109          241 RAKTVLHPNVFSVTTESTAGGVPVGVEVAMQWNDSYSESVLCFTNNIPQRDGGSHLTGLRAAMTRIINKYITDNELAKKA 
R10_02546         241 RAKTVLHPNVFSVTTESTAGGVPVGVEVAMQWNDSYSESVLCFTNNIPQRDGGSHLTGLRAAMTRIINKYITDNELAKKA 
R12_04117         241 RAKTVLHPNVFSVTTESTAGGVPVGVEVAMQWNDSYSESVLCFTNNIPQRDGGSHLTGLRAAMTRIINKYITDNELAKKA 
R13_03776         241 RAKTVLHPNVFSVTTESTAGGVPVGVEVAMQWNDSYSESVLCFTNNIPQRDGGSHLTGLRAAMTRIINKYITDNELAKKA 
R14_04290         241 RAKTVLHPNVFSVTTESTAGGVPVGVEVAMQWNDSYSESVLCFTNNIPQRDGGSHLTGLRAAMTRIINKYITDNELAKKA 
R1_04574          241 RAKTVLHPNVFSVTTESTAGGVPVGVEVAMQWNDSYSESVLCFTNNIPQRDGGSHLTGLRAAMTRIINKYITDNELAKKA 
R2_00592          241 RAKTVLHPNVFSVTTESTAGGVPVGVEVAMQWNDSYSESVLCFTNNIPQRDGGSHLTGLRAAMTRIINKYITDNELAKKA 
R3_02923          241 RAKTVLHPNVFSVTTESTAGGVPVGVEVAMQWNDSYSESVLCFTNNIPQRDGGSHLTGLRAAMTRIINKYITDNELAKKA 
R4_01893          241 RAKTVLHPNVFSVTTESTAGGVPVGVEVAMQWNDSYSESVLCFTNNIPQRDGGSHLTGLRAAMTRIINKYITDNELAKKA 
R5_01403          241 RAKTVLHPNVFSVTTESTAGGVPVGVEVAMQWNDSYSESVLCFTNNIPQRDGGSHLTGLRAAMTRIINKYITDNELAKKA 
R6_03122          241 RAKTVLHPNVFSVTTESTAGGVPVGVEVAMQWNDSYSESVLCFTNNIPQRDGGSHLTGLRAAMTRIINKYITDNELAKKA 
R7_03015          241 RAKTVLHPNVFSVTTESTAGGVPVGVEVAMQWNDSYSESVLCFTNNIPQRDGGSHLTGLRAAMTRIINKYITDNELAKKA 
R8_01986          241 RAKTVLHPNVFSVTTESTAGGVPVGVEVAMQWNDSYSESVLCFTNNIPQRDGGSHLTGLRAAMTRIINKYITDNELAKKA 
R9_00581          241 RAKTVLHPNVFSVTTESTAGGVPVGVEVAMQWNDSYSESVLCFTNNIPQRDGGSHLTGLRAAMTRIINKYITDNELAKKA 
NH44784_1996      241 RAKTVLHPNVFSVTTESTAGGVPVGVEVAMQWNDSYSESVLCFTNNIPQRDGGSHLTGLRAAMTRIINKYITDNELAKKA 
NCIMB11015_01803  241 RAKTVLHPNVFSVTTESTAGGVPVGVEVAMQWNDSYSESVLCFTNNIPQRDGGSHLTGLRAAMTRIINKYITDNELAKKA 
 
  321        400 
L5_03504          321 KVETSGDDMREGLACVLSVKVPEPKFSSQTKDKLVSSEVRPAVEEAVARTLETWLLEHPNDAKALCGKIVEAARAREAAR 
R11_03913         321 KVETSGDDMREGLACVLSVKVPEPKFSSQTKDKLVSSEVRPAVEEAVARTLETWLLEHPNDAKALCGKIVEAARAREAAR 
DSM2402_04205     321 KVETSGDDMREGLACVLSVKVPEPKFSSQTKDKLVSSEVRPAVEEAVARTLETWLLEHPNDAKALCGKIVEAARAREAAR 
L10_03108         321 KVETSGDDMREGLACVLSVKVPEPKFSSQTKDKLVSSEVRPAVEEAVARTLETWLLEHPNDAKALCGKIVEAARAREAAR 
L11_01822         321 KVETSGDDMREGLACVLSVKVPEPKFSSQTKDKLVSSEVRPAVEEAVARTLETWLLEHPNDAKALCGKIVEAARAREAAR 
L14_04214         321 KVETSGDDMREGLACVLSVKVPEPKFSSQTKDKLVSSEVRPAVEEAVARTLETWLLEHPNDAKALCGKIVEAARAREAAR 
L15_02710         321 KVETSGDDMREGLACVLSVKVPEPKFSSQTKDKLVSSEVRPAVEEAVARTLETWLLEHPNDAKALCGKIVEAARAREAAR 
L16_01630         321 KVETSGDDMREGLACVLSVKVPEPKFSSQTKDKLVSSEVRPAVEEAVARTLETWLLEHPNDAKALCGKIVEAARAREAAR 
L17_02230         321 KVETSGDDMREGLACVLSVKVPEPKFSSQTKDKLVSSEVRPAVEEAVARTLETWLLEHPNDAKALCGKIVEAARAREAAR 
L1_00569          321 KVETSGDDMREGLACVLSVKVPEPKFSSQTKDKLVSSEVRPAVEEAVARTLETWLLEHPNDAKALCGKIVEAARAREAAR 
L8_02109          321 KVETSGDDMREGLACVLSVKVPEPKFSSQTKDKLVSSEVRPAVEEAVARTLETWLLEHPNDAKALCGKIVEAARAREAAR 
R10_02546         321 KVETSGDDMREGLACVLSVKVPEPKFSSQTKDKLVSSEVRPAVEEAVARTLETWLLEHPNDAKALCGKIVEAARAREAAR 
R12_04117         321 KVETSGDDMREGLACVLSVKVPEPKFSSQTKDKLVSSEVRPAVEEAVARTLETWLLEHPNDAKALCGKIVEAARAREAAR 
R13_03776         321 KVETSGDDMREGLACVLSVKVPEPKFSSQTKDKLVSSEVRPAVEEAVARTLETWLLEHPNDAKALCGKIVEAARAREAAR 
R14_04290         321 KVETSGDDMREGLACVLSVKVPEPKFSSQTKDKLVSSEVRPAVEEAVARTLETWLLEHPNDAKALCGKIVEAARAREAAR 
R1_04574          321 KVETSGDDMREGLACVLSVKVPEPKFSSQTKDKLVSSEVRPAVEEAVARTLETWLLEHPNDAKALCGKIVEAARAREAAR 
R2_00592          321 KVETSGDDMREGLACVLSVKVPEPKFSSQTKDKLVSSEVRPAVEEAVARTLETWLLEHPNDAKALCGKIVEAARAREAAR 
R3_02923          321 KVETSGDDMREGLACVLSVKVPEPKFSSQTKDKLVSSEVRPAVEEAVARTLETWLLEHPNDAKALCGKIVEAARAREAAR 
R4_01893          321 KVETSGDDMREGLACVLSVKVPEPKFSSQTKDKLVSSEVRPAVEEAVARTLETWLLEHPNDAKALCGKIVEAARAREAAR 
R5_01403          321 KVETSGDDMREGLACVLSVKVPEPKFSSQTKDKLVSSEVRPAVEEAVARTLETWLLEHPNDAKALCGKIVEAARAREAAR 
R6_03122          321 KVETSGDDMREGLACVLSVKVPEPKFSSQTKDKLVSSEVRPAVEEAVARTLETWLLEHPNDAKALCGKIVEAARAREAAR 
R7_03015          321 KVETSGDDMREGLACVLSVKVPEPKFSSQTKDKLVSSEVRPAVEEAVARTLETWLLEHPNDAKALCGKIVEAARAREAAR 
R8_01986          321 KVETSGDDMREGLACVLSVKVPEPKFSSQTKDKLVSSEVRPAVEEAVARTLETWLLEHPNDAKALCGKIVEAARAREAAR 
R9_00581          321 KVETSGDDMREGLACVLSVKVPEPKFSSQTKDKLVSSEVRPAVEEAVARTLETWLLEHPNDAKALCGKIVEAARAREAAR 
NH44784_1996      321 KVETSGDDMREGLACVLSVKVPEPKFSSQTKDKLVSSEVRPAVEEAVARTLETWLLEHPNDAKALCGKIVEAARAREAAR 
NCIMB11015_01803  321 KVETSGDDMREGLACVLSVKVPEPKFSSQTKDKLVSSEVRPAVEEAVARTLETWLLEHPNDAKALCGKIVEAARAREAAR 
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  401        480 
L5_03504          401 KAREMTRRKSVLEGAGLPGKLADCQEKDPALCELYIVEGDSAGGSAKQGRDRKFQAILPLRGKVLNVEKARFDRLIASEQ 
R11_03913         401 KAREMTRRKSVLEGAGLPGKLADCQEKDPALCELYIVEGDSAGGSAKQGRDRKFQAILPLRGKVLNVEKARFDRLIASEQ 
DSM2402_04205     401 KAREMTRRKSVLEGAGLPGKLADCQEKDPALCELYIVEGDSAGGSAKQGRDRKFQAILPLRGKVLNVEKARFDRLIASEQ 
L10_03108         401 KAREMTRRKSVLEGAGLPGKLADCQEKDPALCELYIVEGDSAGGSAKQGRDRKFQAILPLRGKVLNVEKARFDRLIASEQ 
L11_01822         401 KAREMTRRKSVLEGAGLPGKLADCQEKDPALCELYIVEGDSAGGSAKQGRDRKFQAILPLRGKVLNVEKARFDRLIASEQ 
L14_04214         401 KAREMTRRKSVLEGAGLPGKLADCQEKDPALCELYIVEGDSAGGSAKQGRDRKFQAILPLRGKVLNVEKARFDRLIASEQ 
L15_02710         401 KAREMTRRKSVLEGAGLPGKLADCQEKDPALCELYIVEGDSAGGSAKQGRDRKFQAILPLRGKVLNVEKARFDRLIASEQ 
L16_01630         401 KAREMTRRKSVLEGAGLPGKLADCQEKDPALCELYIVEGDSAGGSAKQGRDRKFQAILPLRGKVLNVEKARFDRLIASEQ 
L17_02230         401 KAREMTRRKSVLEGAGLPGKLADCQEKDPALCELYIVEGDSAGGSAKQGRDRKFQAILPLRGKVLNVEKARFDRLIASEQ 
L1_00569          401 KAREMTRRKSVLEGAGLPGKLADCQEKDPALCELYIVEGDSAGGSAKQGRDRKFQAILPLRGKVLNVEKARFDRLIASEQ 
L8_02109          401 KAREMTRRKSVLEGAGLPGKLADCQEKDPALCELYIVEGDSAGGSAKQGRDRKFQAILPLRGKVLNVEKARFDRLIASEQ 
R10_02546         401 KAREMTRRKSVLEGAGLPGKLADCQEKDPALCELYIVEGDSAGGSAKQGRDRKFQAILPLRGKVLNVEKARFDRLIASEQ 
R12_04117         401 KAREMTRRKSVLEGAGLPGKLADCQEKDPALCELYIVEGDSAGGSAKQGRDRKFQAILPLRGKVLNVEKARFDRLIASEQ 
R13_03776         401 KAREMTRRKSVLEGAGLPGKLADCQEKDPALCELYIVEGDSAGGSAKQGRDRKFQAILPLRGKVLNVEKARFDRLIASEQ 
R14_04290         401 KAREMTRRKSVLEGAGLPGKLADCQEKDPALCELYIVEGDSAGGSAKQGRDRKFQAILPLRGKVLNVEKARFDRLIASEQ 
R1_04574          401 KAREMTRRKSVLEGAGLPGKLADCQEKDPALCELYIVEGDSAGGSAKQGRDRKFQAILPLRGKVLNVEKARFDRLIASEQ 
R2_00592          401 KAREMTRRKSVLEGAGLPGKLADCQEKDPALCELYIVEGDSAGGSAKQGRDRKFQAILPLRGKVLNVEKARFDRLIASEQ 
R3_02923          401 KAREMTRRKSVLEGAGLPGKLADCQEKDPALCELYIVEGDSAGGSAKQGRDRKFQAILPLRGKVLNVEKARFDRLIASEQ 
R4_01893          401 KAREMTRRKSVLEGAGLPGKLADCQEKDPALCELYIVEGDSAGGSAKQGRDRKFQAILPLRGKVLNVEKARFDRLIASEQ 
R5_01403          401 KAREMTRRKSVLEGAGLPGKLADCQEKDPALCELYIVEGDSAGGSAKQGRDRKFQAILPLRGKVLNVEKARFDRLIASEQ 
R6_03122          401 KAREMTRRKSVLEGAGLPGKLADCQEKDPALCELYIVEGDSAGGSAKQGRDRKFQAILPLRGKVLNVEKARFDRLIASEQ 
R7_03015          401 KAREMTRRKSVLEGAGLPGKLADCQEKDPALCELYIVEGDSAGGSAKQGRDRKFQAILPLRGKVLNVEKARFDRLIASEQ 
R8_01986          401 KAREMTRRKSVLEGAGLPGKLADCQEKDPALCELYIVEGDSAGGSAKQGRDRKFQAILPLRGKVLNVEKARFDRLIASEQ 
R9_00581          401 KAREMTRRKSVLEGAGLPGKLADCQEKDPALCELYIVEGDSAGGSAKQGRDRKFQAILPLRGKVLNVEKARFDRLIASEQ 
NH44784_1996      401 KAREMTRRKSVLEGAGLPGKLADCQEKDPALCELYIVEGDSAGGSAKQGRDRKFQAILPLRGKVLNVEKARFDRLIASEQ 
NCIMB11015_01803  401 KAREMTRRKSVLEGAGLPGKLADCQEKDPALCELYIVEGDSAGGSAKQGRDRKFQAILPLRGKVLNVEKARFDRLIASEQ 
 
  481        560 
L5_03504          481 IATLITALGTSIGPDFNVDKLRYHRLIIMTDADVDGAHIRTLLLTLLYRQMPELVQRGYVYIAQPPLYKVKVGREERYLK 
R11_03913         481 IATLITALGTSIGPDFNVDKLRYHRLIIMTDADVDGAHIRTLLLTLLYRQMPELVQRGYVYIAQPPLYKVKVGREERYLK 
DSM2402_04205     481 IATLITALGTSIGPDFNVDKLRYHRLIIMTDADVDGAHIRTLLLTLLYRQMPELVQRGYVYIAQPPLYKVKVGREERYLK 
L10_03108         481 IATLITALGTSIGPDFNVDKLRYHRLIIMTDADVDGAHIRTLLLTLLYRQMPELVQRGYVYIAQPPLYKVKVGREERYLK 
L11_01822         481 IATLITALGTSIGPDFNVDKLRYHRLIIMTDADVDGAHIRTLLLTLLYRQMPELVQRGYVYIAQPPLYKVKVGREERYLK 
L14_04214         481 IATLITALGTSIGPDFNVDKLRYHRLIIMTDADVDGAHIRTLLLTLLYRQMPELVQRGYVYIAQPPLYKVKVGREERYLK 
L15_02710         481 IATLITALGTSIGPDFNVDKLRYHRLIIMTDADVDGAHIRTLLLTLLYRQMPELVQRGYVYIAQPPLYKVKVGREERYLK 
L16_01630         481 IATLITALGTSIGPDFNVDKLRYHRLIIMTDADVDGAHIRTLLLTLLYRQMPELVQRGYVYIAQPPLYKVKVGREERYLK 
L17_02230         481 IATLITALGTSIGPDFNVDKLRYHRLIIMTDADVDGAHIRTLLLTLLYRQMPELVQRGYVYIAQPPLYKVKVGREERYLK 
L1_00569          481 IATLITALGTSIGPDFNVDKLRYHRLIIMTDADVDGAHIRTLLLTLLYRQMPELVQRGYVYIAQPPLYKVKVGREERYLK 
L8_02109          481 IATLITALGTSIGPDFNVDKLRYHRLIIMTDADVDGAHIRTLLLTLLYRQMPELVQRGYVYIAQPPLYKVKVGREERYLK 
R10_02546         481 IATLITALGTSIGPDFNVDKLRYHRLIIMTDADVDGAHIRTLLLTLLYRQMPELVQRGYVYIAQPPLYKVKVGREERYLK 
R12_04117         481 IATLITALGTSIGPDFNVDKLRYHRLIIMTDADVDGAHIRTLLLTLLYRQMPELVQRGYVYIAQPPLYKVKVGREERYLK 
R13_03776         481 IATLITALGTSIGPDFNVDKLRYHRLIIMTDADVDGAHIRTLLLTLLYRQMPELVQRGYVYIAQPPLYKVKVGREERYLK 
R14_04290         481 IATLITALGTSIGPDFNVDKLRYHRLIIMTDADVDGAHIRTLLLTLLYRQMPELVQRGYVYIAQPPLYKVKVGREERYLK 
R1_04574          481 IATLITALGTSIGPDFNVDKLRYHRLIIMTDADVDGAHIRTLLLTLLYRQMPELVQRGYVYIAQPPLYKVKVGREERYLK 
R2_00592          481 IATLITALGTSIGPDFNVDKLRYHRLIIMTDADVDGAHIRTLLLTLLYRQMPELVQRGYVYIAQPPLYKVKVGREERYLK 
R3_02923          481 IATLITALGTSIGPDFNVDKLRYHRLIIMTDADVDGAHIRTLLLTLLYRQMPELVQRGYVYIAQPPLYKVKVGREERYLK 
R4_01893          481 IATLITALGTSIGPDFNVDKLRYHRLIIMTDADVDGAHIRTLLLTLLYRQMPELVQRGYVYIAQPPLYKVKVGREERYLK 
R5_01403          481 IATLITALGTSIGPDFNVDKLRYHRLIIMTDADVDGAHIRTLLLTLLYRQMPELVQRGYVYIAQPPLYKVKVGREERYLK 
R6_03122          481 IATLITALGTSIGPDFNVDKLRYHRLIIMTDADVDGAHIRTLLLTLLYRQMPELVQRGYVYIAQPPLYKVKVGREERYLK 
R7_03015          481 IATLITALGTSIGPDFNVDKLRYHRLIIMTDADVDGAHIRTLLLTLLYRQMPELVQRGYVYIAQPPLYKVKVGREERYLK 
R8_01986          481 IATLITALGTSIGPDFNVDKLRYHRLIIMTDADVDGAHIRTLLLTLLYRQMPELVQRGYVYIAQPPLYKVKVGREERYLK 
R9_00581          481 IATLITALGTSIGPDFNVDKLRYHRLIIMTDADVDGAHIRTLLLTLLYRQMPELVQRGYVYIAQPPLYKVKVGREERYLK 
NH44784_1996      481 IATLITALGTSIGPDFNVDKLRYHRLIIMTDADVDGAHIRTLLLTLLYRQMPELVQRGYVYIAQPPLYKVKVGREERYLK 
NCIMB11015_01803  481 IATLITALGTSIGPDFNVDKLRYHRLIIMTDADVDGAHIRTLLLTLLYRQMPELVQRGYVYIAQPPLYKVKVGREERYLK 
 
  561        640 
L5_03504          561 DDQEEAQFMLQLALKDAEIISGGNIIRGDELGELARQYVAADGVIARLSRVFDVAALSAMAEGVEINLDTAEAAADSAKR 
R11_03913         561 DDQEEAQFMLQLALKDAEIISGGNIIRGDELGELARQYVAADGVIARLSRVFDVAALSAMAEGVEINLDTAEAAADSAKR 
DSM2402_04205     561 DDQEEAQFMLQLALKDAEIIAGGNIIRGDELNELARQYVAADGVIARLSRVFDVAALSAMAEGVEINLDTAEAAADSAKR 
L10_03108         561 DDQEEAQFMLQLALKDAEIIAGGNIIRGDELNELARQYVAADGVIARLSRVFDVAALSAMAEGVEINLDTAEAAADSAKR 
L11_01822         561 DDQEEAQFMLQLALKDAEIIAGGNIIRGDELNELARQYVAADGVIARLSRVFDVAALSAMAEGVEINLDTAEAAADSAKR 
L14_04214         561 DDQEEAQFMLQLALKDAEIIAGGNIIRGDELNELARQYVAADGVIARLSRVFDVAALSAMAEGVEINLDTAEAAADSAKR 
L15_02710         561 DDQEEAQFMLQLALKDAEIIAGGNIIRGDELNELARQYVAADGVIARLSRVFDVAALSAMAEGVEINLDTAEAAADSAKR 
L16_01630         561 DDQEEAQFMLQLALKDAEIIAGGNIIRGDELNELARQYVAADGVIARLSRVFDVAALSAMAEGVEINLDTAEAAADSAKR 
L17_02230         561 DDQEEAQFMLQLALKDAEIIAGGNIIRGDELNELARQYVAADGVIARLSRVFDVAALSAMAEGVEINLDTAEAAADSAKR 
L1_00569          561 DDQEEAQFMLQLALKDAEIIAGGNIIRGDELNELARQYVAADGVIARLSRVFDVAALSAMAEGVEINLDTAEAAADSAKR 
L8_02109          561 DDQEEAQFMLQLALKDAEIIAGGNIIRGDELNELARQYVAADGVIARLSRVFDVAALSAMAEGVEINLDTAEAAADSAKR 
R10_02546         561 DDQEEAQFMLQLALKDAEIIAGGNIIRGDELNELARQYVAADGVIARLSRVFDVAALSAMAEGVEINLDTAEAAADSAKR 
R12_04117         561 DDQEEAQFMLQLALKDAEIIAGGNIIRGDELNELARQYVAADGVIARLSRVFDVAALSAMAEGVEINLDTAEAAADSAKR 
R13_03776         561 DDQEEAQFMLQLALKDAEIIAGGNIIRGDELNELARQYVAADGVIARLSRVFDVAALSAMAEGVEINLDTAEAAADSAKR 
R14_04290         561 DDQEEAQFMLQLALKDAEIIAGGNIIRGDELNELARQYVAADGVIARLSRVFDVAALSAMAEGVEINLDTAEAAADSAKR 
R1_04574          561 DDQEEAQFMLQLALKDAEIIAGGNIIRGDELNELARQYVAADGVIARLSRVFDVAALSAMAEGVEINLDTAEAAADSAKR 
R2_00592          561 DDQEEAQFMLQLALKDAEIIAGGNIIRGDELNELARQYVAADGVIARLSRVFDVAALSAMAEGVEINLDTAEAAADSAKR 
R3_02923          561 DDQEEAQFMLQLALKDAEIIAGGNIIRGDELNELARQYVAADGVIARLSRVFDVAALSAMAEGVEINLDTAEAAADSAKR 
R4_01893          561 DDQEEAQFMLQLALKDAEIIAGGNIIRGDELNELARQYVAADGVIARLSRVFDVAALSAMAEGVEINLDTAEAAADSAKR 
R5_01403          561 DDQEEAQFMLQLALKDAEIIAGGNIIRGDELNELARQYVAADGVIARLSRVFDVAALSAMAEGVEINLDTAEAAADSAKR 
R6_03122          561 DDQEEAQFMLQLALKDAEIIAGGNIIRGDELNELARQYVAADGVIARLSRVFDVAALSAMAEGVEINLDTAEAAADSAKR 
R7_03015          561 DDQEEAQFMLQLALKDAEIIAGGNIIRGDELNELARQYVAADGVIARLSRVFDVAALSAMAEGVEINLDTAEAAADSAKR 
R8_01986          561 DDQEEAQFMLQLALKDAEIIAGGNIIRGDELNELARQYVAADGVIARLSRVFDVAALSAMAEGVEINLDTAEAAADSAKR 
R9_00581          561 DDQEEAQFMLQLALKDAEIIAGGNIIRGDELNELARQYVAADGVIARLSRVFDVAALSAMAEGVEINLDTAEAAADSAKR 
NH44784_1996      561 DDQEEAQFMLQLALKDAEIIAGGNIIRGDELNELARQYVAADGVIARLSRVFDVAALSAMAEGVEINLDTAEAAADSAKR 
NCIMB11015_01803  561 DDQEEAQFMLQLALKDAEIIAGGNIIRGDELNELARQYVAADGVIARLSRVFDVAALSAMAEGVEINLDTAEAAADSAKR 
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  641        720 
L5_03504          641 LADAMRDPISGNGVEVVPEFDAATERHRLSIQRMHHGNVRVSIIDADFIGGSDYAILSKAAKSFSGKVGPQSLVARGEGD 
R11_03913         641 LADAMRDPISGNGVEVVPEFDAATERHRLSIQRMHHGNVRVSIIDADFIGGSDYAILSKAAKSFSGKVGPQSLVARGEGD 
DSM2402_04205     641 LADAMRDPISGNGVEVVPEFDAATERHRLSIQRMHHGNVRVSIIDADFIGGSDYAILSKAAKSFSGKVGPQSLVARGEGD 
L10_03108         641 LADAMRDPISGNGVEVVPEFDAATERHRLSIQRMHHGNVRVSIIDADFIGGSDYAILSKAAKSFSGKVGPQSLVARGEGD 
L11_01822         641 LADAMRDPISGNGVEVVPEFDAATERHRLSIQRMHHGNVRVSIIDADFIGGSDYAILSKAAKSFSGKVGPQSLVARGEGD 
L14_04214         641 LADAMRDPISGNGVEVVPEFDAATERHRLSIQRMHHGNVRVSIIDADFIGGSDYAILSKAAKSFSGKVGPQSLVARGEGD 
L15_02710         641 LADAMRDPISGNGVEVVPEFDAATERHRLSIQRMHHGNVRVSIIDADFIGGSDYAILSKAAKSFSGKVGPQSLVARGEGD 
L16_01630         641 LADAMRDPISGNGVEVVPEFDAATERHRLSIQRMHHGNVRVSIIDADFIGGSDYAILSKAAKSFSGKVGPQSLVARGEGD 
L17_02230         641 LADAMRDPISGNGVEVVPEFDAATERHRLSIQRMHHGNVRVSIIDADFIGGSDYAILSKAAKSFSGKVGPQSLVARGEGD 
L1_00569          641 LADAMRDPISGNGVEVVPEFDAATERHRLSIQRMHHGNVRVSIIDADFIGGSDYAILSKAAKSFSGKVGPQSLVARGEGD 
L8_02109          641 LADAMRDPISGNGVEVVPEFDAATERHRLSIQRMHHGNVRVSIIDADFIGGSDYAILSKAAKSFSGKVGPQSLVARGEGD 
R10_02546         641 LADAMRDPISGNGVEVVPEFDAATERHRLSIQRMHHGNVRVSIIDADFIGGSDYAILSKAAKSFSGKVGPQSLVARGEGD 
R12_04117         641 LADAMRDPISGNGVEVVPEFDAATERHRLSIQRMHHGNVRVSIIDADFIGGSDYAILSKAAKSFSGKVGPQSLVARGEGD 
R13_03776         641 LADAMRDPISGNGVEVVPEFDAATERHRLSIQRMHHGNVRVSIIDADFIGGSDYAILSKAAKSFSGKVGPQSLVARGEGD 
R14_04290         641 LADAMRDPISGNGVEVVPEFDAATERHRLSIQRMHHGNVRVSIIDADFIGGSDYAILSKAAKSFSGKVGPQSLVARGEGD 
R1_04574          641 LADAMRDPISGNGVEVVPEFDAATERHRLSIQRMHHGNVRVSIIDADFIGGSDYAILSKAAKSFSGKVGPQSLVARGEGD 
R2_00592          641 LADAMRDPISGNGVEVVPEFDAATERHRLSIQRMHHGNVRVSIIDADFIGGSDYAILSKAAKSFSGKVGPQSLVARGEGD 
R3_02923          641 LADAMRDPISGNGVEVVPEFDAATERHRLSIQRMHHGNVRVSIIDADFIGGSDYAILSKAAKSFSGKVGPQSLVARGEGD 
R4_01893          641 LADAMRDPISGNGVEVVPEFDAATERHRLSIQRMHHGNVRVSIIDADFIGGSDYAILSKAAKSFSGKVGPQSLVARGEGD 
R5_01403          641 LADAMRDPISGNGVEVVPEFDAATERHRLSIQRMHHGNVRVSIIDADFIGGSDYAILSKAAKSFSGKVGPQSLVARGEGD 
R6_03122          641 LADAMRDPISGNGVEVVPEFDAATERHRLSIQRMHHGNVRVSIIDADFIGGSDYAILSKAAKSFSGKVGPQSLVARGEGD 
R7_03015          641 LADAMRDPISGNGVEVVPEFDAATERHRLSIQRMHHGNVRVSIIDADFIGGSDYAILSKAAKSFSGKVGPQSLVARGEGD 
R8_01986          641 LADAMRDPISGNGVEVVPEFDAATERHRLSIQRMHHGNVRVSIIDADFIGGSDYAILSKAAKSFSGKVGPQSLVARGEGD 
R9_00581          641 LADAMRDPISGNGVEVVPEFDAATERHRLSIQRMHHGNVRVSIIDADFIGGSDYAILSKAAKSFSGKVGPQSLVARGEGD 
NH44784_1996      641 LADAMRDPISGNGVEVVPEFDAATERHRLSIQRMHHGNVRVSIIDADFIGGSDYAILSKAAKSFSGKVGPQSLVARGEGD 
NCIMB11015_01803  641 LADAMRDPISGNGVEVVPEFDAATERHRLSIQRMHHGNVRVSIIDADFIGGSDYAILSKAAKSFSGKVGPQSLVARGEGD 
 
  721        800 
L5_03504          721 KRKEQTVSDFREAMQWLRSEADRGISKQRYKGLGEMNPDQLWETTMDPKVRRLLRVQIEDAIAADEVFTTLMGDDVEPRR 
R11_03913         721 KRKEQTVSDFREAMQWLRSEADRGISKQRYKGLGEMNPDQLWETTMDPKVRRLLRVQIEDAIAADEVFTTLMGDDVEPRR 
DSM2402_04205     721 KRKEQTVSDFREAMQWLRSEADRGISKQRYKGLGEMNPDQLWETTMDPKVRRLLRVQIEDAIAADEVFTTLMGDDVEPRR 
L10_03108         721 KRKEQTVSDFREAMQWLRSEADRGISKQRYKGLGEMNPDQLWETTMDPKVRRLLRVQIEDAIAADEVFTTLMGDDVEPRR 
L11_01822         721 KRKEQTVSDFREAMQWLRSEADRGISKQRYKGLGEMNPDQLWETTMDPKVRRLLRVQIEDAIAADEVFTTLMGDDVEPRR 
L14_04214         721 KRKEQTVSDFREAMQWLRSEADRGISKQRYKGLGEMNPDQLWETTMDPKVRRLLRVQIEDAIAADEVFTTLMGDDVEPRR 
L15_02710         721 KRKEQTVSDFREAMQWLRSEADRGISKQRYKGLGEMNPDQLWETTMDPKVRRLLRVQIEDAIAADEVFTTLMGDDVEPRR 
L16_01630         721 KRKEQTVSDFREAMQWLRSEADRGISKQRYKGLGEMNPDQLWETTMDPKVRRLLRVQIEDAIAADEVFTTLMGDDVEPRR 
L17_02230         721 KRKEQTVSDFREAMQWLRSEADRGISKQRYKGLGEMNPDQLWETTMDPKVRRLLRVQIEDAIAADEVFTTLMGDDVEPRR 
L1_00569          721 KRKEQTVSDFREAMQWLRSEADRGISKQRYKGLGEMNPDQLWETTMDPKVRRLLRVQIEDAIAADEVFTTLMGDDVEPRR 
L8_02109          721 KRKEQTVSDFREAMQWLRSEADRGISKQRYKGLGEMNPDQLWETTMDPKVRRLLRVQIEDAIAADEVFTTLMGDDVEPRR 
R10_02546         721 KRKEQTVSDFREAMQWLRSEADRGISKQRYKGLGEMNPDQLWETTMDPKVRRLLRVQIEDAIAADEVFTTLMGDDVEPRR 
R12_04117         721 KRKEQTVSDFREAMQWLRSEADRGISKQRYKGLGEMNPDQLWETTMDPKVRRLLRVQIEDAIAADEVFTTLMGDDVEPRR 
R13_03776         721 KRKEQTVSDFREAMQWLRSEADRGISKQRYKGLGEMNPDQLWETTMDPKVRRLLRVQIEDAIAADEVFTTLMGDDVEPRR 
R14_04290         721 KRKEQTVSDFREAMQWLRSEADRGISKQRYKGLGEMNPDQLWETTMDPKVRRLLRVQIEDAIAADEVFTTLMGDDVEPRR 
R1_04574          721 KRKEQTVSDFREAMQWLRSEADRGISKQRYKGLGEMNPDQLWETTMDPKVRRLLRVQIEDAIAADEVFTTLMGDDVEPRR 
R2_00592          721 KRKEQTVSDFREAMQWLRSEADRGISKQRYKGLGEMNPDQLWETTMDPKVRRLLRVQIEDAIAADEVFTTLMGDDVEPRR 
R3_02923          721 KRKEQTVSDFREAMQWLRSEADRGISKQRYKGLGEMNPDQLWETTMDPKVRRLLRVQIEDAIAADEVFTTLMGDDVEPRR 
R4_01893          721 KRKEQTVSDFREAMQWLRSEADRGISKQRYKGLGEMNPDQLWETTMDPKVRRLLRVQIEDAIAADEVFTTLMGDDVEPRR 
R5_01403          721 KRKEQTVSDFREAMQWLRSEADRGISKQRYKGLGEMNPDQLWETTMDPKVRRLLRVQIEDAIAADEVFTTLMGDDVEPRR 
R6_03122          721 KRKEQTVSDFREAMQWLRSEADRGISKQRYKGLGEMNPDQLWETTMDPKVRRLLRVQIEDAIAADEVFTTLMGDDVEPRR 
R7_03015          721 KRKEQTVSDFREAMQWLRSEADRGISKQRYKGLGEMNPDQLWETTMDPKVRRLLRVQIEDAIAADEVFTTLMGDDVEPRR 
R8_01986          721 KRKEQTVSDFREAMQWLRSEADRGISKQRYKGLGEMNPDQLWETTMDPKVRRLLRVQIEDAIAADEVFTTLMGDDVEPRR 
R9_00581          721 KRKEQTVSDFREAMQWLRSEADRGISKQRYKGLGEMNPDQLWETTMDPKVRRLLRVQIEDAIAADEVFTTLMGDDVEPRR 
NH44784_1996      721 KRKEQTVSDFREAMQWLRSEADRGISKQRYKGLGEMNPDQLWETTMDPKVRRLLRVQIEDAIAADEVFTTLMGDDVEPRR 
NCIMB11015_01803  721 KRREQTVSDFREAMQWLRSEADRGISKQRYKGLGEMNPDQLWETTMDPKVRRLLRVQIEDAIAADEVFTTLMGDDVEPRR 
 
  801     815 
L5_03504          801 NFIEAHALSAGNIDV 
R11_03913         801 NFIEAHALSAGNIDV 
DSM2402_04205     801 NFIEAHALSAGNIDV 
L10_03108         801 NFIEAHALSAGNIDV 
L11_01822         801 NFIEAHALSAGNIDV 
L14_04214         801 NFIEAHALSAGNIDV 
L15_02710         801 NFIEAHALSAGNIDV 
L16_01630         801 NFIEAHALSAGNIDV 
L17_02230         801 NFIEAHALSAGNIDV 
L1_00569          801 NFIEAHALSAGNIDV 
L8_02109          801 NFIEAHALSAGNIDV 
R10_02546         801 NFIEAHALSAGNIDV 
R12_04117         801 NFIEAHALSAGNIDV 
R13_03776         801 NFIEAHALSAGNIDV 
R14_04290         801 NFIEAHALSAGNIDV 
R1_04574          801 NFIEAHALSAGNIDV 
R2_00592          801 NFIEAHALSAGNIDV 
R3_02923          801 NFIEAHALSAGNIDV 
R4_01893          801 NFIEAHALSAGNIDV 
R5_01403          801 NFIEAHALSAGNIDV 
R6_03122          801 NFIEAHALSAGNIDV 
R7_03015          801 NFIEAHALSAGNIDV 
R8_01986          801 NFIEAHALSAGNIDV 
R9_00581          801 NFIEAHALSAGNIDV 
NH44784_1996      801 NFIEAHALSAGNIDV 
NCIMB11015_01803  801 NFIEAHALSAGNIDV 
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C) Topoisomerase IV subunit A 
  1        80 
R4_03393            1 MTDSNQQGLFDAAPDEGGDAAITLARYAEQAYLDYAVSVVRGRALPDVGDGQKPVQRRILFAMQAMGLAAGAKPVKSARV 
NCIMB11015_03245    1 MTDSNQQGLFDAAPDEGGDAAITLARYAEQAYLDYAVSVVRGRALPDVGDGQKPVQRRILFAMQAMGLAAGAKPVKSARV 
L17_01347           1 MTDSNQQGLFDAAPDEGGDAAITLARYAEQAYLDYAVSVVRGRALPDVGDGQKPVQRRILFAMQAMGLAAGAKPVKSARV 
L8_00647            1 MTDSNQQGLFDAAPDEGGDAAITLARYAEQAYLDYAVSVVRGRALPDVGDGQKPVQRRILFAMQAMGLAAGAKPVKSARV 
R13_01575           1 MTDSNQQGLFDAAPDEGGDAAITLARYAEQAYLDYAVSVVRGRALPDVGDGQKPVQRRILFAMQAMGLAAGAKPVKSARV 
R6_01020            1 MTDSNQQGLFDAAPDEGGDAAITLARYAEQAYLDYAVSVVRGRALPDVGDGQKPVQRRILFAMQAMGLAAGAKPVKSARV 
R7_03580            1 MTDSNQQGLFDAAPDEGGDAAITLARYAEQAYLDYAVSVVRGRALPDVGDGQKPVQRRILFAMQAMGLAAGAKPVKSARV 
L5_04553            1 MTDSNQQGLFDAAPDEGGDAAITLARYAEQAYLDYAVSVVRGRALPDVGDGQKPVQRRILFAMQAMGLAAGAKPVKSARV 
R11_00072           1 MTDSNQQGLFDAAPDEGGDAAITLARYAEQAYLDYAVSVVRGRALPDVGDGQKPVQRRILFAMQAMGLAAGAKPVKSARV 
DSM2402_00569       1 MTDSNQQGLFDAAPDEGGDAAITLARYAEQAYLDYAVSVVRGRALPDVGDGQKPVQRRILFAMQAMGLAAGAKPVKSARV 
L14_05853           1 MTDSNQQGLFDAAPDEGGDAAITLARYAEQAYLDYAVSVVRGRALPDVGDGQKPVQRRILFAMQAMGLAAGAKPVKSARV 
L16_01230           1 MTDSNQQGLFDAAPDEGGDAAITLARYAEQAYLDYAVSVVRGRALPDVGDGQKPVQRRILFAMQAMGLAAGAKPVKSARV 
L1_02272            1 MTDSNQQGLFDAAPDGGGDAAITLARYAEQAYLDYAVSVVRGRALPDVGDGQKPVQRRILFAMQAMGLAAGAKPVKSARV 
NH44784_1996        1 MTDSNQQGLFDAAPDGGGDAAITLARYAEQAYLDYAVSVVRGRALPDVGDGQKPVQRRILFAMQAMGLAAGAKPVKSARV 
L10_00751           1 MTDSNQQGLFDAAPDEGGDAAITLARYAEQAYLDYAVSVVRGRALPDVGDGQKPVQRRILFAMQAMGLAAGAKPVKSARV 
L11_02235           1 MTDSNQQGLFDAAPDEGGDAAITLARYAEQAYLDYAVSVVRGRALPDVGDGQKPVQRRILFAMQAMGLAAGAKPVKSARV 
L15_00736           1 MTDSNQQGLFDAAPDEGGDAAITLARYAEQAYLDYAVSVVRGRALPDVGDGQKPVQRRILFAMQAMGLAAGAKPVKSARV 
R12_00729           1 MTDSNQQGLFDAAPDEGGDAAITLARYAEQAYLDYAVSVVRGRALPDVGDGQKPVQRRILFAMQAMGLAAGAKPVKSARV 
R14_05528           1 MTDSNQQGLFDAAPDEGGDAAITLARYAEQAYLDYAVSVVRGRALPDVGDGQKPVQRRILFAMQAMGLAAGAKPVKSARV 
R1_00146            1 MTDSNQQGLFDAAPDEGGDAAITLARYAEQAYLDYAVSVVRGRALPDVGDGQKPVQRRILFAMQAMGLAAGAKPVKSARV 
R2_00458            1 MTDSNQQGLFDAAPDEGGDAAITLARYAEQAYLDYAVSVVRGRALPDVGDGQKPVQRRILFAMQAMGLAAGAKPVKSARV 
R3_01677            1 MTDSNQQGLFDAAPDEGGDAAITLARYAEQAYLDYAVSVVRGRALPDVGDGQKPVQRRILFAMQAMGLAAGAKPVKSARV 
R5_02499            1 MTDSNQQGLFDAAPDEGGDAAITLARYAEQAYLDYAVSVVRGRALPDVGDGQKPVQRRILFAMQAMGLAAGAKPVKSARV 
R8_03474            1 MTDSNQQGLFDAAPDEGGDAAITLARYAEQAYLDYAVSVVRGRALPDVGDGQKPVQRRILFAMQAMGLAAGAKPVKSARV 
 
  81        160 
R4_03393           81 VGDVLGKYHPHGDQAAYDAMVRMAQDFSLRYPLIDGQGNFGSRDGDNAAAMRYTEARLTPIAKLLLDELDEGTVDFVPNY 
NCIMB11015_03245   81 VGDVLGKYHPHGDQAAYDAMVRMAQDFSLRYPLIDGQGNFGSRDGDNAAAMRYTEARLTPIAKLLLDELDEGTVDFVPNY 
L17_01347          81 VGDVLGKYHPHGDQAAYDAMVRMAQDFSLRYPLIDGQGNFGSRDGDNAAAMRYTEARLTPIAKLLLDELDEGTVDFVPNY 
L8_00647           81 VGDVLGKYHPHGDQAAYDAMVRMAQDFSLRYPLIDGQGNFGSRDGDNAAAMRYTEARLTPIAKLLLDELDEGTVDFVPNY 
R13_01575          81 VGDVLGKYHPHGDQAAYDAMVRMAQDFSLRYPLIDGQGNFGSRDGDNAAAMRYTEARLTPIAKLLLDELDEGTVDFVPNY 
R6_01020           81 VGDVLGKYHPHGDQAAYDAMVRMAQDFSLRYPLIDGQGNFGSRDGDNAAAMRYTEARLTPIAKLLLDELDEGTVDFVPNY 
R7_03580           81 VGDVLGKYHPHGDQAAYDAMVRMAQDFSLRYPLIDGQGNFGSRDGDNAAAMRYTEARLTPIAKLLLDELDEGTVDFVPNY 
L5_04553           81 VGDVLGKYHPHGDQAAYDAMVRMAQDFSLRYPLIDGQGNFGSRDGDNAAAMRYTEARLTPIAKLLLDELDEGTVDFVPNY 
R11_00072          81 VGDVLGKYHPHGDQAAYDAMVRMAQDFSLRYPLIDGQGNFGSRDGDNAAAMRYTEARLTPIAKLLLDELDEGTVDFVPNY 
DSM2402_00569      81 VGDVLGKYHPHGDQAAYDAMVRMAQDFSLRYPLIDGQGNFGSRDGDNAAAMRYTEARLTPIAKLLLDELDEGTVDFVPNY 
L14_05853          81 VGDVLGKYHPHGDQAAYDAMVRMAQDFSLRYPLIDGQGNFGSRDGDNAAAMRYTEARLTPIAKLLLDELDEGTVDFVPNY 
L16_01230          81 VGDVLGKYHPHGDQAAYDAMVRMAQDFSLRYPLIDGQGNFGSRDGDNAAAMRYTEARLTPIAKLLLDELDEGTVDFVPNY 
L1_02272           81 VGDVLGKYHPHGDQAAYDAMVRMAQDFSLRYPLIDGQGNFGSRDGDNAAAMRYTEARLTPIAKLLLDELDEGTVDFVPNY 
NH44784_1996       81 VGDVLGKYHPHGDQAAYDAMVRMAQDFSLRYPLIDGQGNFGSRDGDNAAAMRYTEARLTPIAKLLLDELDEGTVDFVPNY 
L10_00751          81 VGDVLGKYHPHGDQAAYDAMVRMAQDFSLRYPLIDGQGNFGSRDGDNAAAMRYTEARLTPIAKLLLDELDEGTVDFVPNY 
L11_02235          81 VGDVLGKYHPHGDQAAYDAMVRMAQDFSLRYPLIDGQGNFGSRDGDNAAAMRYTEARLTPIAKLLLDELDEGTVDFVPNY 
L15_00736          81 VGDVLGKYHPHGDQAAYDAMVRMAQDFSLRYPLIDGQGNFGSRDGDNAAAMRYTEARLTPIAKLLLDELDEGTVDFVPNY 
R12_00729          81 VGDVLGKYHPHGDQAAYDAMVRMAQDFSLRYPLIDGQGNFGSRDGDNAAAMRYTEARLTPIAKLLLDELDEGTVDFVPNY 
R14_05528          81 VGDVLGKYHPHGDQAAYDAMVRMAQDFSLRYPLIDGQGNFGSRDGDNAAAMRYTEARLTPIAKLLLDELDEGTVDFVPNY 
R1_00146           81 VGDVLGKYHPHGDQAAYDAMVRMAQDFSLRYPLIDGQGNFGSRDGDNAAAMRYTEARLTPIAKLLLDELDEGTVDFVPNY 
R2_00458           81 VGDVLGKYHPHGDQAAYDAMVRMAQDFSLRYPLIDGQGNFGSRDGDNAAAMRYTEARLTPIAKLLLDELDEGTVDFVPNY 
R3_01677           81 VGDVLGKYHPHGDQAAYDAMVRMAQDFSLRYPLIDGQGNFGSRDGDNAAAMRYTEARLTPIAKLLLDELDEGTVDFVPNY 
R5_02499           81 VGDVLGKYHPHGDQAAYDAMVRMAQDFSLRYPLIDGQGNFGSRDGDNAAAMRYTEARLTPIAKLLLDELDEGTVDFVPNY 
R8_03474           81 VGDVLGKYHPHGDQAAYDAMVRMAQDFSLRYPLIDGQGNFGSRDGDNAAAMRYTEARLTPIAKLLLDELDEGTVDFVPNY 
 
  161        240 
R4_03393          161 DGSQQEPQMLPARLPVMLLNGASGIAVGMATEIPPHNLREVAQACVALIKQPQLPDAELFGMIPGPDSAGGGQIITPAAD 
NCIMB11015_03245  161 DGSQQEPQMLPARLPVMLLNGASGIAVGMATEIPPHNLREVAQACVALIKQPQLPDAELFGMIPGPDFAGGGQIITPAAD 
L17_01347         161 DGSQQEPQMLPARLPVMLLNGASGIAVGMATEIPPHNLREVAQACVALIKQPQLPDAELFGMIPGPDFAGGGQIITPAAD 
L8_00647          161 DGSQQEPQMLPARLPVMLLNGASGIAVGMATEIPPHNLREVAQACVALIKQPQLPDAELFGMIPGPDFAGGGQIITPAAD 
R13_01575         161 DGSQQEPQMLPARLPVMLLNGASGIAVGMATEIPPHNLREVAQACVALIKQPQLPDAELFGMIPGPDFAGGGQIITPAAD 
R6_01020          161 DGSQQEPQMLPARLPVMLLNGASGIAVGMATEIPPHNLREVAQACVALIKQPQLPDAELFGMIPGPDFAGGGQIITPAAD 
R7_03580          161 DGSQQEPQMLPARLPVMLLNGASGIAVGMATEIPPHNLREVAQACVALIKQPQLPDAELFGMIPGPDFAGGGQIITPAAD 
L5_04553          161 DGSQQEPQMLPARLPVMLLNGASGIAVGMATEIPPHNLREVAQACVALIKQPQLPDAELFGMIPGPDFAGGGQIITPAAD 
R11_00072         161 DGSQQEPQMLPARLPVMLLNGASGIAVGMATEIPPHNLREVAQACVALIKQPQLPDAELFGMIPGPDFAGGGQIITPAAD 
DSM2402_00569     161 DGSQQEPQMLPARLPVMLLNGASGIAVGMATEIPPHNLREVAQACVALIKQPQLPDAELFGMIPGPDFAGGGQIITPAAD 
L14_05853         161 DGSQQEPQMLPARLPVMLLNGASGIAVGMATEIPPHNLREVAQACVALIKQPQLPDAELFGMIPGPDFAGGGQIITPAAD 
L16_01230         161 DGSQQEPQMLPARLPVMLLNGASGIAVGMATEIPPHNLREVAQACVALIKQPQLPDAELFGMIPGPDFAGGGQIITPAAD 
L1_02272          161 DGSQQEPQMLPARLPVMLLNGASGIAVGMATEIPPHNLREVAQACVALIKQPQLPDAELFGMIPGPDFAGGGQIITPAAD 
NH44784_1996      161 DGSQQEPQMLPARLPVMLLNGASGIAVGMATEIPPHNLREVAQACVALIKQPQLPDAELFGMIPGPDFAGGGQIITPAAD 
L10_00751         161 DGSQQEPQMLPARLPVMLLNGASGIAVGMATEIPPHNLREVAQACVALIKQPQLPDAELFGMIPGPDFAGGGQIITPAAD 
L11_02235         161 DGSQQEPQMLPARLPVMLLNGASGIAVGMATEIPPHNLREVAQACVALIKQPQLPDAELFGMIPGPDFAGGGQIITPAAD 
L15_00736         161 DGSQQEPQMLPARLPVMLLNGASGIAVGMATEIPPHNLREVAQACVALIKQPQLPDAELFGMIPGPDFAGGGQIITPAAD 
R12_00729         161 DGSQQEPQMLPARLPVMLLNGASGIAVGMATEIPPHNLREVAQACVALIKQPQLPDAELFGMIPGPDFAGGGQIITPAAD 
R14_05528         161 DGSQQEPQMLPARLPVMLLNGASGIAVGMATEIPPHNLREVAQACVALIKQPQLPDAELFGMIPGPDFAGGGQIITPAAD 
R1_00146          161 DGSQQEPQMLPARLPVMLLNGASGIAVGMATEIPPHNLREVAQACVALIKQPQLPDAELFGMIPGPDFAGGGQIITPAAD 
R2_00458          161 DGSQQEPQMLPARLPVMLLNGASGIAVGMATEIPPHNLREVAQACVALIKQPQLPDAELFGMIPGPDFAGGGQIITPAAD 
R3_01677          161 DGSQQEPQMLPARLPVMLLNGASGIAVGMATEIPPHNLREVAQACVALIKQPQLPDAELFGMIPGPDFAGGGQIITPAAD 
R5_02499          161 DGSQQEPQMLPARLPVMLLNGASGIAVGMATEIPPHNLREVAQACVALIKQPQLPDAELFGMIPGPDFAGGGQIITPAAD 
R8_03474          161 DGSQQEPQMLPARLPVMLLNGASGIAVGMATEIPPHNLREVAQACVALIKQPQLPDAELFGMIPGPDFAGGGQIITPAAD 
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  241        320 
R4_03393          241 IAQIYAGGRGSLKVRARWQFEEMARGQWQLVVTELPPGTSCQKVLEEIEEITNPKVKSGKKSLTPEQTQAKAVMLNLLDA 
NCIMB11015_03245  241 IAQIYAGGRGSLKVRARWQFEEMARGQWQLVVTELPPGTSCQKVLEEIEEITNPKVKSGKKSLTPEQTQAKAVMLNLLDA 
L17_01347         241 IAQIYAGGRGSLKVRARWQFEEMARGQWQLVVTELPPGTSCQKVLEEIEEITNPKVKSGKKSLTPEQTQAKAVMLNLLDA 
L8_00647          241 IAQIYAGGRGSLKVRARWQFEEMARGQWQLVVTELPPGTSCQKVLEEIEEITNPKVKSGKKSLTPEQTQAKAVMLNLLDA 
R13_01575         241 IAQIYAGGRGSLKVRARWQFEEMARGQWQLVVTELPPGTSCQKVLEEIEEITNPKVKSGKKSLTPEQTQAKAVMLNLLDA 
R6_01020          241 IAQIYAGGRGSLKVRARWQFEEMARGQWQLVVTELPPGTSCQKVLEEIEEITNPKVKSGKKSLTPEQTQAKAVMLNLLDA 
R7_03580          241 IAQIYAGGRGSLKVRARWQFEEMARGQWQLVVTELPPGTSCQKVLEEIEEITNPKVKSGKKSLTPEQTQAKAVMLNLLDA 
L5_04553          241 IAQIYAGGRGSLKVRARWQFEEMARGQWQLVVTELPPGTSCQKVLEEIEEITNPKVKSGKKSLTPEQTQAKAVMLNLLDA 
R11_00072         241 IAQIYAGGRGSLKVRARWQFEEMARGQWQLVVTELPPGTSCQKVLEEIEEITNPKVKSGKKSLTPEQTQAKAVMLNLLDA 
DSM2402_00569     241 IAQIYAGGRGSLKVRARWQFEEMARGQWQLVVTELPPGTSCQKVLEEIEEITNPKVKSGKKSLTPEQTQAKAVMLNLLDA 
L14_05853         241 IAQIYAGGRGSLKVRARWQFEEMARGQWQLVVTELPPGTSCQKVLEEIEEITNPKVKSGKKSLTPEQTQAKAVMLNLLDA 
L16_01230         241 IAQIYAGGRGSLKVRARWQFEEMARGQWQLVVTELPPGTSCQKVLEEIEEITNPKVKSGKKSLTPEQTQAKAVMLNLLDA 
L1_02272          241 IAQIYAGGRGSLKVRARWQFEEMARGQWQLVVTELPPGTSCQKVLEEIEEITNPKVKSGKKSLTPEQTQAKAVMLNLLDA 
NH44784_1996      241 IAQIYAGGRGSLKVRARWQFEEMARGQWQLVVTELPPGTSCQKVLEEIEEITNPKVKSGKKSLTPEQTQAKAVMLNLLDA 
L10_00751         241 IAQIYAGGRGSLKVRARWQFEEMARGQWQLVVTELPPGTSCQKVLEEIEEITNPKVKSGKKSLTPEQTQAKAVMLNLLDA 
L11_02235         241 IAQIYAGGRGSLKVRARWQFEEMARGQWQLVVTELPPGTSCQKVLEEIEEITNPKVKSGKKSLTPEQTQAKAVMLNLLDA 
L15_00736         241 IAQIYAGGRGSLKVRARWQFEEMARGQWQLVVTELPPGTSCQKVLEEIEEITNPKVKSGKKSLTPEQTQAKAVMLNLLDA 
R12_00729         241 IAQIYAGGRGSLKVRARWQFEEMARGQWQLVVTELPPGTSCQKVLEEIEEITNPKVKSGKKSLTPEQTQAKAVMLNLLDA 
R14_05528         241 IAQIYAGGRGSLKVRARWQFEEMARGQWQLVVTELPPGTSCQKVLEEIEEITNPKVKSGKKSLTPEQTQAKAVMLNLLDA 
R1_00146          241 IAQIYAGGRGSLKVRARWQFEEMARGQWQLVVTELPPGTSCQKVLEEIEEITNPKVKSGKKSLTPEQTQAKAVMLNLLDA 
R2_00458          241 IAQIYAGGRGSLKVRARWQFEEMARGQWQLVVTELPPGTSCQKVLEEIEEITNPKVKSGKKSLTPEQTQAKAVMLNLLDA 
R3_01677          241 IAQIYAGGRGSLKVRARWQFEEMARGQWQLVVTELPPGTSCQKVLEEIEEITNPKVKSGKKSLTPEQTQAKAVMLNLLDA 
R5_02499          241 IAQIYAGGRGSLKVRARWQFEEMARGQWQLVVTELPPGTSCQKVLEEIEEITNPKVKSGKKSLTPEQTQAKAVMLNLLDA 
R8_03474          241 IAQIYAGGRGSLKVRARWQFEEMARGQWQLVVTELPPGTSCQKVLEEIEEITNPKVKSGKKSLTPEQTQAKAVMLNLLDA 
 
  321        400 
R4_03393          321 VRDESGKDAAVRLVFEPKTSRVDRDEFVNTLLAQTSMESSASVNLVCIGTDGRPRQKGLRDILTEWLAFRTHTVLRRTRF 
NCIMB11015_03245  321 VRDESGKDAAVRLVFEPKTSRVDRDEFVNTLLAQTSMESSASVNLVCIGTDGRPRQKGLRDILTEWLAFRTHTVLRRTRF 
L17_01347         321 VRDESGKDAAVRLVFEPKTSRVDRDEFVNTLLAQTSMESSASVNLVCIGTDGRPRQKGLRDILTEWLAFRTHTVLRRTRF 
L8_00647          321 VRDESGKDAAVRLVFEPKTSRVDRDEFVNTLLAQTSMESSASVNLVCIGTDGRPRQKGLRDILTEWLAFRTHTVLRRTRF 
R13_01575         321 VRDESGKDAAVRLVFEPKTSRVDRDEFVNTLLAQTSMESSASVNLVCIGTDGRPRQKGLRDILTEWLAFRTHTVLRRTRF 
R6_01020          321 VRDESGKDAAVRLVFEPKTSRVDRDEFVNTLLAQTSMESSASVNLVCIGTDGRPRQKGLRDILTEWLAFRTHTVLRRTRF 
R7_03580          321 VRDESGKDAAVRLVFEPKTSRVDRDEFVNTLLAQTSMESSASVNLVCIGTDGRPRQKGLRDILTEWLAFRTNTVLRRTRF 
L5_04553          321 VRDESGKDAAVRLVFEPKTSRVDRDEFVNTLLAQTSMESSASVNLVCIGTDGRPRQKGLRDILTEWLAFRTNTVLRRTRF 
R11_00072         321 VRDESGKDAAVRLVFEPKTSRVDRDEFVNTLLAQTSMESSASVNLVCIGTDGRPRQKGLRDILTEWLAFRTNTVLRRTRF 
DSM2402_00569     321 VRDESGKDAAVRLVFEPKTSRVDRDEFVNTLLAQTSMESSASVNLVCIGTDGRPRQKGLRDILAEWLAFRTNTVLRRTRF 
L14_05853         321 VRDESGKDAAVRLVFEPKTSRVDRDEFVNTLLAQTSMESSASVNLVCIGTDGRPRQKGLRDILAEWLAFRTNTVLRRTRF 
L16_01230         321 VRDESGKDAAVRLVFEPKTSRVDRDEFVNTLLAQTSMESSASVNLVCIGTDGRPRQKGLRDILAEWLAFRTNTVLRRTRF 
L1_02272          321 VRDESGKDAAVRLVFEPKTSRVDRDEFVNTLLAQTSMESSASVNLVCIGTDGRPRQKGLRDILTEWLAFRTNTVLRRTRF 
NH44784_1996      321 VRDESGKDAAVRLVFEPKTSRVDRDEFVNTLLAQTSMESSASVNLVCIGTDGRPRQKGLRDILTEWLAFRTNTVLRRTRF 
L10_00751         321 VRDESGKDAAVRLVFEPKTSRVDRDEFVNTLLAQTSMESSASVNLVCIGTDGRPRQKGLRDILTEWLAFRTNTVLRRTRF 
L11_02235         321 VRDESGKDAAVRLVFEPKTSRVDRDEFVNTLLAQTSMESSASVNLVCIGTDGRPRQKGLRDILTEWLAFRTNTVLRRTRF 
L15_00736         321 VRDESGKDAAVRLVFEPKTSRVDRDEFVNTLLAQTSMESSASVNLVCIGTDGRPRQKGLRDILTEWLAFRTNTVLRRTRF 
R12_00729         321 VRDESGKDAAVRLVFEPKTSRVDRDEFVNTLLAQTSMESSASVNLVCIGTDGRPRQKGLRDILTEWLAFRTNTVLRRTRF 
R14_05528         321 VRDESGKDAAVRLVFEPKTSRVDRDEFVNTLLAQTSMESSASVNLVCIGTDGRPRQKGLRDILTEWLAFRTNTVLRRTRF 
R1_00146          321 VRDESGKDAAVRLVFEPKTSRVDRDEFVNTLLAQTSMESSASVNLVCIGTDGRPRQKGLRDILTEWLAFRTNTVLRRTRF 
R2_00458          321 VRDESGKDAAVRLVFEPKTSRVDRDEFVNTLLAQTSMESSASVNLVCIGTDGRPRQKGLRDILTEWLAFRTNTVLRRTRF 
R3_01677          321 VRDESGKDAAVRLVFEPKTSRVDRDEFVNTLLAQTSMESSASVNLVCIGTDGRPRQKGLRDILTEWLAFRTNTVLRRTRF 
R5_02499          321 VRDESGKDAAVRLVFEPKTSRVDRDEFVNTLLAQTSMESSASVNLVCIGTDGRPRQKGLRDILTEWLAFRTNTVLRRTRF 
R8_03474          321 VRDESGKDAAVRLVFEPKTSRVDRDEFVNTLLAQTSMESSASVNLVCIGTDGRPRQKGLRDILTEWLAFRTNTVLRRTRF 
 
  401        480 
R4_03393          401 RLDKVIDRIHVLEGRMVVYLNVDEVIQTIRESDEPRAALMERFNLSDRQAEDILEMRLRQLARLEGFKIEQELEDKRKEQ 
NCIMB11015_03245  401 RLDKVIDRIHVLEGRMVVYLNVDEVIQTIRESDEPRAALMERFNLSDRQAEDILEMRLRQLARLEGFKIEQELEDKRKEQ 
L17_01347         401 RLDKVIDRIHVLEGRMVVYLNVDEVIQTIRESDEPRAALMERFNLSDRQAEDILEMRLRQLARLEGFKIEQELEDKRKEQ 
L8_00647          401 RLDKVIDRIHVLEGRMVVYLNVDEVIQTIRESDEPRAALMERFNLSDRQAEDILEMRLRQLARLEGFKIEQELEDKRKEQ 
R13_01575         401 RLDKVIDRIHVLEGRMVVYLNVDEVIQTIRESDEPRAALMERFNLSDRQAEDILEMRLRQLARLEGFKIEQELEDKRKEQ 
R6_01020          401 RLDKVIDRIHVLEGRMVVYLNVDEVIQTIRESDEPRAALMERFNLSDRQAEDILEMRLRQLARLEGFKIEQELEDKRKEQ 
R7_03580          401 RLDKVIDRIHVLEGRMVVYLNVGEVIQTIRESDEPRAALMERFNLSDRQAEDILEMRLRQLARLEGFKIEQELEDKRKEQ 
L5_04553          401 RLDKVIDRIHVLEGRMVVYLNVDEVIQTIRESDEPRAALMERFNLSDRQAEDILEMRLRQLARLEGFKIEQELEDKRKEQ 
R11_00072         401 RLDKVIDRIHVLEGRMVVYLNVDEVIQTIRESDEPRAALMERFNLSDRQAEDILEMRLRQLARLEGFKIEQELEDKRKEQ 
DSM2402_00569     401 RLDKVIDRIHVLEGRMVVYLNVDEVIQTIRESDEPRAALMERFNLSDRQAEDILEMRLRQLARLEGFKIEQELEDKRKEQ 
L14_05853         401 RLDKVIDRIHVLEGRMVVYLNVDEVIQTIRESDEPRAALMERFNLSDRQAEDILEMRLRQLARLEGFKIEQELEDKRKEQ 
L16_01230         401 RLDKVIDRIHVLEGRMVVYLNVDEVIQTIRESDEPRAALMERFNLSDRQAEDILEMRLRQLARLEGFKIEQELEDKRKEQ 
L1_02272          401 RLDKVIDRIHVLEGRMVVYLNVDEVIQTIRESDEPRAALMERFNLSDRQAEDILEMRLRQLARLEGFKIEQELEDKRKEQ 
NH44784_1996      401 RLDKVIDRIHVLEGRMVVYLNVDEVIQTIRESDEPRAALMERFNLSDRQAEDILEMRLRQLARLEGFKIEQELEDKRKEQ 
L10_00751         401 RLDKVIDRIHVLEGRMVVYLNVDEVIQTIRESDEPRAALMERFNLSDRQAEDILEMRLRQLARLEGFKIEQELEDKRKEQ 
L11_02235         401 RLDKVIDRIHVLEGRMVVYLNVDEVIQTIRESDEPRAALMERFNLSDRQAEDILEMRLRQLARLEGFKIEQELEDKRKEQ 
L15_00736         401 RLDKVIDRIHVLEGRMVVYLNVDEVIQTIRESDEPRAALMERFNLSDRQAEDILEMRLRQLARLEGFKIEQELEDKRKEQ 
R12_00729         401 RLDKVIDRIHVLEGRMVVYLNVDEVIQTIRESDEPRAALMERFNLSDRQAEDILEMRLRQLARLEGFKIEQELEDKRKEQ 
R14_05528         401 RLDKVIDRIHVLEGRMVVYLNVDEVIQTIRESDEPRAALMERFNLSDRQAEDILEMRLRQLARLEGFKIEQELEDKRKEQ 
R1_00146          401 RLDKVIDRIHVLEGRMVVYLNVDEVIQTIRESDEPRAALMERFNLSDRQAEDILEMRLRQLARLEGFKIEQELEDKRKEQ 
R2_00458          401 RLDKVIDRIHVLEGRMVVYLNVDEVIQTIRESDEPRAALMERFNLSDRQAEDILEMRLRQLARLEGFKIEQELEDKRKEQ 
R3_01677          401 RLDKVIDRIHVLEGRMVVYLNVDEVIQTIRESDEPRAALMERFNLSDRQAEDILEMRLRQLARLEGFKIEQELEDKRKEQ 
R5_02499          401 RLDKVIDRIHVLEGRMVVYLNVDEVIQTIRESDEPRAALMERFNLSDRQAEDILEMRLRQLARLEGFKIEQELEDKRKEQ 
R8_03474          401 RLDKVIDRIHVLEGRMVVYLNVDEVIQTIRESDEPRAALMERFNLSDRQAEDILEMRLRQLARLEGFKIEQELEDKRKEQ 
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  481        560 
R4_03393          481 VALQELLDNPNTLKRLLIKEIEADAKQYGDDRRTLIETAERAVLETKVLDEPVTVIVSQKGWLRARQGHGHDASQFGFKQ 
NCIMB11015_03245  481 VALQELLDNPNTLKRLLIKEIEADAKQYGDDRRTLIETAERAVLETKVLDEPVTVIVSQKGWLRARQGHGHDASQFGFKQ 
L17_01347         481 VALQELLDNPNTLKRLLIKEIEADAKQYGDDRRTLIETAERAVLETKVLDEPVTVIVSQKGWLRARQGHGHDASQFGFKQ 
L8_00647          481 VALQELLDNPNTLKRLLIKEIEADAKQYGDDRRTLIETAERAVLETKVLDEPVTVIVSQKGWLRARQGHGHDASQFGFKQ 
R13_01575         481 VALQELLDNPNTLKRLLIKEIEADAKQYGDDRRTLIETAERAVLETKVLDEPVTVIVSQKGWLRARQGHGHDASQFGFKQ 
R6_01020          481 VALQELLDNPNTLKRLLIKEIEADAKQYGDDRRTLIETAERAVLETKVLDEPVTVIVSQKGWLRARQGHGHDASQFGFKQ 
R7_03580          481 VALQELLDNPNTLKRLLIKEIEADAKQYGDDRRTLIETAERAVLETKVLDEPVTVIVSQKGWLRARQGHGHDASQFGFKQ 
L5_04553          481 VALQELLDNPNTLKRLLIKEIEADAKQYGDDRRTLIETAERAVLETKVLDEPVTVIVSQKGWLRARQGHGHDASQFGFKQ 
R11_00072         481 VALQELLDNPNTLKRLLIKEIEADAKQYGDDRRTLIETAERAVLETKVLDEPVTVIVSQKGWLRARQGHGHDASQFGFKQ 
DSM2402_00569     481 VALQELLDNPNTLKRLLIKEIEADAKQYGDDRRTLIETAERAVLETKVLDEPVTVIVSQKGWLRARQGHGHDASQFGFKQ 
L14_05853         481 VALQELLDNPNTLKRLLIKEIEADAKQYGDDRRTLIETAERAVLETKVLDEPVTVIVSQKGWLRARQGHGHDASQFGFKQ 
L16_01230         481 VALQELLDNPNTLKRLLIKEIEADAKQYGDDRRTLIETAERAVLETKVLDEPVTVIVSQKGWLRARQGHGHDASQFGFKQ 
L1_02272          481 VALQELLDNPNTLKRLLIKEIEADAKQYGDDRRTLIETAERAVLETKVLDEPVTVIVSQKGWLRARQGHGHDASQFGFKQ 
NH44784_1996      481 VALQELLDNPNTLKRLLIKEIEADAKQYGDDRRTLIETAERAVLETKVLDEPVTVIVSQKGWLRARQGHGHDASQFGFKQ 
L10_00751         481 VALQELLDNPNTLKRLLIKEIEADAKQYGDDRRTLIETAERAVLETKVLDEPVTVIVSQKGWLRARQGHGHDASQFGFKQ 
L11_02235         481 VALQELLDNPNTLKRLLIKEIEADAKQYGDDRRTLIETAERAVLETKVLDEPVTVIVSQKGWLRARQGHGHDASQFGFKQ 
L15_00736         481 VALQELLDNPNTLKRLLIKEIEADAKQYGDDRRTLIETAERAVLETKVLDEPVTVIVSQKGWLRARQGHGHDASQFGFKQ 
R12_00729         481 VALQELLDNPNTLKRLLIKEIEADAKQYGDDRRTLIETAERAVLETKVLDEPVTVIVSQKGWLRARQGHGHDASQFGFKQ 
R14_05528         481 VALQELLDNPNTLKRLLIKEIEADAKQYGDDRRTLIETAERAVLETKVLDEPVTVIVSQKGWLRARQGHGHDASQFGFKQ 
R1_00146          481 VALQELLDNPNTLKRLLIKEIEADAKQYGDDRRTLIETAERAVLETKVLDEPVTVIVSQKGWLRARQGHGHDASQFGFKQ 
R2_00458          481 VALQELLDNPNTLKRLLIKEIEADAKQYGDDRRTLIETAERAVLETKVLDEPVTVIVSQKGWLRARQGHGHDASQFGFKQ 
R3_01677          481 VALQELLDNPNTLKRLLIKEIEADAKQYGDDRRTLIETAERAVLETKVLDEPVTVIVSQKGWLRARQGHGHDASQFGFKQ 
R5_02499          481 VALQELLDNPNTLKRLLIKEIEADAKQYGDDRRTLIETAERAVLETKVLDEPVTVIVSQKGWLRARQGHGHDASQFGFKQ 
R8_03474          481 VALQELLDNPNTLKRLLIKEIEADAKQYGDDRRTLIETAERAVLETKVLDEPVTVIVSQKGWLRARQGHGHDASQFGFKQ 
 
  561        640 
R4_03393          561 GDDLYGAFECRTTDTLIAMGDNGRVYSVPVAGLPSARGDGQPVTTMIDLESGTRIVHTIAAAADSRWLLATRGGYGFAAK 
NCIMB11015_03245  561 GDDLYGAFECRTTDTLIAMGDNGRVYSVPVAGLPSARGDGQPVTTMIDLESGTRIVHTIAAAADSRWLLATRGGYGFAAK 
L17_01347         561 GDDLYGAFECRTTDTLIAMGDNGRVYSVPVAGLPSARGDGQPVTTMIDLESGTRIVHTIAAAADSRWLLATRGGYGFAAK 
L8_00647          561 GDDLYGAFECRTTDTLIAMGDNGRVYSVPVAGLPSARGDGQPVTTMIDLESGTRIVHTIAAAADSRWLLATRGGYGFAAK 
R13_01575         561 GDDLYGAFECRTTDTLIAMGDNGRVYSVPVAGLPSARGDGQPVTTMIDLESGTRIVHTIAAAADSRWLLATRGGYGFAAK 
R6_01020          561 GDDLYGAFECRTTDTLIAMGDNGRVYSVPVAGLPSARGDGQPVTTMIDLESGTRIVHTIAAAADSRWLLATRGGYGFAAK 
R7_03580          561 GDDLYGAFECRTTDTLIAMGDNGRVYSVPVSGLPSARGDGQPVTTMIDLESGTRIVHTIAAAADSRWLLATRGGYGFAAK 
L5_04553          561 GDDLYGAFECRTTDTLIAMGDNGRVYSVPVSGLPSARGDGQPVTTMIDLESGTRIVHTIAAAADSRWLLATRGGYGFAAK 
R11_00072         561 GDDLYGAFECRTTDTLIAMGDNGRVYSVPVAGLPSARGDGQPVTTMIDLESGTRIVHTIAAAADSRWLLATRGGYGFAAK 
DSM2402_00569     561 GDDLYGAFECRTTDTLIAMGDNGRVYSVPVAGLPSARGDGQPVTTMIDLESGTRIVHTIAAAADSRWLLATRGGYGFAAK 
L14_05853         561 GDDLYGAFECRTTDTLIAMGDNGRVYSVPVAGLPSARGDGQPVTTMIDLESGTRIVHTIAAAADSRWLLATRGGYGFAAK 
L16_01230         561 GDDLYGAFECRTTDTLIAMGDNGRVYSVPVAGLPSARGDGQPVTTMIDLESGTRIVHTIAAAADSRWLLATRGGYGFAAK 
L1_02272          561 GDDLYGAFECRTTDTLIAMGDNGRVYSVPVAGLPSARGDGQPVTTMIDLESGTRIVHTIAAAADSRWLLATRGGYGFAAK 
NH44784_1996      561 GDDLYGAFECRTTDTLIAMGDNGRVYSVPVAGLPSARGDGQPVTTMIDLESGTRIVHTIAAAADSRWLLATRGGYGFAAK 
L10_00751         561 GDDLYGAFECRTTDTLIAMGDNGRVYSVPVAGLPSARGDGQPVTTMIDLESGTRIVHTIAAAADSRWLLATRGGYGFAAK 
L11_02235         561 GDDLYGAFECRTTDTLIAMGDNGRVYSVPVAGLPSARGDGQPVTTMIDLESGTRIVHTIAAAADSRWLLATRGGYGFAAK 
L15_00736         561 GDDLYGAFECRTTDTLIAMGDNGRVYSVPVAGLPSARGDGQPVTTMIDLESGTRIVHTIAAAADSRWLLATRGGYGFAAK 
R12_00729         561 GDDLYGAFECRTTDTLIAMGDNGRVYSVPVAGLPSARGDGQPVTTMIDLESGTRIVHTIAAAADSRWLLATRGGYGFAAK 
R14_05528         561 GDDLYGAFECRTTDTLIAMGDNGRVYSVPVAGLPSARGDGQPVTTMIDLESGTRIVHTIAAAADSRWLLATRGGYGFAAK 
R1_00146          561 GDDLYGAFECRTTDTLIAMGDNGRVYSVPVAGLPSARGDGQPVTTMIDLESGTRIVHTIAAAADSRWLLATRGGYGFAAK 
R2_00458          561 GDDLYGAFECRTTDTLIAMGDNGRVYSVPVAGLPSARGDGQPVTTMIDLESGTRIVHTIAAAADSRWLLATRGGYGFAAK 
R3_01677          561 GDDLYGAFECRTTDTLIAMGDNGRVYSVPVAGLPSARGDGQPVTTMIDLESGTRIVHTIAAAADSRWLLATRGGYGFAAK 
R5_02499          561 GDDLYGAFECRTTDTLIAMGDNGRVYSVPVAGLPSARGDGQPVTTMIDLESGTRIVHTIAAAADSRWLLATRGGYGFAAK 
R8_03474          561 GDDLYGAFECRTTDTLIAMGDNGRVYSVPVAGLPSARGDGQPVTTMIDLESGTRIVHTIAAAADSRWLLATRGGYGFAAK 
 
  641        720 
R4_03393          641 LSDMTSRQRAGKQFITLEAGDELLRPVPLFEGATQLALLSQKGKFLVFGLDEVKSLSGGGRGTILMGLDGADKLDQTVPI 
NCIMB11015_03245  641 LSDMTSRQRAGKQFITLEAGDELLRPVPLFEGATQLALLSQKGKFLVFGLDEVKSLSGGGRGTILMGLDGADKLDQTVPI 
L17_01347         641 LSDMTSRQRAGKQFITLEAGDELLRPVPLFEGATQLALLSQKGKFLVFGLDEVKSLSGGGRGTILMGLDGADKLDQTVPI 
L8_00647          641 LSDMTSRQRAGKQFITLEAGDELLRPVPLFEGATQLALLSQKGKFLVFGLDEVKSLSGGGRGTILMGLDGADKLDQTVPI 
R13_01575         641 LSDMTSRQRAGKQFITLEAGDELLRPVPLFEGATQLALLSQKGKFLVFGLDEVKSLSGGGRGTILMGLDGADKLDQTVPI 
R6_01020          641 LSDMTSRQRAGKQFITLEAGDELLRPVPLFEGATQLALLSQKGKFLVFGLDEVKSLSGGGRGTILMGLDGADKLDQTVPI 
R7_03580          641 LSDMTSRQRAGKQFITLEAGDELLRPVPLFEGATQLALLSQKGKFLVFGLDEVKSLSGGGRGTILMGLDGADKLDQTVPI 
L5_04553          641 LSDMTSRQRAGKQFITLEAGDELLRPVPLFEGATQLALLSQKGKFLVFGLDEVKSLSGGGRGTILMGLDGADKLDQTVPI 
R11_00072         641 LSDMTSRQRAGKQFITLEAGDELLRPVPLFEGATQLALLSQKGKFLVFGLDEVKSLSGGGRGTILMGLDGADKLDQTVPI 
DSM2402_00569     641 LSDMTSRQRAGKQFITLEAGDELLRPVPLFEGATQLALLSQKGKFLVFGLDEVKSLSGGGRGTILMGLDGADKLDQTVPI 
L14_05853         641 LSDMTSRQRAGKQFITLEAGDELLRPVPLFEGATQLALLSQKGKFLVFGLDEVKSLSGGGRGTILMGLDGADKLDQTVPI 
L16_01230         641 LSDMTSRQRAGKQFITLEAGDELLRPVPLFEGATQLALLSQKGKFLVFGLDEVKSLSGGGRGTILMGLDGADKLDQTVPI 
L1_02272          641 LSDMTSRQRAGKQFITLEAGDELLRPVPLFEGATQLALLSQKGKFLVFGLDEVKSLSGGGRGTILMGLDGADKLDQTVPI 
NH44784_1996      641 LSDMTSRQRAGKQFITLEAGDELLRPVPLFEGATQLALLSQKGKFLVFGLDEVKSLSGGGRGTILMGLDGADKLDQTVPI 
L10_00751         641 LSDMTSRQRAGKQFITLEAGDELLRPVPLFEGATQLALLSQKGKFLVFGLDEVKSLSGGGRGTILMGLDGADKLDQTVPI 
L11_02235         641 LSDMTSRQRAGKQFITLEAGDELLRPVPLFEGATQLALLSQKGKFLVFGLDEVKSLSGGGRGTILMGLDGADKLDQTVPI 
L15_00736         641 LSDMTSRQRAGKQFITLEAGDELLRPVPLFEGATQLALLSQKGKFLVFGLDEVKSLSGGGRGTILMGLDGADKLDQTVPI 
R12_00729         641 LSDMTSRQRAGKQFITLEAGDELLRPVPLFEGATQLALLSQKGKFLVFGLDEVKSLSGGGRGTILMGLDGADKLDQTVPI 
R14_05528         641 LSDMTSRQRAGKQFITLEAGDELLRPVPLFEGATQLALLSQKGKFLVFGLDEVKSLSGGGRGTILMGLDGADKLDQTVPI 
R1_00146          641 LSDMTSRQRAGKQFITLEAGDELLRPVPLFEGATQLALLSQKGKFLVFGLDEVKSLSGGGRGTILMGLDGADKLDQTVPI 
R2_00458          641 LSDMTSRQRAGKQFITLEAGDELLRPVPLFEGATQLALLSQKGKFLVFGLDEVKSLSGGGRGTILMGLDGADKLDQTVPI 
R3_01677          641 LSDMTSRQRAGKQFITLEAGDELLRPVPLFEGATQLALLSQKGKFLVFGLDEVKSLSGGGRGTILMGLDGADKLDQTVPI 
R5_02499          641 LSDMTSRQRAGKQFITLEAGDELLRPVPLFEGATQLALLSQKGKFLVFGLDEVKSLSGGGRGTILMGLDGADKLDQTVPI 
R8_03474          641 LSDMTSRQRAGKQFITLEAGDELLRPVPLFEGATQLALLSQKGKFLVFGLDEVKSLSGGGRGTILMGLDGADKLDQTVPI 
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  721       773 
R4_03393          721 GALGLRAAGIYRNKHTEDILAGAALAVYVGKRARKGRALDVRPKQPLLSPVLG 
NCIMB11015_03245  721 GALGLRAAGIYRNKHTEDILAGAALAVYVGKRARKGRALDVRPKQPLLSPVLG 
L17_01347         721 GALGLRAAGIYRNKHTEDILAGAALAVYVGKRARKGRALDVRPKQPLLSPVLG 
L8_00647          721 GALGLRAAGIYRNKHTEDILAGAALAVYVGKRARKGRALDVRPKQPLLSPVLG 
R13_01575         721 GALGLRAAGIYRNKHTEDILAGAALAVYVGKRARKGRALDVRPKQPLLSPVLG 
R6_01020          721 GALGLRAAGIYRNKHTEDILAGAALAVYVGKRARKGRALDVRPKQPLLSPVLG 
R7_03580          721 GALGLRAAGIYRNKHTEDILAGAALAVYVGKRARKGRALDVRPKQPLLSPVLG 
L5_04553          721 GALGLRAAGIYRNKHTEDILAGAALAVYVGKRARKGRALDVRPKQPLLSPVLG 
R11_00072         721 GALGLRAAGIYRNKHTEDILAGAALAVYVGKRARKGRALDVRPKQPLLSPMLG 
DSM2402_00569     721 GALGLRAAGIYRNKHTEDILAGAALAVYVGKRARKGRALDVRPKQPLLSPVLG 
L14_05853         721 GALGLRAAGIYRNKHTEDILAGAALAVYVGKRARKGRALDVRPKQPLLSPVLG 
L16_01230         721 GALGLRAAGIYRNKHTEDILAGAALAVYVGKRARKGRALDVRPKQPLLSPVLG 
L1_02272          721 GALGLRAAGIYRNKHTEDILAGAALAVYVGKRARKGRALDVRPKQPLLSPVLG 
NH44784_1996      721 GALGLRAAGIYRNKHTEDILAGAALAVYVGKRARKGRALDVRPKQPLLSPVLG 
L10_00751         721 GALGLRAAGIYRNKHTEDILAGAALAVYVGKRARKGRALDVRPKQPLLSPVLG 
L11_02235         721 GALGLRAAGIYRNKHTEDILAGAALAVYVGKRARKGRALDVRPKQPLLSPVLG 
L15_00736         721 GALGLRAAGIYRNKHTEDILAGAALAVYVGKRARKGRALDVRPKQPLLSPVLG 
R12_00729         721 GALGLRAAGIYRNKHTEDILAGAALAVYVGKRARKGRALDVRPKQPLLSPVLG 
R14_05528         721 GALGLRAAGIYRNKHTEDILAGAALAVYVGKRARKGRALDVRPKQPLLSPVLG 
R1_00146          721 GALGLRAAGIYRNKHTEDILAGAALAVYVGKRARKGRALDVRPKQPLLSPVLG 
R2_00458          721 GALGLRAAGIYRNKHTEDILAGAALAVYVGKRARKGRALDVRPKQPLLSPVLG 
R3_01677          721 GALGLRAAGIYRNKHTEDILAGAALAVYVGKRARKGRALDVRPKQPLLSPVLG 
R5_02499          721 GALGLRAAGIYRNKHTEDILAGAALAVYVGKRARKGRALDVRPKQPLLSPVLG 
R8_03474          721 GALGLRAAGIYRNKHTEDILAGAALAVYVGKRARKGRALDVRPKQPLLSPVLG 
 
 
D) Topoisomerase IV subunit B 
  1        80 
R7_03582            1 LATPRYNEASIRVLKGLEPVRQRPGMYTRTENPLHIVQEVIDNAADEALAGHGKQILVTLHIDGSVSVEDDGRGIPVGLH 
L10_00753           1 LATPRYNEASIRVLKGLEPVRQRPGMYTRTENPLHIVQEVIDNAADEALAGHGKQILVTLHIDGSVSVEDDGRGIPVGLH 
NCIMB11015_03243    1 LATPRYNEASIRVLKGLEPVRQRPGMYTRTENPLHIVQEVIDNAADEALAGHGKQILVTLHIDGSVSVEDDGRGIPVGLH 
L14_05855           1 LATPRYNEASIRVLKGLEPVRQRPGMYTRTENPLHIVQEVIDNAADEALAGHGKQILVTLHIDGSVSVEDDGRGIPVGLH 
L17_01345           1 LATPRYNEASIRVLKGLEPVRQRPGMYTRTENPLHIVQEVIDNAADEALAGHGKQILVTLHIDGSVSVEDDGRGIPVGLH 
L8_00649            1 LATPRYNEASIRVLKGLEPVRQRPGMYTRTENPLHIVQEVIDNAADEALAGHGKQILVTLHIDGSVSVEDDGRGIPVGLH 
R6_01018            1 LATPRYNEASIRVLKGLEPVRQRPGMYTRTENPLHIVQEVIDNAADEALAGHGKQILVTLHIDGSVSVEDDGRGIPVGLH 
DSM2402_00571       1 LATPRYNEASIRVLKGLEPVRQRPGMYTRTENPLHIVQEVIDNAADEALAGHGKQILVTLHIDGSVSVEDDGRGIPVGLH 
L11_02233           1 LATPRYNEASIRVLKGLEPVRQRPGMYTRTENPLHIVQEVIDNAADEALAGHGKQILVTLHIDGSVSVEDDGRGIPVGLH 
L15_00734           1 LATPRYNEASIRVLKGLEPVRQRPGMYTRTENPLHIVQEVIDNAADEALAGHGKQILVTLHIDGSVSVEDDGRGIPVGLH 
L16_01228           1 LATPRYNEASIRVLKGLEPVRQRPGMYTRTENPLHIVQEVIDNAADEALAGHGKQILVTLHIDGSVSVEDDGRGIPVGLH 
L1_02274            1 LATPRYNEASIRVLKGLEPVRQRPGMYTRTENPLHIVQEVIDNAADEALAGHGKQILVTLHIDGSVSVEDDGRGIPVGLH 
L5_04551            1 LATPRYNEASIRVLKGLEPVRQRPGMYTRTENPLHIVQEVIDNAADEALAGHGKQILVTLHIDGSVSVEDDGRGIPVGLH 
R10_03725           1 LATPRYNEASIRVLKGLEPVRQRPGMYTRTENPLHIVQEVIDNAADEALAGHGKQILVTLHIDGSVSVEDDGRGIPVGLH 
R11_00070           1 LATPRYNEASIRVLKGLEPVRQRPGMYTRTENPLHIVQEVIDNAADEALAGHGKQILVTLHIDGSVSVEDDGRGIPVGLH 
R12_00731           1 LATPRYNEASIRVLKGLEPVRQRPGMYTRTENPLHIVQEVIDNAADEALAGHGKQILVTLHIDGSVSVEDDGRGIPVGLH 
R13_01577           1 LATPRYNEASIRVLKGLEPVRQRPGMYTRTENPLHIVQEVIDNAADEALAGHGKQILVTLHIDGSVSVEDDGRGIPVGLH 
R14_05526           1 LATPRYNEASIRVLKGLEPVRQRPGMYTRTENPLHIVQEVIDNAADEALAGHGKQILVTLHIDGSVSVEDDGRGIPVGLH 
R1_00144            1 LATPRYNEASIRVLKGLEPVRQRPGMYTRTENPLHIVQEVIDNAADEALAGHGKQILVTLHIDGSVSVEDDGRGIPVGLH 
R2_00456            1 LATPRYNEASIRVLKGLEPVRQRPGMYTRTENPLHIVQEVIDNAADEALAGHGKQILVTLHIDGSVSVEDDGRGIPVGLH 
R3_01679            1 LATPRYNEASIRVLKGLEPVRQRPGMYTRTENPLHIVQEVIDNAADEALAGHGKQILVTLHIDGSVSVEDDGRGIPVGLH 
R4_03391            1 LATPRYNEASIRVLKGLEPVRQRPGMYTRTENPLHIVQEVIDNAADEALAGHGKQILVTLHIDGSVSVEDDGRGIPVGLH 
R5_02497            1 LATPRYNEASIRVLKGLEPVRQRPGMYTRTENPLHIVQEVIDNAADEALAGHGKQILVTLHIDGSVSVEDDGRGIPVGLH 
R8_03472            1 LATPRYNEASIRVLKGLEPVRQRPGMYTRTENPLHIVQEVIDNAADEALAGHGKQILVTLHIDGSVSVEDDGRGIPVGLH 
R9_01247            1 LATPRYNEASIRVLKGLEPVRQRPGMYTRTENPLHIVQEVIDNAADEALAGHGKQILVTLHIDGSVSVEDDGRGIPVGLH 
NH44784_1996        1 LATPRYNEASIRVLKGLEPVRQRPGMYTRTENPLHIVQEVIDNAADEALAGHGKQILVTLHIDGSVSVEDDGRGIPVGLH 
 
  81        160 
R7_03582           81 PEENAPVVELVFTRLHAGGKFDKAGGGAYAFSGGLHGVGVSVTNALATRLEVVVWRDGAVNRLVFKGGDVAEPLAPYDQG 
L10_00753          81 PEENAPVVELVFTRLHAGGKFDKAGGGAYAFSGGLHGVGVSVTNALATRLEVVVWRDGTVNRLVFKGGDVAEPLAPYDQG 
NCIMB11015_03243   81 PEENAPVVELVFTRLHAGGKFDKAGGGAYAFSGGLHGVGVSVTNALATRLEVVVWRDGAVNRLVFKGGDVAEPLAPYDQG 
L14_05855          81 PEENAPVVELVFTRLHAGGKFDKAGGGAYAFSGGLHGVGVSVTNALATRLEVVVWRDGAVNRLVFKGGDVAEPLAPYDQG 
L17_01345          81 PEENAPVVELVFTRLHAGGKFDKAGGGAYAFSGGLHGVGVSVTNALATRLEVVVWRDGAVNRLVFKGGDVAEPLAPYDQG 
L8_00649           81 PEENAPVVELVFTRLHAGGKFDKAGGGAYAFSGGLHGVGVSVTNALATRLEVVVWRDGAVNRLVFKGGDVAEPLAPYDQG 
R6_01018           81 PEENAPVVELVFTRLHAGGKFDKAGGGAYAFSGGLHGVGVSVTNALATRLEVVVWRDGAVNRLVFKGGDVAEPLAPYDQG 
DSM2402_00571      81 PEENAPVVELVFTRLHAGGKFDKAGGGAYAFSGGLHGVGVSVTNALATRLEVVVWRDGAVNRLVFKGGDVAEPLAPYDQG 
L11_02233          81 PEENAPVVELVFTRLHAGGKFDKAGGGAYAFSGGLHGVGVSVTNALATRLEVVVWRDGAVNRLVFKGGDVAEPLAPYDQG 
L15_00734          81 PEENAPVVELVFTRLHAGGKFDKAGGGAYAFSGGLHGVGVSVTNALATRLEVVVWRDGAVNRLVFKGGDVAEPLAPYDQG 
L16_01228          81 PEENAPVVELVFTRLHAGGKFDKAGGGAYAFSGGLHGVGVSVTNALATRLEVVVWRDGAVNRLVFKGGDVAEPLAPYDQG 
L1_02274           81 PEENAPVVELVFTRLHAGGKFDKAGGGAYAFSGGLHGVGVSVTNALATRLEVVVWRDGAVNRLVFKGGDVAEPLAPYDQG 
L5_04551           81 PEENAPVVELVFTRLHAGGKFDKAGGGAYAFSGGLHGVGVSVTNALATRLEVVVWRDGAVNRLVFKGGDVAEPLAPYDQG 
R10_03725          81 PEENAPVVELVFTRLHAGGKFDKAGGGAYAFSGGLHGVGVSVTNALATRLEVVVWRDGAVNRLVFKGGDVAEPLAPYDQG 
R11_00070          81 PEENAPVVELVFTRLHAGGKFDKAGGGAYAFSGGLHGVGVSVTNALATRLEVVVWRDGAVNRLVFKGGDVAEPLAPYDQG 
R12_00731          81 PEENAPVVELVFTRLHAGGKFDKAGGGAYAFSGGLHGVGVSVTNALATRLEVVVWRDGAVNRLVFKGGDVAEPLAPYDQG 
R13_01577          81 PEENAPVVELVFTRLHAGGKFDKAGGGAYAFSGGLHGVGVSVTNALATRLEVVVWRDGAVNRLVFKGGDVAEPLAPYDQG 
R14_05526          81 PEENAPVVELVFTRLHAGGKFDKAGGGAYAFSGGLHGVGVSVTNALATRLEVVVWRDGAVNRLVFKGGDVAEPLAPYDQG 
R1_00144           81 PEENAPVVELVFTRLHAGGKFDKAGGGAYAFSGGLHGVGVSVTNALATRLEVVVWRDGAVNRLVFKGGDVAEPLAPYDQG 
R2_00456           81 PEENAPVVELVFTRLHAGGKFDKAGGGAYAFSGGLHGVGVSVTNALATRLEVVVWRDGAVNRLVFKGGDVAEPLAPYDQG 
R3_01679           81 PEENAPVVELVFTRLHAGGKFDKAGGGAYAFSGGLHGVGVSVTNALATRLEVVVWRDGAVNRLVFKGGDVAEPLAPYDQG 
R4_03391           81 PEENAPVVELVFTRLHAGGKFDKAGGGAYAFSGGLHGVGVSVTNALATRLEVVVWRDGAVNRLVFKGGDVAEPLAPYDQG 
R5_02497           81 PEENAPVVELVFTRLHAGGKFDKAGGGAYAFSGGLHGVGVSVTNALATRLEVVVWRDGAVNRLVFKGGDVAEPLAPYDQG 
R8_03472           81 PEENAPVVELVFTRLHAGGKFDKAGGGAYAFSGGLHGVGVSVTNALATRLEVVVWRDGAVNRLVFKGGDVAEPLAPYDQG 
R9_01247           81 PEENAPVVELVFTRLHAGGKFDKAGGGAYAFSGGLHGVGVSVTNALATRLEVVVWRDGAVNRLVFKGGDVAEPLAPYDQG 
NH44784_1996       81 PEENAPVVELVFTRLHAGGKFDKAGGGAYAFSGGLHGVGVSVTNALATRLEVVVWRDGAVNRLVFKGGDVAEPLAPYDQG 
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  161        240 
R7_03582          161 GRKKSGTRVRVWPDAKYFDSPNIPLGELTHLLRSKAVLLPGVKVSLVNEKTGDTKTWQYQDGLRGYLSEALAGAELMVPF 
L10_00753         161 GRKKSGTRVRVWPDAKYFDSPNIPLGELTHLLRSKAVLLPGVKVSLVNEKTGDTKTWQYQDGLRGYLSEALAGAELMVPF 
NCIMB11015_03243  161 GRKKSGTRVRVWPDAKYFDSPNIPLGELTHLLRSKAVLLPGVKVSLVNEKTGDTKTWQYQDGLRGYLSEALAGAELMVPF 
L14_05855         161 GRKKSGTRVRVWPDAKYFDSPNIPLGELTHLLRSKAVLLPGVKVSLVNEKTGDTKTWQYQDGLRGYLSEALAGAELMVPF 
L17_01345         161 GRKKSGTRVRVWPDAKYFDSPNIPLGELTHLLRSKAVLLPGVKVSLVNEKTGDTKTWQYQDGLRGYLSEALAGAELMVPF 
L8_00649          161 GRKKSGTRVRVWPDAKYFDSPNIPLGELTHLLRSKAVLLPGVKVSLVNEKTGDTKTWQYQDGLRGYLSEALAGAELMVPF 
R6_01018          161 GRKKSGTRVRVWPDAKYFDSPNIPLGELTHLLRSKAVLLPGVKVSLVNEKTGDTKTWQYQDGLRGYLSEALAGAELMVPF 
DSM2402_00571     161 GRKKSGTRVRVWPDAKYFDSPNIPLGELTHLLRSKAVLLPGVKVSLVNEKTGDTKTWQYQDGLRGYLSEALAGAELMVPF 
L11_02233         161 GRKKSGTRVRVWPDAKYFDSPNIPLGELTHLLRSKAVLLPGVKVSLVNEKTGDTKTWQYQDGLRGYLSEALAGAELMVPF 
L15_00734         161 GRKKSGTRVRVWPDAKYFDSPNIPLGELTHLLRSKAVLLPGVKVSLVNEKTGDTKTWQYQDGLRGYLSEALAGAELMVPF 
L16_01228         161 GRKKSGTRVRVWPDAKYFDSPNIPLGELTHLLRSKAVLLPGVKVSLVNEKTGDTKTWQYQDGLRGYLSEALAGAELMVPF 
L1_02274          161 GRKKSGTRVRVWPDAKYFDSPNIPLGELTHLLRSKAVLLPGVKVSLVNEKTGDTKTWQYQDGLRGYLSEALAGAELMVPF 
L5_04551          161 GRKKSGTRVRVWPDAKYFDSPNIPLGELTHLLRSKAVLLPGVKVSLVNEKTGDTKTWQYQDGLRGYLSEALAGAELMVPF 
R10_03725         161 GRKKSGTRVRVWPDAKYFDSPNIPLGELTHLLRSKAVLLPGVKVSLVNEKTGDTKTWQYQDGLRGYLSEALAGAELMVPF 
R11_00070         161 GRKKSGTRVRVWPDAKYFDSPNIPLGELTHLLRSKAVLLPGVKVSLVNEKTGDTKTWQYQDGLRGYLSEALAGAELMVPF 
R12_00731         161 GRKKSGTRVRVWPDAKYFDSPNIPLGELTHLLRSKAVLLPGVKVSLVNEKTGDTKTWQYQDGLRGYLSEALAGAELMVPF 
R13_01577         161 GRKKSGTRVRVWPDAKYFDSPNIPLGELTHLLRSKAVLLPGVKVSLVNEKTGDTKTWQYQDGLRGYLSEALAGAELMVPF 
R14_05526         161 GRKKSGTRVRVWPDAKYFDSPNIPLGELTHLLRSKAVLLPGVKVSLVNEKTGDTKTWQYQDGLRGYLSEALAGAELMVPF 
R1_00144          161 GRKKSGTRVRVWPDAKYFDSPNIPLGELTHLLRSKAVLLPGVKVSLVNEKTGDTKTWQYQDGLRGYLSEALAGAELMVPF 
R2_00456          161 GRKKSGTRVRVWPDAKYFDSPNIPLGELTHLLRSKAVLLPGVKVSLVNEKTGDTKTWQYQDGLRGYLSEALAGAELMVPF 
R3_01679          161 GRKKSGTRVRVWPDAKYFDSPNIPLGELTHLLRSKAVLLPGVKVSLVNEKTGDTKTWQYQDGLRGYLSEALAGAELMVPF 
R4_03391          161 GRKKSGTRVRVWPDAKYFDSPNIPLGELTHLLRSKAVLLPGVKVSLVNEKTGDTKTWQYQDGLRGYLSEALAGAELMVPF 
R5_02497          161 GRKKSGTRVRVWPDAKYFDSPNIPLGELTHLLRSKAVLLPGVKVSLVNEKTGDTKTWQYQDGLRGYLSEALAGAELMVPF 
R8_03472          161 GRKKSGTRVRVWPDAKYFDSPNIPLGELTHLLRSKAVLLPGVKVSLVNEKTGDTKTWQYQDGLRGYLSEALAGAELMVPF 
R9_01247          161 GRKKSGTRVRVWPDAKYFDSPNIPLGELTHLLRSKAVLLPGVKVSLVNEKTGDTKTWQYQDGLRGYLSEALAGAELMVPF 
NH44784_1996      161 GRKKSGTRVRVWPDAKYFDSPNIPLGELTHLLRSKAVLLPGVKVSLVNEKTGDTKTWQYQDGLRGYLSEALAGAELMVPF 
 
  241        320 
R7_03582          241 FEGQQYAGADHETFAEGEGAQWVVAWTEDGNAVRESYVNLIPTPAGGTHESGLREGLFGAVKGFAELHSLLPKGVKLLPE 
L10_00753         241 FEGQQYAGADHETFAEGEGAQWVVAWTEDGNAVRESYVNLIPTPAGGTHESGLREGLFGAVKGFAELHSLLPKGVKLLPE 
NCIMB11015_03243  241 FEGQQYAGADHETFAEGEGAQWVVAWTEDGNAVRESYVNLIPTPAGGTHESGLREGLFGAVKGFAELHSLLPKGVKLLPE 
L14_05855         241 FEGQQYAGADHETFAEGEGAQWVVAWTEDGNAVRESYVNLIPTPAGGTHESGLREGLFGAVKGFAELHSLLPKGVKLLPE 
L17_01345         241 FEGQQYAGADHETFAEGEGAQWVVAWTEDGNAVRESYVNLIPTPAGGTHESGLREGLFGAVKGFAELHSLLPKGVKLLPE 
L8_00649          241 FEGQQYAGADHETFAEGEGAQWVVAWTEDGNAVRESYVNLIPTPAGGTHESGLREGLFGAVKGFAELHSLLPKGVKLLPE 
R6_01018          241 FEGQQYAGADHETFAEGEGAQWVVAWTEDGNAVRESYVNLIPTPAGGTHESGLREGLFGAVKGFAELHSLLPKGVKLLPE 
DSM2402_00571     241 FEGQQYAGADHETFAEGEGAQWVVAWTEDGNAVRESYVNLIPTPAGGTHESGLREGLFGAVKGFAELHSLLPKGVKLLPE 
L11_02233         241 FEGQQYAGADHETFAEGEGAQWVVAWTEDGNAVRESYVNLIPTPAGGTHESGLREGLFGAVKGFAELHSLLPKGVKLLPE 
L15_00734         241 FEGQQYAGADHETFAEGEGAQWVVAWTEDGNAVRESYVNLIPTPAGGTHESGLREGLFGAVKGFAELHSLLPKGVKLLPE 
L16_01228         241 FEGQQYAGADHETFAEGEGAQWVVAWTEDGNAVRESYVNLIPTPAGGTHESGLREGLFGAVKGFAELHSLLPKGVKLLPE 
L1_02274          241 FEGQQYAGADHETFAEGEGAQWVVAWTEDGNAVRESYVNLIPTPAGGTHESGLREGLFGAVKGFAELHSLLPKGVKLLPE 
L5_04551          241 FEGQQYAGADHETFAEGEGAQWVVAWTEDGNAVRESYVNLIPTPAGGTHESGLREGLFGAVKGFAELHSLLPKGVKLLPE 
R10_03725         241 FEGQQYAGADHETFAEGEGAQWVVAWTEDGNAVRESYVNLIPTPAGGTHESGLREGLFGAVKGFAELHSLLPKGVKLLPE 
R11_00070         241 FEGQQYAGADHETFAEGEGAQWVVAWTEDGNAVRESYVNLIPTPAGGTHESGLREGLFGAVKGFAELHSLLPKGVKLLPE 
R12_00731         241 FEGQQYAGADHETFAEGEGAQWVVAWTEDGNAVRESYVNLIPTPAGGTHESGLREGLFGAVKGFAELHSLLPKGVKLLPE 
R13_01577         241 FEGQQYAGADHETFAEGEGAQWVVAWTEDGNAVRESYVNLIPTPAGGTHESGLREGLFGAVKGFAELHSLLPKGVKLLPE 
R14_05526         241 FEGQQYAGADHETFAEGEGAQWVVAWTEDGNAVRESYVNLIPTPAGGTHESGLREGLFGAVKGFAELHSLLPKGVKLLPE 
R1_00144          241 FEGQQYAGADHETFAEGEGAQWVVAWTEDGNAVRESYVNLIPTPAGGTHESGLREGLFGAVKGFAELHSLLPKGVKLLPE 
R2_00456          241 FEGQQYAGADHETFAEGEGAQWVVAWTEDGNAVRESYVNLIPTPAGGTHESGLREGLFGAVKGFAELHSLLPKGVKLLPE 
R3_01679          241 FEGQQYAGADHETFAEGEGAQWVVAWTEDGNAVRESYVNLIPTPAGGTHESGLREGLFGAVKGFAELHSLLPKGVKLLPE 
R4_03391          241 FEGQQYAGADHETFAEGEGAQWVVAWTEDGNAVRESYVNLIPTPAGGTHESGLREGLFGAVKGFAELHSLLPKGVKLLPE 
R5_02497          241 FEGQQYAGADHETFAEGEGAQWVVAWTEDGNAVRESYVNLIPTPAGGTHESGLREGLFGAVKGFAELHSLLPKGVKLLPE 
R8_03472          241 FEGQQYAGADHETFAEGEGAQWVVAWTEDGNAVRESYVNLIPTPAGGTHESGLREGLFGAVKGFAELHSLLPKGVKLLPE 
R9_01247          241 FEGQQYAGADHETFAEGEGAQWVVAWTEDGNAVRESYVNLIPTPAGGTHESGLREGLFGAVKGFAELHSLLPKGVKLLPE 
NH44784_1996      241 FEGQQYAGADHETFAEGEGAQWVVAWTEDGNAVRESYVNLIPTPAGGTHESGLREGLFGAVKGFAELHSLLPKGVKLLPE 
 
  321        400 
R7_03582          321 DVFARASFVLSAKVLDPQFQGQIKERLNSRDAVRLVGGFAKSALDLWLHSNVEYGKKLAELAIRQAQARQRSAQKVEKRK 
L10_00753         321 DVFARASFVLSAKVLDPQFQGQIKERLNSRDAVRLVGGFAKSALDLWLHSNVEYGKKLAELAIRQAQARQRSAQKVEKRK 
NCIMB11015_03243  321 DVFARASFVLSAKVLDPQFQGQIKERLNSRDAVRLVGGFAKSALDLWLHSNVEYGKKLAELAIRQAQARQRSAQKVEKRK 
L14_05855         321 DVFARASFVLSAKVLDPQFQGQIKERLNSRDAVRLVGGFAKSALDLWLHSNVEYGKKLAELAIRQAQARQRSAQKVEKRK 
L17_01345         321 DVFARASFVLSAKVLDPQFQGQIKERLNSRDAVRLVGGFAKSALDLWLHSNVEYGKKLAELAIRQAQARQRSAQKVEKRK 
L8_00649          321 DVFARASFVLSAKVLDPQFQGQIKERLNSRDAVRLVGGFAKSALDLWLHSNVEYGKKLAELAIRQAQARQRSAQKVEKRK 
R6_01018          321 DVFARASFVLSAKVLDPQFQGQIKERLNSRDAVRLVGGFAKSALDLWLHSNVEYGKKLAELAIRQAQARQRSAQKVEKRK 
DSM2402_00571     321 DVFARASFVLSAKVLDPQFQGQIKERLNSRDAVRLVGGFAKSALDLWLHSNVEYGKKLAELAIRQAQARQRSAQKVEKRK 
L11_02233         321 DVFARASFVLSAKVLDPQFQGQIKERLNSRDAVRLVGGFAKSALDLWLHSNVEYGKKLAELAIRQAQARQRSAQKVEKRK 
L15_00734         321 DVFARASFVLSAKVLDPQFQGQIKERLNSRDAVRLVGGFAKSALDLWLHSNVEYGKKLAELAIRQAQARQRSAQKVEKRK 
L16_01228         321 DVFARASFVLSAKVLDPQFQGQIKERLNSRDAVRLVGGFAKSALDLWLHSNVEYGKKLAELAIRQAQARQRSAQKVEKRK 
L1_02274          321 DVFARASFVLSAKVLDPQFQGQIKERLNSRDAVRLVGGFAKSALDLWLHSNVEYGKKLAELAIRQAQARQRSAQKVEKRK 
L5_04551          321 DVFARASFVLSAKVLDPQFQGQIKERLNSRDAVRLVGGFAKSALDLWLHSNVEYGKKLAELAIRQAQARQRSAQKVEKRK 
R10_03725         321 DVFARASFVLSAKVLDPQFQGQIKERLNSRDAVRLVGGFAKSALDLWLHSNVEYGKKLAELAIRQAQARQRSAQKVEKRK 
R11_00070         321 DVFARASFVLSAKVLDPQFQGQIKERLNSRDAVRLVGGFAKSALDLWLHSNVEYGKKLAELAIRQAQARQRSAQKVEKRK 
R12_00731         321 DVFARASFVLSAKVLDPQFQGQIKERLNSRDAVRLVGGFAKSALDLWLHSNVEYGKKLAELAIRQAQARQRSAQKVEKRK 
R13_01577         321 DVFARASFVLSAKVLDPQFQGQIKERLNSRDAVRLVGGFAKSALDLWLHSNVEYGKKLAELAIRQAQARQRSAQKVEKRK 
R14_05526         321 DVFARASFVLSAKVLDPQFQGQIKERLNSRDAVRLVGGFAKSALDLWLHSNVEYGKKLAELAIRQAQARQRSAQKVEKRK 
R1_00144          321 DVFARASFVLSAKVLDPQFQGQIKERLNSRDAVRLVGGFAKSALDLWLHSNVEYGKKLAELAIRQAQARQRSAQKVEKRK 
R2_00456          321 DVFARASFVLSAKVLDPQFQGQIKERLNSRDAVRLVGGFAKSALDLWLHSNVEYGKKLAELAIRQAQARQRSAQKVEKRK 
R3_01679          321 DVFARASFVLSAKVLDPQFQGQIKERLNSRDAVRLVGGFAKSALDLWLHSNVEYGKKLAELAIRQAQARQRSAQKVEKRK 
R4_03391          321 DVFARASFVLSAKVLDPQFQGQIKERLNSRDAVRLVGGFAKSALDLWLHSNVEYGKKLAELAIRQAQARQRSAQKVEKRK 
R5_02497          321 DVFARASFVLSAKVLDPQFQGQIKERLNSRDAVRLVGGFAKSALDLWLHSNVEYGKKLAELAIRQAQARQRSAQKVEKRK 
R8_03472          321 DVFARASFVLSAKVLDPQFQGQIKERLNSRDAVRLVGGFAKSALDLWLHSNVEYGKKLAELAIRQAQARQRSAQKVEKRK 
R9_01247          321 DVFARASFVLSAKVLDPQFQGQIKERLNSRDAVRLVGGFAKSALDLWLHSNVEYGKKLAELAIRQAQARQRSAQKVEKRK 
NH44784_1996      321 DVFARASFVLSAKVLDPQFQGQIKERLNSRDAVRLVGGFAKSALDLWLHSNVEYGKKLAELAIRQAQARQRSAQKVEKRK 
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  401        480 
R7_03582          401 SSGVAVLPGKLTDCESSDATRTEVFLVEGDSAGGSAKMGRDKEFQAILPLRGKVLNSWEVDRDRLFANNEIHDISVAIGV 
L10_00753         401 SSGVAVLPGKLTDCESSDATRTEVFLVEGDSAGGSAKMGRDKEFQAILPLRGKVLNSWEVDRDRLFANNEIHDISVAIGV 
NCIMB11015_03243  401 SSGVAVLPGKLTDCESSDATRTEVFLVEGDSAGGSAKMGRDKEFQAILPLRGKVLNSWEVDRDRLFANNEIHDISVAIGV 
L14_05855         401 SSGVAVLPGKLTDCESSDATRTEVFLVEGDSAGGSAKMGRDKEFQAILPLRGKVLNSWEVDRDRLFANNEIHDISVAIGV 
L17_01345         401 SSGVAVLPGKLTDCESSDATRTEVFLVEGDSAGGSAKMGRDKEFQAILPLRGKVLNSWEVDRDRLFANNEIHDISVAIGV 
L8_00649          401 SSGVAVLPGKLTDCESSDATRTEVFLVEGDSAGGSAKMGRDKEFQAILPLRGKVLNSWEVDRDRLFANNEIHDISVAIGV 
R6_01018          401 SSGVAVLPGKLTDCESSDATRTEVFLVEGDSAGGSAKMGRDKEFQAILPLRGKVLNSWEVDRDRLFANNEIHDISVAIGV 
DSM2402_00571     401 SSGVAVLPGKLTDCESSDATRTEVFLVEGDSAGGSAKMGRDKEFQAILPLRGKVLNSWEVDRDRLFANNEIHDISVAIGV 
L11_02233         401 SSGVAVLPGKLTDCESSDATRTEVFLVEGDSAGGSAKMGRDKEFQAILPLRGKVLNSWEVDRDRLFANNEIHDISVAIGV 
L15_00734         401 SSGVAVLPGKLTDCESSDATRTEVFLVEGDSAGGSAKMGRDKEFQAILPLRGKVLNSWEVDRDRLFANNEIHDISVAIGV 
L16_01228         401 SSGVAVLPGKLTDCESSDATRTEVFLVEGDSAGGSAKMGRDKEFQAILPLRGKVLNSWEVDRDRLFANNEIHDISVAIGV 
L1_02274          401 SSGVAVLPGKLTDCESSDATRTEVFLVEGDSAGGSAKMGRDKEFQAILPLRGKVLNSWEVDRDRLFANNEIHDISVAIGV 
L5_04551          401 SSGVAVLPGKLTDCESSDATRTEVFLVEGDSAGGSAKMGRDKEFQAILPLRGKVLNSWEVDRDRLFANNEIHDISVAIGV 
R10_03725         401 SSGVAVLPGKLTDCESSDATRTEVFLVEGDSAGGSAKMGRDKEFQAILPLRGKVLNSWEVDRDRLFANNEIHDISVAIGV 
R11_00070         401 SSGVAVLPGKLTDCESSDATRTEVFLVEGDSAGGSAKMGRDKEFQAILPLRGKVLNSWEVDRDRLFANNEIHDISVAIGV 
R12_00731         401 SSGVAVLPGKLTDCESSDATRTEVFLVEGDSAGGSAKMGRDKEFQAILPLRGKVLNSWEVDRDRLFANNEIHDISVAIGV 
R13_01577         401 SSGVAVLPGKLTDCESSDATRTEVFLVEGDSAGGSAKMGRDKEFQAILPLRGKVLNSWEVDRDRLFANNEIHDISVAIGV 
R14_05526         401 SSGVAVLPGKLTDCESSDATRTEVFLVEGDSAGGSAKMGRDKEFQAILPLRGKVLNSWEVDRDRLFANNEIHDISVAIGV 
R1_00144          401 SSGVAVLPGKLTDCESSDATRTEVFLVEGDSAGGSAKMGRDKEFQAILPLRGKVLNSWEVDRDRLFANNEIHDISVAIGV 
R2_00456          401 SSGVAVLPGKLTDCESSDATRTEVFLVEGDSAGGSAKMGRDKEFQAILPLRGKVLNSWEVDRDRLFANNEIHDISVAIGV 
R3_01679          401 SSGVAVLPGKLTDCESSDATRTEVFLVEGDSAGGSAKMGRDKEFQAILPLRGKVLNSWEVDRDRLFANNEIHDISVAIGV 
R4_03391          401 SSGVAVLPGKLTDCESSDATRTEVFLVEGDSAGGSAKMGRDKEFQAILPLRGKVLNSWEVDRDRLFANNEIHDISVAIGV 
R5_02497          401 SSGVAVLPGKLTDCESSDATRTEVFLVEGDSAGGSAKMGRDKEFQAILPLRGKVLNSWEVDRDRLFANNEIHDISVAIGV 
R8_03472          401 SSGVAVLPGKLTDCESSDATRTEVFLVEGDSAGGSAKMGRDKEFQAILPLRGKVLNSWEVDRDRLFANNEIHDISVAIGV 
R9_01247          401 SSGVAVLPGKLTDCESSDATRTEVFLVEGDSAGGSAKMGRDKEFQAILPLRGKVLNSWEVDRDRLFANNEIHDISVAIGV 
NH44784_1996      401 SSGVAVLPGKLTDCESSDATRTEVFLVEGDSAGGSAKMGRDKEFQAILPLRGKVLNSWEVDRDRLFANNEIHDISVAIGV 
 
  481        560 
R7_03582          481 DPHGPGDTPDLSGLRYGRICILSDADVDGSHIQVLLLTLFYKHFPKLVEAGHVYVAKPPLFRLDVPAQGKRPARKIYCLD 
L10_00753         481 DPHGPGDTPDLSGLRYGRICILSDADVDGSHIQVLLLTLFYKHFPKLVEAGHVYVAKPPLFRLDVPAQGKRPARKIYCLD 
NCIMB11015_03243  481 DPHGPGDSPDLSGLRYGRICILSDADVDGSHIQVLLLTLFYKHFPKLVEAGHVYVAKPPLFRLDVPAQGKRPARKIYCLD 
L14_05855         481 DPHGPGDSPDLSGLRYGRICILSDADVDGSHIQVLLLTLFYKHFPKLVEAGHVYVAKPPLFRLDVPAQGKRPARKIYCLD 
L17_01345         481 DPHGPGDSPDLSGLRYGRICILSDADVDGSHIQVLLLTLFYKHFPKLVEAGHVYVAKPPLFRLDVPAQGKRPARKIYCLD 
L8_00649          481 DPHGPGDSPDLSGLRYGRICILSDADVDGSHIQVLLLTLFYKHFPKLVEAGHVYVAKPPLFRLDVPAQGKRPARKIYCLD 
R6_01018          481 DPHGPGDSPDLSGLRYGRICILSDADVDGSHIQVLLLTLFYKHFPKLVEAGHVYVAKPPLFRLDVPAQGKRPARKIYCLD 
DSM2402_00571     481 DPHGPGDTPDLSGLRYGRICILSDADVDGSHIQVLLLTLFYKHFPKLVEAGHVYVAKPPLFRLDVPAQGKRPARKIYCLD 
L11_02233         481 DPHGPGDTPDLSGLRYGRICILSDADVDGSHIQVLLLTLFYKHFPKLVEAGHVYVAKPPLFRLDVPAQGKRPARKIYCLD 
L15_00734         481 DPHGPGDTPDLSGLRYGRICILSDADVDGSHIQVLLLTLFYKHFPKLVEAGHVYVAKPPLFRLDVPAQGKRPARKIYCLD 
L16_01228         481 DPHGPGDTPDLSGLRYGRICILSDADVDGSHIQVLLLTLFYKHFPKLVEAGHVYVAKPPLFRLDVPAQGKRPARKIYCLD 
L1_02274          481 DPHGPGDTPDLSGLRYGRICILSDADVDGSHIQVLLLTLFYKHFPKLVEAGHVYVAKPPLFRLDVPAQGKRPARKIYCLD 
L5_04551          481 DPHGPGDTPDLSGLRYGRICILSDADVDGSHIQVLLLTLFYKHFPKLVEAGHVYVAKPPLFRLDVPAQGKRPARKIYCLD 
R10_03725         481 DPHGPGDTPDLSGLRYGRICILSDADVDGSHIQVLLLTLFYKHFPKLVEAGHVYVAKPPLFRLDVPAQGKRPARKIYCLD 
R11_00070         481 DPHGPGDTPDLSGLRYGRICILSDADVDGSHIQVLLLTLFYKHFPKLVEAGHVYVAKPPLFRLDVPAQGKRPARKIYCLD 
R12_00731         481 DPHGPGDTPDLSGLRYGRICILSDADVDGSHIQVLLLTLFYKHFPKLVEAGHVYVAKPPLFRLDVPAQGKRPARKIYCLD 
R13_01577         481 DPHGPGDTPDLSGLRYGRICILSDADVDGSHIQVLLLTLFYKHFPKLVEAGHVYVAKPPLFRLDVPAQGKRPARKIYCLD 
R14_05526         481 DPHGPGDTPDLSGLRYGRICILSDADVDGSHIQVLLLTLFYKHFPKLVEAGHVYVAKPPLFRLDVPAQGKRPARKIYCLD 
R1_00144          481 DPHGPGDTPDLSGLRYGRICILSDADVDGSHIQVLLLTLFYKHFPKLVEAGHVYVAKPPLFRLDVPAQGKRPARKIYCLD 
R2_00456          481 DPHGPGDTPDLSGLRYGRICILSDADVDGSHIQVLLLTLFYKHFPKLVEAGHVYVAKPPLFRLDVPAQGKRPARKIYCLD 
R3_01679          481 DPHGPGDTPDLSGLRYGRICILSDADVDGSHIQVLLLTLFYKHFPKLVEAGHVYVAKPPLFRLDVPAQGKRPARKIYCLD 
R4_03391          481 DPHGPGDTPDLSGLRYGRICILSDADVDGSHIQVLLLTLFYKHFPKLVEAGHVYVAKPPLFRLDVPAQGKRPARKIYCLD 
R5_02497          481 DPHGPGDTPDLSGLRYGRICILSDADVDGSHIQVLLLTLFYKHFPKLVEAGHVYVAKPPLFRLDVPAQGKRPARKIYCLD 
R8_03472          481 DPHGPGDTPDLSGLRYGRICILSDADVDGSHIQVLLLTLFYKHFPKLVEAGHVYVAKPPLFRLDVPAQGKRPARKIYCLD 
R9_01247          481 DPHGPGDTPDLSGLRYGRICILSDADVDGSHIQVLLLTLFYKHFPKLVEAGHVYVAKPPLFRLDVPAQGKRPARKIYCLD 
NH44784_1996      481 DPHGPGDTPDLSGLRYGRICILSDADVDGSHIQVLLLTLFYKHFPKLVEAGHVYVAKPPLFRLDVPAQGKRPARKIYCLD 
 
  561        640 
R7_03582          561 EGELEAAQDKLRKEGSRESSWSVSRFKGLGEMNPEQLWETTMNPDTRRLLPVGYGDQTPEDTTRMFDMLMGKGESSQRRA 
L10_00753         561 EGELEAAQDKLRKEGSRESSWAVSRFKGLGEMNPEQLWETTMNPDTRRLLPVGYGDQTPEDTTRMFDMLMGKGESSQRRA 
NCIMB11015_03243  561 EGELEAAQDKLRKEGSRESSWAVSRFKGLGEMNPEQLWETTMNPDTRRLLPVGYGDQTPEDTTRMFDMLMGKGESSQRRA 
L14_05855         561 EGELEAAQDKLRKEGSRESSWAVSRFKGLGEMNPEQLWETTMNPDTRRLLPVGYGDQTPEDTTRMFDMLMGKGESSQRRA 
L17_01345         561 EGELEAAQDKLRKEGSRESSWAVSRFKGLGEMNPEQLWETTMNPDTRRLLPVGYGDQTPEDTTRMFDMLMGKGESSQRRA 
L8_00649          561 EGELEAAQDKLRKEGSRESSWAVSRFKGLGEMNPEQLWETTMNPDTRRLLPVGYGDQTPEDTTRMFDMLMGKGESSQRRA 
R6_01018          561 EGELEAAQDKLRKEGSRESSWAVSRFKGLGEMNPEQLWETTMNPDTRRLLPVGYGDQTPEDTTRMFDMLMGKGESSQRRA 
DSM2402_00571     561 EGELEAAQDKLRKEGSRESSWAVSRFKGLGEMNPEQLWETTMNPDTRRLLPVGYGDQTPEDTTRMFDMLMGKGESSQRRA 
L11_02233         561 EGELEAAQDKLRKEGSRESSWAVSRFKGLGEMNPEQLWETTMNPDTRRLLPVGYGDQTPEDTTRMFDMLMGKGESSQRRA 
L15_00734         561 EGELEAAQDKLRKEGSRESSWAVSRFKGLGEMNPEQLWETTMNPDTRRLLPVGYGDQTPEDTTRMFDMLMGKGESSQRRA 
L16_01228         561 EGELEAAQDKLRKEGSRESSWAVSRFKGLGEMNPEQLWETTMNPDTRRLLPVGYGDQTPEDTTRMFDMLMGKGESSQRRA 
L1_02274          561 EGELEAAQDKLRKEGSRESSWAVSRFKGLGEMNPEQLWETTMNPDTRRLLPVGYGDQTPEDTTRMFDMLMGKGESSQRRA 
L5_04551          561 EGELEAAQDKLRKEGSRESSWAVSRFKGLGEMNPEQLWETTMNPDTRRLLPVGYGDQTPEDTTRMFDMLMGKGESSQRRA 
R10_03725         561 EGELEAAQDKLRKEGSRESSWAVSRFKGLGEMNPEQLWETTMNPDTRRLLPVGYGDQTPEDTTRMFDMLMGKGESSQRRA 
R11_00070         561 EGELEAAQDKLRKEGSRESSWAVSRFKGLGEMNPEQLWETTMNPDTRRLLPVGYGDQTPEDTTRMFDMLMGKGESSQRRA 
R12_00731         561 EGELEAAQDKLRKEGSRESSWAVSRFKGLGEMNPEQLWETTMNPDTRRLLPVGYGDQTPEDTTRMFDMLMGKGESSQRRA 
R13_01577         561 EGELEAAQDKLRKEGSRESSWAVSRFKGLGEMNPEQLWETTMNPDTRRLLPVGYGDQTPEDTTRMFDMLMGKGESSQRRA 
R14_05526         561 EGELEAAQDKLRKEGSRESSWAVSRFKGLGEMNPEQLWETTMNPDTRRLLPVGYGDQTPEDTTRMFDMLMGKGESSQRRA 
R1_00144          561 EGELEAAQDKLRKEGSRESSWAVSRFKGLGEMNPEQLWETTMNPDTRRLLPVGYGDQTPEDTTRMFDMLMGKGESSQRRA 
R2_00456          561 EGELEAAQDKLRKEGSRESSWAVSRFKGLGEMNPEQLWETTMNPDTRRLLPVGYGDQTPEDTTRMFDMLMGKGESSQRRA 
R3_01679          561 EGELEAAQDKLRKEGSRESSWAVSRFKGLGEMNPEQLWETTMNPDTRRLLPVGYGDQTPEDTTRMFDMLMGKGESSQRRA 
R4_03391          561 EGELEAAQDKLRKEGSRESSWAVSRFKGLGEMNPEQLWETTMNPDTRRLLPVGYGDQTPEDTTRMFDMLMGKGESSQRRA 
R5_02497          561 EGELEAAQDKLRKEGSRESSWAVSRFKGLGEMNPEQLWETTMNPDTRRLLPVGYGDQTPEDTTRMFDMLMGKGESSQRRA 
R8_03472          561 EGELEAAQDKLRKEGSRESSWAVSRFKGLGEMNPEQLWETTMNPDTRRLLPVGYGDQTPEDTTRMFDMLMGKGESSQRRA 
R9_01247          561 EGELEAAQDKLRKEGSRESSWAVSRFKGLGEMNPEQLWETTMNPDTRRLLPVGYGDQTPEDTTRMFDMLMGKGESSQRRA 
NH44784_1996      561 EGELEAAQDKLRKEGSRESSWAVSRFKGLGEMNPEQLWETTMNPDTRRLLPVGYGDQTPEDTTRMFDMLMGKGESSQRRA 
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  641    530 
R7_03582          641 WIEEKGNLAELDI 
L10_00753         641 WIEEKGNLAELDI 
NCIMB11015_03243  641 WIEEKGNLAELDI 
L14_05855         641 WIEEKGNLAELDI 
L17_01345         641 WIEEKGNLAELDI 
L8_00649          641 WIEEKGNLAELDI 
R6_01018          641 WIEEKGNLAELDI 
DSM2402_00571     641 WIEEKGNLAELDI 
L11_02233         641 WIEEKGNLAELDI 
L15_00734         641 WIEEKGNLAELDI 
L16_01228         641 WIEEKGNLAELDI 
L1_02274          641 WIEEKGNLAELDI 
L5_04551          641 WIEEKGNLAELDI 
R10_03725         641 WIEEKGNLAELDI 
R11_00070         641 WIEEKGNLAELDI 
R12_00731         641 WIEEKGNLAELDI 
R13_01577         641 WIEEKGNLAELDI 
R14_05526         641 WIEEKGNLAELDI 
R1_00144          641 WIEEKGNLAELDI 
R2_00456          641 WIEEKGNLAELDI 
R3_01679          641 WIEEKGNLAELDI 
R4_03391          641 WIEEKGNLAELDI 
R5_02497          641 WIEEKGNLAELDI 
R8_03472          641 WIEEKGNLAELDI 
R9_01247          641 WIEEKGNLAELDI 
NH44784_1996      641 WIEEKGNLAELDI 
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Table A3.1: A table to show the zone of inhibition for cephalosporin 
antibiotic determined on 25 isolates of A. xylosoxidans 
 
Isolates 
Zone of inhibition (mm) 
CXM CTX CAZ CRO FEP 
R1 5 11 30 11 31 
R2 5 7 30 12 36 
R3 5 7 28 11 30 
R4 5 5 5 5 19 
R5 5 5 27 10 31 
R6 5 12 30 12 26 
R7 5 12 34 24 11 
R8 5 5 21 22 22 
R9 5 25 27 24 38 
R10 5 9 27 11 31 
R11 5 17 34 17 26 
R12 5 13 28 12 32 
R13 5 5 32 10 30 
R14 5 5 30 10 30 
L1 5 10 34 15 30 
L5 5 7 34 16 25 
L8 5 12 32 15 23 
L10 5 15 32 20 28 
L11 5 19 36 28 30 
L14 5 7 33 20 20 
L15 5 20 30 24 32 
L16 5 14 30 20 17 
L17 5 13 30 17 26 
NCIMB 11015 5 12 34 16 28 
DSM 2402 5 18 32 12 18 
 
 
  
Appendices 
 292 
A
p
p
en
d
ices 
Table A3.2: A table to show the zone of inhibition for antibiotic in category: 
fluoroquinolone and aminoglycoside determined on 25 isolates of A. 
xylosoxidans 
 
Isolates 
Zone of inhibition (mm) 
LEV CIP GEN AMK SXT TGC 
R1 22 17 9 15 26 30 
R2 21 18 11 12 26 28 
R3 20 17 10 12 20 24 
R4 20 16 5 13 5 25 
R5 21 19 5 12 22 29 
R6 30 24 12 22 25 32 
R7 19 20 5 5 30 20 
R8 12 12 16 14 14 22 
R9 19 8 8 16 24 26 
R10 20 17 10 11 20 24 
R11 24 20 15 21 42 30 
R12 18 18 9 16 24 25 
R13 14 19 5 11 20 25 
R14 18 22 9 11 27 26 
L1 26 22 15 16 42 30 
L5 25 22 12 14 42 27 
L8 32 28 18 16 36 39 
L10 25 21 13 17 50 30 
L11 28 26 20 29 38 25 
L14 20 20 5 21 40 25 
L15 26 15 14 25 34 26 
L16 14 15 4 5 34 24 
L17 25 25 25 20 34 33 
NCIMB 11015 22 22 14 16 26 32 
DSM 2402 12 12 12 11 14 18 
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Table A3.3: A table to show the zone of inhibition for antibiotic in category: 
aminopenicillin, ureidopenicillin and carbapenem determined on 25 isolates 
of A. xylosoxidans 
 
Isolates 
Zone of inhibition (mm) 
AMP AMC TZP IPM MEM ETP 
R1 14 21 38 22 28 32 
R2 16 26 38 30 31 36 
R3 14 24 36 21 28 32 
R4 12 12 38 17 5 12 
R5 14 20 39 21 28 30 
R6 32 38 54 39 42 50 
R7 20 27 50 36 48 32 
R8 12 19 22 16 5 13 
R9 16 30 38 30 28 38 
R10 12 22 32 21 28 32 
R11 25 30 50 36 46 42 
R12 16 30 34 30 48 36 
R13 14 22 32 20 30 30 
R14 14 22 38 21 30 30 
L1 21 28 48 24 40 40 
L5 21 32 53 31 46 44 
L8 20 28 46 35 24 26 
L10 25 28 48 34 44 42 
L11 30 32 50 38 56 48 
L14 20 28 48 32 42 44 
L15 30 32 52 40 48 46 
L16 23 25 44 34 36 30 
L17 23 30 44 33 40 43 
NCIMB 11015 22 32 38 36 32 32 
DSM 2402 12 18 32 34 28 32 
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Table A3.4: A table to show minimum inhibitory concentration of Thai isolates of A. xylosoxidans for antimicrobial agents 
 
Isolates 
Minimum inhibitory Concentration (μg/ml) 
AMP AMC TZP CXM CTX CAZ CRO FEP IPM MEM ETP CIP LEV GEN AMK TGC SXT 
R1 16 8 ≤8 >16 >32 2 >32 16 4 ≤0.5 ≤0.5 2 1 >8 >32 ≤0.25 ≤1 
R2 ≤8 ≤4 ≤8 >16 >32 2 >32 8 1 ≤0.5 ≤0.5 >2 4 >8 >32 0.5 ≤1 
R3 ≤8 8 ≤8 >16 >32 2 >32 8 2 ≤0.5 ≤0.5 >2 2 >8 >32 0.5 ≤1 
R4 >16 >16 ≤8 >16 >32 >32 >32 >32 8 >8 4 1 1 >8 >32 ≤0.25 >4 
R5 16 8 ≤8 >16 >32 4 >32 16 4 ≤0.5 ≤0.5 2 1 >8 >32 ≤0.25 ≤1 
R6 ≤8 ≤4 ≤8 >16 8 ≤1 8 4 ≤0.5 ≤0.5 ≤0.5 >2 2 4 16 ≤0.25 ≤1 
R7 ≤8 ≤4 ≤8 >16 32 2 32 16 ≤0.5 ≤0.5 ≤0.5 >2 4 >8 >32 1 ≤1 
R8 >16 >16 32 >16 >32 >32 >32 >32 >8 >8 >4 >2 8 >8 >32 1 >4 
R9 ≤8 ≤4 ≤8 >16 32 2 32 8 1 ≤0.5 ≤0.5 >2 2 >8 >32 0.5 ≤1 
R10 ≤8 8 ≤8 >16 >32 2 >32 8 2 ≤0.5 ≤0.5 >2 2 >8 >32 0.5 ≤1 
R11 ≤8 ≤4 ≤8 >16 >32 2 >32 8 1 ≤0.5 ≤0.5 >2 4 >8 >32 0.5 ≤1 
R12 ≤8 ≤4 ≤8 >16 >32 2 >32 8 ≤0.5 ≤0.5 ≤0.5 >2 4 >8 >32 0.5 ≤1 
R13 16 16 ≤8 >16 >32 4 >32 16 2 ≤0.5 ≤0.5 >2 4 >8 >32 ≤0.25 ≤1 
R14 16 8 ≤8 >16 >32 4 >32 16 4 ≤0.5 ≤0.5 2 2 >8 >32 ≤0.25 ≤1 
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Table A3.5: A table to show the ration of UV absorbance at 390 nm to UV absorbance at 486 nm in each strain. Data were collected 
using FLUOstar Omega for 25 minutes of incubation. 
 
Incubation 
Time (min) 
Strain 
R1 R2 R3 R4 R5 R6 R7 R8 R9 R10 R11 R12 R13 R14 
0 0.521 0.510 0.502 0.633 0.503 0.458 0.491 0.668 0.466 0.497 0.500 0.469 0.457 0.506 
1 0.562 0.554 0.539 1.039 0.552 0.482 0.547 0.779 0.503 0.526 0.543 0.514 0.486 0.576 
2 0.581 0.571 0.553 1.089 0.561 0.494 0.558 0.825 0.524 0.531 0.560 0.526 0.505 0.594 
3 0.548 0.560 0.541 1.104 0.556 0.493 0.559 0.849 0.525 0.542 0.563 0.534 0.525 0.592 
4 0.540 0.554 0.528 1.125 0.541 0.490 0.552 0.854 0.509 0.532 0.560 0.527 0.544 0.574 
5 0.582 0.572 0.558 1.144 0.575 0.509 0.597 0.879 0.548 0.543 0.586 0.538 0.570 0.614 
6 0.576 0.590 0.572 1.153 0.590 0.520 0.607 0.894 0.548 0.570 0.604 0.548 0.589 0.614 
7 0.556 0.564 0.541 1.132 0.563 0.507 0.578 0.887 0.533 0.531 0.577 0.529 0.606 0.572 
8 0.582 0.572 0.556 1.132 0.560 0.518 0.593 0.914 0.555 0.557 0.612 0.542 0.628 0.577 
9 0.557 0.554 0.559 1.123 0.541 0.521 0.593 0.914 0.532 0.545 0.589 0.546 0.647 0.576 
10 0.586 0.608 0.590 1.138 0.601 0.548 0.655 0.946 0.574 0.583 0.653 0.569 0.674 0.628 
11 0.584 0.596 0.577 1.125 0.594 0.546 0.638 0.954 0.573 0.578 0.638 0.572 0.690 0.615 
12 0.619 0.615 0.592 1.121 0.601 0.557 0.656 0.970 0.585 0.577 0.644 0.582 0.708 0.616 
13 0.606 0.612 0.598 1.120 0.589 0.563 0.674 0.976 0.594 0.589 0.665 0.588 0.724 0.602 
14 0.601 0.600 0.604 1.112 0.592 0.569 0.660 0.985 0.563 0.592 0.647 0.575 0.743 0.608 
15 0.564 0.599 0.584 1.107 0.587 0.569 0.668 0.985 0.569 0.586 0.630 0.590 0.758 0.609 
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Table A3.5: A table to show the ration of UV absorbance at 486 nm to UV absorbance at 390 nm in each strain. Data were collected using 
FLUOstar Omega for 25 minutes of incubation (Continued). 
 
Incubation 
Time (min) 
Strain 
R1 R2 R3 R4 R5 R6 R7 R8 R9 R10 R11 R12 R13 R14 
(Continued) 
16 0.597 0.617 0.589 1.104 0.572 0.572 0.680 0.996 0.591 0.596 0.678 0.584 0.778 0.599 
17 0.606 0.620 0.599 1.102 0.606 0.587 0.706 1.009 0.603 0.591 0.667 0.601 0.798 0.604 
18 0.619 0.637 0.629 1.111 0.615 0.593 0.724 1.031 0.620 0.625 0.701 0.622 0.819 0.637 
19 0.613 0.640 0.626 1.102 0.607 0.601 0.724 1.035 0.641 0.625 0.696 0.635 0.837 0.642 
20 0.625 0.654 0.628 1.104 0.603 0.607 0.740 1.050 0.650 0.632 0.708 0.638 0.858 0.638 
21 0.625 0.652 0.642 1.104 0.613 0.614 0.740 1.057 0.640 0.630 0.721 0.635 0.875 0.633 
22 0.635 0.660 0.659 1.108 0.632 0.624 0.758 1.069 0.669 0.643 0.735 0.656 0.896 0.681 
23 0.653 0.664 0.655 1.106 0.629 0.629 0.775 1.071 0.654 0.657 0.747 0.656 0.908 0.659 
24 0.641 0.659 0.642 1.094 0.597 0.626 0.765 1.082 0.671 0.642 0.741 0.651 0.919 0.631 
25 0.644 0.676 0.663 1.099 0.652 0.642 0.789 1.086 0.661 0.669 0.770 0.662 0.946 0.665 
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Table A3.6: Output from CARD-enriched OrthoMCL‟s group 
 
ID Annotation 
ORTHOMCL0 RND efflux system, inner membrane transporter CmeB 
ORTHOMCL1 AcrB AcrD AcrF family protein 
ORTHOMCL2 
Cobalt zinc cadmium resistance protein CzcA, Cation efflux system protein 
CusA 
ORTHOMCL3 RND efflux system, outer membrane lipoprotein CmeC 
ORTHOMCL4 Transcriptional regulatory protein OmpR 
ORTHOMCL5 ABC transporter, ATP binding permease protein 
ORTHOMCL7 Chloramphenicol acetyltransferase 
ORTHOMCL8 RND efflux system, membrane fusion protein CmeA   
ORTHOMCL9 Transport ATP binding protein CydCD   
ORTHOMCL10 Fosmidomycin resistance protein 
ORTHOMCL11 Lipid A export ATP binding permease protein MsbA 
ORTHOMCL12 Topoisomerase IV subunit B 
ORTHOMCL13 Inner membrane component of tripartite multidrug resistance system 
ORTHOMCL14 Dihydropteroate synthase 
ORTHOMCL15 RND efflux system, membrane fusion protein CmeA 
ORTHOMCL16 Translation elongation factor Tu 
ORTHOMCL17 DNA gyrase subunit B 
ORTHOMCL18 RND multidrug efflux transporter, Acriflavin resistance protein 
ORTHOMCL19 Macrolide export ATP binding permease protein MacB 
ORTHOMCL20 RND multidrug efflux transporter, Acriflavin resistance protein 
ORTHOMCL21 RND efflux system, membrane fusion protein CmeA 
ORTHOMCL22 Lipid A export ATP binding permease protein MsbA  
ORTHOMCL23 DNA gyrase subunit A 
ORTHOMCL24 Lipid A export ATP binding permease protein MsbA 
ORTHOMCL25 Translation elongation factor G 
ORTHOMCL26 DNA directed RNA polymerase beta subunit 
ORTHOMCL27 RND efflux system, outer membrane lipoprotein CmeC 
ORTHOMCL29 Topoisomerase IV subunit A  
ORTHOMCL30 MFS permease  
ORTHOMCL31 
Putative ABC iron siderophore transporter, fused permease and ATPase 
domains 
ORTHOMCL32 Lipid A export ATP binding permease protein MsbA  
ORTHOMCL33 Putative streptomycin phosphotransferase 
ORTHOMCL34 Membrane fusion component of tripartite multidrug resistance system 
ORTHOMCL35 RND efflux system, outer membrane lipoprotein CmeC 
ORTHOMCL36 RND efflux system, outer membrane lipoprotein CmeC 
ORTHOMCL37 Inner membrane component of tripartite multidrug resistance system  
ORTHOMCL38 RND efflux system, outer membrane lipoprotein CmeC 
ORTHOMCL39 Cyclolysin secretion ATP binding protein 
ORTHOMCL40 Tetracycline efflux protein TetA 
ORTHOMCL41 Putative transmembrane efflux protein 
ORTHOMCL43 RND efflux system, membrane fusion protein CmeA 
ORTHOMCL44 RND efflux system, membrane fusion protein CmeA 
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ORTHOMCL45 Membrane fusion protein MexC 
ORTHOMCL46 Transport ATP binding protein CydCD 
ORTHOMCL47 Dihydropteroate synthase 
ORTHOMCL48 ABC type multidrug transport system ATPase and permease component 
ORTHOMCL49 Streptomycin-6-kinase 
ORTHOMCL50 Streptomycin resistance protein B 
ORTHOMCL51 Tetracycline resistance protein 
ORTHOMCL52 Aminoglycoside-6' N-acetyltransferase 
ORTHOMCL53 Beta lactamase class C and other penicillin binding proteins 
ORTHOMCL54 Beta lactamase 
ORTHOMCL55 Beta lactamase class C and other penicillin binding proteins 
ORTHOMCL56 Metallo-beta lactamase superfamily protein PA0057 
ORTHOMCL57 Beta lactamase 
ORTHOMCL58 Metallo-beta lactamase family protein 
ORTHOMCL59 Oxacillinase OXA-114 
ORTHOMCL60 Beta lactamase 
ORTHOMCL61 Beta lactamase domain-containing protein 
ORTHOMCL62 Beta lactamase 
ORTHOMCL63 Metallo-beta lactamase family protein, RNA specific 
ORTHOMCL64 Beta lactamase domain containing protein 
ORTHOMCL65 Beta lactamase domain protein 
ORTHOMCL66 Metallo-beta lactamase 
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Table A3.7: Acquired resistance genes and the presence/absence in each strain 
 
  
Group number 
Reference gene 
ID 
Gene annotation 
N
C
IM
B
 1
1
0
1
5
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2
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4
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B
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ORTHOMCL53 AHY18660.1 IMP-14 metallo beta lactamase - - - - - - - - - - - - - - - + - - - + - - - - - - 
ORTHOMCL72 CDI94943.1 Beta lactamase domain containing protein - - - - - - + + - + - - - - - - - - - - - - - - - - 
ORTHOMCL71 YP_008031839.1 Metallo beta lactamase family protein, RNA specific - - + + + - - + - + - - - - - - - - - - - - + - - - 
ORTHOMCL70 YP_008027752.1 Beta lactamase - - + + - - - - - - - - + - + - + - - + - + - - + + 
ORTHOMCL69 AIR52250.1 Beta lactamase domain containing protein - + - - + - + - - - + - + + - + + + - + + - + - + + 
ORTHOMCL68 YP_008029689.1  Beta lactamase + + + + + + + + + + + + + + - + + + - + + - + + + + 
E
ff
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x
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n
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o
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y
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ORTHOMCL1 WP_020925327.1 AcrB/AcrD/AcrF family protein + + + + - + + + - - + + + + + + + + + + + + + - + + 
ORTHOMCL2 CKG72640.1 Cation efflux system protein CzcA + + + + + + + + + + + + + + - + - + + + + + + + + + 
ORTHOMCL27 YP_008027732.1 RND efflux system,outer membrane CmeC + + + + + + + + + + + + + + + + + + - + + + + + + + 
ORTHOMCL30 YP_008028726.1 MFS permease + + + + + + + + + + + + - + + + + + + + + + + + + - 
ORTHOMCL31 YP_008030221.1 
Putative ABC iron siderophore transporter, fused 
permease and ATPase domains + + + + + + + + + + - + + + - + - + + + + - + + - + 
ORTHOMCL32 CKH86978.1 
Putative multidrug export ATP-binding/permease protein 
SAV1866 - + + + + - + + - + - - + + - + + + - + + + + + + + 
ORTHOMCL34 YP_008030767.1 
Membrane fusion component of tripartite multidrug 
resistance system + + + + + + + + + - + + + + - + + - - + - - + + + - 
ORTHOMCL35 YP_008032982.1 RND efflux system  outer membrane lipoprotein CmeC - - + + + - + + + + + + + + - - + + - + + - + - + + 
ORTHOMCL36 YP_008027734.1 RND efflux system  outer membrane lipoprotein CmeC + + + + + + + + + + + + + + - + - - - + - - - + - - 
ORTHOMCL37 YP_008033107.1 
Inner membrane component of tripartite multidrug 
resistance system + + + + - + + - + - + + - - + + - + + + - - - + + - 
ORTHOMCL38 YP_008029977.1 RND efflux system  outer membrane lipoprotein CmeC + + + + - + + + + - + + + + - + + - - + - - - - - - 
ORTHOMCL39 YP_008032049.1 Cyclolysin secretion ATP binding protein - - + + - + - - - - - + - + - - - + + + - - - + - - 
ORTHOMCL40 YP_008031167.1 Tetracycline efflux protein TetA + + + + - + + - + - - + - + - + - - - + - - - - - - 
ORTHOMCL41 CKI18085.1 Spectinomycin tetracycline efflux pump + - + + - + - - + - + + - - - + - - - + - - + + - - 
  
3
0
0
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ORTHOMCL43 YP_008033425.1 RND efflux system  membrane fusion protein CmeA + - + + - + + - - - - + - - - + - - - + - - - - - + 
ORTHOMCL44 YP_008028035.1 RND efflux system  membrane fusion protein CmeA - - + + - + - - - - + + + - - - + - - - - - - - - + 
ORTHOMCL45 ADP16465.1 Periplasmic linker protein 2 - - - - - - + - + - - - - + - - - + - + + - - + - - 
ORTHOMCL46 YP_008031197.1 Transport ATP binding protein CydCD + - - - - - + + - - + - - - - + - - - + - - - + - - 
ORTHOMCL48 CKG97466.1 Iron import ATP-binding/permease protein IrtB - + - - - + - + - + - + - + - - - - - - - - - - - - 
ORTHOMCL51 AKE04698.1 MFS Transporter - - - - - - - - - - - - - - - + - - - + - - - - - - 
ORTHOMCL54 YP_008032981.1 
RND multidrug efflux transporter  Acriflavin resistance 
protein - + + + + + + + + + + + + + + - + - + + + + + - + + 
ORTHOMCL55 YP_008027731.1 RND efflux system, inner membrane transporter CmeB  + + + + + + + + + + + + + + - + + + - + + - + + + + 
ORTHOMCL58 YP_008031293.1 RND efflux system, outer membrane lipoprotein CmeC  + + + + + + + + + - + + + + - + - + + + + + + + - + 
ORTHOMCL59 WP_013393781.1 Acriflavine resistance protein B - - - - - - + - + - - - - + + - - + + + + + - + - - 
ORTHOMCL60 YP_008028715.1 AcrB/AcrD/AcrF family protein + + + + + - + + - + + - - + + + + + + + + + + + + + 
ORTHOMCL61 YP_008032003.1 
RND multidrug efflux transporter; Acriflavin resistance 
protein  + + + + + + + + - + + + + + + + + + + + + + + + + + 
ORTHOMCL62 WP_020925545.1 Cobalt-zinc-cadmium resistance protein CzcA + + + + + + + - + - + + + - + + + + - + - - + + - - 
ORTHOMCL63 WP_019396923.1 Cation transporter - - - - - - + + - + - - + - - - + - - - - - - - - + 
R
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ORTHOMCL16 YP_008029342.1 Translation elongation factor Tu + + + + - + - + + + + - + - + + + + + + + + + + + + 
ORTHOMCL25 YP_008029360.1 Translation elongation factor G + + + + + + + + + + + + + + + + - + + + + + + + + + 
ORTHOMCL26 YP_008029349.1 DNA directed RNA polymerase beta subunit + + + + + + + + + + + + + + + + + + + + + + + - + + 
ORTHOMCL29 YP_008030789.1 Topoisomerase IV subunit A + + + + + + + + + + + + + + + + + + + + - - + + + + 
ORTHOMCL33 YP_008031164.1 Putative streptomycin phosphotransferase + - + + + + + + + - + + + + - + + + - + - - + + + - 
ORTHOMCL47 AHY18660.1 Dihydropteroate synthase - + - - - - - - - - - - - - - + - - - + - - - - - - 
ORTHOMCL49 BAN89135.1 Streptomycin-6-kinase - - - - - - - - - - - - - - - + - - - + - - - - - - 
ORTHOMCL50 AIA53578.1 3'-kinase - - - - - - - - - - - - - - - + - - - + - - - - - - 
ORTHOMCL52 AHY18660.1 Aminoglycoside-6',N-acetyltransferase - - - - - - - - - - - - - - - + - - - + - - - - - - 
+, Presence; -, Absence
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Table A3.8: The appearance of AxyXY-OprZ-homologous CmeABC efflux 
pump across 26 genomes of A. xylosoxidans. NH44784-1996, A. xylosoxidans 
NH44784-1996, NCIMB 11015, A. xylosoxidans NCIMB 11015; DSM 2402, A. 
xylosoxidans DSM 2402; L-strain, Liverpool’s clinical isolates; R-strain, Thai 
clinical isolates. 
 
Gene annotation CmeA(AxyX) CmeB(AxyY)  CmeC(OprZ) 
Ref ID YP_008027730.1 YP_008027731.1  YP_008027732.1 
NCIMB 11015     
DSM 2402     
NH44784-1996     
L1     
L5     
L8     
L10     
L11     
L14     
L15     
L16     
L17     
R1     
R2     
R3     
R4     
R5     
R6     
R7     
R8     
R9     
R10     
R11     
R12     
R13     
R14     
= Presence;  = Absence 
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Table A3.9: The appearance of AxyAMB-homologous CmeABC efflux 
pump across 26 genomes of A. xylosoxidans. NH44784-1996, A. xylosoxidans 
NH44784-1996, NCIMB 11015, A. xylosoxidans NCIMB 11015; DSM 2402, A. 
xylosoxidans DSM 2402; L-strain, Liverpool’s clinical isolates; R-strain, Thai 
clinical isolates. 
Gene annotation CmeA(AxyA) CmeB(AxyB) CmeC(AxyM) 
Ref ID YP_008031291.1 YP_008031292.1 YP_008031293.1 
NCIMB 11015    
DSM 2402    
NH44784-1996    
L1    
L5    
L8    
L10    
L11    
L14    
L15    
L16    
L17    
R1    
R2    
R3    
R4    
R5    
R6    
R7    
R8    
R9    
R10    
R11    
R12    
R13    
R14    
= Presence;  = Absence 
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Table A3.10: Antibiotic susceptibility of type strains of genus Achromobacter 
to commonly used antibiotics using disc diffusion. The table presents 
susceptibility interpretation using cut-off level based on BSAC guideline. The 
susceptibility interpretation was illustrated as „Resistant (R, Red)‟, „Intermediate 
(I, Yellow)‟ and „Susceptible (S, Green)‟. NCIMB 11015, A. xylosoxidans 
NCIMB 11015; DSM 2402, A. xylosoxidans DSM 2402 
 
 Cephalosporin Aminoglycoside 
Isolates CXM CTX CAZ CRO FEP CN AK 
NCIMB 11015 R R S R I R I 
A. denitrificans R I S S I R I 
A. ruhlandii R R S I S S S 
A. piechaudii R R S R S S S 
A. spanius R R S I S S S 
A. insolitus R R S R R I S 
DSM 2402 R R S R R R R 
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Appendix 4 Virulence determinants of A. 
xylosoxidans 
 
Figure A4.1: Lethal dose-50 (LD50) of A. xylosoxidans strains in G. 
mellonella. The larvae were infected with two A. xylosoxidans strains: NCIMB 
11015 and DSM 2402, and incubated for 96 hr at 37°C. LD50s were determined 
using R programme. Bars represent the means and standard deviation of three 
replicates. Student‟s t-test was used as statistical test. ***; p-value < 0.005. 
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Figure A4.2: The prediction of secondary structure of virulence-associated 
α/β -hydrolase domain-containing protein. The analysis was performed using 
Psipred (http://bioinf.cs.ucl.ac.uk/psipred/). 
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Figure A4.3: Heatmap presenting hierarchical cluster of A. xylosoxidans 
isolates based on virulence gene candidates. A dendrogram represents the 
clustering by using UPGMA method. Colours on the heatmap indicate the 
correlation between isolates based on the occurrence of VFDB-matched 
virulence gene. Lethality and isolates‟ name were labelled on the right-hand side 
of the heatmap. NCIMB 11015, A. xylosoxidans NCIMB 11015; DSM 2402, A. 
xylosoxidans DSM 2402. L-strain, Liverpool‟s clinical isolates; R-strain, Thai 
clinical isolates. 
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Table A4.1: A list of VFDB-enriched OrthoMCL‟s groups that are shared 
amongst A. xylosoxidans isolates in this study 
ID Annotation 
ORTHOMCL0 General secretion pathway protein E 
ORTHOMCL1 Heat shock protein 60 family chaperone GroEL 
ORTHOMCL2 Outer membrane receptor for ferric pyochelin FptA 
ORTHOMCL3 Phospholipase C4 precursor 
ORTHOMCL4 Iron siderophore Alcaligin receptor/TonB-dependent siderophore receptor 
ORTHOMCL5 Arginine decarboxylase 
ORTHOMCL6 RND efflux system outer membrane lipoprotein CmeC 
ORTHOMCL7 Isocitrate lyase 
ORTHOMCL8 Co activator of prophage gene expression IbrA 
ORTHOMCL9 ABC transporter ATP binding permease protein 
ORTHOMCL10 GDP mannose-4,6-dehydratase 
ORTHOMCL11 Mannose-1-phosphate guanylyltransferase GDP 
ORTHOMCL12 UDP glucose 4 epimerase 
ORTHOMCL13 Succinate semialdehyde dehydrogenase NADP  
ORTHOMCL14 ClpB protein 
ORTHOMCL15 5-carboxymethyl-2-hydroxymuconate semialdehyde dehydrogenase 
ORTHOMCL16 Superoxide dismutase Fe  
ORTHOMCL17 ATP dependent Clp protease ATP binding subunit ClpA 
ORTHOMCL18 ATP dependent Clp protease proteolytic subunit 
ORTHOMCL19 Lysyl tRNA synthetase class II 
ORTHOMCL20 Methyl accepting chemotaxis protein I serine chemoreceptor protein 
ORTHOMCL21 putative protein ImpC 
ORTHOMCL22 Methyl accepting chemotaxis protein I serine chemoreceptor protein 
ORTHOMCL23 Sulfite oxidase 
ORTHOMCL24 Two-component response regulator 
ORTHOMCL25 Respiratory nitrate reductase beta chain 
ORTHOMCL26 2-keto-3-deoxy-D-arabino-heptulosonate-7-phosphate synthase I alpha 
ORTHOMCL27 Vi polysaccharide export protein vexE 
ORTHOMCL28 Vi polysaccharide biosynthesis protein tviE 
ORTHOMCL29 putative capsular polysaccharide biosynthesis protein 
ORTHOMCL30 UDP glucose dehydrogenase 
ORTHOMCL31 Glutamine synthetase type I 
ORTHOMCL32 Flagellar M ring protein FliF 
ORTHOMCL33 Flagellar motor switch protein FliG 
ORTHOMCL34 Flagellum specific ATP synthase FliI 
Appendices 
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ORTHOMCL35 Flagellar motor switch protein FliM 
ORTHOMCL36 Flagellar biosynthesis protein FliP 
ORTHOMCL37 Flagellar hook associated protein FlgK 
ORTHOMCL38 Flagellar protein FlgJ peptidoglycan hydrolase  
ORTHOMCL39 Flagellar P ring protein FlgI 
ORTHOMCL40 Flagellar basal body rod protein FlgG 
ORTHOMCL41 Flagellar biosynthesis protein FlhB 
ORTHOMCL42 Chemotaxis protein methyltransferase CheR 
ORTHOMCL43 Positive regulator of CheA protein activity CheW 
ORTHOMCL44 Signal transduction histidine kinase CheA 
ORTHOMCL45 Flagellar motor rotation protein MotB 
ORTHOMCL46 RNA polymerase sigma factor for flagellar operon 
ORTHOMCL47 Aldehyde dehydrogenase 
ORTHOMCL48 Transport ATP binding protein CydCD 
ORTHOMCL49 Tetrathionate reductase subunit B 
ORTHOMCL50 Biofilm PGA synthesis N glycosyltransferase PgaC 
ORTHOMCL51 Lipid A export ATP binding permease protein MsbA 
ORTHOMCL52 Putative ABC transporter 
ORTHOMCL53 Phenylacetaldehyde dehydrogenase 
ORTHOMCL54 C4 dicarboxylate transport transcriptional regulatory protein 
ORTHOMCL55 Putative ATP binding component of ABC transporter 
ORTHOMCL56 Hemin transport protein HmuS 
ORTHOMCL57 ATP dependent Clp protease proteolytic subunit 
ORTHOMCL58 2-aminomuconate-semialdehyde dehydrogenase 
ORTHOMCL59 UDP-glucose 4-epimerase 
ORTHOMCL60 UDP-glucose dehydrogenase 
ORTHOMCL61 TonB-dependent siderophore receptor 
ORTHOMCL62 Polymyxin resistance protein ArnC glycosyl transferase 
ORTHOMCL63 DNA binding heavy metal response regulator 
ORTHOMCL64 Aldehyde dehydrogenase 
ORTHOMCL65 Polymyxin resistance protein ArnC glycosyl transferase 
ORTHOMCL66 Pyruvate kinase 
ORTHOMCL67 Gamma-glutamyltranspeptidase 
ORTHOMCL68 Mg 2 transport ATPase P type 
ORTHOMCL69 UTP-glucose-1-phosphate uridylyltransferase 
ORTHOMCL70 TonB-dependent siderophore receptor 
ORTHOMCL71 RNA polymerase sigma factor RpoE 
ORTHOMCL72 Lipid A export ATP binding permease protein MsbA 
ORTHOMCL73 ADP-L-glycero-D-manno-heptose 6-epimerase 
ORTHOMCL74 2-keto-3-deoxy-D-arabino-heptulosonate-7-phosphate synthase I alpha 
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ORTHOMCL75 Lipid A export ATP binding permease protein MsbA 
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Appendix 5 Complete genome of Achromobacter 
xylosoxidans strain NCIMB 11015, a clinical-naïve strain 
 
The genome of clinically-naïve strain of A. xylosoxidans included in this study 
was revealed with the combination between short read sequencing and single 
molecule sequencing technology. Genome assembly presented 6.5 Mb genome 
long, with 67.6% of G+C content. Rapid gene calling and genes annotation with 
Prokka annotator resulted in 5,864 CDS from the genome with 1,072 
hypothetical genes. There were 71 tRNA genes and 3 rRNA operons predicted 
on the genome.  
 
With functional annotation of genome based on eggNOG database (Appendix 
Table A5.1), approximately one-fourth of genes were assigned as „function 
unknown‟.  Besides genes with unknown function, genes associated with amino 
acid metabolism/transport and gene associated with transcription ranked the most 
and the second most abundant genes in the genome with 12 percent and 9.8 
percent, respectively. In comparison to average of COGs assigned in other strains, 
A. xylosoxidans NCIMB 11015 had less number of genes annotated with „poor 
characterized‟. 
 
Whole genome comparison of the genome of NCIMB 11015 to the other genome 
was performed with BLAST-based comparison and graphical view was 
generated using BRIG software (Appendix Figure A5.1). Using visualised 
comparative genomic approach, there were 8 regions that are unique to strain 
NCIMB 11015, as illustrated by black boxes in Appendix Figure A5.1 and genes 
in each region were described in Appendix Table 5.2. The first region (Box I in 
Appendix Figure A5.1) was located at 1,495,202 bp to 1,513,912 bp on the 
genome. Most of the genes in this region were hypothetical genes. The presence 
of a gene encoding „integrase‟ at the end of the segment suggested the 
acquisition of this DNA fragment from environment (Appendix Table A5.2). The 
second region spanned from 1,710,796 to 1,730,209 bp (Box II in Appendix 
Figure A5.1). Genes in this region were also mostly hypothetical genes. 
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UvrD/REP helicase and precursor of type III restriction (Res subunit) were 
present in this DNA region. The third region (Box III in Appendix Figure A5.1), 
which located at position approximately 2.2 Mbp, was composed of genes 
associating with Lipopolysaccharide (LPS) biosysnthesis, such as, LPS-
heptosyltransferase and 3-deoxy-D-manno-octulosonic acid transferase. In 
addition, genes involved in bacterial capsule biosynthesis, including UDP-
glucose 4-epimerase and UDP-N-acetylglucosamine 2-epimerase, were present 
in this region. Genes with incomplete sequence or pseudo-genes of transposase 
were also found in this region. The fourth region (Box IV in Appendix Figure 
A5.1), was comprised of components of type IV secretion system, including 
inner membrane protein and minor pilin. Moreover, this region included major 
facilitator, transcription regulators, kinase and integrase family protein. The fifth 
region (Box V in Appendix Figure A5.1), located on genome spanning from 
coordination 3,388,522 to 3,444,827, included type III secretion system‟s 
subunits and integrase/terminase genes.  The sixth and the largest region covered 
77,774 bp (3,819,279 – 3,897,053) on the genome (Box VI in Appendix Figure 
A5.1). This region consisted of genes involved in flagella, two-component 
systems, pilus and secretion system‟s components. In region VII (Box VII in 
Appendix Figure A5.1), most of the genes were hypothetical genes. This region 
could be phage-related due to the presence of phage protein. The last region (Box 
VIII in Appendix Figure A5.1) was composed of only single gene, which is 
hypothetical protein. 
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Figure A5.1: A circular genome map comparing A. xylosoxidans NCIMB 
11015 to the other isolates of A. xylosoxidans used in this study. Eight black 
boxes indicate regions where are unique to strain NCIMB 11015.  
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Table A5.1: The functional annotation of complete genome of A. 
xylosoxidans strain NCIMB 11015 compared to other 25 A. xylosoxidans 
genomes 
 
Categories COGs function 
NCIMB 
11015 
Mean of 25 
strains 
Information 
storage and 
processing 
(A) RNA processing and modification 0.002 0.02% 
(B) Chromatin structure and dynamics 0.1 0.09% 
(J) Translation 3.1 2.84% 
(K) Transcription 9.8 7.91% 
(L) Replication, recombination, repair 2.4 2.27% 
Cellular 
processes 
(D) Cell cycle control, mitosis, meiosis 0.5 0.49% 
(M) Cell wall/membrane biogenesis 4.5 4.19% 
(N) Cell motility 0.8 0.75% 
(O) Posttranslational modification, protein 
turnover, chaperones 3.0 2.68% 
(T) Signal transduction mechanisms 3.5 3.12% 
(U) Intracellular trafficking, secretion 1.7 1.33% 
(V) Defense mechanisms 1.3 0.97% 
(W) Extracellular structures 0.0 0.01% 
(Z) Cytoskeleton 0.0 0.00% 
Metabolism 
(C) Energy production, conversion 6.2 4.87% 
(E) Amino acid transport, metabolism 12.0 9.70% 
(F) Nucleotide transport, metabolism 1.2 1.03% 
(G) Carbohydrate transport, metabolism 3.1 12.98% 
(H) Coenzyme transport, metabolism 1.9 1.85% 
(I) Lipid transport, metabolism 4.1 3.51% 
(P) Inorganic ion transport, metabolism 6.4 5.55% 
(Q) Secondary metabolites 1.8 3.84% 
Poorly 
characterised 
(R) General function prediction 6.0 5.02% 
(S) Function unknown 15.1 24.96 
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Table A5.2: A table to show unique genomic regions of A. xylosoxidans 
NCIMB 11015 compared to other strains. 
Region I Start Stop 
Conjugal Transfer Protein 1,495,202 1,495,816 
Hypothetical Protein 1,495,903 1,496,466 
Hypothetical Protein 1,496,268 1,496,657 
Hypothetical Protein 1,496,667 1,497,119 
Outer Membrane Porin Protein Precursor 1,497,142 1,497,948 
Hypothetical Protein 1,498,214 1,499,188 
Hypothetical Protein 1,499,317 1,502,292 
Hypothetical Protein 1,502,945 1,503,229 
Putative Transcriptional Regulator 1,503,213 1,503,533 
Parb Domain Protein Nuclease 1,503,652 1,504,212 
Hypothetical Protein 1,504,475 1,505,377 
Hypothetical Protein 1,506,782 1,510,327 
Integrase Family Protein 1,512,743 1,513,912 
Region II     
Putative Type III Restriction Protein, Res Subunit 1,710,796 1,713,393 
Hypothetical Protein 1,713,390 1,715,387 
Hypothetical Protein 1,715,384 1,716,721 
Hypothetical Protein 1,716,841 1,717,791 
Hypothetical Protein 1,717,887 1,718,834 
Uvrd/REP Helicase 1,718,827 1,722,030 
Hypothetical Protein 1,722,033 1,724,726 
Hypothetical Protein 1,724,799 1,726,454 
Putative Transcriptional Regulator 1,727,234 1,728,259 
Hypothetical Protein 1,728,388 1,729,116 
Hypothetical Protein 1,729,586 1,730,209 
Region III     
Transposase (Pseudogene?) 2,164,425 2,164,742 
Transposase (Pseudogene?) 2,164,736 2,165,050 
Transposase (Pseudogene?) 2,165,051 2,165,230 
Carbon Monoxide Degydrogenase G Protein 2,165,347 2,165,916 
Hypothetical Protein 2,166,489 2,168,213 
Hypothetical Protein 2,169,073 2,169,846 
Hypothetical Protein 2,169,882 2,170,880 
Degt/Dnrj/Eryc1/Strs 2,170,877 2,172,094 
Hypothetical Protein 2,172,091 2,173,647 
Hypothetical Protein 2,173,671 2,174,936 
Hypothetical Protein 2,174,957 2,176,666 
Dolichol-Phosphate Mannosyltransferase 2,176,859 2,177,665 
UDP-N-Acetylglucosamine 2-Epimerase 2,177,955 2,178,746 
Hypothetical Protein 2,179,365 2,180,216 
Multidrug MFS Transporter 2,180,741 2,182,579 
Acetyltransferase 2,182,599 2,183,198 
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Glycosyl Transferase 2,183,252 2,184,283 
NAD-Dependent Epimerase/Dehydratase Family Protein 7 2,184,341 2,185,222 
Glycosyl Transferase Family 1 2,185,219 2,186,472 
UDP-N-Acetylglucosamine 2-Epimerase 2,186,454 2,187,587 
UDP-2-Acetamido-2,6-Dideoxy-Beta-L-Talose 4 Dehydrogenase 2,187,589 2,188,695 
UDP-Glucose 4-Epimerase 2,188,698 2,189,735 
Imidazole Glyceraol Phosphate Synthase 2,189,774 2,190,559 
Imidazole Glyceraol Phosphate Synthase 2,190,561 2,191,175 
LPS Biosynthesis Protein Wbpg 2,191,172 2,192,311 
Glycosyl Transferase 2,192,346 2,193,275 
Hypothetical Protein 2,193,658 2,194,986 
Polysaccharide Biosynthesis Protein (O-Antigen-Associated) 2,194,997 2,196,223 
Aminotransferase Degt 2,196,361 2,197,473 
Serine Acetyltransferase 2,197,473 2,198,060 
Oxidoreductase 2,198,057 2,198,950 
Hypothetical Protein 2,199,640 2,200,710 
LPS-Heptosyltransferase 2,201,112 2,202,140 
3-Deoxy-D-Manno-Octulosonic Acid Transferase 2,202,142 2,203,443 
Region IV     
Hypothetical Protein 2,588,317 2,588,919 
Addiction Module Antidote Protein 2,589,058 2,589,360 
Peptidase C14, Caspase Catalytic Subunit P20 2,589,725 2,590,822 
Hypothetical Protein 2,590,847 2,593,336 
Hypothetical Protein 2,593,341 2,594,180 
Hypothetical Protein 2,594,184 2,594,969 
Hypothetical Protein 2,595,140 2,596,435 
Integral Inner Membrane Protein Of Type IV Secretion Complex, Virb6 2,597,641 2,598,693 
Hypothetical Protein 2,598,695 2,598,955 
Hypothetical Protein 2,598,952 2,599,398 
Minor Pilin Of Type IV Secretion Complex, Virb5 2,599,409 2,600,134 
Hypothetical Protein 2,600,392 2,600,649 
Hypothetical Protein 2,600,675 2,601,670 
Hypothetical Protein 2,601,667 2,602,206 
Hypothetical Protein 2,602,203 2,603,213 
Phosphoprotein Phosphatase 2,603,904 2,604,593 
Alkylhydroperoxidase 2,605,471 2,606,010 
Major Facilitator Superfamily 2,606,079 2,607,272 
Short-Chain Dehydrogenase/Reductase 2,607,330 2,608,088 
Arac Family Transcriptional Regulator 2,608,217 2,609,167 
Hypothetical Protein 2,611,601 2,611,726 
Integrase Family Protein 2,611,849 2,612,475 
Alkylhydroperoxidase 2,612,645 2,613,091 
Transcriptional Regulator, Gntr Family Domain/ Aspartate 
Aminotransferase 2,613,248 2,614,666 
Putative Kinase 2,614,909 2,616,003 
Hypothetical Protein 2,616,000 2,616,428 
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Region V     
Hypothetical Protein 3,388,522 3,388,611 
Hypothetical Protein 3,388,637 3,389,155 
Hypothetical Protein 3,389,209 3,390,186 
Hypothetical Protein 3,390,868 3,391,515 
Hypothetical Protein 3,392,054 3,393,040 
Hypothetical Protein 3,393,522 3,393,653 
Terminase 3,393,798 3,394,067 
Hypothetical Protein 3,394,398 3,394,667 
Integrase Family Protein 3,394,621 3,395,319 
Hypothetical Protein 3,395,876 3,397,282 
Hypothetical Protein 3,397,358 3,398,707 
Hypothetical Protein 3,398,704 3,398,826 
Hypothetical Protein 3,398,911 3,400,080 
Srcm 3,400,107 3,400,565 
Putative Inner Membrane Transporter Protein 3,400,562 3,403,057 
ABC Transporter, Substrate-Binding Protein 3,403,258 3,404,421 
Tir Chaperone Protein 3,404,703 3,405,146 
Hypothetical Protein 3,405,319 3,406,368 
Hypothetical Protein 3,406,449 3,406,910 
Hypothetical Protein 3,406,932 3,408,209 
Hypothetical Protein 3,408,310 3,409,290 
Hypothetical Protein 3,409,512 3,409,763 
Hypothetical Protein 3,409,804 3,410,061 
Putative Type III Secretion Protein 3,410,091 3,411,413 
Type III Secretion Inner Membrane Channel Protein 3,411,410 3,413,503 
Hypothetical Protein 3,413,496 3,413,864 
Hypothetical Protein 3,413,861 3,414,259 
Hypothetical Protein 3,414,298 3,414,666 
Putative Outer Protein B 3,414,663 3,415,808 
Inositol Phosphate Phosphatase 3,415,983 3,418,691 
Hypothetical Protein 3,418,736 3,419,206 
Secreted Protein 22 3,419,312 3,419,911 
Type III Secretion Chaperone For Yopd 3,420,262 3,420,762 
Hypothetical Protein 3,420,773 3,421,675 
Putative Outer Protein B 3,421,713 3,422,942 
Hypothetical Protein 3,419,913 3,420,218 
Putative Regulator Protein 3,422,970 3,423,455 
Hypothetical Protein 3,423,574 3,423,882 
Putative Type III Secretion Protein 3,423,891 3,424,325 
Type III Secretion Bridge Between Inner And Outer Membrane 
Lipoprotein 3,424,325 3,425,179 
Bsck 3,425,176 3,425,826 
Type III Secretion Cytoplasmic Protein 3,425,796 3,426,434 
Flagellum-Specific ATP Synthase Fli 1 3,426,431 3,427,798 
Hypothetical Protein 3,428,317 3,428,892 
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Type III Secretion Spans Bacterial Envelope Protein 3,427,812 3,428,330 
Hypothetical Protein 3,428,914 3,430,089 
Hypothetical Protein 3,430,086 3,430,778 
Hypothetical Protein 3,430,807 3,431,073 
Hypothetical Protein 3,431,093 3,431,893 
Hypothetical Protein 3,431,890 3,432,951 
Hypothetical Protein 3,432,938 3,433,354 
Type III Secretion Outer Membrane Pore Forming Protein 3,433,351 3,435,345 
RNA Polymerase ECF-Type Sigma Factor 3,435,380 3,435,985 
Response Regulator, Narl Family 3,436,323 3,436,994 
ABC Transporter Substrate Protein 3,437,355 3,438,575 
Serine Phosphatase Rsbu, Regulator Of Sigma Subunit 3,438,572 3,440,578 
Putative Anti-Sigma Factor 3,440,766 3,441,206 
Putative Anti-Sigma Factor Antagonist 3,441,357 3,441,716 
Hypothetical Protein 3,441,918 3,443,339 
Hypothetical Protein 3,443,469 3,444,827 
Region VI     
Hypothetical Protein 3,819,279 3,820,289 
Hypothetical Protein 3,822,085 3,822,789 
Hypothetical Protein 3,823,862 3,825,661 
Flagellar Transcriptional Regulator 3,825,827 3,826,375 
Hypothetical Protein 3,827,419 3,828,396 
Putative Two-Component Response Regulator 3,829,378 3,830,238 
Flagellar Transcriptional Activator 3,826,403 3,826,738 
Hypothetical Protein 3,830,379 3,830,747 
Multi- Hybrid Histidine Kinase 3,831,126 3,834,236 
Luxr-Family DNA-Binding Response Regulator 3,834,284 3,834,937 
Glutamate-Aspartate Periplasmic Binding Proterin Precursor 3,835,007 3,836,032 
Periplasmic Thiol:Disulfide Interchange Protein 3,836,191 3,836,802 
CS1 Type Fimbrial Major Subunit 3,836,874 3,837,401 
Putative Periplasmic Chaperone 3,837,507 3,838,220 
Putative Outer Membrane Usher 3,838,318 3,841,134 
Putative Minor Pilin And Initiator 3,841,257 3,842,336 
Glycoside Hydrolase Family 3,842,594 3,845,857 
Type II Secretion System Protein G 3,846,224 3,846,664 
Invasion Protin Iagb 3,846,639 3,847,151 
Type II Secretion System Protein 3,847,148 3,848,332 
Type II Secretion System Protein E 3,848,405 3,850,009 
Hypothetical Protein 3,849,990 3,850,763 
Hypothetical Protein 3,850,760 3,851,290 
Hypothetical Protein 3,851,287 3,851,841 
Hypothetical Protein 3,851,838 3,852,308 
Bacterial Type II And III Secretion System Amily Protein 3,852,312 3,854,327 
General Secretion Pathway Family Protein G 3,854,324 3,854,824 
Type II Secretion System Protein G 3,854,799 3,855,194 
Hypothetical Protein 3,855,181 3,855,681 
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Two-Component Transcriptional Regulator, Winged Helix Family 3,855,720 3,856,403 
Putative Transmembrane Sensor Domain Protein 3,856,410 3,857,714 
Histidine Kinase A Phosphoacceptor Domain-Containing Protein 3,857,711 3,858,784 
Type III Secretion System Protein 3,858,741 3,859,907 
Ysat 3,859,904 3,860,686 
Putative Type III Secretion 318Ystem Protein 3,860,686 3,860,940 
Epap 3,860,953 3,861,645 
Type III Secretion Apparatus Protein 3,861,642 3,862,574 
Hypothetical Protein 3,862,589 3,864,451 
Hypothetical Protein 3,864,441 3,864,905 
Type III Secretion System Atpase 3,864,892 3,866,151 
Hypothetical Protein 3,866,193 3,866,603 
Inva 3,866,611 3,868,680 
Hypothetical Protein 3,868,714 3,869,034 
Type Secretion System Regulator 3,869,027 3,870,157 
Type III Secretion Apparatus 3,870,150 3,871,985 
Hypothetical Protein 3,871,976 3,872,275 
Transcriptional Regulator 3,872,253 3,873,032 
Hypothetical Protein 3,873,210 3,873,350 
Hypothetical Protein 3,873,558 3,874,730 
Hypothetical Protein 3,874,850 3,875,131 
Hypothetical Protein 3,875,159 3,875,455 
Hypothetical Protein 3,875,452 3,876,210 
Hypothetical Protein 3,876,940 3,877,467 
Hypothetical Protein 3,877,559 3,878,659 
Chaperone Protein 3,878,893 3,879,390 
Hypothetical Protein 3,879,383 3,881,341 
Hypothetical Protein 3,881,409 3,882,311 
Hypothetical Protein 3,882,395 3,885,583 
Hypothetical Protein 3,885,790 3,886,077 
Hypothetical Protein 3,886,608 3,888,113 
Hypothetical Protein 3,888,209 3,889,687 
Hypothetical Protein 3,889,851 3,890,489 
Hypothetical Protein 3,890,523 3,891,545 
RNA 2‟-Phosphotranferase 3,891,908 3,892,735 
Hypothetical Protein 3,892,926 3,897,053 
Region VII     
Hypothetical Protein 6,282,837 6,283,502 
Hypothetical Protein 6,283,506 6,283,694 
Hypothetical Protein 6,283,783 6,284,076 
Hypothetical Protein 6,284,086 6,284,304 
Hypothetical Protein 6,284,301 6,284,828 
Glycosyl Hydrolase 6,284,825 6,285,319 
Hypothetical Protein 6,285,316 6,285,648 
Hypothetical Protein 6,285,781 6,286,167 
Hypothetical Protein 6,286,170 6,287,210 
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Hypothetical Protein 6,287,211 6,287,861 
Hypothetical Protein 6,287,858 6,289,048 
Hypothetical Protein 6,289,041 6,289,385 
Hypothetical Protein 6,289,382 6,290,089 
Hypothetical Protein 6,290,074 6,290,898 
Hypothetical Protein 6,290,891 6,291,184 
Hypothetical Protein 6,291,196 6,291,738 
Peptidoglycan-Binding Protein 6,291,738 6,293,354 
Hypothetical Protein 6,293,445 6,293,900 
Hypothetical Protein 6,293,910 6,294,359 
Hypothetical Protein 6,294,418 6,295,926 
Hypothetical Protein 6,295,936 6,296,463 
Hypothetical Protein 6,296,460 6,296,828 
Hypothetical Protein 6,296,825 6,297,301 
Hypothetical Protein 6,297,298 6,297,726 
Hypothetical Protein 6,297,728 6,298,078 
Hypothetical Protein 6,298,138 6,299,220 
Hypothetical Protein 6,299,236 6,299,718 
Hypothetical Protein 6,299,715 6,300,980 
Phage Head Protein 6,300,961 6,301,713 
Head Protein 6,301,742 6,303,277 
Phage Terminase, Large Subunit 6,303,274 6,304,395 
Terminase 6,304,499 6,304,918 
Hypothetical Protein 6,304,969 6,305,265 
Hypothetical Protein 6,305,262 6,305,543 
Hypothetical Protein 6,305,606 6,305,815 
Hypothetical Protein 6,305,952 6,306,320 
DNA Helicase 6,306,321 6,307,709 
Hypothetical Protein 6,307,706 6,308,551 
Hypothetical Protein 6,308,551 6,308,916 
Hypothetical Protein 6,309,006 6,309,416 
Phage-Related Transcriptional Regulator 6,309,416 6,309,730 
Hypothetical Protein 6,309,769 6,309,933 
Hypothetical Protein 6,309,936 6,310,199 
Putative Phage Repressor Protein 6,310,276 6,311,373 
Hypothetical Protein 6,311,443 6,312,246 
Hypothetical Protein 6,312,847 6,313,503 
Hypothetical Protein 6,314,034 6,314,243 
Hypothetical Protein 6,314,318 6,314,497 
Pentapeptide Repeat Protein 6,314,781 6,315,374 
Hypothetical Protein 6,315,388 6,315,924 
Hypothetical Protein 6,316,737 6,316,937 
Hypothetical Protein 6,317,590 6,317,679 
Hypothetical Protein 6,317,681 6,317,953 
Hypothetical Protein 6,317,956 6,318,462 
Hypothetical Protein 6,318,459 6,318,644 
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Hypothetical Protein 6,318,683 6,319,336 
Single-Stranded DNA-Binding Protein 6,319,336 6,319,779 
Hypothetical Protein 6,319,788 6,320,291 
Hypothetical Protein 6,320,377 6,320,523 
Hypothetical Protein 6,320,525 6,321,073 
Hypothetical Protein 6,321,076 6,321,309 
Hypothetical Protein 6,321,313 6,321,495 
Hypothetical Protein 6,321,492 6,322,457 
Hypothetical Protein 6,322,450 6,323,115 
Hypothetical Protein 6,323,108 6,323,323 
Hypothetical Protein 6,323,323 6,323,613 
Hypothetical Protein 6,323,890 6,324,063 
Hypothetical Protein 6,324,072 6,324,293 
Integrase Family Protein 6,324,269 6,325,444 
Region VIII   
Hypothetical Gene 6,378,002 6,392,161 
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Appendix 6 Additional recombination analysis  
 
Figure A6.1: Recombination analysis on the core genomes of 26 A. xylosoxidans isolates using ClonalframML. Dark blue dots illustrate 
recombination detected by the software 
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Figure A6.2: A plot of recombination distribution across 21 B. hensalae 
genomes. A PSA tree is shown on the right side and the names of the strains are 
shown on the left side of the plot. Colour of each bar in a plot indicates 
recombined sequences obtained from a corresponding cluster in a dendogram. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
